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Abstract
Thrombocytosis (raised platelet count) has recently been identified as a pre-
diagnostic risk marker of cancer; however, the association has not been fully
investigated. This thesis aimed to explore the relationship between throm-
bocytosis and a future diagnosis of cancer through three complementary
pieces of research.
Firstly, a systematic review was carried out which aimed to identify studies
that had investigated thrombocytosis as a diagnostic marker of cancer. Four
case-control studies were identified that had found thrombocytosis to be a
significant predictor of lung, oesophago-gastric, uterine, and renal cancer.
A further four studies found that thrombocytosis did not predict pancreatic,
breast, ovarian, or colorectal cancer. One further study had collected, but
not analysed, platelet count data. Data from all nine studies were included
in a meta-analysis. The findings of the review suggest that thrombocytosis
is a marker of some, but not all, types of cancer.
The second study used data from the Clinical Practice Research Datalink
(CPRD) and the English cancer registry. This cohort study examined the
relationship between thrombocytosis and cancer using two groups of pa-
tients. The first included 40, 000 patients with a raised platelet count (a
platelet count of > 400 × 109/L). The second cohort included 10, 000 pa-
tients with a normal platelet count (150 - 400× 109/L) who were age, sex,
and practice matched to a random quarter of the first cohort. This study
found that the risk of cancer was greater in patients with thrombocyto-
sis compared to those with a normal platelet count. The one year cancer
incidence was 11.6% (95% CI 11.0 - 12.3) for male patients with thrombocy-
tosis, and 4.1% (95% CI 3.4 - 4.9) in males with a normal platelet count. In
female patients, the one year cancer incidence was 6.2% (95% CI 5.9 - 6.5)
for those with thrombocytosis and 2.2% (95% CI 1.8 - 2.6) for those with
a normal platelet count. Lung and colorectal cancer were more likely to be
diagnosed in patients with thrombocytosis than in patients with a normal
platelet count, and breast and prostate cancer less likely. In patients with
a sustained increase in platelet count over six months, the risk of cancer in-
creased to 18.1% in males (95% CI 15.9 - 20.5) and 10.1% in females (95%
CI 9.0 - 11.3). Around a third of patients with lung or colorectal cancer
and thrombocytosis had no other symptoms prior to diagnosis that would
have prompted investigation for cancer as per current NICE guidance.
The third study compared cancer recording in the CPRD and in the English
cancer registry. The aim of this study was to examine the validity of cancer
recording in the CPRD using cancer registry recording as the gold standard,
and to estimate predictors of concordance between the two data sources. A
sensitivity analysis repeated the primary analysis from the second study
to estimate the effect of including unverified CPRD cancer diagnoses. The
CPRD identified 5,924 of 7,785 cancers recorded in the cancer registry (sen-
sitivity 76.1%, 95% CI 75.1 - 77.0). 36,255 patients with no record of cancer
in the CPRD also had no cancer record in the cancer registry (specificity
97.0%, 95% CI 96.1 - 97.2). 5,924 of 7,028 CPRD cancer diagnoses were
confirmed by the cancer registry data; the positive predictive value (PPV)
of a CPRD recorded diagnosis was 84.3% (95% CI 83.4 - 85.1). Male can-
cers, those in younger patients, and those recorded from 2005 onwards were
more likely to be recorded in both sources. In a sensitivity analysis, the
exclusion of cancer diagnoses that were only recorded in the CPRD did not
significantly alter findings from the cohort study described above.
The findings from this thesis show that thrombocytosis is an important
predictor of undiagnosed cancer in adults aged 40 years and over. Patients
with thrombocytosis are more likely to be diagnosed with lung and colorec-
tal cancer than other types. These results suggest that cancer should be
considered as an underlying diagnosis in patients with unexpectedly raised
platelets, even if cancer was not suspected at the time that the blood test
was ordered. For at least a third of patients with thrombocytosis and cancer,
there will be no other clinical features of malignancy; for this proportion,
thrombocytosis has great potential to expedite diagnosis and improved sur-
vival.
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Chapter 1
Introduction
1.1 Thesis introduction
This thesis investigates thrombocytosis, or raised platelet count, as a possible risk
marker of malignancy in adults, which could be used to identify undiagnosed cancer.
This is the first newly discovered marker of cancer in years, one which is commonly
measured in primary care as part of a full blood count. Previous primary care-based
studies have identified thrombocytosis as a marker of some types of cancer (namely
lung, uterine, renal, and oesophago-gastric cancer); secondary care studies have found
thrombocytosis to be a marker of poor prognosis; and biological studies have proposed
several theories that could explain the link between thrombocytosis and cancer. How-
ever, no study to date has comprehensively investigated thrombocytosis across all types
of cancer, or examined the relationship within the context of other patient factors. This
PhD aimed to address that gap. The work presented in this thesis uses data from the
Clinical Practice Research Datalink (CPRD). The accuracy and reliability of the work
is only as good as the data source; therefore this PhD also presents a validation study
of cancer recording in the CPRD. The structure of the thesis is outlined below, and a
brief description of the contents of each chapter is given.
1.2 Aims and objectives
Here, the overall aims and objectives of this PhD are set out. The thesis includes three
pieces of work that address two main aims; the first relates to the investigation of the
relationship between thrombocytosis and cancer diagnosis. This aim is addressed in two
parts: firstly with a systematic review of studies that have examined the association
between thrombocytosis and cancer, and secondly with a cohort study using CPRD
and cancer registry data. Results from the systematic review feed into and inform the
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cohort study.
The second aim takes a methodological perspective. Using data from the cohort
study, it provides an essential estimate of the accuracy and validity of cancer recording
in the CPRD, and a sensitivity analysis to determine how certain we can be of results
using CPRD data.
Overall PhD aims:
1. To investigate the relationship between thrombocytosis and cancer di-
agnosis in adults aged 40 years and over.
Objectives:
i. To carry out a systematic review of studies that have examined the association
between platelet count and cancer in a diagnostic context to identify what is
currently known about thrombocytosis as a risk marker of cancer.
ii. To examine the incidence of cancer in two cohorts of patients; those with throm-
bocytosis and those with a normal platelet count, to determine the risk of cancer
in each cohort.
iii. To compare the cancer incidence between these two cohorts to determine the
absolute increase in risk associated with thrombocytosis.
iv. To examine how the relationship between thrombocytosis and cancer differs across
subgroups defined by age, sex, and smoking status.
v. To determine whether some types of cancer are more likely to be diagnosed
than others in patients with thrombocytosis compared to patients with a nor-
mal platelet count.
vi. To investigate how the risk of cancer changes depending on how the patient’s
platelet count changes over time.
vii. To investigate the risk of cancer in patients who report symptoms in addition to
thrombocytosis.
viii. To investigate the stage at which cancers are diagnosed in patients with throm-
bocytosis and with a normal platelet count.
ix. To estimate the potential impact of the recognition of thrombocytosis as a marker
of cancer in UK suspected cancer guidance by examining the proportion of pa-
tients who have thrombocytosis but no other cancer symptoms or markers.
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2. To assess the validity of cancer recording in the Clinical Practice Re-
search Datalink used in this thesis, using cancer recording in the En-
glish cancer registry as the ‘gold standard’.
Objectives:
i. To compare cancer recording in the CPRD and in the cancer registry to determine
the level of concordance between the two sources.
ii. To compare the age and sex of patients recorded in both, or either, source.
iii. For cancers recorded in both sources, to compare the date of recording between
the two.
iv. To estimate predictors of concordance between the two data sources.
v. To examine the extent to which the inclusion of unverified CPRD-recorded cancer
diagnoses causes overestimates in incidence figures from CPRD data, by repeat-
ing the primary analysis from Chapter 4 including only cancer registry recorded
diagnoses.
1.3 Thesis structure
Chapter 2 - Thesis background
Chapter 2 sets out the background and context for this work, and justification in terms
of what is already known about thrombocytosis and cancer. The chapter begins by
outlining normal platelet production and function and describing thrombocytosis. It
sets out the justification for this work by reviewing the existing evidence supporting the
theory of a relationship between thrombocytosis and cancer. This is split in to three
areas: primary care studies that have examined thrombocytosis as a diagnostic marker
of cancer; secondary care studies that have examined thrombocytosis as a prognostic
marker in patients already diagnosed with cancer; and studies of the physiological
mechanisms that could underlie the relationship between thrombocytosis and cancer.
Although the research presented in this thesis primarily concerns thrombocytosis as a
diagnostic rather than prognostic marker, a section on evidence from secondary care is
included because it strongly indicates a relationship between platelet count and cancer
in a broader sense.
In the second part of the chapter, the context for this thesis is given by providing an
overview of the burden of cancer in the UK by reviewing cancer incidence, mortality, and
survival. The current issues surrounding primary care cancer diagnosis are considered,
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and a section describes how thrombocytosis fits in here and could potentially contribute
to the research area and to clinical practice.
In the final part of the chapter, the two data sources used in this PhD, the Clinical
Practice Research Datalink (CPRD) and the English cancer registry, are introduced
and the accuracy and validity of the CPRD as a data source are explored.
Chapter 3 - Systematic review of evidence of a relationship between
thrombocytosis and cancer diagnosis
Chapter 3 presents a systematic review and meta-analysis to address objective i of the
first aim of the PhD. The systematic review identifies and critically examines existing
research that has investigated the diagnostic potential of the platelet count in patients
diagnosed with cancer. The systematic review determines what evidence already ex-
ists concerning the effects of age, sex, and change in platelet count over time on the
relationship. The types of cancer diagnosed in patients with thrombocytosis are exam-
ined to inform the analyses presented later in this thesis. The key findings from the
systematic review which partly informed the cohort study presented in Chapter 4 are
described at the end of the chapter.
Chapter 4 - The association between thrombocytosis and cancer
Chapter 4 begins with an introduction to the cohort study on the association between
thrombocytosis and cancer, and a description of the methods used. The main body
presents the results from the analyses which address objectives ii to ix of the first aim
of the thesis. The characteristics of the cohort are examined and compared to the UK
general population. The one year cancer incidence for patients with thrombocytosis and
patients with a normal platelet count is presented. The effects of age, sex, and smoking
status on the relationship are examined, and the time interval between blood test
results and cancer diagnosis is calculated for patients in each of the two cohorts. The
risk of cancer is estimated for patients with thrombocytosis plus symptoms indicative
of malignancy. The impact of changes in platelet count over time on the risk of cancer is
examined. The potential impact of this work on cancer diagnosis in the UK is estimated
by examining the proportion of cancer patients who had thrombocytosis, but did not
have symptoms that warranted investigation for cancer under the UK suspected cancer
guidance for clinicians.
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Chapter 5 - CPRD validation study and main study sensitivity analysis
Chapter 5 presents the results of a study to examine the validity of cancer diagnosis
recording in the CPRD, to address the second aim of the PhD. This is done by com-
paring cancer recording in the CPRD to recording in the cancer registry; considered
the ‘gold standard’ of cancer diagnosis registration. A sensitivity analysis is reported
to judge the reliability of the results presented in Chapter 4, given the results of the
CPRD validation study.
Chapter 6 - Discussion and conclusions
In Chapter 6, the results from the three main pieces of work in this thesis are drawn
together to address the overall aims of the thesis and to draw conclusions. The strengths
and limitations are critically examined. The implications of the findings for research
and for clinical practices are presented. Finally, future directions and recommendations
for ongoing research are discussed.
1.4 Chapter summary
This chapter has briefly outlined the aims and objectives of this thesis, and has outlined
the content that will be presented in each of the subsequent chapters. The next chapter
presents the justification for this work in terms of what is already known about the
association between thrombocytosis and cancer, and where this work fits in. The
context is set for the work in terms of the burden of cancer in the UK and the issues
surrounding the diagnosis of cancer in primary care, and the two data sources used in
the final two studies are presented.
5
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Chapter 2
Thesis background
2.1 Chapter introduction
In this chapter, the justification and context for this thesis is presented. This begins
in Section 2.2 with an exploration of normal platelet function and the physiological
processes underlying thrombocytosis, including usual causes. The proposed biological
mechanisms underlying the thrombocytosis-cancer relationship are explored. Although
the main focus of this thesis is thrombocytosis as a risk marker of cancer within a
primary care setting, examining the physiological theories supporting the association
is contextually valuable in providing useful background knowledge and understanding
to support the clinical evidence. Following this, Section 2.3 examines the burden of
cancer in the UK in terms of incidence, survival, and mortality. Cancer outcomes in
the UK are compared to those in other countries, and reasons for the differences in
outcomes are explored. The issues surrounding cancer diagnosis in UK primary care
are discussed within the context of earlier diagnosis, where the main body of work from
this thesis aims to have an impact. Finally, Section 2.5 introduces the two data sources
used in this PhD study: the Clinical Practice Research Datalink (CPRD) and the UK
cancer registry, and the strengths and limitations of these are discussed.
2.2 Platelets, thrombocytosis, and their link with cancer
2.2.1 The roles of platelets
Platelets are small, anucleate cells which circulate in the blood in an inactive state.
They are activated by a number of factors relating to their roles in haemostasis, most
notably in the clotting process when membrane damage is detected, and in inflamma-
tory response (Daly, 2011). A normal platelet count in an adult is in the range of 150
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- 400× 109/L (Biino et al., 2013; Giles, 1981). The platelet count is on average higher
in women than in men, most likely mediated by hormonal differences; it declines with
age (Bain, 1996; Daly, 2011). When cellular or epithelial lining damage is detected,
platelets are involved in the subsequent cascade of cell activity that results in a mesh
being formed over the damaged area, and a thrombus forming to allow the membrane
to heal (Gay & Felding-Habermann, 2011). Platelets are also involved in inflammatory
processes, but their exact role is the subject of ongoing research and debate. Upon
activation, platelets release a number of pro-inflammatory cytokines and express cell
surface receptors which are activated by key factors in the inflammatory process (Herter
et al., 2014). This process was summarised recently in Nature Immunology (Mantovani
et al., 2008).
2.2.2 Thrombopoiesis
Thrombopoiesis, the process of platelet production, begins with megakaryocytes (Deutsch
& Tomer, 2006). These cells are found primarily in the bone marrow, but have also
been isolated from secondary lymphoid tissue. The process of platelet formation is not
fully understood, but it is known to start with megakaryocytes responding to throm-
bopoeitin produced in the liver (Kuter, 1996). Upon stimulation by thrombopoietin,
megakaryocytes generate the organelles needed to form platelets within their matrix.
The megakaryocytes extend long processes known as ‘proplatelets’ through the cell
wall of the bone marrow into capillaries that lie alongside the marrow (Machlus &
Italiano, 2013). Internal cellular structures are assembled within the megakaryocytes
and along the proplatelets to carry the component parts needed for platelet formation
to the tip of the structure. In response to shear forces within blood vessels, these pro-
platelets break off into the blood circulation (Geddis, 2009). These are then known
as preplatelets. Preplatelets are barbell shaped and once within the blood, they split
to become two platelets. The exact cause of proplatelet formation is unknown, but
it is believed that megakaryocyte migration during proplatelet formation is driven by
differences in chemical gradients between the osteoblastic and vascular niches.
The process of platelet production is believed to happen in locations all over the
body but there is evidence to suggest that the lungs may be the site of particular sig-
nificance. Megakaryocytes are found at higher concentration in central venous arteries
compared to peripheral arteries. Higher platelet counts are found in post-pulmonary
blood vessels compared to pre-pulmonary (Zucker-Franklin & Philipp, 2000). Rat mod-
els with lung damage were found to have decreased platelet counts (Xiao da et al., 2006).
There is also evidence from human studies to support this hypothesis. Low platelet
count (thrombocytopenia) is common in patients with lung disease, with the degree of
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reduction correlating to the severity of disease (Xiao da et al., 2006) and thrombocytosis
has been identified as an early marker of lung cancer (Hamilton et al., 2005a).
Thrombopoeitin is the strongest influence on thrombopoiesis. Knockout of throm-
bopoeitin or thrombopoeitin cell surface receptors on megakaryocytes leads to low levels
of platelets, but does not eliminate them altogether (Kaushansky, 2005). This suggests
that although thrombopoeitin is a strong mediator of platelet production, it is not the
only influencing factor. Up to 60% of thrombopoeitin is produced in parenchymal cells
in the liver, but it is also produced in the kidneys and in bone marrow. The produc-
tion of thrombopoeitin is strongly influenced by interleukin-6 (IL-6), the number of
circulating platelets in the blood, and other factors (Kaushansky, 2005). IL-6 is an
inflammatory cytokine which has been linked to malignancy (summarised in Schafer &
Brugge (2007)); IL-6 is released by tumours in a number of cancer types including lung
(Gao et al., 2007), colorectal (Waldner et al., 2012), and ovarian (Offner et al., 1995).
IL-6 has been linked to tumour stem cell renewal (Sansone et al., 2007), and elevated
levels of IL-6 are associated with poorer prognosis in several types of cancer including
myeloma, lymphoma, ovarian, prostate, and renal. (Hong et al., 2007)
2.2.3 Thrombocytosis
Thrombocytosis is a condition in which the platelet count exceeds the normal range
(> 400 × 109/L). Thrombocytosis can be classified as primary or secondary; primary
thrombocytosis occurs as a result of a genetic or myoproliferative disorders, whereas
secondary or reactive thrombocytosis occurs as a result of another underlying condition
(Schafer, 2002). Most commonly, thrombocytosis is secondary in response to another
underlying disorder. These disorders include anaemia, acute blood loss, inflammatory
and infectious conditions, and recovery from low platelet count. A platelet count of
over 1, 000× 109/L is usually associated with primary thrombocytosis; commonly my-
oproliferative disorders or splenectomy (Griesshammer et al., 1999).
2.2.4 Diagnosing thrombocytosis
Thrombocytosis is rarely a diagnosis in itself but is more commonly used as an indica-
tor of underlying disease. The platelet count is one component of the full blood count
(FBC); this involves the measurement of red blood cell numbers and cellular charac-
teristics, white blood cells, and platelets in the blood (Cancer Research UK, 2015a).
Clinically, such blood tests are carried out for a wide range of reasons, either to aid with
diagnosis or routinely to check general health. The platelet count per se is rarely used
to diagnose an underlying disease in practice but can be used with other symptoms and
test results to determine the likelihood of a disease being present. Blood tests are rarely
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carried out with the sole intention of measuring platelet count, and thrombocytosis is
often discovered as an incidental finding (Bleeker & Hogan, 2011; Khan et al., 2009).
2.2.5 Evidence supporting a link between thrombocytosis and cancer
The link between platelet count and cancer has long been acknowledged (Levin &
Conley, 1964). In this early study, Levin and Conley examined 82 patients with throm-
bocytosis within a hospital setting (already selected for investigation) and found that
31 (38%) had an underlying cancer. They subsequently examined platelet counts in
268 patients with cancer of any type, and found that 40% had thrombocytosis. A
number of primary and secondary care-based studies have found evidence to support
this link, although few studies have investigated thrombocytosis as a predictor of can-
cer, and only some cancer sites have been studied. In secondary care, thrombocytosis
is an established marker of poor cancer prognosis, although the relationship between
thrombocytosis and prognosis varies by cancer site (Hauser et al., 2006). There is also
a range of research exploring the biological theories for the processes that underlie
the thrombocytosis-cancer association. The three key bodies of evidence from primary
care, secondary care, and biological studies are summarised here.
1. Evidence from primary care studies
A number of case-control studies have aimed to identify the early markers of certain
types of cancer and to quantify the risk of cancer in patients with these markers,
to enable general practitioners to direct patients to appropriate investigative services.
In these studies, ‘early markers’ are defined as symptoms that patients subsequently
diagnosed with cancer report to their GP in the year prior to their cancer diagnosis.
The systematic review presented in Chapter 3 of this thesis found four matched case-
control studies that had identified thrombocytosis as a significant predictor of cancer
in multivariable models. (Hamilton et al., 2005a,b; Shephard et al., 2013; Walker et al.,
2013). A further four studies were identified in which thrombocytosis did not predict
cancer (Hamilton, 2009; Stapley et al., 2012, 2013; Walker et al., 2014). One study
had collected platelet count data but did not include thrombocytosis in any analysis,
as was present in less than 5% of bladder cancer cases (Shephard et al., 2012). Only
features present in more than 5% of cases were included in the analysis in that study.
A study in 2012 examined paraneoplastic thrombocytosis in 619 patients with ovar-
ian cancer (here, thrombocytosis was defined as a platelet count over 450 × 109/L)
(Stone et al., 2012). Although that study was set in secondary care, it reported that
31% of patients had thrombocytosis at the time they were diagnosed. The median
platelet count was 542 × 109/L in patients with thrombocytosis, and 318 × 109/L in
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patients without thrombocytosis. Patients with ovarian cancer and thrombocytosis
also had shorter survival and more advanced disease at diagnosis than those with-
out thrombocytosis. Stone et al. (2012) also investigated the mechanisms underlying
the association between platelets and ovarian cancer using mouse models. Evidence
presented in the same study points to excess tumour-derived IL-6 promoting throm-
bopoeitin production, which in turn increases platelet production and number which
supports tumour growth and development.
2. Evidence from secondary care studies
Although evidence of a post-diagnosis association between platelet count and cancer
is of little use in judging the value of thrombocytosis in detecting malignancy, it does
strengthen the theory that a link between cancer and platelet count exists. It can also
be useful to determine which cancer sites may be linked with thrombocytosis, and which
may not. Thrombocytosis has been found to be a marker of poor prognosis in several
cancers (Buergy et al., 2012) including gastrointestinal (Ikeda et al., 2002; Voutsadakis,
2014), lung (Aoe et al., 2004; Pedersen & Milman, 1996), ovarian (Allensworth et al.,
2013; Stone et al., 2012), endometrial (Gu¨cer et al., 1998; Njølstad et al., 2013), bladder
(Todenho¨fer et al., 2012), and renal (Suppiah et al., 2006) cancers.
The study by Pedersen & Milman (1996), although set in secondary care, examined
126 patients who were admitted for further investigation for cancer following an abnor-
mal chest x-ray. Thrombocytosis was observed in 35 of 61 patients (57%) who went on
to be diagnosed with lung cancer and only 5 of 65 patients (8%) who did not.
A study in 1972 examined the clinical utility of thrombocytosis in predicting malig-
nancy in 100 consecutive patients of any age (60 female and 40 male) seen in hospital
for a variety of reasons (Davis & Mendez Ross, 1972). In this study, thrombocytosis
was defined as a platelet count of > 500 × 109/L. 36 of 100 patients with thrombo-
cytosis (36%) were found to have cancer; the most commonly diagnosed types were
ovarian (n = 7), lymphoma (n = 7), breast (n = 5), lung (n = 4), and colon (n = 4).
The secondary care setting of this study, in which patients have already been selected
for investigation, means that a greater proportion of patients are likely to have cancer
than in the primary care population. Patients are also more likely to have another
condition which would mean that thrombocytosis is an expected finding. In this sam-
ple, there were 19 such patients; either post-surgery or post-splenectomy, and a further
eight with myoproliferative disorders. Therefore, thrombocytosis could be considered
‘unexpected’ in the remaining 75 patients. All 36 cancers were in this subgroup; so the
cancer incidence in patients with unexpected thrombocytosis was 48%.
A cross-sectional survey of 1,007 patients enrolled in the Vermont Diabetes Informa-
tion System investigated the association between anti-platelet drug use and history of
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cancer (Holmes et al., 2010). 50% of included patients were using anti-platelet drugs;
these were associated with a significant reduction in self-reported cancer diagnoses
(odds ratio 0.66, 95% CI 0.44-0.99; p = 0.045). This model was adjusted for age, sex,
body mass index, co-morbidities, and other medications. Although self-reported data
are considered low quality evidence, this supports the theory of a relationship between
cancer and platelets as anti-platelet drugs appeared to have an anti-cancer effect, in
patients with diabetes. This study did not distinguish between type I and type II
diabetes, diagnoses were unconfirmed, and there were no data on cancer site.
3. Evidence from biological studies
Despite the large body of evidence from primary and secondary care studies supporting
the theory of a relationship between platelets and cancer, the exact mechanisms perpe-
trating the association is unknown. There are three main theories that could explain
the relationship (Buergy et al., 2012):
 Platelets augment tumour growth
 Platelets promote tumour metastasis
 Tumour enhances platelet production
The first two of these theories are supported by findings from secondary care studies
showing that thrombocytosis is associated with poorer survival outcomes in patients
diagnosed with cancer. They imply that a raised platelet count is occurring indepen-
dently of cancer and promoting its development. The last of the three is strongly
supported by findings from primary care studies that thrombocytosis is a marker of an
undiagnosed cancer; it implies that the malignancy precedes and causes the subsequent
rise in platelet count, whether directly or indirectly. In a review published in 2012,
Buergy et al. (2012) present these three theories and suggest that all are likely to be
occurring in a cancer patient in a cycle of platelet production and cancer development.
The evidence supporting each of these theories is summarised below.
Platelets augment tumour growth:
The process of platelet production involves a number of cells and factors acting in cas-
cade (Deutsch & Tomer, 2006), described in brief earlier in this chapter, throughout
which platelets secrete various cytokines. This theory purports that thrombocytosis
occurs independently of cancer in response to another condition, and that proangio-
genic cytokines secreted by platelets as part of the body’s response to that condition
promote the development of blood vessels in the growing tumour (Jain et al., 2010).
Therefore, patients with independently occurring thrombocytosis and cancer will have
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poorer prognosis as their high number of circulating activated platelets promotes cancer
development and hastens disease progression (Buergy et al., 2012).
Platelets promote tumour metastasis
Similarly, in this second theory, another unrelated condition independent of malignancy
is causing thrombocytosis in patients with cancer. There are three ways platelets could
be promoting metastasis: 1) by protecting and stabilising circulating tumour cells
from the body’s immune response (Borsig et al., 2001); 2) by stimulating tumour cell
proliferation (Buergy et al., 2012); 3) by promoting tumour cell angiogenesis (Gay &
Felding-Habermann, 2011). This theory is supported by evidence of thrombocytosis
being associated with metastases and more advanced disease in secondary care studies
(Yu et al., 2015).
Tumour enhances platelet production
This theory suggests that tumours secrete a number of factors which interfere with
and promote platelet production. The primary factor believed to be involved in this
is interleukin-6 (IL-6), which is involved in inflammatory processes and platelet pro-
duction (Scheller et al., 2011). As described earlier in this introduction, the primary
mediator of platelet production is thrombopoietin; although this is not directly pro-
duced by tumour cells, its production is mediated by a number of cytokines that include
IL-6 (Kaser et al., 2001). Elevated IL-6 levels have been found in a number of can-
cers including gastro-intestinal (De Vita et al., 2001), renal (Blay et al., 1992), prostate
(Nakashima et al., 2000), ovarian (Plante et al., 1994), and lung (Takeuchi et al., 1996).
Elevated IL-6 has also been found to be associated with poorer outcomes and later dis-
ease stage in cancer patients (Hong et al., 2007), but it is not clear whether this is a
direct effect or mediated by increased platelet count.
2.2.6 Platelet activation in cancer
As described previously, platelets circulate in the blood in an inactive state, and are
activated in response to various stimuli. The platelet membrane contains glycoprotein
receptors which, when stimulated, result in the activation and aggregation of platelets,
usually in response to tissue or blood vessel damage. Several studies have found ad-
vanced cancer patients to have increased levels of activated platelets in their circulation
(Boneu et al., 1984). Mechanisms of tumour-related platelet activation are likely to in-
volve tumour-derived thrombin, which stimulates tumour cell growth in addition to
platelet activation; adenosine diphosphate, another tumour-derived factor which ac-
tivates platelets; and direct activation of platelets through contact with tumour cell
surface. Interestingly, thrombocytosis has been found to decline following solid tumour
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resection (Nash et al., 2002) lending further evidence to the theory that solid tumours
increase platelet production.
2.2.7 Section summary
In the first section of this chapter, platelet production and function were described
and the background evidence from primary care, secondary care, and biological studies
supporting a link between platelet count and cancer has been presented. Evidence from
primary care is promising but insufficient to draw conclusions about the nature of the
relationship in a clinical setting; no studies have fully investigated the significance of
the relationship for all cancer sites, or investigated how the relationship might vary
with age, sex, or other factors. It is here that this PhD aims to contribute to the body
of knowledge and have clinical utility. Secondary care evidence, although prognostic
rather than diagnostic, clearly supports a link between platelet count and cancer, as
does the evidence from biological studies. From a biological perspective, there is still
insufficient evidence to support a single unifying theory of the processes mediating the
association between platelet count and cancer; it is possible that elements of each of
the proposed theories could be correct.
2.3 Cancer burden and cancer diagnosis in the UK
In the second section of this chapter, the burden of cancer in the UK is evaluated
in terms of incidence, survival, and mortality. UK cancer outcomes are compared to
those in other countries, and the reasons for differences are explored. The diagnostic
and primary care factors influencing cancer outcomes in the UK are discussed, and the
causes of delays in the diagnostic process are examined. This section also considers
where the work presented in this thesis fits in and potentially advances the area.
2.3.1 UK cancer incidence
Cancer incidence statistics in the UK are compiled by the Office of National Statistics,
Cancer Research UK, the Welsh Cancer Intelligence and Surveillance Unit, and the
Information Services Division in Scotland. Since the late 1970s, cancer incidence has
risen steadily in England - by 35% in females and by 15% in males. Similar figures are
seen in Wales and Scotland; between 2004 and 2013 cancer incidence increased 12%
in Wales. There were 352,000 newly registered cancer diagnoses in England, 19,000 in
Wales, and 42,000 in Scotland in 2013 (Cancer Research UK, 2014b; Information Ser-
vices Division Scotland, 2014; Welsh Cancer Intelligence and Surveillance Unit, 2014).
Across all three regions, the greatest incidence is in adults in their late 60s and early
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70s. Although an overall increase in cancer incidence is evident throughout the UK, the
change in incidence varies considerably by the type of cancer diagnosed; for example,
breast cancer incidence has risen 9% in the last decade in Scotland (although this could
be an artefact of increased screening), whereas prostate cancer incidence has remained
constant in the same time period. Lung cancer incidence in males has decreased in
the last decade by 15%, whereas it increased in females in the same time period by
13%; this may reflect changes in the epidemiology of smoking during this time. The
four most commonly diagnosed cancers, accounting for around a half of all new cases
in the UK, are breast, prostate, lung, and colorectal cancer. In Scotland, the incidence
of these types of cancer have decreased 4% for men and increased 7% for women in the
last decade.
Changes in cancer incidence over time also vary by age and sex: the greatest in-
creases in incidence over the last ten years are in adults aged 65-74 years, and the
age-specific cancer incidence increases more sharply in men than in women in those
aged 70 years and over. In this age group, incidence rates are over 50% higher in men
than in women. In England, the majority of new cancer cases recorded between 2011
and 2013 were diagnosed in those aged 50-74 years, but the greatest incidence is still
in those aged over 75 years. This is partly due to age being a risk factor for cancer,
and partly due to the larger number of people in this age group.
The steady increases in cancer incidence observed over the last few decades can
be attributed to several factors; although there has been an increase in risk factors
associated with cancer such as alcohol consumption and obesity, there is also greater
awareness of early cancer symptoms and uptake of screening programmes in the general
public due to public health campaigns, and a decrease in smoking.
2.3.2 UK cancer mortality and survival
Cancer of any kind is still the leading cause of death in England and Wales (Office of
National Statistics, 2015) although in the last decade, the number of deaths attributed
to cancer in England has fallen by about 10%. In 2013, there were approximately
160,000 deaths from cancer; the four most common cancers (breast, prostate, colorectal,
and lung) account for around half of these. Three quarters of cancer deaths were in
those aged 65 and over (Cancer Research UK, 2014b). In Wales, cancer mortality is
similar for men and women up to the ages of 55 to 59 years, after which it is greater
in men than in women (Welsh Cancer Intelligence and Surveillance Unit, 2014). There
were around 15,000 deaths from cancer in Scotland in 2014, and lung cancer accounted
for around a quarter of these (Information Services Division Scotland, 2014). Mortality
has decreased in Scotland in the last ten years in men (14.9% decrease) and women
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(5.7% decrease). Most types of cancer show a decrease in mortality in recent years,
with the exception of liver cancer, for which mortality has increased 42% in males and
44% in women in the last decade.
Overall, improvements in cancer survival have outweighed increases in incidence
and this means that, for most cancers, mortality is improving. In England, survival for
all types of cancer has doubled in the last decade, and in 2014 the ten year survival rate
was 50%. Although survival is improving year on year, there is still a discrepancy in
survival between different cancer types. For men, this ranges from a ten year survival
rate of 1% for pancreatic cancer to 98% for testicular cancer. Survival is generally
higher in women than in men, and mostly poorer with older age, although the four
most common types of cancer have their best survival rates in middle aged adults
(Cancer Research UK, 2014a). Survival has also shown a consistent improvement over
the last decade in Wales, and is also higher in women than in men in this principality.
In Scotland, survival is also increasing; all cancer five year survival based on data from
2007 to 2011 is 54% for women and 48% for men. Here, pancreatic cancer has the
poorest survival (3.6% in men and 5.5% in women) but at the other end of the scale,
testicular cancer has a 93% five year survival rate.
2.3.3 Comparing UK cancer survival to other countries
Whilst UK cancer survival is improving, data from the EUROCARE studies shows that
there are still substantial differences in survival rates between the UK and the rest of
Europe, with the UK performing poorly (Berrino et al., 2007; De Angelis et al., 2013;
Quaresma et al., 2015; Thomson & Forman, 2009; Walters et al., 2015).
The International Cancer Benchmarking Partnership (ICBP) (Butler et al., 2013)
was established between Australia, Canada, Denmark, Norway, Sweden, and the UK
to estimate survival trends for selected types of cancer, and to investigate the causes of
differences in these rates between countries. The ICBP has five modules: epidemiology;
population awareness and beliefs; beliefs, behaviours and systems in primary care; root
cause of treatment and diagnosis delays; and exploration of early deaths.
The first publication from the ICBP in 2011 reported on population-based trends
in survival for colorectal, lung, breast, and ovarian cancer between 1995 and 2007. The
study found that, although there were improvements in survival in all countries during
this time, the one year survival for lung, colorectal, and ovarian cancer was consistently
poorer in the UK and Denmark compared to the other included countries (Coleman
et al., 2011). Although surgical and treatment differences were considered as potential
causes of this variance, the paper concluded that late stage diagnosis in the UK and
Denmark compared to the other countries was the root cause of much of the variation.
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An updated comparison of cancer survival in England and Australia, Canada, Norway,
and Sweden was published four years later (Walters et al., 2015). This study found that,
although survival in England improved from 1999-2005, it was still lower than in the
other countries included in the study. Abdel-Rahman et al. (2009) used EUROCARE
data to estimate the avoidable premature cancer mortality in the UK as a result of
poorer survival in this country compared to better survival rates seen in Europe. The
study estimated that 6-7% of cancer mortality in the UK is ‘avoidable’ in the sense that
it would not exist if UK survival was as good as the best in Europe. Richards (2009)
estimated that at least 5,000 deaths within five years of a cancer diagnosis could be
prevented annually in England with better diagnostic and treatment services.
Differences in data reporting may account for some of the variation between coun-
tries (Butler et al., 2006) but the main factors identified as reasons for the differences in
survival are differences in patient awareness and attitudes (Forbes et al., 2013); primary
care (Rose et al., 2015); and stage-related differences (Maringe et al., 2012, 2013; Wal-
ters et al., 2013a,b). Lung and colorectal cancer, for example, are generally diagnosed
at a later stage in the UK than in the rest of Europe and their survival is generally
poorer. Although we cannot infer causation from this correlation, this along with other
evidence presented here strongly suggests a link between the stage at which cancer is
diagnosed and patient survival.
Overall, later stage diagnosis in the UK is believed to be one of the key contributory
factors to poor disease outcomes. Reducing the interval from symptom reporting to
diagnosis is generally accepted to be a key strategy to identify cancers at an earlier stage
of disease progression, which in turn should result in better outcomes, achieving the
ultimate aim of reduced premature cancer mortality and improved survival. However,
the evidence base to support these ideas is varied and dominated by observational study
design. Differences in how studies define and measure delay and outcomes, combined
with differences in how types of cancers act (both different sites and different cancers
within the same primary site) can make it difficult to compare and contrast different
studies.
2.4 Primary care cancer diagnosis in the UK
As the majority of cancers are diagnosed in patients who present to their general
practitioners (GP) with symptoms, primary care is a crucial setting for diagnosing
cancer. In the UK, 98% of the population are registered with a NHS primary care
practice. GPs are the first point of contact for most health issues and act as gatekeepers
to secondary care services, accessed through referrals. Each patient has an individual
electronic medical record and a unique NHS identification number. Patient data are
17
2. Thesis background
routinely collected in practice, including consultations with GPs, signs and symptoms
of disease, tests and immunisations and any prescribed medications. Data on diagnoses
and treatments are fed back to practices from secondary care.
In a retrospective analysis of primary care consultations, the crude annual consul-
tation rate per person was found to be 5.16 consultations per year (Hobbs et al., 2016).
Consultation rates were found to increase with age, and generally women consulted
more often than men. Independently calculated ratios using data presented in Hobbs
et al. (2016) show that the male to female consulting ratio increases from 0.71 in those
aged 45 to 64 years to 0.93 in those aged 65 to 74 years; 0.96 in those aged 75 to 84
years; and 1.01 in those aged 85 years and over. This is supported by a cohort study
from 2013 which examined gender differences in consulting and found that the crude
consultation rate was 32% lower in men compared to women of all ages, but the con-
sultation rate was more similar between men and women in older age. In those aged
40 to 57 years, the rate ratio of male to female consultations was 0.62 (0.62-0.63) and
in patients aged over 58 years, the rate ratio narrowed to 0.92 (0.91-0.93) (Wang et al.,
2013).
2.4.1 The difficulties of diagnosing cancer in primary care
Although the majority of cancers are diagnosed in this setting, cancer is still a relatively
rare diagnosis for a general practitioner. Identifying symptomatic cancer is difficult be-
cause even the most well-known ‘alarm’ symptoms have low relative predictive values
and are most likely to be caused by benign disease. Most cancer symptoms are vague,
such as feeling tired or weight loss. For GPs, identifying which patients have undiag-
nosed cancer from vague, common symptoms is a challenge. Identifying the symptoms,
or combination of symptoms, that are most likely to be indicative of underlying malig-
nancy can aid GPs in deciding which patients to refer to further investigation.
2.4.2 Policy and guidance for diagnosing cancer in general practice
In the UK, the guidance underlying the investigation and diagnosis of suspected cancer
in primary care is developed by the National Institute for Health and Care Excellence
(NICE). The current version of the guidance (Suspected cancer: recognition and refer-
ral, NG12), an update of the 2005 version, was published in 2015. The evidence-based
recommendations advise clinicians on the appropriate course of action depending on
the patient’s symptoms; any patient with a symptom profile with a greater than 3%
chance of cancer is to be referred for further investigation (NICE, 2015).
The Department of Health’s Cancer Reform Strategy (2007) stated that more work
was needed to enable earlier diagnosis in symptomatic patients, as a key strategy to
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improve cancer outcomes in the UK and bring them in line with cancer survival in
other countries. The National Awareness and Early Diagnosis Initiative (NAEDI) was
launched by the UK Department of Health and the charity Cancer Research UK in 2008
in response to the Cancer Reform Strategy, with the aim of improving earlier diagnosis
of cancer through the coordination and support of activities and research to improve
survival and reduce mortality (Richards, 2009). In 2011, the Department of Health’s
‘Improving outcomes: a strategy for cancer’ policy stated that avoidable deaths from
cancer in the UK would be prevented ‘mainly through earlier diagnosis’ (Department
of Health, 2011).
The NAEDI pathway shows factors that influence cancer outcomes and survival.
Any one of these features can result in a delay in the pathway to diagnosis (Hiom,
2015) (see Figure 2.1). The work presented in this thesis aims to influence and improve
the ‘delays in primary care interval’ box (2); the interval between patients presenting
to their GP and being referred to hospital services for diagnostics, by identifying a new
risk marker of cancer that could prompt GPs to suspect cancer (and so refer) sooner.
The primary care interval forms part of the diagnostic interval; the time from first
symptomatic presentation of the patient to diagnosis (Weller et al., 2012).
2.4.3 Is earlier diagnosis better?
Earlier diagnosis is hailed as the key to improving cancer outcomes for the UK, through
the identification of cancers at an earlier and therefore more treatable disease stage.
Earlier diagnosis is sometimes used interchangeably to mean either diagnosing cancer
at an earlier stage in the progression of the disease, or to mean a shorter diagnostic
interval (shorter time from first symptomatic presentation of the patient to diagnosis).
The evidence for whether earlier diagnosis is better within each of these two contexts
is summarised below.
2.4.3.1 Earlier diagnosis: earlier disease stage
Previous research has examined the causes of delays in diagnosis and developed strate-
gies to promote earlier diagnosis. It is generally assumed that diagnosis at an earlier
stage will improve cancer outcomes. However, the evidence supporting this assump-
tion is mixed, and there are potential harms from earlier diagnosis which should be
considered. It can be difficult to separate the true effects of earlier diagnosis from con-
founding and bias; particularly symptom lead time bias (whereby patients diagnosed
with symptoms at an earlier stage appear to have greater survival time because of the
earlier diagnosis date; they may not actually survive longer than they would have if
they had been diagnosed later).
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Figure 2.1: Factors influencing cancer survival and premature mortality (Hiom,
2015).
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Studies that have investigated the causes of poorer cancer outcomes in the UK com-
pared to the rest of Europe (described above) have concluded that late stage diagnosis
is one important contributing factor. Certainly, late stage diagnosis is associated with
poorer outcomes, and there is evidence to suggest that lower rates of investigation for
cancer result in poorer survival: Møller et al. (2015) found low use of urgent referral
pathways in GP practices to be associated with increased risk of death in cancer pa-
tients (hazard ratio 1.07; 95% CI 1.05-1.08). A survey of GPs in countries involved in
the ICPB found increased diagnostics to be associated with better outcomes; there was
strong correlation between readiness to investigate for cancer and cancer survival rates
(Rose et al., 2015). Although there could be other explanations for this association,
such as greater cancer awareness in GPs who investigate more often, or the influence
of ascertainment bias (as the population under study is not representative of the gen-
eral population, being at greater risk of disease), overall there is strong evidence that
greater investigation for suspected cancer is associated with better survival. Localised,
smaller, earlier stage cancers are easier (and less expensive) (Insicive Health, 2014) to
treat than more advanced disease. Patients want earlier diagnosis (and want investi-
gation for cancer at lower risk thresholds when faced with hypothetical situations), as
do other stakeholders including the government and the media (Banks et al., 2014).
There are harms associated with later diagnosis; poorer survival and prognosis, greater
morbidity from the disease and from treatment, and greater psychological trauma for
patients and their families.
However, there are other considerations which mean that earlier diagnosis may
not always be better. Earlier diagnosis could result in the identification of small, slow-
developing cancers that may not have caused any additional morbidity or mortality over
the patient’s life course (this is known as over-diagnosis) (Marcus et al., 2015). This will
however result in the patient being subjected to otherwise unnecessary treatment. It is
not always clear whether survival actually improves with earlier diagnosis or whether
improved survival time is an artefact of symptom lead time bias. The issue is further
confused by the fact that more aggressive, late stage cancers presenting with clearly
identifiable symptoms will often have a very short diagnostic interval, and have poor
outcomes and short survival time; this is known as the waiting time paradox, defined
by Crawford et al. (2002).
2.4.3.2 Earlier diagnosis: shorter diagnostic interval
The previous section described earlier diagnosis in terms of aiming to diagnose patients
at an earlier disease stage. Earlier diagnosis can also refer to a diagnosis happening
more quickly after symptomatic presentation, reducing the time known as the diagnostic
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interval. The diagnostic interval is closely related to stage at diagnosis and also has
an impact on cancer outcomes. It could be assumed that a shorter diagnostic interval,
and therefore shorter time to treatment, would mean better survival but the evidence
surrounding this issue is mixed.
In a cohort study in 2002, the relationship between treatment delay and survival
was explored for 703 women with endometrial cancer (Crawford et al., 2002). The
study found delayed time to treatment to be inversely related to survival; patients with
the longest wait for surgical treatment survived significantly longer than those with a
shorter time to wait. This may be the result of more serious, advanced disease cases
being prioritised for treatment over less serious cases. Although this study focusses
on the time from GP referral to surgical treatment, the concept of the waiting time
paradox has been applied in other studies. Rupassara et al. (2006) studied this effect
further in 154 patients with colorectal cancer. In this study, the interval of interest
was the time from GP referral to a diagnosis of cancer being made. In a stratified
analysis, 44 patients with a longer diagnostic interval (more than or equal to 50 days
from referral to diagnosis) had a 93.7% 5-year survival rate; 110 patients with a shorter
diagnostic interval (less than 50 days from referral to diagnosis) had a 5-year survival
rate of 65.3%. The longer diagnostic interval group also had smaller tumours, more
low-risk symptoms, and more early stage disease than patients with a shorter diagnostic
interval.
2.4.3.3 The association between diagnostic interval and cancer outcomes
The relationship between longer diagnostic interval and poorer cancer outcomes has
been investigated in a number of observational studies. It can be difficult to compare or
combine results from studies of this type due to heterogeneity in measures of ‘diagnostic
interval’; in a systematic review of diagnostic intervals discussed later in this section,
15 different definitions for diagnostic interval were used in 177 articles. Studies also
use varying measures of outcomes.
Neal et al. (2015) carried out a systematic review to assess the evidence for whether a
more timely diagnosis improves cancer outcomes. Of the 1,036 full text papers assessed
for inclusion, 177 articles were included in their narrative synthesis, which reported on
209 studies. They found that only seven of these addressed the waiting time paradox
(described by Crawford et al. (2002)). 28 different cancer sites were investigated by
the included papers, and 15 different time intervals were described as the ‘diagnostic
interval’. The methodology of the included papers was too heterogeneous for meta-
analysis.
The results from the included studies were mixed, and there was variation in the
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methodological quality. Even within specific types of cancer the authors found contra-
dictory evidence about whether a shorter diagnostic interval had no effect on survival,
improved survival, or in some cases decreased survival. An extensive analysis of the
findings is presented in the original publication; the results for the four most common
cancers are summarised here. For lung cancer, studies supporting a positive association
between diagnostic interval and outcomes (shorter interval meaning better outcomes),
no association, and a negative association (shorter interval meaning poorer outcomes)
were found. Only one of these accounted for the waiting time paradox in the analysis;
in that study, a positive association was found. For colorectal cancer, more studies
showing a positive association than a negative association were found. Three of the
four colorectal cancer studies that accounted for the waiting time paradox had found a
positive association. For breast cancer, all included studies reported either a positive
association, or no association. For prostate cancer, two studies reported a positive
association (one of which accounted for the waiting time paradox) and the remaining
four found no association. There was also strong evidence for benefits of a shorter
diagnostic interval for head and neck, testicular, and melanoma. To a lesser extent,
the same was also true for pancreatic and bladder cancer. Of the seven studies that
had taken the waiting time paradox into consideration, most reported poorer outcomes
associated with shorter diagnostic intervals.
Overall, this systematic review concluded that it is ‘reasonable to assume’ that
shorter diagnostic intervals are associated with better survival, reduced mortality, and
improved outcomes. This takes into account the effects of late stage disease with symp-
toms very strongly suggestive of cancer having short diagnostic intervals and poor out-
comes. The methodological heterogeneity makes it difficult to sum or directly compare
papers, but the recently published Aarhus statement which promotes greater precision
and transparency in definitions and methods in early diagnosis research should mean
that this improves with time (Weller et al., 2012). Aside from the effects on outcomes,
shorter diagnostic intervals are also desirable as patients and other stakeholders want
quicker diagnosis (Banks et al., 2014), and earlier stage cancers are easier and less
expensive to treat (Insicive Health, 2014).
2.4.3.4 What factors contribute to delays in diagnosis?
The process of diagnosing cancer is complex and multi-factorial and there are many
potential causes of delay throughout the process (see the NAEDI pathway discussed in
Section 2.4.2); these fit in to three broad areas: the patient interval (delay in presenting
to primary care); the primary care interval (delay in diagnosis); and the secondary care
interval (delays to treatment). Delays at any of these stages can result in poorer
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outcomes, and delays in the patient and primary care intervals can contribute to delays
in diagnosis.
Within primary care, missed opportunities to diagnose can result in longer diag-
nostic intervals, longer time to treatment, and potentially later stage diagnosis (Lyrat-
zopoulos et al., 2015). A missed opportunity occurs when an alternative course of
action would have resulted in the diagnosis being made sooner (McGlynn et al., 2015).
Missed opportunities for diagnosis often result in repeated primary care consultations
all cause delay and increase the primary care interval; an increased number of consulta-
tions in primary care is associated with a longer primary care interval (Lyratzopoulos
et al., 2013), although not all of these consultations will reflect missed opportunities.
Lyratzopoulos et al. (2013) found that one in five patients diagnosed with cancer con-
sulted their GP ≥ 3 times before being referred; this varied by type of cancer from
7.4% of breast cancer patients to 50.6% of multiple myeloma patients. This study did
not examine whether patients with more pre-referral consultations were diagnosed at
a later disease stage, or had poorer survival.
2.4.4 Where does thrombocytosis fit in?
Thrombocytosis may have the potential to contribute to the earlier diagnosis of cancer
and a reduction in diagnostic delay by prompting GPs to consider a cancer diagnosis
earlier. This could be particularly useful in cases where multiple pre-referral consulta-
tions occur due to vague symptoms; one of the objectives of this thesis is to investigate
the risk of cancer in patients who report symptoms in addition to thrombocytosis; two
vague symptoms, weight loss and loss of appetite, are included as part of this. As
thrombocytosis is often an incidental finding, one which is reported as part of a full
blood count but rarely tested for for its own sake, the discovery and promotion of
thrombocytosis as a previously unknown risk marker of cancer could prompt clinicians
to investigate where they otherwise might not have done until the patient’s symptoms
worsened; this could take more time and repeated consultations. The patients who
have the most potential for improvements to their cancer outcomes as a result of the
recognition of thrombocytosis as a risk marker of cancer are those whose platelet counts
are elevated at an early disease stage, and who do not have any classic alarm symptoms
of cancer or do not have symptoms that match NICE guidance for urgent referral. The
proportion of cancer patients who could fall in to this category is explored in this thesis.
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2.5 Data sources used in this thesis
The final section of this introductory chapter describes the two data sources used in
the thesis; the Clinical Practice Research Datalink (CPRD) and the English cancer
registry.
2.5.1 The Clinical Practice Research Datalink (CPRD)
The CPRD is a government-funded organisation which collates anonymised electronic
patient records into a longitudinal dataset for research purposes. It was founded in Lon-
don in 1987 as the Value Added Medical Products dataset, which expanded to become
the General Practice Research Database (GPRD) in 1993, and later the Clinical Prac-
tice Research Datalink (CPRD) in 2012. As of 2016, 674 UK practices were registered
with the CPRD, contributing over 11.4 million patient records, a representative sample
of around 8% of the UK population. 4.4 million patients in the database are ‘active’
(alive and currently registered with a CPRD practice) (Boggon et al., 2013). Individual
primary care practices register with the CPRD and all patient records from that prac-
tice contribute to the CPRD, unless patients individually opt out. Patient records are
updated monthly, and are subject to strict quality control procedures (Herrett et al.,
2010). Practices contributing to the CPRD must follow set recording guidelines which
outline precisely how to record patient events. Data quality is monitored at two levels;
at practice level (with the practice required to meet certain data recording standards)
and at patient level (with internal consistency required for sex, age, event recording,
and registration details) (Khan et al., 2010). All patients’ consultations, laboratory
results, and referrals are dated and coded with an internal coding system, mapped to
the Read codes used in clinical practice (Williams et al., 2012). Read codes are a stan-
dard set of coded medical terms used in the UK to record patient symptoms, diagnoses,
findings and procedures (Booth, 1994). The observational data provided by the CPRD
have been used for a wide range of studies.
2.5.2 Accuracy and validity of CPRD data
Despite the stringent quality controls, it cannot be overlooked that CPRD data are
primarily recorded in practice for clinical use, not for research purposes, and therefore it
is important to consider the quality of the data and their limitations for use in research.
Some elements of the dataset, such as blood test results, have a high degree of accuracy
due to being electronically transmitted to patient records directly from the laboratory.
The accuracy of patient symptoms and diagnoses, recorded during consultations with
GPs and retrospectively by practice staff, is subject to greater uncertainty.
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A number of studies have aimed to assess the validity of the coded data in the
CPRD, and these were recently summarised in a systematic review (Khan et al., 2010).
The authors carried out a comprehensive literature search of six bibliographies, which
found 40 studies that had assessed the accuracy of data recording in the CPRD, and 12
that had evaluated the completeness of data recording. Studies that had assessed data
accuracy compared CPRD diagnostic coding to a ‘gold standard’; either a questionnaire
to GPs (n = 19), comparison to hospital letters or records (n = 16) or both (n = 5).
The systematic review found that the diagnostic accuracy of CPRD coding has been
assessed for a range of acute and chronic conditions. The accuracy of CPRD coding
was reported as the positive predictive value (PPV) of a code for a true diagnosis. The
PPV varied dramatically between studies from 16.5% for acute liver injury to 100%
for coarctation of the aorta, pressure ulcer, and non-organic psychosis. The majority
of the 51 conditions assessed by the included papers had a PPV of over 50%, with 32
having a PPV of over 80%. The review did not find any studies that had assessed the
validity of cancer diagnosis recording in the CPRD. The accuracy of the date of diag-
nosis was assessed by only three of the included studies for dementia, irritable bowel
disease, and acute myocardial infarction. There was evidence of some differences in
date of diagnosis, but these differences were generally small. Of the studies that had
assessed completeness of data recording in the CPRD, there was generally evidence of
under-reporting of disease incidence. However, although other sources were used as the
‘gold standard’, it is not always possible to say whether one database is ‘better’ or more
complete than another. The systematic review included some papers that had assessed
the validity of smoking status records in the CPRD. Compared to the Living in Britain
National Household Survey of 1996, current smoking rates in the CPRD were 79% of
expected rates. For previous smokers, the level was 29%. This suggests that previous
smoking is considerably under reported in the CPRD. The review concluded that the
validity and completeness of diagnostic coding in the CPRD is generally good, and rec-
ommended that researchers use several codes to identify diagnoses when working with
CPRD data, or use internal validation methods such as looking for relevant referrals
after particular diagnoses.
Other studies have looked specifically at cancer recording in the CPRD. Boggon
et al. (2013) examined the concordance of cancer recording in the CPRD and the
English cancer registry from 1997-2006. Both sources were searched for cancer-related
codes, and where a diagnosis was recorded in the CPRD only, attempts were made
to validate the record with hospital data or death certificates. Where only the cancer
registry held a record of the diagnosis, the CPRD free text section was searched for
selected text strings to confirm the diagnosis. Age, sex, and history of diabetes were
investigated as potential predictors of non-concordance using logistic regression. The
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study found 5,797 cancers recorded in the CPRD; 4,830 were also recorded in the cancer
registry (83.3% agreement). Of the 967 CPRD cancer records that were not matched
by a record in the cancer registry, 528 (54.6%) were confirmed using hospital statistics
or death certificates. 307 of the 341 diagnoses recorded only in the cancer registry
were confirmed in the same way. Age was found to be a predictor of non-concordance,
which increased with increasing age. The majority of cancer registry diagnoses were
recorded within one month of the CPRD record (63.1%). 23.5% were recorded within
1-3 months. 3.3% of cancer registry records were made more than a year before the
first CPRD record. Conversely, 1.6% of cancer registry records were made more than
one year after the first CPRD records. The authors suggest that more severe cases,
where the patient dies soon after diagnosis, are less likely to be recorded in the CPRD
as there is not enough time for the data to be fed back and obviously the patient
does not attend again. They also suggest that cases missed from the cancer registry
are more likely to be cancers for which diagnosis does not rely on histology (cancer
registry recording being over reliant on histopathology in some areas). Other sources
of discrepancy could be disagreements in coding between different clinicians, different
coding patterns between the two sources, or errors in recording patient ID number.
Overall, however, the paper concluded that the level of concordance between the two
data sources is reasonably high.
Dregan et al. (2012) specifically evaluated the accuracy of lung, colorectal, gastro-
oesophago, and urinary cancers in the CPRD compared to the cancer registry, from
2001-2007. Patient records were compared in the two sources and concordance was eval-
uated in terms of the positive predictive value (PPV) of a CPRD record (the proportion
of CPRD diagnoses confirmed by the cancer registry), and the sensitivity (proportion
of patients with a cancer record in the cancer registry also having cancer in the CPRD)
and specificity (proportion of patients with no CPRD cancer record, who also had no
cancer record in the cancer registry). During the study timeframe there were 5,429
cancers recorded in the CPRD and 5,710 in the cancer registry; they agreed on 5,216
of these (91%). 494 cancer registry cancers were not recorded in the CPRD, and 213
CPRD cancers were not recorded in the cancer registry. The PPV of a CPRD cancer
record varied by cancer type: for lung cancer it was 96%, for urinary cancers it was
92%, for gastro-oesophageal cancers it was 97%, and for colorectal cancer it was 98%.
The sensitivity varied from 85% for urinary cancers to 94% for lung cancers, and the
specificity was generally high at 99% for all cancer types. The median difference in
date of diagnosis between the two sources was 11 days (IQR -6 to 30); that is 11 days
sooner in the cancer registry than in the CPRD, and the interquartile range is 30 days
sooner in the cancer registry to six days later in the CPRD.
The authors explored possible reasons for discrepancies in diagnoses between the
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two data sources. These included differences in the nature of the diagnosis, or recording
of the diagnosis close to the end or just before the beginning of the study period. The
patient may have transferred out of their CPRD-participating practice before their
diagnosis could be coded in their CPRD record. It is possible that CPRD-only cancers
were actually coded as ‘suspected’ cancer; if the suspicion was not confirmed and no
diagnosis was made, there would be no accompanying cancer registry record: 77%
of patients with a CPRD record but no cancer registry record had a cancer ‘alarm’
symptom which could have prompted a suspected cancer record. Different types of
cancer may be recorded in each source if the ‘suspected’ cancer site was recorded first
in the CPRD, then further investigation revealed the ‘correct’ cancer site, which is then
recorded in the cancer registry. The patient’s CPRD record is rarely (if ever) updated
to reflect this. This study concluded that cancer diagnoses in the CPRD can be used
with ‘reasonable confidence’ for the four types of cancer investigated. Some limitations
of the study were noted, which will apply to other studies using CPRD data; namely
that there may be differences in recording patterns between CPRD practices that do
and do not subscribe to the cancer registry linkage system.
Overall, there is evidence to suggest that recording in the CPRD is of a reasonably
high quality and that using linked cancer registry data when using cancer data from the
CPRD can increase the degree of certainty in results. However, the results presented
in Dregan et al. (2012) and Boggon et al. (2013) are based on data collected up to and
including 2007. There are likely to have been improvements in data recording since
this time as a result of policy initiatives in the UK in 2011 so we can assume that the
quality of recording in the data used in the studies presented in this thesis is at least
as good as the evidence described here.
2.5.3 The Cancer Registry
The National Cancer Registration Service for England (NCRS), the English cancer
registry (hereafter referred to as the cancer registry), gathers patient data under strict
collection, storage, and usage policies. It is run by Public Health England. The cancer
registry dates back to 2000, when the Somerset Cancer Register was set up as part of the
NHS Cancer Plan, before being extended across England where eight regional cancer
registries operated. In 2013, the eight registries were combined into the National Can-
cer Registration Service for England (NCRS) which used the English National Cancer
Online Registration Environment (ENCORE) database to collect data. The alternative
services in other parts of the UK are the Information and Services Division in Scot-
land, the Welsh Cancer and Intelligence Surveillance Unit, and the Northern Ireland
Cancer Registry. All four organisations feed data back to Public Health England. Data
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are collected directly from healthcare providers including screening services, imaging
services, Hospital Episode Data, pathology, chemotherapy and radiotherapy, secondary
care patient administration systems, palliative care data, and death certificates. The
single registration service aimed to standardise data collection for improved consistency
and comparability. Data recording has improved steadily in the cancer registry since
its inception. Currently, the database holds information on stage at diagnosis for about
80% of incident cases (100% coverage is not possible as not all cancers can be staged);
this is a vast improvement on levels of staging recording in 2011, when levels were as
low as 15% in some regions (Rashbass, 2014).
2.5.4 CPRD and cancer registry data linkage
A data linkage exists between the CPRD and the cancer registry. The primary function
of the data linkage is to enable cancer registry records to supplement CPRD data. The
linkage also allows cancer records in the CPRD to be validated by the cancer registry.
The linkage is carried out by the Health and Social Care Information Centre (HSCIC),
a trusted third party, using key identifying information such as date of birth, postcode,
and NHS ID number (Boggon et al., 2013). Around 75% of English CPRD practices
and 58% of all CPRD practices consent to data linkage with the cancer registry.
2.6 Chapter summary
This chapter has presented a range of background information to enable a wider un-
derstanding of the context in which this PhD is set, and justification for the topic
under study. The basic biology of platelet and thrombocytosis has been discussed,
and the three pools of evidence underpinning the work done in the PhD have been
presented. The burden of cancer in the UK has been described, and the processes in
general practice around diagnosing cancer have been examined in terms of achieving
earlier diagnosis to improve cancer outcomes. Finally, the data sources used in this
PhD have been introduced. The next chapter presents the first study of the thesis; a
systematic review and meta-analysis examining evidence of the relationship between
thrombocytosis and cancer in a primary care setting.
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Chapter 3
Systematic review of evidence
of a relationship between
thrombocytosis and cancer
diagnosis
3.1 Chapter summary
In this chapter, the association between thrombocytosis and cancer is explored through
a systematic review, the aim of which was to find evidence on this subject in a primary
care setting. The methods used in undertaking the review are described, the results
are presented, and the implications of the findings are considered.
3.2 Chapter introduction
Earlier diagnosis of cancer is a leading objective to improve cancer outcomes in the UK
and address the gap in cancer survival between the UK and other European countries.
It has been estimated that at least 5,000 cancer deaths annually could be prevented in
England by improvements in early diagnosis (Richards, 2009). Screening can identify
cancers at an early stage which may contribute to improved survival, although false
negatives do occur, and screening programmes only exist for some types of cancer.
Therefore, most diagnosed cancers (around 80% in the UK) present with symptoms to
primary care (Hamilton, 2010). Although some symptoms of cancer are classic ‘alarm’
symptoms like a breast lump, many other symptoms are vague (such as tiredness and
weight loss) and are more likely to be caused by other acute or chronic conditions. A
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range of initiatives have been developed and implemented in UK healthcare systems
to hasten cancer diagnosis, but most of these target the later stages of the diagnostic
interval, after the general practitioner (GP) has considered the possibility of cancer.
In the UK, these include two-week wait clinics, open access GP investigation and ap-
propriate NICE guidance (NICE, 2015). Other work has identified the early symptoms
and markers of cancer, which has resulted in the widespread use of tables of risk pro-
files for specific cancers in UK general practice (60,000 mousemats with risk assessment
tables (RATs) printed on them were sent to general practices, and eRATs are being
used in 1,000 practices) (Barrett et al., 2010; Hamilton et al., 2005a,b; Shephard et al.,
2013; Stapley et al., 2006, 2012, 2013; Walker et al., 2014). So far, thrombocytosis
has received little attention in these studies, although some have considered it. As
described in Chapter 2, there is evidence to suggest that earlier diagnosis leads to bet-
ter outcomes and better survival. Earlier diagnosis is likely to identify cancer at an
earlier pathological stage, where it is not only easier to treat, but also also more likely
to be followed by longer survival than late stage cancers. Early stage cancers are also
less expensive to treat than late stage (Insicive Health, 2014). All of this supports the
notion that diagnosing cancer earlier is beneficial. However, achieving this in practice
can be difficult.
Thrombocytosis has recently been identified as a marker of cancer present before
diagnosis. Previous studies have reported on the usefulness of platelet count as a prog-
nostic tool in secondary care and have described the mechanisms that could underlie
this association (see Chapter 2) but there is a relative dearth of evidence from primary
care, where the initial suspicion of cancer is generally first made. A range of case-control
studies have been carried out with patients with particular types of cancer, and control
patients with no cancer diagnosis, to compare the symptoms these patients presented
with to their GP in the year prior to their diagnosis. Some of these have investigated
thrombocytosis as a potential risk marker of malignancy.
In order to answer the general question of whether thrombocytosis is a marker of
undiagnosed cancer, this systematic review aimed to identify studies that have investi-
gated whether adults aged ≥ 40 presenting with thrombocytosis in primary care are at
greater risk of having a currently undiagnosed cancer than those with a normal platelet
count and to bring the results together in a narrative synthesis and meta-analysis.
3.2.1 Systematic reviews
A systematic review is a method of identifying and collating evidence from previously
published studies which enables the gathering of a large body of evidence to answer a
research question. The review is designed to identify studies with a degree of homogene-
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ity within the research question so that it is possible and valid to draw their individual
results together and base conclusions on the overall picture. Collation of results takes
the strength of the evidence in to account. It is sometimes possible as part of a sys-
tematic review to carry out a meta-analysis; this is a method of statistically combining
numerical results from individual studies to get an larger overall result, usually with
a greater degree of precision than results from individual studies with smaller sample
sizes can provide (Deeks et al., 2008). In a meta-analysis, greater weight is generally
given to larger studies. The degree of heterogeneity between studies is assessed within
the meta-analysis using the I2 statistic which is the proportion of variation between
studies that can be accounted for by heterogeneity (Higgins et al., 2003).
3.2.2 Chapter research questions
This systematic review addresses the first objective outlined in Chapter 1: to carry out
a systematic review of studies that have reported on the association between platelet
count and cancer in a diagnostic context to identify what is currently known about
thrombocytosis as a risk marker of cancer. The research questions for this review are:
 Are adults aged 40 years and over with thrombocytosis at greater risk of cancer
than those with normal platelet counts?
 Which cancer sites have been found to be associated with thrombocytosis in
primary care (as risk markers of cancer), and which have not?
3.3 Methods
The protocol for this systematic review is available online and as an appendix (see
Appendix A).
3.3.1 Scoping search
Before the full search strategy for this systematic review was finalised, a scoping search
was carried out. This included informal, unstructured searching using internet search
engines and Pubmed, and key terms relating to thrombocytosis, cancer, and primary
care. A few key papers were known prior to beginning the review. The scoping search
tested the search strategy to ensure it was effective at identifying the known key papers.
If they were found by the search strategy, it is possible to have more confidence in the
search strategy’s ability to identify unknown yet relevant papers.
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3.3.2 Search strategy
The search strategy was developed using three key terms: “thrombocytosis”, “cancer”,
and “primary care”. A range of additional search terms were derived from each of these;
for thrombocytosis the following terms were used: “thrombocytosis” or “platelet” or
“thrombocyte” or “thrombocyte count”. For cancer, “neoplasm” was also included.
Additional terms for primary care included “primary medical care” or “family practice”
or “family medicine”. The full search strategy is included in Appendix A.
The search was limited to English language papers due to a lack of available trans-
lating facilities. The search was also limited to results published in the last 30 years
(the scoping search found no results beyond 30 years). The following databases were
searched: EMBASE (OvidSP); Medline (Ovid); Web of Science, The Cochrane Library.
Forwards and backwards citation searching was carried out on included papers. This
involved checking the papers referenced in included studies for eligibility for inclusion,
and examining later published works for eligibility which had referenced the included
papers. In addition to searching electronic databases, a range of national and interna-
tional experts were contacted to ask if they knew of any other relevant studies. The
need for this strategy became apparent as, prior to starting the systematic review, I
was aware of four studies that had collected data relevant to the systematic review
but had not published the results because they were negative, and one further study
which had collected but not analysed platelet count data. Publication bias is a well-
documented limitation of systematic reviews, and it was a strength of this review that
experts were contacted to ask about what data they may have that were relevant to the
review, even if the results were negative. In addition to approaching other researchers
directly, I attended a number of national and international conferences throughout the
term of this PhD, delivered several oral and poster presentations, and had numerous
discussions with other researchers at these events. Through this process I was able to
determine if anyone else within the cancer diagnostics field was pursuing this line of
investigation, or had collected relevant data.
All of the relevant papers identified by the literature search were exported to End-
note X5 and de-duplicated. Relevant papers identified through non-literature search
were included.
3.3.3 Study selection
The search aimed to identify any study that had investigated the association between
thrombocytosis and a new diagnosis of cancer of any type in a primary care setting.
Inclusion criteria were:
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 Adults aged ≥ 40 years;
 Primary care setting;
 Observational, case-control or cohort study, or any literature review.
Exclusion criteria were:
 Adults under 40 years of age. These were excluded because cancers in this age
group tend to be familial or atypical.
 Studies that had investigated platelet count as a prognostic tool or guide for
cancer therapy. These were excluded as the systematic review specifically aimed
to find studies that had used thrombocytosis in a diagnostic capacity.
Titles and abstracts were screened by myself and ES, a supervisor of this PhD
and co-author on the subsequent publication, and full text articles were retrieved and
assessed for inclusion.
3.3.4 Study quality assessment
The quality of included studies was assessed using the Quality Assessment of Diagnostic
Accuracy Studies-2 (QUADAS-2) tool (Whiting et al., 2011). This is a tool for assessing
the quality of diagnostic test studies. Although the overall aim of this PhD is to
investigate thrombocytosis as a marker of cancer, not as a diagnostic test for cancer,
this quality assessment tool was chosen as it best fits the type of studies that the review
expected to identify and the types of studies that were found in the scoping search.
The QUADAS-2 tool assesses studies for risk of bias and applicability concerns. The
domains within these two areas are:
Risk of bias:
 Patient selection - could the patient selection procedure have introduced bias?
 Index test - could the conduct or interpretation of the index test have introduced
bias?
 Reference standard - could the reference standard, its conduct, or interpretation
have introduced bias?
 Flow and timing - could the patient flow have introduced bias? Are there any
concerns about the time interval between the index test and the reference stan-
dard? Are all patients receiving the same reference standard and are all patients
included in the analysis?
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Applicability concerns:
 Patient selection - do the included patients and the setting match the review
question?
 Index test - are there any concerns that the index test differs from that in the
review question?
 Reference standard - are there any concerns that the target condition, as defined
by the reference standard, does not match the review question?
3.3.5 Data extraction
A range of data relating to the number of patients with and without the cancers of
interest, and the number of these with and without thrombocytosis prior to diagnosis
were extracted from papers or from personal communications with the authors onto
custom-made data extraction forms (see Appendix B). These forms also held details of
the study design, patient or data sources, and patient characteristics. Data extraction
was primarily carried out by myself, and was checked by WH, a supervisor of this PhD
and co-author on the publication which resulted from this systematic review.
3.3.6 Data analysis: narrative synthesis
Two methods were used to collate and analyse data. Firstly, the extracted data were
drawn together in a narrative synthesis following the general framework set out in the
Centre for Reviews and Dissemination’s Guidance for Undertaking Reviews in Health-
care (Centre for Reviews and Dissemination, 2009). In the first instance, a preliminary
synthesis of findings was carried out which involved a textual description of studies,
tabulating raw data and key features of studies.
The raw data extracted from each study were used to calculate the likelihood ratio
(LR: the probability of raised platelets in patients with cancer divided by the probability
of raised platelets in patients without the disease) and the positive predictive value
(PPV) using Bayes’ Theorem. The PPV reflects the probability that a patient with
a positive test result has the disease in question. It is calculated as the proportion of
patients with a positive test result who have the disease in question. This approach to
calculating PPVs is used with case-control study data as it accommodates the lower
prevalence in the general population, a necessary adjustment as prevalence is artificially
high in case-control studies. Thus, PPVs were calculated as the LR multiplied by the
prior odds of the disease (Knottnerus, 2002); in this case incidence data were used to
calculate prior odds.
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The analysis examined two subgroups which were defined based on (1) whether the
cancer being studied affects both sexes or only one (this latter group transpired to be
females only as no male-only cancer sites were identified by the searches), and (2) the
data sources used by the studies. The relationships within and between studies were
explored, and the strength and robustness of the evidence was assessed.
3.3.7 Data analysis: meta-analysis
Where available, the odds ratios from relevant studies were pooled using the random ef-
fects meta-analysis model in RevMan 5.3. (RevMan, 2014). The primary meta-analysis
included all studies, and two sensitivity analyses examined the effect of pooling results
from the two subgroups defined above. Heterogeneity in these models was examined us-
ing I-squared (I2) statistic. The primary meta-analysis included several studies which
had each investigated a specific cancer site. There were no studies that had investigated
all or any type of cancer (two studies that have investigated the risk of any type of
cancer in patients (Hippisley-Cox & Coupland, 2013a,b) did not include platelet count
data) It is possible that the strength of any association between thrombocytosis and
cancer may vary between different cancer sites. Furthermore, not all cancer sites had
been investigated by studies identified by this review. 95% prediction intervals were
calculated for pooled odds. There may not be one true single effect for the relationship
between thrombocytosis and cancer; it may vary greatly between different types of
cancer giving multiple different true effects. The 95% prediction interval quantifies the
range of odds ratios across different cancer sites to provide an estimate of the interval
in which the measure of association for another, as yet unreported, cancer site may lie.
Rather than simply presenting the mean of the different effect of different cancer sites,
the prediction interval reflects the range in which most of the different true effects lie.
3.4 Results
The process of selecting papers for inclusion in the review is summarised in Figure 3.1.
A total of 98 papers were identified by the literature search. After duplicates were
removed, 79 titles and abstracts were screened for inclusion. This screening was carried
out by myself, and by ES, a supervisor of this PhD and a co-author on the resulting
publication. WH was nominated to adjudicate with any papers that were a source of
disagreement. Five full text papers were retrieved; both screening authors agreed on
these five. The reasons for exclusion are shown in the study selection flow diagram; to
summarise, the reasons are:
 Studies not being primary care-based (n = 21)
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 Study did not include adults aged 40 years and over (n = 13)
 Studies not having a focus on cancer (n = 32)
 Not relevant study design (n = 4)
 Study did not investigate thrombocytosis (n = 4)
After reviewing full texts, four of the five papers identified through the litera-
ture search met the inclusion criteria (Hamilton et al., 2005a; Shephard et al., 2013;
Stapley et al., 2013; Walker et al., 2013). All were case-control studies. A further
five case-control studies were included through other channels described in the meth-
ods.(Hamilton et al., 2005b, 2009; Shephard et al., 2012; Stapley et al., 2012; Walker
et al., 2014). All of these studies were carried out within the same research group, led
by WH. This is a limitation of this review, but unavoidable; as yet (autumn 2016), no
other research group has published work investigating thrombocytosis, although rele-
vant work is ongoing and not yet published. Others who have investigated markers
of cancer have not included thrombocytosis. A group in Sweden are collecting data
on thrombocytosis and cancer, and work in Nottingham on the association has been
initiated by the results of this thesis. Due to reporting bias four of these studies were
not found by the literature search because, although they had collected and analysed
platelet count data in relation to cancer diagnosis, they did not report this in the pub-
lication as the results were negative. As they did not report platelet data, the papers
did not contain any keywords related to thrombocytosis or platelets. The fifth study,
Shephard et al. (2012), had collected but not analysed platelet count data so was also
not identified by the literature search. It was known that these studies had investi-
gated a range of early markers of cancer and following discussion with the authors
of these studies it became apparent that they had collected platelet data, and were
able and willing to contribute raw data for this systematic review. In total, therefore,
nine case-control studies were included, each investigating a different cancer site. Six
of these studies had used data from the Clinical Practice Research Datalink (CPRD).
The remainder of studies had used general practice records in a specific geographical
location.
3.4.1 Study quality
The results of the QUADAS-2 assessment are shown in Table 3.1; the overall study
quality was judged to be high.
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Figure 3.1: Study selection process including excluded papers and reasons for exclu-
sion.
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3.4.1.1 Patient selection
For all included studies, the methods of patient selection were well described. The
studies that had used CPRD data had included all patients in the database with the
specific cancer type being investigated. For those studies using general practice records,
all patients with the cancer of interest identified from the records were included. The
control patients were randomly selected age, sex, and practice matched patients from
the CPRD, or age and sex matched patients from the same practice in the non-CPRD
studies. In all cases, appropriate exclusions were applied (described in full in the next
section). The selection of patients in a case-control study often introduces a degree of
bias; in the CPRD studies found by the review, all existing eligible cases in the data
source were included, reducing this selection bias (some diagnosed cases may be missing
from the data source, and there could be non-random differences between those that
are and are not recorded). There were no concerns that the included patients did not
match the review question.
3.4.1.2 Index test
The index test, referred to in QUADAS-2, is the diagnostic test under investigation. It
is compared to the reference standard. All of the studies included in this review aimed to
estimate the diagnostic value of signs and symptoms in identifying patients with cancer.
This review specifically sought data on platelet count as a diagnostic marker of cancer.
Therefore, the index test was platelet count, typically taken as part of a full blood count.
In all included studies, a blood test was used to determine platelet count, and all blood
tests were carried out prospectively, prior to patients being diagnosed with cancer, so
without knowledge of the reference standard. The threshold for thrombocytosis was
pre-defined and taken as the local laboratory thresholds, generally > 400 × 109/L or
> 450× 109/L. As blood tests were ordered by GPs in practice prior to patients being
diagnosed with cancer, there is little chance of any degree of bias being introduced; the
control patients also had blood tests and platelet counts measured. The CPRD studies
included patients with no platelet count available as having a normal platelet count.
This may introduce a degree of bias, and could dilute any true association between
thrombocytosis and cancer.
3.4.1.3 Reference standard
The reference standard determines whether or not a patient is classed as having the
disease in question. For CPRD studies, patients were classified as having cancer if
they had a code in their electronic medical records identifying them as being diagnosed
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Table 3.1: Results of QUADAS-2 study quality assessment.
Risk of Bias Applicability concerns
Citation
Patient
selection
Index
test
Reference
standard
Flow &
timing
Patient
selection
Index
test
Reference
standard
Walker et al.
(2014)
3 3 ? ? 3 3 3
Shephard et al.
(2013)
3 3 ? ? 3 3 3
Stapley et al.
(2013)
3 3 ? ? 3 3 3
Walker et al.
(2014)
3 3 ? ? 3 3 3
Shephard et al.
(2012)
3 3 ? ? 3 3 3
Stapley et al.
(2012)
3 3 ? ? 3 3 3
Hamilton et al.
(2009)
3 3 3 ? 3 3 3
Hamilton et al.
(2005a)
3 3 3 7 3 3 3
Hamilton et al.
(2005b)
3 3 3 ? 3 3 3
with the particular type of cancer being investigated. Histological confirmation was not
sought; cancer recording in the CPRD is considered to be of high quality (discussed in
Chapter 2 and confirmed by the validation study in Chapter 5), but recording errors do
occur, and the quality of cancer recording in the CPRD is known to vary by cancer type
(Dregan et al., 2012). For studies that used GP practice data, cancer diagnoses were
confirmed with histological reports. It is very likely that patients are correctly classified
as histological confirmation is considered the gold standard of reference standards.
All included studies used observational data in which cancer diagnoses were made or
recorded by practice staff with no knowledge of the research study so there is unlikely
to be any introduction of bias by prior knowledge of the results of the index test.
3.4.1.4 Flow and timing
It is not clear whether platelet count was available for all patients in the studies. If
thrombocytosis was present it was coded as such. Normal platelet counts and missing
platelet counts were grouped together into a ‘no thrombocytosis’, assumed normal
platelet count group. In Hamilton et al. (2005a), the number of patients with a platelet
count was available. Of 1,482 patients in the study, 528 had a platelet count available.
This may have introduced a degree of bias if the patients with a platelet count available
were somehow different from those with no platelet count data. In all studies, platelet
counts taken up to a year before a cancer diagnosis were included. Older data were
excluded to ensure that any symptoms and test results were related to the cancer
41
3. Systematic review of thrombocytosis and cancer diagnosis
diagnosis which defined the cases.
3.4.2 Study characteristics
The included studies are summarised in Table 3.2. Six of the nine case-control studies
used data from the Clinical Practice Research Datalink (CPRD) database. Cases were
all patients in the CPRD database with oesophago-gastric, pancreatic, bladder, breast,
kidney, or uterine cancer diagnosed from 2000 to the year of study. These patients were
classified as cases by the identification of a site-specific cancer code in their records:
no histology was available to confirm this diagnosis. Up to five age, sex, and practice
matched controls were included per case. These were randomly selected from the CPRD
database.
The remaining three studies had included all patients diagnosed with the cancer
of interest (ovarian, colorectal or lung) within particular geographical areas, identified
from cancer registry data (including histology) and from searching general practice
records. Controls were age- and sex-matched patients randomly selected from the same
practices.
3.4.3 Study exclusions
All studies excluded patients with metastatic cancer from a different primary site (al-
though included patients with metastatic disease from the cancer of interest at the time
of diagnosis), patients for whom no matching controls were available, patients with no
data available in the year prior to diagnosis, duplicates, or controls whose matching case
had been excluded. Other cancer-specific exclusions were applied that varied between
studies; uterine cancer controls with a hysterectomy prior to the cancer diagnosis date
of their associated cases were excluded from Walker et al. (2013) (uterine cancer) and
patients with a mastectomy more than three months prior to their cancer diagnosis
date in Walker et al. (2014) (breast cancer). All studies had included only adults aged
40 years and over.
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Table 3.2: Characteristics of included studies, including study type, cancer site, source of data used in the study, and the number of
cases and controls and proportion of females included in the study.
Citation
Cancer
Site
Study
Type
Data Source Cases Controls
Walker et al.
(2014)
Breast Case-control All women in the CPRD database diagnosed with breast
cancer from 2000-2009.
n = 4, 407
100% female
n = 21, 755
100% female
Shephard et al.
(2013)
Kidney Case-control All patients in the CPRD database diagnosed with kidney
cancer from 2000-2009.
n = 3, 183
38.7% female
n = 15, 707
40.2% female
Stapley et al.
(2013)
Oesophago-
gastric
Case-control All patients in the CPRD database diagnosed with
oesophago-gastric cancer from 2000-2009.
n = 7, 657
34.6% female
n = 37, 699
34.6% female
Walker et al.
(2013)
Uterine Case-control All women in the CPRD database diagnosed with uterine
cancer from 2000-2009.
n = 3, 166
100% female
n = 9, 537
100% female
Shephard et al.
(2012)
Bladder Case-control All patients in the CPRD database diagnosed with bladder
cancer from 2000-2009.
n = 4, 935
27.5% female
n = 24, 098
28.9% female
Stapley et al.
(2012)
Pancreatic Case-control All patients in the CPRD database diagnosed with pancre-
atic cancer from 2000-2009.
n = 3, 635
52.0% female
n = 16, 459
52.0% female
Hamilton et al.
(2009)
Ovarian Case-control All women in Exeter and mid- and east Devon diagnosed
with ovarian cancer from 2000-2007, identified from the
Royal Devon and Exeter hospital Cancer Registry, and elec-
tronic records of all patients at 39 general practices in Ex-
eter, mid-Devon and east Devon, UK.
n = 212
100% female
n = 1, 060
100% female
Hamilton et al.
(2005b)
Colorectal Case-control All patients in Exeter, Devon, diagnosed with colorectal
cancer from 1998-2002, identified from the Royal Devon and
Exeter hospital Cancer Registry, and electronic records of
all patients at 21 general practices in Exeter, UK.
n = 349
49.3% female
n = 1, 744
49.3% female
Hamilton et al.
(2005a)
Lung Case-control All patients in Exeter, Devon, diagnosed with lung cancer
from 1998-2002, identified from the Royal Devon and Ex-
eter hospital Cancer Registry, and electronic records of all
patients at 21 general practices in Exeter, UK.
n = 247
31.9% female
n = 1, 235
31.9% female
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3.4.4 Association between thrombocytosis and cancer
The four studies identified by the literature search had reported multivariable (adjusted
for potential confounders) analyses and found a statistically significant association be-
tween thrombocytosis and their specific cancer site (Hamilton et al., 2005a; Shephard
et al., 2013; Stapley et al., 2013; Walker et al., 2013). These had investigated lung,
kidney, oesophago-gastric, and uterine cancer. The adjusted odds ratios as presented
in the publications were:
 Lung cancer 9.3 (95% CI 3.4 to 26)
 Kidney cancer 2.2 (95% CI 1.7 to 2.7)
 Oesophago-gastric cancer 2.4 (95% CI 2.0 to 2.9)
 Uterine cancer 1.50 (95% CI 1.00 to 2.25)
Of the remaining five studies, four reported no significant association between
thrombocytosis and cancer and the fifth did not include thrombocytosis in the analysis;
these were the studies identified through channels other than the literature search.
My independently calculated likelihood ratios (LRs) and positive predictive values
(PPVs) for each cancer site are presented in Table 3.3; all with the exception of breast
cancer indicate an increased probability of malignancy in patients with a blood test
showing thrombocytosis. LRs were highest in ovarian, lung, renal, colorectal, and
oesophago-gastric cancer, but due to differences in the prevalence of these cancers in
the consulting population, lung and colorectal (the most common cancers of the nine)
had the highest PPVs for cancer. Ovarian cancer, with the greatest LR of 14.61, had
a relatively small PPV of 0.65 which reflects the relative rarity of this diagnosis.
Generally, studies that used the CPRD as their primary data source achieved larger
sample sizes than those that used cancer registry and general practice records for pa-
tients within defined practice areas: CPRD studies included patient numbers in the
thousands, with the smallest including 2,732 cases and 9,537 controls, up to the largest
which included 7,481 cases and 32,877 controls. This is because all patients diagnosed
with the cancer of interest were included as cases, from any CPRD-registered practice
in the UK, rather than being restricted to cases within a set geographical area. In con-
trast, the non-CPRD studies included patients diagnosed with the cancer of interest
from set geographical areas within South-West England and were much smaller; the
largest recruited 349 cases and 1,744 controls. The confidence intervals were generally
narrower and showed less overlap in CPRD studies when compared to the non-CPRD
studies, reflecting their larger sample sizes. The lack of overlap between confidence
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intervals for individual cancer sites suggests that thrombocytosis is more strongly pre-
dictive of some types of cancer than others.
The sex of included patients was another key difference between studies; three in-
cluded only female patients due to the type of cancer (breast, ovarian and uterine)
whilst the other studies included both males and females, it was not clear from the
mixed-sex studies how many males and females were identified as having thrombo-
cytosis. Breast cancer was the only one of the three female only cancers to show no
statistically significant association with thrombocytosis (LR 1.22, 95% CI 0.97 to 1.53).
This was one of the larger studies which used the CPRD as a data source; reflected in
the narrow confidence interval. Thrombocytosis was predictive of the other two female
cancers, uterine and ovarian; although the ovarian cancer study had the greatest LR of
14.61, it also had the widest confidence interval (95% CI 6.94 to 30.73) reflecting the
smaller sample size. The LR for uterine cancer was smaller at 1.60, and the confidence
interval narrower (95% CI 1.27 to 2.01); this study also used the CPRD as its primary
data source and achieved a larger sample size.
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Table 3.3: Analysis of data from included studies. Table details the number of cases and controls in each study and how many of
these had a blood test result showing thrombocytosis. Independently calculated likelihood ratios (LR) and positive predictive values
(PPV) are presented along with 95% confidence intervals (CI).
Reference
Study
source
Cancer site
Cases n,
n (%) with
thrombocytosis
Controls n,
n (%) with
thrombocytosis
LR
(95% CI)
PPV %
(95% CI)
Hamilton et al.
(2005a)
Literature
search
Lung
247
34 (13.8)
1,235
19 (1.5)
8.9
(5.19 - 15.41)
1.63
(0.92 - 2.90)
Shephard et al.
(2013)
Literature
search
Kidney
3,183
348 (10.9)
15,707
251 (1.6)
6.20
(5.3 - 7.3)
0.17
(0.15 - 0.20)
Stapley et al.
(2013)
Literature
search
Oesophago-
gastric
7,657
707 (9.2)
37,699
568 (1.5)
5.28
(4.73 - 5.90)
0.47
(0.42 - 0.52)
Walker et al.
(2013)
Literature
search
Uterine
3,166
110 (3.5)
9,537
207 (2.2)
1.60
(1.27 - 2.01)
0.08
(0.07 - 0.11)
Walker et al.
(2014)
Contact with
experts
Breast
4,407
91 (2.1)
21,755
369 (1.7)
1.22
(0.97 - 1.53)
0.38
(0.31 - 0.48)
Shephard et al.
(2012)
Contact with
experts
Bladder
4,935
156 (3.2)
24,098
247 (1.0)
3.08
(2.53 - 3.76)
0.10
(0.08 - 0.12)
Stapley et al.
(2012)
Contact with
experts
Pancreatic
3,635
214 (5.9)
16,459
222 (1.3)
4.36
(3.63 - 5.25)
0.13
(0.11 - 0.15)
Hamilton et al.
(2009)
Contact with
experts
Ovarian
212
26 (12.3)
1,060
9 (0.8)
14.61
(6.94 - 30.73)
0.65
(0.31 - 1.36)
Hamilton et al.
(2005b)
Contact with
experts
Colorectal
349
48 (13.8)
1,744
42 (2.4)
5.71
(3.84 - 8.50)
1.39
(0.94 - 2.09)
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Figure 3.2: Forest plot and pooled result for meta-analysis including all nine studies
identified by the review.
3.4.5 Meta-analysis
Data from all nine studies were pooled in the primary meta-analysis (Figure 3.2). This
gave an overall odds ratio of 3.98 (95% CI: 2.55 to 6.20). The prediction interval for
the odds ratios was 0.77 to 20.5; this indicates the range in which the odds ratio for a
new cancer site not included in the meta-analysis might fall. Heterogeneity was high
in this model, with an I2 of 97%.
The high heterogeneity in this model prompted two sensitivity analyses which aimed
to identify and (if suitable) eliminate the primary source of heterogeneity. It is possible
that the heterogeneity is caused by differences between cancer sites in their relationship
with thrombocytosis. It could also be caused by differences in the platelet-cancer
relationship between men and women, or differences between data sources used by the
studies - some used CPRD data and others used paper records in practices.
The first sensitivity analysis repeated the meta-analysis excluding the female-specific
cancers from the model (breast, ovarian and uterine). The resulting OR was slightly
higher than in the primary meta-analysis at 4.79 (95% CI: 3.59 to 6.38) and the predic-
tion interval was 1.75 to 13.1. In this model heterogeneity was still high (I2 = 91%).
The forest plot is shown in Figure 3.3.
The high heterogeneity in this sensitivity analysis suggested that differences between
men and women in the relationship between thrombocytosis and cancer did not account
(or at most accounted for only a small part) for the degree of difference between study
results.
A second sensitivity analysis was carried out only including studies that had used
CPRD data; and excluded data from the non-CPRD studies. The non-CPRD studies
used primarily paper records, were much smaller, and focused on one geographical area
(Hamilton et al., 2005a,b, 2009). In this analysis, the OR was 3.19 (95% CI 1.87 - 5.45)
with a prediction interval of 0.96 to 24.1, and I2 value of 98%. The high heterogeneity
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Figure 3.3: Forest plot and pooled result for meta-analysis including six studies
identified by the literature review which included both male and female patients;
female-specific cancers are excluded.
Figure 3.4: Forest plot and pooled result for meta-analysis including the five studies
identified by the literature review which used CPRD data; non-CPRD studies are
excluded.
indicates that the differences between studies again cannot be explained simply by
differences in the primary data sources between studies. The results from the second
sensitivity analysis are shown in Figure 3.4.
Overall, although the broad conclusions drawn for each study based on their individ-
ual ORs are generally in the same direction (with the exception of breast cancer), there
are still differences between different cancer sites and their relationship with throm-
bocytosis that cannot be explained by different data sources or sex differences in the
relationship.
3.5 Chapter discussion
3.5.1 Summary of results
This is the first systematic review to identify and collate results from studies inves-
tigating the association between thrombocytosis and diagnosis of cancer in primary
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care. These results suggest that patients with thrombocytosis in primary care have an
increased risk of harbouring an undiagnosed cancer, and that some types of cancer are
more strongly associated with thrombocytosis than others.
The fact that all but one of the nine cancer sites investigated in studies identified
by this review had conventionally significant positive likelihood ratios calculated from
raw data adds strength to this overall conclusion; for four of the nine studies, however,
the significant relationship between thrombocytosis and cancer was not retained in the
multivariable models presented in the original publications. While this does not detract
from the overall conclusion of an association between cancer and thrombocytosis, it does
suggest that the results of this review should be interpreted with caution and supports
the view that the association only exists for certain types of cancer.
There did not appear to be any biological link between those cancer sites that
did and did not have a significant association with thrombocytosis in multivariable
models. When considering the anatomy of cancer sites, there were counter-intuitive
results; firstly that although colorectal and oesophago-gastric cancer, both of the di-
gestive system, had similar odds ratios for cancer (6.5 and 5.9 respectively) presented
in the original publications, only oesophago-gastric cancer retained thrombocytosis as
a significant predictor of cancer in the published multivariable models. In the crude
(unadjusted) analysis presented here, both sites had LRs of around 5, but the PPV for
colorectal cancer was higher than that for oesophago-gastric cancer (oesophago-gastric
0.47% and colorectal 1.39%); this difference can be partly explained by the fact that
colorectal cancer is more common than oesophago-gastric cancer. Secondly, uterine
and ovarian cancer had somewhat disparate results despite both cancers being within
the female reproductive system. Uterine cancer alone retained significance both in the
original publication’s multivariable models, and in my independent analysis (LR 14.61).
Key differences in the way these types of cancer develop or manifest themselves may
underlie these observations. Further investigation of this could provide evidence for
the biological mechanisms that underlie the association between thrombocytosis and
cancer.
The biological processes behind the thrombocytosis-cancer association have been
studied in patients post-diagnosis (Arslan & Coskun (2005); Nash et al. (2002)) but
the effect is not fully understood. It is also uncertain whether the mechanisms behind
the association in secondary care would apply in primary care, before diagnosis is made.
3.5.2 Strengths and limitations
The quality of studies included in this review was judged to be high, and the majority
used CPRD data. The merits of the CPRD as a data source are discussed extensively
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elsewhere in this thesis. Briefly, the CPRD holds primary care records for patients
from 684 GP practices, covering 8.8% of the UK population, with a representative
geographical distribution. This largely representative sample can yield studies with
widely applicable results. It is particularly relevant that the study data are taken from
primary care, as it is in this environment that the study results should be clinically
useful. The validity of CPRD data has been found to be high in one recent systematic
review and two further validation studies (Boggon et al., 2013; Dregan et al., 2012;
Khan et al., 2010), although none of the studies included in those reviews addressed
cancer data specifically. Laboratory results, including platelet counts, are directly
transmitted to the CPRD, greatly reducing the chance for errors in data recording.
The CPRD studies included all patients in the UK within CPRD registered practices
who were diagnosed with the cancer of interest rather than patients within a restricted
geographical area, as in the non-CPRD studies. This reduces the element of selection
bias which is inherent in many case-control studies. It also enables much larger studies,
and consequently more accurate and reliable results. However, CRPD cases are based
on electronic records of cancer diagnoses alone; whereas in the non-CPRD studies,
electronic records from the cancer registry were used as well as paper general practice
records which had the added advantage of histology reports. In terms of the exposure
variable, the platelet counts recorded in the CPRD are electronic and automatically
transmitted from laboratory to the patient records, reducing the chance of human error
and subsequent risk of misclassification bias. In contrast, the non-CPRD studies relied
on manual checking and recording of platelet counts, more open to sources of bias and
error. Overall, the CPRD studies can be considered higher quality than the non-CPRD
studies; these show an overwhelmingly positive association between thrombocytosis and
cancer, although there is marked variation between different cancer sites.
While these results can readily be applied to UK general practice, the lack of any
non-UK studies limits the extent to which these findings can be generalised outside the
UK. Although a wide range of search terms were used, alongside discussion with experts,
supplemented by networking within the cancer diagnostic field, it is possible that some
relevant studies were missed by the search. This is particularly likely if studies were
published in non-English languages (language bias) or did not report non-significant
findings (publication bias). It was not possible to widen our search to non-English
language papers due to a lack of translating facilities, which may have introduced a
degree of language bias. There is conflicting evidence on the extent of language bias
in systematic reviews, summarised in the Cochrane handbook. The evidence cited in
the Cochrane handbook includes a study by Moher et al. (2003) which found that
excluding studies published in non-English language did not markedly alter the results
of a meta-analysis, in a study of two meta-analyses (Moher et al., 2003).
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There is a chance that appropriate data may not have been identified due to pub-
lication bias. Four of the nine studies that contributed raw data to this study were
not identified by the literature review because they did not report non-significant find-
ings. Although relevant experts who have carried out similar studies were contacted to
ask if they had collected platelet count data (they had not), it is possible that other
researchers who were not contacted are carrying out similar work and have collected
data, but that this has remained unpublished due to a lack of significant findings.
No formal method was used to assess publication bias. Publication bias is commonly
assessed in meta-analyses using funnel plots; asymmetry in the funnel plot suggests the
presence of publication bias (although other factors can also cause asymmetry; a more
detailed factor analysis can be used to determine the exact causes). In the present
chapter, publication bias was not formally assessed in this way; it is not recommended
to use this approach when fewer than 10 studies are included in a meta-analysis, or
when there is substantial heterogeneity (Sterne et al., 2011). When there is hetero-
geneity evident in the meta-analysis, an even greater minimum number of studies is
recommended for a funnel plot (Sterne et al., 2011). Some publication bias was ad-
dressed in the present systematic review by the inclusion of data from studies that had
failed to publish their negative (non-significant) findings for thrombocytosis.
A further limitation to this systematic review is that all of the included studies were
carried out in the same research group (although by different researchers in the team),
WH is an author on all, and also an author of the published paper of this systematic
review. This could not be avoided; as far as I am aware, no other relevant studies have
investigated platelet count prior to diagnosis. As described in the methods section of
this chapter, attempts were made to contact researchers who had carried out similar
work, even though they had not published anything regarding platelet count, in case
they had collected data but not used it in any publications.
3.5.3 Implications for research
The results from this review indicate a link between thrombocytosis and cancer, but this
link has not yet been fully investigated. The systematic review identifies significant gaps
in the knowledge which future research should aim to address. Firstly, the association
between thrombocytosis and all cancer sites needs to be investigated; only nine sites
have been examined by existing literature. Secondly there is no indication from existing
studies of how the relationship between thrombocytosis and cancer might differ with
sex and age. Furthermore, existing studies are based on one single platelet count;
in reality, clinicians often have multiple blood counts available or may test again if
uncertain of the diagnosis. The risk of cancer with elevated platelet count over time is
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unknown. Many cancers present in the early stages with vague symptoms and previous
research has shown that the combined predictive value of two or more symptoms can be
more clinically useful. Future research could also combine thrombocytosis with other
symptoms or clinical features to provide greater estimates of cancer risk.
3.5.4 Clinical use of findings
This systematic review suggests that thrombocytosis is an early marker of some cancers
in primary care and will raise awareness of this marker amongst general practitioners.
This finding can be of use in primary care for general practitioners receiving blood
results unexpectedly showing high platelet counts. Simply adding the PPVs from
individual cancers suggests that the overall cancer PPV from thrombocytosis is at least
5% for any of the nine cancers (several cancer sites have not been reported and any
association with thrombocytosis with them would increase this figure). The primary
research in this thesis studies the relationship between thrombocytosis and cancer as a
whole to give a more accurate estimate of the risk, and aims to determine which specific
cancers present with raised platelets as an early marker to allow targeted investigation.
Crucially, this review does not suggest that platelet count should be specifically
used as a diagnostic test for cancer, or as a screening tool. The evidence found in this
systematic review only supports clinicians considering cancer as a diagnosis if a blood
test result shows thrombocytosis. A greater understanding of the biological mecha-
nisms underpinning the association would augment the epidemiological studies called
for earlier. Likewise, knowledge of which cancer sites are most strongly associated with
thrombocytosis could inform research on the mechanisms underlying the association.
Research presented later in this thesis compares the risk for specific patient sub-groups,
including men and women, those in different age groups, and at various levels of el-
evated platelets and combines thrombocytosis with other early markers of cancer to
develop cancer-specific risk values for combinations of symptoms.
3.6 Chapter summary
This chapter has set out the current evidence base for the association between throm-
bocytosis and cancer, which clearly shows that further investigation is needed to fully
understand the relationship. Recommendations for future research, derived from the
findings of this review, are addressed in the next chapter - a prospective cohort study
examining the association between thrombocytosis and cancer.
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Chapter 4
Thrombocytosis as an early
marker of cancer
4.1 Chapter introduction
This chapter presents a cohort study on the relationship between thrombocytosis and
cancer. Background evidence presented in Chapter 2 supports a relationship between
thrombocytosis and cancer, and the systematic review in Chapter 3 found that a raised
platelet count is evident in some cancer patients prior to diagnosis; therefore, it could be
diagnostically useful. However, the relationship has not been fully explored, and further
research is needed to do so. Key factors that have yet to be studied are whether the
link between thrombocytosis and cancer is stronger in some types of cancer than others,
how the relationship changes with age, sex, and change in platelet count over time, and
the usefulness of combining thrombocytosis with other symptoms. Understanding these
important factors will maximise the clinical utility of the platelet-cancer association.
The study presented in this chapter aims to address these factors. This chapter also
examines the potential clinical impact of recognising thrombocytosis as a risk marker
for cancer in UK suspected cancer guidance for clinicians by estimating the number
of patients with thrombocytosis and cancer who had no other symptoms warranting
cancer investigation prior to their diagnosis.
4.2 Chapter aim and objectives
The overarching aim of this chapter is to examine the relationship between thrombo-
cytosis and cancer diagnosis, using individual patient data from the Clinical Practice
Research Datalink (CPRD), and linked patient data from the English cancer registry.
This chapter addresses objectives ii-ix set out in Chapter 1:
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 To examine the incidence of cancer in two cohorts of patients; those with throm-
bocytosis and those with a normal platelet count, to determine the risk of cancer
in each cohort.
 To compare the cancer incidence between these two cohorts to determine the
absolute increase in risk associated with thrombocytosis.
 To examine how the relationship between thrombocytosis and cancer differs across
subgroups defined by age, sex, and smoking status.
 To determine whether some types of cancer are more likely to be diagnosed
than others in patients with thrombocytosis compared to patients with a nor-
mal platelet count.
 To investigate how the risk of cancer changes depending on how the patient’s
platelet count changes over time.
 To investigate the risk of cancer in patients who report symptoms in addition to
thrombocytosis.
 To investigate the stage at which cancers are diagnosed in patients with throm-
bocytosis and with a normal platelet count.
 To estimate the potential impact of the recognition of thrombocytosis as a marker
of cancer in UK suspected cancer guidance by examining the proportion of pa-
tients who have thrombocytosis but no other cancer symptoms or markers.
The methods used in this chapter are fully described in Section 4.3. The complete-
ness of the dataset is explored and patient characteristics are described. The primary
analysis presents the cancer incidence in patients with thrombocytosis; the proportion
of patients diagnosed with cancer within one year of a full blood count showing throm-
bocytosis. This is compared to the incidence of cancer in patients with a full blood
count showing a normal platelet count, in an age, sex, and practice matched sample.
A number of additional analyses are presented. The cancer incidence is estimated
for subgroups defined by age (in 10 year age groups), sex, and primary site of cancer
diagnosis. A crude (unadjusted) logistic regression model is fitted to estimate the
chance of being diagnosed with cancer given a raised platelet count. Smoking status is
tested as a potential moderator of the relationship between thrombocytosis and cancer
incidence. Fractional polynomial models were fitted to examine platelet count as a
continuous predictor of the risk of cancer. The relationship between the change in
a patient’s platelet count over a six month time period and the cancer incidence is
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reported for patients with thrombocytosis. The cancer incidence the second year after
index date is reported to examine whether cancer incidence returns to baseline levels
in patients with thrombocytosis.
In a clinical setting, general practitioners will have additional patient information
such as medical history and other symptoms to help them make a clinical judgement
about whether or not to refer a patient for further investigation for cancer. Therefore, in
this chapter, analyses are presented which investigate the risk of the two most common
types of cancer in patients with thrombocytosis; colorectal and lung, and the most
common symptoms of those cancers (rectal bleeding and change in bowel habit; and
cough, respectively). Weight loss and loss of appetite, symptoms of many types of
cancer, are also investigated.
The UK suspected cancer guidance (NICE, 2015) aims to guide clinicians on diag-
nosing cancer in primary care. The guidance was updated during the execution of this
PhD; the updated version published in June 2015. Thrombocytosis was picked up as
a marker for some, but not all, types of cancer in this guidance. Further analysis in
this chapter examines the potential impact of the recognition of thrombocytosis as a
risk marker of lung and colorectal cancer in the guidance. The methods are described
below.
4.3 Methods
4.3.1 Ethical approval
Ethical approval was granted prior to the commencement of this study by the Indepen-
dent Scientific Advisory Committee (ISAC) reference number 13-007.
4.3.2 Data sources
The study data came from two sources; the Clinical Practice Research Datalink (CPRD)
and the English cancer registry.
4.3.2.1 The Clinical Practice Research Datalink
The CPRD is a government-funded organisation which collates anonymised electronic
patient records from primary care into a longitudinal dataset. As of 2016, 684 UK
practices are registered with the CPRD, contributing over 11.4 million patient records
in total, representing around 8% of the UK population. 4.4 million patients in the
database are ‘active’ (alive and currently registered with a CPRD practice) (Boggon
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et al., 2013). The strengths and weaknesses of CPRD data including accuracy and
validity are examined in Chapter 2.
4.3.2.2 The Cancer Registry
The National Cancer Registration Service for England (NCRS), the English cancer
registry (hereafter referred to as the cancer registry), is run by Public Health England.
It gathers patient data under strict collection, storage, and usage policies concerning
all aspects of cancer diagnoses including staging data. The cancer registry is further
described in Chapter 2. A linkage exists between the CPRD and the cancer registry to
enable cancer registry records to supplement CPRD data. Linked data were requested
from the CPRD for use in this study.
4.3.3 Study definitions
In this study, thrombocytosis is defined as a platelet count over 400× 109/L. There is
some regional variation in the cut-off point defining thrombocytosis between different
laboratories; some take the upper limit as 450 × 109/L. A platelet count of over
400×109/L defining thrombocytosis was chosen for this study to encompass all possible
definitions and to identify any association between thrombocytosis and cancer at only
minimally raised platelet levels. An upper limit of 1, 000 × 109/L platelets was set
as a platelet count over this value is often associated with primary thrombocytosis
(Syed et al., 2007)(Griesshammer et al., 1999) and would be routinely investigated in
practice, with haematological malignancy the first consideration. There is also the
possibility that values over 1000 × 109/L are an artefact; three patients had platelet
counts apparently in the region of 200, 000−300, 000×109/L. These patients had been
classed as having thrombocytosis when it is likely that they had normal platelet counts
of 200− 300× 109/L.
4.3.4 Sample selection
Two cohorts of patients were randomly selected from CPRD records. The thrombocy-
tosis cohort (n = 40, 000) selection criteria were:
i. A blood test result with platelet count available, recorded between 2000 and 2013
ii. The blood test result showing a platelet count of > 400× 109/L for the first time
in the patient’s records
iii. Patient aged ≥ 40 years old at the time of that blood test
iv. Linked data available in the English cancer registry
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The normal platelet count cohort (10,000) selection criteria were:
i. Patient to be age, sex, and practice matched to a patient randomly selected from
the thrombocytosis cohort
ii. A blood test result with platelet count available, recorded between 2000 and 2013
iii. The blood test result showing a platelet count of 150 - 400 × 109/L (within the
normal adult range)
iv. Patient aged ≥ 40 years old at the time of that blood test
v. Linked data available in the English cancer registry
4.3.5 Justification of the two cohorts
The main cohort of 40, 000 patients was selected to address the primary research aim
of investigating the risk of cancer in patients with thrombocytosis. The second cohort
of 10, 000 patients with a normal platelet count was selected to estimate the difference
in cancer risk between those who have a raised platelet count and those who have a
normal platelet count. The total number of 50, 000 was chosen as the CPRD prefer to
limit their datasets to this size. The estimation of the risk of cancer in patients with
thrombocytosis is the main result, and the most clinically useful measure. However
without some comparative measure of risk in patients with a normal platelet count, the
true magnitude of the usefulness of thrombocytosis as a risk marker of cancer would
not be evident. Comparing the risk of cancer in the thrombocytosis cohort to the
risk of cancer in the general population is not a valid comparison because patients
with thrombocytosis, ill enough to consult their GP and ill enough to have a full
blood count ordered, are a select group of patients inherently different from the general
population. Patients with a normal platelet count come from the same select group of
patients (selected to have a full blood count) and are a superior comparator group. The
difference in risk between the two cohorts will reflect increased risk associated with a
raised platelet count, rather than the platelet count plus the risk associated with GP
attendance and blood testing. A ratio of 4:1 patients was chosen because the main
focus of this study was cancer incidence in patients with thrombocytosis; as large a
sample as possible was required to investigate the different types of cancer diagnosed.
The CPRD prefer to limit datasets to 50,000 patients. A ratio of 1:1 patients would
have resulted in a greater degree of imprecision in the thrombocytosis results due to the
smaller sample size. This is particularly important when investigating different types
of cancer, many of which are fairly uncommonly diagnosed.
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4.3.6 Justification of matching patients in the two cohorts
The two cohorts were defined based on their platelet count. The normal platelet count
patients were matched to a random quarter of thrombocytosis patients. Matching is
a technique usually used in case-control studies and it was used in this cohort study
as age, sex, and various geographical factors are known to influence cancer risk. The
main outcome from this study was to estimate the risk of cancer in patients with
thrombocytosis and to compare this to the risk in patients with a normal platelet
count. By matching on these three factors, their influence on the difference in effect
size between the two cohorts can be eliminated.
4.3.7 Data preparation
The next section describes the data files received from each data source and how these
were prepared for analysis.
4.3.8 Data files received from the CPRD
One set of raw data files1 were received in text format from the CPRD, and were
imported in to Stata for analysis. These include the following files:
 The patient file detailed the patients’ personal and demographic factors includ-
ing sex, year and month of birth, marital status, date of registration with their
practice, and date of death (if applicable).
 The clinical and referral files both detail all events in the patients medical history:
all symptoms, referrals, measurements, and the date that these were recorded in
1Actually, there were two. The original CPRD data file was received in February 2014. The cancer
registry data file was received in February 2015. After a few weeks of data manipulation and analysis
it became apparent that there was a very poor level of agreement between the two data sources on
recorded cancer diagnoses. Of approximately 3,000 cancer records, the CPRD and the cancer registry
agreed on 120. Around 2,880 CPRD-recorded cancers had no matching record in the cancer registry
data. Further examination of the data revealed that there were around a thousand records in the cancer
registry data for which no CPRD record existed at all (at least, not in my dataset).
Several weeks of checking and repeating work failed to find an explanatory error. There followed a
chain of email correspondence with the CPRD in which I tried to explain the problem, and they made
many helpful suggestions to try and find the solution. None of these revealed the error. In the end, the
CPRD realised that they had sent me the wrong data file. My CPRD data extraction was completed
in November 2013, and in December 2013 a second extraction was created for an unknown reason.
I was mistakenly sent the December 2013 extraction; the cancer registry data had been matched on
the November 2013 creation. Therefore there were different patients in each of the two datasets. The
CPRD rapidly sent me the November 2013 extraction, and I set about repeating the work I had carried
out on the original extraction. As I take detailed notes and use Stata do files and log files I was able
to replicate the processes I had used with the December 2013 extraction. I estimate that this set the
project back by three months.
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the database. It is also possible to identify the job title of the staff member who
entered the data.
 The test file contains all blood test results, references ranges, and the dates the
test results were received.
 A matching file shows the randomly selected sub-sample of 10, 000 thrombocytosis
patients and the normal platelet count comparator to whom they were matched.
This file also gives the sex, practice, and birth year of each patient, on which they
were matched.
 Therapy and immunisation files detail any prescribed medications and immuni-
sations for the sample, although these were not used in the analysis.
4.3.9 Data files received from the cancer registry
One data file was received from the cancer registry. This included the patient identi-
fication number (identical to the CPRD patient identification number), the patient’s
age at diagnosis, their ethnic background, their year of birth, and the date they started
NHS treatment. The patients’ diagnostic, tumour, and treatment details are also held.
This includes the month and year of diagnosis, and date of diagnosis recorded as the
number of days from the date the patient was registered with their practice. The basis
of the diagnosis is noted; this is either recorded from a death certificate, a clinical in-
vestigation, a tumour marker, cytology, histology, or unknown. One variable identifies
cancers that were diagnosed through a screening programme. The primary cancer site
is recorded using ICD-9 or ICD-10 codes. A series of variables classify the grade, size,
and morphology of the tumour, whether distant metastases were present at diagnosis,
and whether the patient had positive nodes at diagnosis. A further series of variables
note stage details using the TNM (tumour, node, metastasis) format. Where specific
staging systems exist for particular types of cancer, these were also included. Further
variables code treatment and death information. All of this information was received
but only site, staging, and diagnosis date were used.
4.3.10 Data manipulation and work-up
The main dataset created for the analysis included some variables that were transferred
directly from the ‘raw’ CPRD files and used in their original format. Many more vari-
ables were created from the raw data for the analysis. The following section describes
the variables in the dataset, those which were used as supplied from the data source,
and those which were created.
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4.3.11 Raw variables used
Patient ID number, which uniquely identifies each patient in the dataset, was used in
its original form. Sex was also used as supplied. The patients’ platelet count at the date
of their first reading was supplied as a continuous variable. The CPRD also supplied a
binary variable which identified patients as either having thrombocytosis or a normal
platelet count. The practice region variable was used as supplied.
4.3.12 Variables created
A number of additional variables were created during the data work-up stage; these are
described below.
4.3.12.1 Patient index date
For patients with thrombocytosis, the index date was the date of their first raised
platelet count within the study timeframe. This was supplied as a variable in the raw
data file from the CPRD. For patients with a normal platelet count, using the date of
their first normal platelet count within the study timeframe as their index date may have
introduced bias if there was a considerable time difference between this and the index
date of their matched thrombocytosis counterpart. Therefore the date of the platelet
count nearest in time to the index date of their matched thrombocytosis counterpart
was assigned as the index date for patients with a normal platelet count. Because this
index date was sometimes later than the date used to define patients for inclusion in
the cohort, 374 (3.7%) of these ‘normal’ patients actually had thrombocytosis at their
index date and were excluded.
The two cohorts were age matched; patients from each matched pair were the same
age on the index date of the thrombocytosis patient. The process to define index dates
for the normal platelet count patients may have resulted in a difference in the median
age at index date between the two cohorts. This was investigated in the analysis by
comparing the time between index dates between the two cohorts. Due to this method of
selecting index dates for the normal platelet count patients, the time difference between
index dates for thrombocytosis and normal platelet count patients was estimated. This
is because bias may have been introduced to the study if the normal platelet count
patients’ index dates were much later in time (and consequently, when the patients
were older) than the thrombocytosis patients.
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4.3.12.2 Date variables
Stata deals with dates numerically by converting all day-month-year formatted dates
into a number: the number of days that have passed since 1st January 1960. In the
raw data provided by the CPRD, date variables are given as the number of days that
have passed since the patient registered with their practice. As all patients have been
registered for a different number of days (some have been registered with the same
practice since birth whereas others have moved recently), this coding format made
comparisons between patients and variables difficult. Dealing with dates was further
complicated by the fact that cancer registry dates are given as a month and year. Only
the month and year of diagnosis are supplied to protect anonymity, so the first of the
month was arbitrarily assigned to all diagnosis dates. To achieve consistency across all
patients and data sources, new date variables were created for index date, all cancer
diagnosis dates, and the date of any other symptoms. All dates were recorded as the
number of days that had passed since 1st January 1900. This enabled easy comparison
of dates.
Most patients diagnosed with cancer had a record of this in both the CPRD and
the cancer registry, and in this case the first recorded date was taken as the date of
diagnosis. Some patients had cancer recorded in the CPRD but not in the cancer
registry, and vice versa. The date of the present record was taken as the date of
diagnosis. An exploration and comparison of cancer recording in the CPRD and the
cancer registry in Chapter 5, including an analysis of cases recorded in one source and
missing from the other.
4.3.12.3 Age variables
To protect anonymity, only the month and year of birth is provided by the CPRD.
The first of the month was assigned as the day of birth for all patients. Date of birth
was converted to the number of days that had passed since 1st January 1900, and then
subtracted from the ‘days passed since’ variables for index date, diagnosis date, and the
date of other recorded symptoms to determine age at each of these dates. A categorical
age variable was also created with 10 year age brackets; initially this included 40-49
years, 50-59 years, 60-69 years, 70-79 years, 80-89 years, and 90 and over, but there
were too few people in the final category so a 80 and over group was used.
4.3.12.4 Smoking status
Smoking status and behaviour are recorded using a number of variables in the CPRD,
and evidence of the relationship between smoking status and platelet count is mixed
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(Butkiewicz et al., 2006; Green et al., 1992; Sloan et al., 2015; Suwansaksri et al., 2004).
A binary ‘ever smoked’ variable was created (with a ‘missing’ option) using those raw
variables. Smoking status is defined in the CPRD as current, past, or never. Additional
variables record the type of smoking (pipe, cigarette etc.) and the number or amount
smoked per day. Current or past smoking codes were used to define patients as having
‘ever’ smoked or not. This binary variable coded patients who had ever smoked as 1 and
patients who had never smoked as 0. Where smoking status was missing for a patient
but data were available on their smoking habits (type or frequency), this was used to
enter data for the ever smoked variable (classified as ever smoked). Only patients who
were coded as having never smoked in the raw CPRD smoking variable were classed as
having never smoked.
4.3.12.5 Patient symptoms
One of the limitations of this study is that the reasons for patient blood tests being
ordered are unknown. Blood tests are ordered in general practice for a variety of
reasons; this can be in response to symptoms or in asymptomatic patients for routine or
health check reasons. If cancer was already suspected in patients with thrombocytosis
when blood tests were ordered, then the usefulness of thrombocytosis as a clinical
prompt of suspected cancer is limited. In an attempt to address this, the symptoms
reported by all patients in the month prior to their index date were compared for those
with thrombocytosis and those with a normal platelet count. To do this, patients’
electronic records were searched for all recorded medcodes within 28 days before index
date blood test. The 100 most common medcodes in each group were listed. After
excluding ‘organisational’ codes, the 10 most common symptom codes in the two groups
were compared. Eight of these appeared in both cohorts.
4.3.12.6 Geographical region
The geographical region in which the patient’s CPRD practice was based was supplied
in the raw CPRD data. These were tabulated, and the number and percentage in
each region were reported. Whilst the CPRD is commonly cited as a ’geographically
representative sample’, there may be some variation in the proportion in patients in
each region.
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4.3.13 Outcome variables
4.3.14 Cancer variables from the CPRD
All new cancer diagnoses, other than for non-melanoma skin cancer, in the two years
after the patients’ index dates were identified by searching the CPRD records for any
of 2,134 cancer-related codes (see Appendix C). This validated list of cancer codes has
been used in several studies, and is collated into 20 common cancer sites, mapped onto
ICD-10 (World Health Organisation, 2012). A binary cancer variable was created (0 =
no cancer diagnosis, 1 = a cancer diagnosis at any time point) by searching patients’
clinical and referral files for any of these cancer related medcodes. Where more than
one cancer code was found in patient records, the first record in time was taken as the
primary cancer site and date of diagnosis. The 20 cancer sites are: bladder, breast,
cervix, kidney, leukaemia, lymphoma, myeloma, oesophagus, pancreas, stomach, testis,
uterus, brain, colorectal, lung, ovary, oral, melanoma, prostate, and miscellaneous. Any
cancer records lacking an event date were excluded; in every case, patients with undated
records had a second dated record.
4.3.15 Cancer variables from the English cancer registry
New cancer diagnosed recorded in the two years after the patient index date were also
extracted from English cancer registry data. Date variables in the registry data were
used to determine which cancers were recorded within the target time frame, and which
were pre-existing (patients with pre-existing cancer were excluded).
4.3.16 Combining CPRD and cancer registry diagnoses
Patients were counted as having a newly diagnosed cancer if they had a record of one
in either the CPRD or the cancer registry. Where they had a diagnosis recorded in
both sources, the earlier recording was taken as the date of diagnosis.
A range of time-dependent analyses were planned, so a variable was created to record
how many months after the index date the patient’s cancer was diagnosed. From this,
a binary variable was created which coded patients as either diagnosed with cancer in
the first year after their index date or not (1 = patient diagnosed with cancer within
one year of their index date; 0 = patient not diagnosed with cancer within one year of
their index date).
A second year category variable was created for patients who had not been diagnosed
with cancer in the first year: diagnosed in the second year (months 13-24 after the index
date) or not (1=patient diagnosed with cancer within the second year after their index
date; 0 = patient not diagnosed with cancer within the second year after their index
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date). ‘Second year after index date’ reflects months 13-24 after the index date; not
the two year 1-24 month period after index date. An exclusion variable was created
and applied to all analyses relating to cancers in the second year after index date; this
excluded all patients diagnosed with cancer in the first year from second year analyses.
A ‘4-12 months’ variable was created for those not diagnosed in months 1, 2, and 3
which identified patients diagnosed with cancer in months 4-12 after their index date
(1 = patient diagnosed with cancer in months 4-12 after their index date; 0 = patient
not diagnosed with cancer within months 4-12 after their index date).
4.3.17 Staging data
I intended to address the objective of investigating the stage at which cancers are
diagnosed in patients with thrombocytosis and with a normal platelet count using
staging variables in the cancer registry data. However, staging data were only available
for 50% of patients in the sample so this analysis was not completed. Of those 50%,
half had early stage disease and half had late stage disease.
4.3.18 Exclusions
Patients were excluded from all analyses on three criteria. Although patients who met
exclusion criteria could have been removed from the data file altogether, they were
coded and excluded from each analysis so that it was possible to account for each of
the 50, 000 patients initially selected.
4.3.18.1 Pre-existing cancer
The greatest exclusion in terms of the number of patients was on the basis of pre-
existing cancer. Cancer was defined as pre-existing if a record of any cancer existed
prior to the patient’s index date.
4.3.18.2 Platelet count exclusions
Two platelet count exclusions were created; for patients in the thrombocytosis group
who had a platelet count under the 400×109/L threshold or over 1, 000×109/L and for
patients in the normal platelet count group who had a platelet count of over 400×109/L.
4.3.19 Non-melanoma skin cancer
Any patients diagnosed with non-melanoma skin cancer within two years of index date
were excluded. This decision was made because this type of cancer is more common
than other types, it is rarely fatal, and very few cases reach the cancer registry. Many
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non-melanoma skin cancers are managed solely in general practice, although histology
could reach the cancer registry. Those cases that do reach the cancer registry are less
likely to have complete registrations than other cancer types.
4.3.20 Patient selection process: summary
The patient selection process is summarised in Figure 4.1. This figure includes a di-
agram to show the ‘timelines’ used to select patients in the two cohorts, situations in
which exclusions would have arisen, and potential biases that may have been introduced
with different aspects of the patient selection process.
4.4 Statistical methods and analysis
4.4.1 Sex differences in the thrombocytosis-cancer relationship
Most of the analyses in this chapter are presented for men and women separately. This
decision was made in response to early scoping work for this study which revealed
differences in both thrombocytosis and cancer diagnoses between men and women, and
was confirmed when the differences in cancer incidence between men and women were
revealed.
4.4.2 One year cancer incidence
The one year incidence of cancer was calculated for patients with thrombocytosis and
patients with a normal platelet count as the number of new cancer diagnoses recorded
within one year of index date, as a percentage of the number of patients in the cohort,
reported with binomial 95% confidence intervals. The one year incidence was calculated
for men and women separately, and compared between cohorts.
4.4.3 One year cancer incidence: epidemiological measures
A crude (unadjusted) logistic regression model was fitted to estimate the odds of a can-
cer diagnosis in patients with thrombocytosis compared to those with a normal platelet
count. Odds ratios and 95% confidence intervals were reported. Smoking was included
in the logistic regression model as an interaction term to investigate whether the size
of this association differs between smokers and non-smokers. A fractional polynomial
model was used to model the relationship between cancer incidence and platelet count
as a continuous predictor, accommodating non-linearity in the relationship. Again,
these analyses were performed separately for men and women.
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Figure 4.1: Patient selection process summary
Sample selection process 
The sample included 40,000 patients with thrombocytosis, and 10,000 age, sex, and practice matched patients 
with a normal platelet count. There were several steps in the sample selection process which are illustrated here; 
this is also explained in text in chapter 4.  
The timeline below shows several key points in the patient record which were used in the sample selection and 
data analysis process, for patients in each sub-cohort. 
Patients with thrombocytosis: 
 
 
A: Patient birth date 
B: The date the patient joined their CPRD-contributing practice. This date can be any time from birth until one 
year before index date. 
C: Index date: date of patient’s first raised platelet count since they joined their CPRD-contributing practice. Must 
be aged ≥40 years on this date. Date must be 2000-2013.  
C-D: two year time period in which newly diagnosed cancers are ‘counted’. 
Exclusions:   
 Patient with any recorded cancer diagnosis from A – C. 
 Patient with platelet count of >1000x109/L at C.  
 Patients diagnosed with non-melanoma skin cancer from C – D.  
Potential biases and implications: 
 Patient may have a pre-existing cancer in A – C, that was not recorded in either the CPRD or the cancer 
registry. In this case, their thrombocytosis may be relating to this existing diagnosis. A large number of 
patients in this category could result in an over-estimation of the relationship between thrombocytosis 
and cancer.  
 Patient may have had thrombocytosis in A – B, before their CPRD record began. The thrombocytosis 
taken at the index date could have been related to an earlier, benign, health event. This could also 
contribute to an over-estimation of the relationship between thrombocytosis and cancer.  
 
 
 
 
 
 
 
 
A B
  A 
C D Patient with 
thrombocytosis 
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Patients with a normal platelet count: 
 
 
A comparison cohort of 10,000 patients with a normal platelet count was selected. These were age, sex, and 
practice matched to a random quarter of patients from the 40,000 thrombocytosis cohort.  
 
E: Patient birth date – must be within five years of their thrombocytosis counterpart. 
F: The date the patient joined their CPRD-contributing practice. This date can be any time from birth until one 
year before index date. 
G: Index date: date of patient’s blood test nearest in time to C (their matched patient’s index date) 
G – H: two year time period in which newly diagnosed cancers are ‘counted’. 
X: The index date of the matched thrombocytosis patient.  
Additional selection criteria: to be considered eligible as a comparison patient, the patient must have had a 
platelet count from F – C which was within the normal range.  
 
Exclusions: 
 Patient with any recorded cancer diagnosis from E – G. 
 Patients diagnosed with non-melanoma skin cancer from G – H.  
 If G was later in time than C, some patients had thrombocytosis by G and were excluded. 
Example: 
 
 
 
 
 
 If G was earlier in time than C, some were aged <40 years at G and were excluded. 
Example:
 
 
 
 
 
E F
  A 
G H Patient with 
normal pl count 
X 
E F
  A 
G H 
A B
  A 
C 
D 
Patient with 
thrombocytosis 
Patient with 
normal pl count 
Date of matching. At this point, the platelet count is ‘normal’ as per the blood test at Z. But platelet count at G is 
nearer in time than Z, so is taken as the index date. By that point, the patient may have developed thrombocytosis. 
Z 
E F
  A 
H 
A B
  A 
C 
D 
Patient with 
thrombocytosis 
Patient with 
normal pl count 
Date of matching. Patient with normal platelet count may be aged 40 years on this date. In this case, they would be 
aged <40 years at Z, their index date.  
Z 
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Smoking was also investigated later in the analysis using a stratified comparison of
cancer risk in different smoking status groups.
4.4.4 One year cancer incidence by age group
The effect of age on the risk of cancer in each of the two cohorts was examined using a
stratified analysis with sub-groups defined by age at index date. The one year cancer
incidence and corresponding 95% confidence intervals were estimated separately for
men and women in each age group, for patients with thrombocytosis and with normal
platelet count. As the risk of cancer increases with age, the rate of increase with age was
compared between patients with thrombocytosis and patients with a normal platelet
count. Scatter-plots were produced to show the incidence and 95% confidence intervals
for each age group within each cohort.
4.4.5 Diagnostic interval for one year cancer incidence
The number of days between the index date (the date of the first thrombocytosis)
and the cancer diagnosis date (the diagnostic interval) was determined for patients
diagnosed with cancer in each cohort, to examine whether there were any differences
between the two cohorts in the time to diagnosis following a blood test. This was
expressed as the median number of days, with interquartile range. Histograms of the
diagnostic interval in days were also produced for each of the cohorts. This analysis
was carried out to determine whether the time to diagnosis differed between patients
with thrombocytosis and their normal platelet count comparators.
4.4.6 Medium term risk of cancer
Additional investigation of the distribution of diagnoses in the time after index date
was carried out to determine how useful thrombocytosis could be in terms of expediting
diagnosis by more than three months. In this analysis, the diagnoses in each of the two
cohorts were categorised depending on time after index date (measured in months).
The data were then grouped according to whether or not the diagnosis was recorded
within the first three months after index date, or the last nine months after index date.
The rationale for this was to assess the potential for thrombocytosis to expedite cancer
diagnoses by more than three months; if all cancers in patients with thrombocytosis
were diagnosed within three months of a blood test, it is likely that other clinical signs
and symptoms were present in patients which could have been triggering the suspicion
of cancer in the patient’s GP. Moreover, it is the patients whose diagnosis is made more
than three months after their blood test result for whom the recognition of thrombo-
cytosis as a marker of cancer would be the most clinically useful; if thrombocytosis
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was used as a prompt symptom, they may have been referred for investigations and
therefore diagnosed sooner. Patients diagnosed in the first three months were excluded
from the analysis based on the final nine months.
4.4.7 One year cancer incidence by primary cancer site
The types of cancer diagnosed were compared for the two cohorts of patients. The
primary site of diagnosis was determined from medcodes in the CPRD data or cancer
registry data; where patients were diagnosed with more than one type of cancer, the first
recorded site was taken as the primary site. The methods used to determine the primary
cancer site categories are described above. The following 14 categories were included
for all patients: bladder, renal, leukaemia, lymphoma, myeloma, oesophagus, pancreas,
stomach, brain, colorectal, lung, oral, melanoma, and a miscellaneous category. For
male patients a further two categories were used: testicular and prostate. For female
patients a further four categories were added: breast, cervical, uterine, and ovarian.
In total, therefore, there were 16 cancer site categories for men and 18 for women.
Although men can be diagnosed with breast cancer, none in the cohort were.
The one year incidence of each cancer type was calculated for men and women in
each of the two cohorts and compared. This was reported as a percentage, with 95%
confidence intervals. The one year incidence of each type of cancer excluded patients
who were diagnosed with other types of cancer. In addition, the number of cancers of
each type was expressed as a percentage of the overall number of cancers diagnosed in
each of the two cohorts (for example, the proportion of cancers that were lung, out of
all cancers diagnosed). This was displayed in a pie chart for men with thrombocytosis
and with a normal platelet count, and for women with thrombocytosis and with a
normal platelet count. The types of cancer diagnosed in male and female patients with
thrombocytosis were compared to the cancers diagnosed in the general population.
For this comparison, national UK cancer incidence figures were used from the Cancer
Research UK website (Cancer Research UK, 2012).
4.4.8 Change in platelet count over time
This post-hoc analysis1 was developed to examine the risk of cancer in patients depend-
ing on how their platelet count changed over time. Patients’ records were searched to
1Whilst I was conducting the analysis for this thesis, I gave numerous conference presentations to
multidisciplinary audiences including academics, clinicians, and other professionals. During question
and answer sessions, I was asked several times by clinicians what the risk of cancer was in patients
whose platelet count increased or changed over time. Many mentioned that in a clinical setting very
little is ever done in response to a single test result especially when, like platelet count, it has such a
low specificity, and that clinicians are likely to ‘wait and see’ or repeat the test within a few months to
see if there was any change, and what the direction of change is.
69
4. Thrombocytosis as an early marker of cancer
find any second platelet count or blood test result recorded within six months of their
index date. For some patients, no second count was available. Those who had a second
platelet count available were grouped according to how their platelet count had changed
within this time frame. Thus, four categories were created:
 Increased platelets: the patient’s second platelet count had increased compared
to their first count and was still in excess of 400×109/L, or had remained exactly
the same.
 Decreased platelets: the patient’s second platelet count had decreased compared
to their first count, but was still in excess of 400× 109/L.
 Normalised platelets: the patient’s second platelet count showed that their platelets
had returned to the normal range of 100 - 400× 109/L.
 No second platelet count available.
The risk of cancer (as one year cancer incidence, percentage with 95% confidence
intervals) was compared for men and women with thrombocytosis in each of these four
groups.
4.4.9 Thrombocytosis accompanied by symptoms
The main analysis from this study reflects the risk of a patient being diagnosed with
any type of cancer within one year of a blood test result showing thrombocytosis and
no further clinical information. In a clinical setting, GPs have to decide which type
of cancer is likely to know which investigative tests and procedures would be most
appropriate and most likely to reveal an underlying malignancy. Clinicians will have
information about their patient’s medical history, current symptoms, and their own
clinical judgement in addition to blood test results to aid in the decision making pro-
cess. This analysis was carried out to quantify the risk of cancer in patients with
thrombocytosis and one other relevant symptom. The most common symptoms of the
two most commonly diagnosed cancers seen to be associated with thrombocytosis were
chosen; cough for lung cancer, and change in bowel habit and rectal bleeding for col-
orectal cancer (two symptoms were tested for colorectal as they were equally common).
In addition, two ‘generic’ cancer symptoms, loss of appetite and weight loss, were ex-
amined. In order to ensure that only symptoms near in time to the patients’ index
dates were included in this analysis, only those that were recorded in the three months
before or one month after the index date were used.
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For this analysis, a ‘symptom library’ of relevant medcodes developed by the re-
search group in which this PhD was completed was used to identify medcodes that
indicated the symptom of interest (see Appendix D).
4.4.9.1 Lung cancer and cough
Patients were included in this analysis if they had thrombocytosis and a cough reported
within the four month peri-thrombocytosis period; the three months before and the
one month after their index date. A number of medcodes were used to search for
patients reporting a cough. The one year incidence of lung cancer in these patients was
estimated.
4.4.9.2 Colorectal cancer, rectal bleeding, and change in bowel habit
Patients were included in this analysis if they had thrombocytosis and a record of rectal
bleeding, or thrombocytosis and a change in bowel habit. Medcodes included under
change in bowel habit were those pertaining to diarrhoea, constipation, or ‘change
in bowel habit’. The one year incidence of colorectal cancer in these patients was
estimated.
4.4.9.3 Any cancer and loss of appetite
Patients were included in this analysis if they had thrombocytosis and a medcode
indicating loss of appetite within the four month peri-thrombocytosis period. The
incidence of any type of cancer was estimated for these patients.
4.4.9.4 Any cancer and weight loss
Patients were included in this analysis if they had thrombocytosis and a medcode
indicating weight loss within the same four month time period. The incidence of any
type of cancer was estimated for these patients.
4.4.10 Symptom profiles and NICE guidance
The UK national guidance for diagnosing cancer in primary care (Suspected cancer:
recognition and referral, NG12, NICE (2015)) was updated during the course of this
PhD. In the 2015 update to the guidance, thrombocytosis was included as a marker of
some, but not all, types of cancer primarily in response to evidence that was reviewed
in Chapter 3 of this thesis. The following analyses were carried out for the two most
commonly diagnosed cancers in the cohort; lung and colorectal.
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4.4.11 Lung cancer and NICE guidance
This analysis aimed to estimate what, if any, benefit there could be from the addition
of thrombocytosis as an alarm sign of lung cancer to the 2015 NICE guidance update.
The symptoms reported by patients with thrombocytosis and lung cancer in the year
before their diagnosis were identified and compared to see how many more patients
met the NICE criteria for investigation before and after the addition of thrombocyto-
sis. Patient’s electronic records were searched for any of the symptoms listed by the
NICE guidance for lung cancer; this includes cough, fatigue, shortness of breath, chest
pain, weight loss, and loss of appetite. As the lung cancer guidance varies depend-
ing on whether or not the patient has ever smoked, the analysis was stratified in this
way. The proportion of lung cancer patients who had NICE-qualifying symptoms other
than thrombocytosis in the year prior to diagnosis was calculated. If all patients with
thrombocytosis and lung cancer had other symptoms that would have prompted inves-
tigation then there is little, or no, value in adding thrombocytosis. Thrombocytosis has
the most potential clinical use if the results show a proportion of lung cancer patients
who have thrombocytosis but no other investigation-triggering symptoms prior to their
diagnosis.
4.4.12 Colorectal cancer and NICE guidance
The 2015 NICE update did not include thrombocytosis as a marker of colorectal can-
cer. This analysis was carried out to see what additional benefit there could be from
including thrombocytosis as a marker of cancer to the NICE guidance for diagnosing
colorectal cancer. A similar method was employed as for the earlier described lung
cancer analysis. The electronic records of patients with thrombocytosis and colorectal
cancer were searched for any symptoms listed in the 2015 NICE guidance as warranting
investigation in the year prior to their diagnosis; weight loss, abdominal pain, rectal
bleeding, iron-deficient anaemia, change in bowel habit, or a rectal or abdominal mass.
The symptoms reported by patients with thrombocytosis and lung cancer prior to their
cancer diagnosis were examined. The proportion with symptoms that matched NICE
guidance for referral, and the proportion who did not have symptoms that matched the
guidance (other than thrombocytosis) were compared.
4.4.13 Two year cancer incidence
The risk of cancer in the second year after index date, and in the overall two year
period since index date, was investigated as a sensitivity analysis. Previously defined
variables were used to identify patients who were diagnosed with cancer 1-24 months of
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index date and 13-24 months of index date and the cancer incidence was estimated for
patients in each cohort in these timeframes (with 95% confidence intervals). The types
of cancer diagnosed in the second year were compared for patients with thrombocytosis
and with a normal platelet count.
4.5 The association between thrombocytosis and cancer:
sample characteristics
The following analyses are based on 50, 000 patients who had a full blood count, sub-
divided in to two cohorts; those with thrombocytosis (N = 40, 000) and those with a
normal platelet count (N = 10, 000).
4.5.1 Application of exclusion criteria
10,770 patients were excluded for the following reasons (see Figure 4.2):
1. Pre-existing cancer
8,369 thrombocytosis patients and 1, 581 normal platelet count patients with a
cancer diagnosis dated prior to their index date were excluded because it could
not be determined whether any subsequent records were in reference to a new
cancer, a metastasised cancer, or related to a pre-existing cancer.
2. Platelet count exceeded set limits
Patients were excluded if their platelet counts were too high or too low for their re-
spective groups. 92 patients in the thrombocytosis cohort were excluded because
their index date platelet count exceeded 1, 000×109/L. In the case of four of these
patients, it appeared likely that extra zeros had been mistakenly included in the
test result (for example, 360,000 rather than 360) and so patients had incorrectly
been classified as having thrombocytosis when their platelet count was actually
in the normal range (a platelet count in the hundreds of thousands is biologically
implausible). The remaining 88 were excluded because their platelet counts of
over 1, 000× 109/L indicated either an incorrect test result, or a haematological
malignancy; either of which would have confounded the results.
In the normal platelet count cohort, 374 patients were excluded because their
index platelet count exceeded 400 × 109/L. For patients with a normal platelet
count, an index date was assigned which was the date of their platelet count
nearest in time to the index date of their matched case. Because this index date
was sometimes later than the first normal platelet count, these 374 (3.7%) of
these had thrombocytosis at their index date and so were excluded.
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Figure 4.2: The number of patients excluded from the main cohort due to ineligible
platelet count, pre-existing cancer, or being diagnosed with non-melanoma skin cancer.
3. Non-melanoma skin cancer
278 of the thrombocytosis cohort and 76 of the normal platelet cohort were ex-
cluded as they were diagnosed with non-melanoma skin cancer.
4.5.2 Age profile of the cohorts
After application of the exclusion criteria, the thrombocytosis cohort included 31,261
patients and the normal platelet cohort included 7,969 patients (see Figure 4.2). The
median age at the index date was 68.0 (IQR 57.1-78.1) years in the thrombocytosis
cohort. The median age in the normal platelet cohort was 68.3 (IQR 58.1-78.5) years
(see Table 4.1); although patients were matched on age, the selection of index dates for
normal platelet patients resulted in some minor differences in age at index date. The
ages of the two sub-cohorts are presented as box plots in Figure 4.3. When the age of
the two sub-cohorts was grouped into 10 year age bands, there was an even distribution
of ages across the groups (see Table 4.2).
4.5.3 Comparing cohort age profile with the general population
The age profile of the two study cohorts was compared to the age profile of adults aged
40 years and over in the general population in England. Table 4.3 shows the number
and percentage of the population aged 40 years and over in each ten year age brackets
for the thrombocytosis cohort, the normal platelet cohort, and the general population.
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Table 4.1: Characteristics of patients with thrombocytosis and normal platelet counts
in an English primary care setting.
Thrombocytosis
N = 31, 261
Normal platelet
count N = 7, 969
Age at index date
Age in years, median (IQR) 68.0 (57.1 - 78.1) 68.3 (58.1-78.5)
Sex distribution
Men, n (%) 9,435 (30.2) 2,599 (32.6)
Women, n (%) 21,826 (69.8) 5,370 (67.4)
Platelet count
Count ×109/L, median (IQR) 441 (416-488) 255 (218-299)
Smoking status
Ever smoked, n (%) 17,934 (57.4) 4,212 (52.7)
Never smoked, n (%) 12,668 (40.5) 3,688 (46.3)
No data, n (%) 659 (2.1) 69 (1.0)
Figure 4.3: Box plot showing age distribution of all patients in the thrombocytosis
cohort and the normal platelet count cohort.
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Table 4.2: Number and percentage of patients in each age group, for thrombocytosis
and normal platelet count cohorts.
Thrombocytosis N = 31, 261 Normal platelet count N = 7, 969
Age
group
Men n (%) Women n (%) Men n (%) Women n (%)
40-49 831 (8.8) 2, 744 (12.6) 174 (6.7) 612 (11.4)
50-59 2, 195 (23.3) 4, 056 (18.6) 560 (21.6) 1, 001 (18.6)
60-69 2, 719 (28.8) 4, 578 (21.0) 764 (29.4) 1, 175 (21.9)
70-79 2, 303 (24.4) 5, 441 (24.9) 653 (25.1) 1, 319 (24.6)
≥ 80 1, 387 (14.7) 5, 007 (22.9) 448 (17.2) 1, 263 (23.5)
Table 4.3: Age distribution for patients in the thrombocytosis cohort, the normal
platelet cohort, and in the English general population in 2008. Age is divided into
ten year age brackets and the number and percentage of men and women in each age
group is compared.
Thrombocytosis Normal platelet General population
(N = 31, 261) count (N = 7, 969) (1,000s, N = 25, 101.4)
Age
group
Men n (%)
Women
n (%)
Men n (%)
Women
n (%)
Men
n (%)
Women
n (%)
40-49 831 (8.8) 2, 744 (12.6) 174 (6.7) 612 (11.4)
3, 763.1
(31.6)
3, 825.8
(29.0)
50-59 2, 195 (23.3) 4, 056 (18.6) 560 (21.6) 1, 001 (18.6)
3, 052.7
(25.6)
3, 130.4
(23.8)
60-69 2, 719 (28.8) 4, 578 (21.0) 764 (29.4) 1, 175 (21.9)
2, 586.5
(21.7)
2, 737.4
(20.8)
70-79 2, 303 (24.4) 5, 441 (24.9) 653 (25.1) 1, 319 (24.6)
1, 670.0
(14.0)
1, 980.3
(15.0)
≥ 80 1, 387 (14.7) 5, 007 (22.9) 448 (17.2) 1, 263 (23.5) 850.2
(7.1)
1, 505.0
(11.4)
Total 9,435 21,826 2,599 5,370
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The age distribution differs between the study cohorts and the general population.
For men in the study cohorts, the proportion of patients in each age group increases
through the 40s, 50s, and 60s, peaking in the 60s, and declines thereafter. For women,
the proportion in each age group also steadily increases, but peaks in the 70s and
decreases only slightly in the aged ≥ 80 years group. In the general population, the
age distribution peaks in the 40s and steadily declines into the ≥ 80 years group. This
reflects the current age distribution in the UK general population where the number
of people decreases with age, whereas the patients included in this study are a group
selected based on having had a blood test - the age profile in this cohort is different to
that in the general population. The inclusion of a greater proportion of older patients
in the cohort, compared to the general population, may introduce a degree of bias
to the results as cancer incidence increases with age. However, the main analysis in
this study compares the risk of cancer between patients with raised and those with
normal platelet counts, not with the general population. Between the two cohorts, the
age profile was very similar, as patients were matched on age, so this potential source
of bias was eliminated. It is not possible to generalise the results presented in this
chapter to the general population, a concept which is explored in more depth in the
final chapter of this thesis, although they can be generalised to other patients selected
for blood testing in general practice. The age profile of patients selected for a blood
test cannot be determined with the data used in this study as the normal platelet count
patients are age matched to the thrombocytosis cohort.
4.5.4 Gender profile of the cohort
A greater proportion of the cohort were female; 21,826 (69.8%) of the thrombocytosis
cohort were female, and 5,370 (67.4%) of the normal platelet cohort. There is some
evidence to suggest that women consult primary care more often than men (see Chapter
2), which could explain the higher proportion of women in this randomly selected
sample rather than gender differences in the relationship between thrombocytosis and
cancer. Differences in consulting rates between men and women are greatest in mid-life
and equalise in later life. Around a third of patients in this sample are in mid-life
(see Table 4.2) so it is possible that factors other than differences in consulting rate are
contributing to the higher proportion of women in the sample. Thrombocytosis appears
to be more common in women than in men. Evidence summarised in Chapter 2 suggests
that cancer incidence is higher in men than in women; this may affect the difference
in cancer risks reported between men and women within each cohort. However, the
difference will apply equally to men and women in the thrombocytosis and normal
platelet count cohorts and it is the difference between these two cohorts, rather than
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Figure 4.4: Box plot of platelet count at index date in the thrombocytosis and
normal platelet count cohorts.
between the two genders, which is under investigation in this thesis.
4.5.5 Platelet counts in the cohort
As expected, the median platelet count was higher in the thrombocytosis cohort than
in the normal platelet cohort. The median platelet count in the thrombocytosis cohort
was 441 × 109/L (IQR 416-448). In the normal platelet cohort, the median platelet
count was 255× 109/L (IQR 218-299) (see Table 4.1). The boxplots in Figure 4.4 show
the distribution of platelet count in each of the cohorts.
In the thrombocytosis cohort, patients were selected based on their raised platelet
count, defined as any value over 400 × 109/L. The box plot in Figure 4.4 shows the
majority of the thrombocytosis cohort’s platelet count being in the 400 - 500× 109/L
range whereas the normal platelet count cohort shows a largely normal distribution
grouped around the average platelet count in an adult human (220 - 265 × 109/L)
(Balduini & Noris, 2014).
4.5.6 Time interval between thrombocytosis and normal platelet in-
dex dates
The index date for patients with thrombocytosis was the date of their first raised
platelet count. The index date for the normal platelet count patients was based on the
date of their blood test nearest in time to the index date of their matched comparators
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from the thrombocytosis cohort. The time interval between the index dates for those
with thrombocytosis and their matched normal platelet comparators was examined;
bias could have been introduced to the study if the index dates were later in either
group, as those patients would be older and therefore more likely to be diagnosed
with cancer. The median number of days between the index dates for thrombocytosis
patients and their matched normal platelet counterparts was 145 (IQR -110 to 207; from
110 days later in the thrombocytosis patients to 207 days later in the normal platelet
count patients); the index date was on average later in patients with a normal platelet
count. This time difference of around five months is not likely to have introduced an
important degree of bias to the study.
4.5.7 Smoking status
Smoking data were available for 98% of the thrombocytosis cohort. The majority of
patients (n = 17, 934, 57.4%) were either current or ex-smokers (ever smoked). 12,668
(40.5%) had never smoked. Smoking data were not available for 656 (2.1%). Smoking
data were available for 99% of patients in the normal platelet count cohort. The
majority of these patients had ever smoked (n = 4, 212, 52.7%) and 3,688 (46.3%)
had never smoked. Smoking status was not available for 69 (1%). In both cohorts,
the majority of patients were current or ex-smokers, but a slightly greater proportion
of the thrombocytosis cohort had ever smoked (57.4% vs 52.7%). A sub-analysis in
this chapter stratifies the results by smoking status and smoking is examined as an
interaction term in the logistic regression model.
4.5.8 Symptoms prior to diagnosis
The symptoms reported by each group in the month prior to their index date blood test
are reported in Table 4.4. The ten most common symptoms in patients in each cohort
were listed; eight of these were present in both cohorts. In total, therefore, 12 symptoms
are reported in Table 4.4. All are recognised cancer symptoms, but they were reported
by relatively small, and similar, proportions. Additionally, all are low risk symptoms
which would not generally be expected to prompt urgent cancer investigation NICE
(2015). It is unlikely that a great proportion of the blood tests carried out in the
thrombocytosis group were triggered by a specific suspicion of cancer, as the symptoms
were so similar between the groups.
4.5.9 Geographical region
The geographical region of the practices at which the patients were registered is tab-
ulated in Table 4.5. This shows that some regions of England are underrepresented
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Table 4.4: Symptoms reported by patients in the thrombocytosis and normal platelet
count cohorts in the 28 days prior to their index date (date of blood test showing first
raised platelet count, or equivalent in those with normal platelet counts).
Thrombocytosis Normal platelet
N = 31, 261 count N = 7, 969
Symptom
n with
symptom
%
n with
symptom
%
Cough 1, 221 3.9 151 1.9
Fatigue 942 3 205 2.6
Chest infection 935 3 63 0.8
Abdominal pain 826 2.6 133 1.7
Diarrhoea 716 2.3 63 0.8
Joint pain 704 2.3 149 1.9
Back pain 500 1.6 95 1.2
Chest pain 465 1.5 105 1.3
Shortness of breath 360 1.2 47 0.6
UTI 288 0.9 19 0.2
Dizziness 210 0.7 64 0.8
Palpitations 136 0.4 65 0.8
compared to others; the North East, Yorkshire and the Humber, and East Midlands
have smaller proportions than the other regions. As the thrombocytosis and normal
platelet count patients are practice matched, this difference will not have an effect on
the differences in incidence between the two cohorts. However, it does mean that results
from this study may be less readily applicable in these under-represented regions.
4.6 The association between thrombocytosis and cancer:
results
4.7 One year cancer incidence
The one year cancer incidence was estimated in patients with thrombocytosis and a
normal platelet count to address the objective of comparing the incidence between these
two cohorts to determine the absolute increase in risk associated with thrombocytosis.
4.7.1 Thrombocytosis cohort
There were 3, 050 qualifying cancer diagnoses in the thrombocytosis cohort (excluding
non-melanoma skin cancers). The majority (n = 2, 453, 80.4%) were diagnosed within
one year of their index date. 1, 098 (44.8%) of those with cancer were male and 1, 355
(55.2%) were female. The one year cancer incidence for males in the thrombocytosis
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Table 4.5: Number and percentage of patients registered at practices in each geo-
graphical region.
Region n (%)
North East 1,427 (2.9)
North West 8,005 (16.0)
Yorkshire and the Humber 2,097 (4.2)
East Midlands 1,718 (3.4)
West Midlands 6,242 (12.5)
East England 6,176 (12.4)
South West 6,979 (14.0)
South Central 6,103 (12.2)
London 5,310 (10.6)
South East Coast 5,943 (11.9)
cohort was 11.6% (95% CI 11.0-12.3). For females, the one year incidence was 6.2%
(95% CI 5.9-6.5). These results are shown in Table 4.6.
4.7.2 Normal platelet count cohort
The one year incidence of cancer was also estimated for patients with a normal platelet
count. There were 332 qualifying diagnoses in this cohort. The majority (n = 225,
67.8%) were diagnosed within one year of their index date. 106 (47.1%)of these were in
males and 119 (52.9%) were in females. The one year cancer incidence for males with
a normal platelet count was 4.1% (3.4-4.9). For females, the one year incidence was
2.2% (1.8-2.6).
4.7.3 Comparison of one year cancer incidence between cohorts
These results show that the one year incidence of cancer is higher in patients with
thrombocytosis, compared to those with a normal platelet count. The results here
and for the rest of this chapter are presented separately for men and women, due to
the difference in the magnitude of the association between these two sub-groups. In all
patients with thrombocytosis the risk in male patients was almost double that in female
patients. In patients with a normal platelet count the difference in risk between the two
sexes is also roughly doubled. There is a similar magnitude of difference in risk between
men and women with thrombocytosis and men and women with normal platelet counts.
This suggests the higher cancer incidence seen in men is not mediated by differences in
the relationship between platelets and cancer in men and women, but by other factors
such as variance in consulting behaviour (women consult more often than men) or
underlying cancer incidence (which is higher in men than in women), or more benign
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causes of thrombocytosis in women than in men. If there was a relationship between
gender and the platelet-cancer interaction, then we could expect to see a difference in
the magnitude of risk between men and women with thrombocytosis, and men and
women with a normal platelet count. This is explored further in Chapter 6.
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Table 4.6: The one year cancer incidence for patients with thrombocytosis and patients with a normal platelet count. N: number,
CI: confidence interval.
Thrombocytosis Normal platelet count
Men Women Men Women
Time
from
index
date
(months)
N
n cancers
diagnosed,
incidence
% (95% CI)
N
n cancers
diagnosed,
incidence
% (95% CI)
N
n cancers
diagnosed,
incidence
% (95% CI)
N
n cancers
diagnosed,
incidence
% (95% CI)
1-12 9, 435
1, 098
11.6 (11.0-12.3)
21, 826
1, 355
6.2 (5.9-6.5)
2, 599
106
4.1 (3.4-4.9)
5, 370
119
2.2 (1.8-2.6)
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4.8 Epidemiological measures
The relationship between thrombocytosis and cancer was investigated using logistic
regression to examine cancer occurrence (outcome) in relation to thrombocytosis as a
binary predictor. In a crude (unadjusted) model, patients with thrombocytosis were
more likely to be diagnosed with cancer than those with normal platelet counts (OR 2.9,
95% CI 2.6-3.4, p < 0.0001). Logistic regression was used to examine the interaction
between patients’ smoking status and platelet count with respect to cancer incidence.
There was little evidence of an interaction between smoking and thrombocytosis (p =
0.94).
Cancer occurrence was also examined in relation to platelet count as a continuous
variable (see Figure 4.5). The one year cancer incidence for the entire cohort of patients,
including those with thrombocytosis and normal platelet count, is shown in Figure
4.5 for men (a) and women (b). Both show a steady increase in the risk of cancer
(and corresponding confidence intervals) with increasing platelet count. The graph for
male patients (a) shows an increasing risk of cancer with increasing platelet count. In
contrast, the graph for female patients (b) shows a convex profile in the increase in
risk of cancer with increasing platelet count, suggesting that the effect is limited above
platelet counts of 1, 000× 109/L.
4.9 Diagnostic interval for one year cancer incidence
The diagnostic interval was calculated for each cohort; this is the number of days
between the patient’s index date and their recorded cancer diagnosis date, summarised
using the median and interquartile range. The diagnostic interval was also examined
graphically, to compare the distribution between the two cohorts. The results that
follow are based on the one year cancer incidence. For this analysis the diagnostic
interval is defined as the time between a blood test result and the patients’ cancer
being diagnosed.
4.9.1 Thrombocytosis cohort
The median number of days from index date to diagnosis in this cohort was 33 (IQR
2-106) and ranged from 1 to 353 days. The diagnostic interval in this cohort of patients
is shown in Figure 4.6 (a). The histogram shows that the majority of cancers in this
cohort were diagnosed within the first 100 days after diagnosis.
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(a)
(b)
Figure 4.5: (a) fractional polynomial logistic regression model with platelet count as
a continuous predictor variable for men aged over 40 years. (b) fractional polynomial
logistic regression model with platelet count as a continuous predictor variable for
women aged over 40 years.
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4.9.2 Normal platelet count cohort
The median number of days from index date to diagnosis in this cohort was 50 (IQR
21-129) and ranged from 1 to 365 days. The diagnostic interval in this group of patients
is shown in Figure 4.6 (b). This histogram also shows the majority of cancer diagnoses
in this cohort are recorded within 100 days of the blood test date.
4.9.3 Comparison of diagnostic intervals between cohorts
When comparing the histograms of the diagnostic interval in days between index date
and date of cancer diagnosis for patients with thrombocytosis and normal platelets,
both show most diagnoses being recorded within the first 100 days after the blood test
result. The median number of days to diagnosis was greater by 17 days in the normal
platelet count cohort. One potential limitation of this study is that, in patients with
thrombocytosis, blood tests may have been ordered by general practitioners who already
suspected malignancy in the patients for other reasons. The similar pattern of interval
prior to diagnosis in each cohort suggest that cancer diagnoses were made slightly
earlier in the thrombocytosis cohort compared to the normal platelet count cohort.
A sub-analysis presented in the next section of this chapter compares the proportion
of new diagnoses made 1-3 and 4-12 months after index date on the assumption that
cancers in the latter time period were unlikely to be have been suspected at the time
of the blood test.
4.10 Medium term risk of cancer
This sub-analysis split the one year incidence of cancer in to two time periods; the
first three months and the last nine months after index date. Of the 2, 453 new cancer
diagnoses made in the thrombocytosis cohort, 1, 610 (65.6%) were made in the 1-3
month time period and 843 (34.4%) were made within the 4-12 month time period.
Thus, around one third of cancers in patients with thrombocytosis are diagnosed more
than three months after a blood test result showing raised platelets.
4.11 One year cancer incidence by age group
The relationship between age and cancer incidence is estimated here with an analysis
stratified by age group. The risk of most types of cancer increases with age. The data
were examined to determine whether the risk of cancer in patients with thrombocytosis
increases with age in line with or beyond the increase that would be expected with age,
as measured against patients with normal platelet counts.
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(a)
(b)
Figure 4.6: Histograms to show the number of days between patient’s index date
and their cancer diagnosis for (a) thrombocytosis cohort and (b) normal platelet count
cohort.
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Table 4.7: Table to show the number and percentage of patients in each age group in
the thrombocytosis and normal platelet count cohorts, and the number and percentage
of these with a new cancer diagnosis within a year of index date age brackets and the
number and percentage of men and women in each age group is compared.
Thrombocytosis Normal platelet
N = 31, 261 count N = 7, 969
Age
group
(years)
n in
group
n diagnosed,
% (95% CI)
n in
group
n diagnosed,
% (95% CI)
40-49 3, 575 78, 2.2 (1.7-2.7) 786 10, 1.3 (0.9-2.1)
50-59 6, 251 300, 4.8 (4.3-5.3) 1, 561 25, 1.6 (1.0-2.2)
60-69 7, 297 642, 8.8 (8.1-9.4) 1, 939 52, 2.7 (2.0-3.4)
70-79 7, 744 826, 10.7 (10.0-11.4) 1, 972 76, 3.9 (3.0-4.7)
≥ 80 6, 394 607, 9.5 (8.8-10.2) 1, 711 62, 3.6 (2.7-4.5)
4.11.1 Thrombocytosis cohort
The risk of malignancy increased with age in the thrombocytosis cohort. The one year
cancer incidence increased from 2.2% in patients aged 40-49 years and peaked at 10.7%
in those aged 70-79 years (see Table 4.7). The scatter plot in Figure 4.7 shows the one
year cancer incidence by age group for male and female patients with thrombocytosis
separately. In those aged 40-49 years and 50-59 years there was no difference in the
risk between males and females. However, with increasing age, the difference between
males and females became more pronounced. Men were at significantly higher risk than
women from age 60 years onwards. The line of best fit for men with thrombocytosis
shows a continued increase in later years compared to female patients for whom the risk
appears to decline slightly with age over about 80 years. UK cancer incidence figures
discussed in Chapter 2 show a decrease in new diagnoses in this age group.
4.11.2 Normal platelet count cohort
For patients with a normal platelet count, the cancer risk also increases with age,
similarly to national statistics. The risk increases from 1.3% in those aged 40-49 and
peaks at 3.9% in those aged 70-79 (see Table 4.7). Although the risk increases with
each decade of age, the actual increase from one group to the next is small. The scatter
plot in Figure 4.8 shows the one year cancer incidence for male and female patients
with a normal platelet count separately. While the plot shows an upwards trend, the
line of best fit suggests that cancer incidence continues to rise in men, but does not rise
further above a certain age in women.
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Figure 4.7: Scatter plot to show the risk of cancer diagnosis for men and women
with thrombocytosis in five age groups.
Figure 4.8: Scatter plot to show the risk of cancer diagnosis for men and women
with a normal platelet count in five age groups.
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(a)
(b)
Figure 4.9: The percentage of men (a) and women (b) with thrombocytosis and
normal platelet counts in different age groups diagnosed with cancer within one year
of a platelet count record, with 95% confidence intervals.
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4.11.3 Comparison of risk with age between cohorts
The risk of cancer increased with age in both cohorts but those with thrombocytosis
were at consistently greater risk than those with normal platelet counts across all ages,
except for those in their 40s. The greatest difference in risk between thrombocytosis
and normal platelet was in those aged 60-69 years. The confidence intervals for each
group suggest that there is a difference in risk between the two groups in those aged 50
and over. These results are presented graphically in Figure 4.8; this shows the cancer
risk increasing with age in both thrombocytosis and normal platelet cohorts, but the
steeper gradient in patients with thrombocytosis indicates that the risk increases with
age at a greater rate than in those with a normal platelet count. These differences are
likely to be due to differences in platelet count and incidence with age, not differences in
the biology of the interaction between cancer and platelets between patients of different
ages.
4.11.4 Cancer incidence stratified by smoking status
Patients in each of the two cohorts were grouped based on whether they had ever
smoked (current or past, or never smoked) and the incidence of cancer was compared
between the two groups. For men with thrombocytosis, the cancer incidence among
those who had ever smoked was 11.8 % (95% CI 11.1-12.6), and the incidence in those
who had never smoked was 9.9% (95% CI 8.7-11.2).
For women with thrombocytosis, the cancer incidence among those who had ever
smoked was 6.4% (95% CI 5.9-6.9), and the incidence in those who had never smoked
was 5.7% (95% CI 5.3-6.2).
4.12 One year cancer incidence by primary cancer site
The following analysis will address the objective of determining whether some types of
cancer are more likely to be diagnosed in patients with thrombocytosis compared to
patients with a normal platelet count.
The type of cancer (primary cancer site) diagnosed in patients with thrombocytosis
and with normal platelet counts is described below. All cancer diagnoses in the cohort
were categorised into 20 groups based on site of diagnosis - these are described in the
methods section 4.4.7.
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Table 4.8: Cancers diagnosed in patients with thrombocytosis (TH) and a normal platelet count (NPC) within one year of index
date. Each column shows the number of each type of cancer, the percentage of all cancers in this group, and the incidence of that
type of cancer in that group, for men and women. Each incidence figure excludes patients diagnosed with any of the other types of
cancer. n = number of cancer diagnoses recorded for that group. % = percentage of all cancers diagnosed in that group.
1st year after index date 1st year after index date
Men with TH Men with NPC Women with TH Women with NPC
Cancer site n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
Bladder 45 4.1 0.6 (0.4-0.7) 11 10.4 0.4 (0.2-0.8) 36 2.7 0.2 (0.1-0.2) 3 2.5 0.1 (0.0-0.2)
Brain 8 0.73 0.3 (0.2-0.5) 2 1.9 0.2 (0.1-0.5) 10 0.7 0.2 (0.1-0.2) 3 2.5 0.1 (0.0-0.2)
Breast - - - - - - 77 5.7 0.4 (0.3-0.5) 23 19.3 0.5 (0.3-0.7)
Cervix - - - - - - 10 0.7 0.1 (0.0-0.1) 4 3.4 0.1 (0.0-0.2)
Colorectal 226 20.6 2.7 (2.4-3.1) 10 9.4 0.4 (0.2-0.7) 317 23.4 1.6 (1.4-1.7) 22 18.5 0.4 (0.3-0.6)
Kidney 30 2.7 0.4 (0.2-0.5) 1 0.9 0.0 (0.0-0.2) 37 2.7 0.2 (0.1-0.3) 2 1.7 0.0 (0.0-0.1)
Leukaemia 20 1.8 0.3 (0.2-0.3) 4 3.8 0.2 (0.1-0.2) 29 2.1 0.1 (0.1-0.2) 2 1.7 0.0 (0.0-0.1)
Lung 273 24.9 3.2 (2.9-3.6) 11 10.4 0.4 (0.2-0.7) 220 16.3 1.1 (0.9-1.2) 13 10.9 0.3 (0.1-0.4)
Lymphoma 31 2.8 0.4 (0.3-0.5) 3 2.8 0.1 (0.0-0.4) 34 2.5 0.2 (0.1-0.2) 3 2.5 0.1 (0.0-0.2)
Melanoma 7 0.6 0.1 (0.0-0.2) 2 1.9 0.1 (0.0-0.3) 16 1.2 0.1 (0.0-0.1) 1 0.8 0.0 (0.0-0.1)
Myeloma 11 1 0.1 (0.1-0.2) 0 0 0 11 0.8 0.1 (0.0-0.1) 1 0.8 0.0 (0.0-0.1)
Oesophagus 43 3.9 0.5 (0.4-0.7) 5 4.7 0.2 (0.1-0.5) 22 1.6 0.1 (0.1-0.2) 1 0.8 0.0 (0.0-0.1)
Oral 14 1.3 0.2 (0.1-0.2) 1 0.9 0.0 (0.0-0.2) 4 0.3 0.0 (0.0-0.1) 1 0.8 0.0 (0.0-0.1)
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1st year after index date 1st year after index date
Men with TH Men with NPC Women with TH Women with NPC
Cancer site n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
Other 177 16.1 2.0 (1.7-2.3) 19 17.9 0.7 (0.4-1.2) 290 21.4 1.4 (1.2-1.5) 17 14.3 0.3 (0.2-0.5)
Ovary - - - - - - 105 7.8 1.3 (1.1-1.4) 5 4.2 0.8 (0.7-0.9)
Pancreas 39 3.6 0.5 (0.3-0.7) 6 5.7 0.2 (0.1-0.5) 47 3.5 0.2 (0.2-0.3) 4 3.4 0.1 (0.0-0.2)
Prostate 120 10.9 1.4 (1.2-1.7) 28 26.4 1.1 (0.7-1.6) - - - - - -
Stomach 45 4.1 0.7 (0.5-0.9) 3 2.8 0.1 (0.0-0.4) 45 3.3 0.2 (0.2-0.3) 3 2.5 0.1 (0.0-0.2)
Testis 2 18 0.0 0 0 0 - - - - - -
Uterus - - - - - - 40 3.0 0.2 (0.2-0.3) 9 7.6 0.2 (0.1-0.2)
All cancers 1, 098 100
11.6
(11.0-12.3)
106 100 2.7 (2.4-3.1) 1,355 100 6.2 (5.9-6.5) 119 100 1.8 (1.6-2.0)93
4. Thrombocytosis as an early marker of cancer
4.12.1 Thrombocytosis cohort
For men with thrombocytosis, there were 1, 098 cancers diagnosed in the first year after
their index date. The incidence of each type of cancer diagnosed is shown by primary
cancer site in Table 4.8. The three most commonly diagnosed cancers in men in the
general population are lung, colorectal, and prostate cancer - this was also the case for
men with thrombocytosis. The one year incidence of lung cancer was 3.2% (95% CI
2.9-3.6). For colorectal cancer, it was 2.7% (95% CI 2.4-3.1) and for prostate cancer
it was 1.4% (95% CI 1.2-1.7). The proportion of each type of cancer diagnosed out of
all cancers is shown in the pie chart in Figure 4.10. The most commonly diagnosed
cancers were lung (n = 273, 24.9% of cancers diagnosed); colorectal (n = 226, 20.6%);
and prostate (n = 120, 10.9%). There were fewer cases in the next most commonly
diagnosed cancers: bladder (n = 45, 4.1%) and stomach (n = 45, 4.1%).
For female patients with thrombocytosis, there were 1, 355 cancers diagnosed in the
first year after index date. The one year incidence of each type of cancer diagnosed
is shown by primary cancer site in Table 4.8. For lung cancer this was 1.1% (95% CI
0.9-1.2). For colorectal cancer, it was 1.6% (95% CI 1.4-1.7) and for breast cancer it
was 0.4% (95% CI 0.3-0.5). The proportion of each type of cancer diagnosed out of all
cancers in women with thrombocytosis is shown in the pie chart in Figure 4.11. In this
sub-group, the most common diagnosed cancers were colorectal (n = 317, n=23.4%);
lung (n = 220, 16.2%); and ovarian (n = 105, 7.8%).
4.12.2 Normal platelet count cohort
For men with a normal platelet count, there were 106 cancers diagnosed in the first
year after their index date. The incidence of each type of cancer diagnosed is shown by
primary cancer site in Table 4.9. For men with a normal platelet count, the one year
incidence of the most commonly diagnosed cancers was 0.4% (95% CI 0.2-0.8) for lung
cancer. For colorectal cancer, it was 0.4% (95% CI 0.2-0.7) and for prostate cancer it
was 1.1% (95% CI 0.7-1.6). When each type of cancer was reported as the proportion
of all cancers diagnosed, the most commonly diagnosed cancers were prostate (n = 28,
26.4 of all diagnosed cancers in this group); lung (n = 11, 10.4%); bladder (n = 11,
10.4%); and colorectal (n = 10, 9.4%) (see Figure 4.12).
For female patients with a normal platelet count, there were 119 cancers diagnosed
in the first year after index date. The incidence of each type of cancer diagnosed is
shown by primary cancer site in Table 4.9. The one year incidence of lung cancer was
0.3% (95% CI 0.1-0.4). For colorectal cancer, it was 0.4% (95% CI 0.3-0.6) and for
breast cancer it was 0.5% (95% CI 0.3-0.7). When each type of cancer was reported
as the proportion of all cancers diagnosed, the most commonly diagnosed cancers were
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Figure 4.10: Pie chart to show the proportion of different types of cancer diagnosed
in men with thrombocytosis within one year of index date (date of first raised platelet
count). Corresponding values available in Table 4.8.
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Figure 4.11: Pie chart to show the proportion of different types of cancer diagnosed
in women with thrombocytosis within one year of index date (date of first raised
platelet count). Corresponding values available in Table 4.8.
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breast (n = 23, 19.3%); colorectal (n = 22, 18.5); lung (n = 13, 10.9%); uterine (n = 9,
7.6%); ovarian (n = 5, 4.2%). The percentage of cancers diagnosed at each site in
female patients is presented in the pie chart (see Figure 4.13).
97
4
.
T
h
ro
m
b
o
c
y
to
sis
a
s
a
n
e
a
rly
m
a
rk
e
r
o
f
c
a
n
c
e
r
Table 4.9: Cancers diagnosed in patients with thrombocytosis (TH) and a normal platelet count (NPC) within the second year after
index date. Each column shows the number of each type of cancer, the percentage of all cancers in this group, and the incidence of
that type of cancer in that group, for men and women. Each incidence figure excludes patients diagnosed with any of the other types
of cancer, and patients diagnosed in the first year. % =percentage of all cancers diagnosed in that group.
2nd year after index date 2nd year after index date
Men with TH Men with NPC Women with TH Women with NPC
Cancer site n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
Bladder 13 5.8 0.2 (0.1-0.3) 3 8.6 0.1 (0.0-0.4) 11 3 0.1 (0.0-0.1) 1 1.4 0.0 (0.0-0.1)
Brain 0 0 0 1 2.9 0.2 (0.0-0.4) 6 1.6 0.1 (0.1-0.2) 0 0 0
Breast - - - - - - 57 15.3 0.3 (0.2-0.4) 17 23.6 0.3 (0.2-0.5)
Cervix - - - - - - 4 1.1 0.0 (0.0-0.1) 3 4.1 0.1 (0.0-0.1)
Colorectal 30 13.4 0.4 (0.2-0.5) 0 0 0 54 14.5 0.3 (0.2-0.3) 7 9.7 0.1 (0.0-0.3)
Kidney 8 3.6 0.1 (0.0-0.2) 1 2.9 0.0 (0.0-0.2) 7 1.9 0.0 (0.0-0.1) 1 1.4 0.0 (0.0-0.1)
Leukaemia 11 4.9 0.1 (0.0-0.1) 1 2.9 0.0 (0.0-0.2) 21 5.6 0.2 (0.1-0.2) 4 5.6 0.1 (0.0-0.1)
Lung 45 20.1 0.6 (0.4-0.7) 5 14.3 0.2 (0.0-0.5) 35 9.4 0.2 (0.1-0.2) 8 11.1 0.2 (0.0-0.3)
Lymphoma 6 2.7 0.1 (0.0-0.2) 1 2.9 0.0 (0.0-0.2) 7 1.9 0.0 (0.0-0.1) 1 1.4 0.0 (0.0-0.1)
Melanoma 3 1.3 0.0 (0.0-0.1) 0 0 0 14 3.8 0.1 (0.0-0.1) 3 4.2 0.1 (0.0-0.2)
Myeloma 3 1.3 0.0 (0.0-0.1) 0 0 0 4 1.1 0.0 (0.0-0.1) 1 1.4 0.0 (0.0-0.1)
Oesophagus 7 3.1 0.1 (0.0-0.2) 2 5.7 0.1 (0.0-0.3) 7 1.9 0.0 (0.0-0.1) 2 2.8 0.0 (0.0-0.1)
Oral 2 0.9 0.0 (0.0-0.1) 3 8.6 0.0 (0.0-0.3) 7 1.9 0.0 (0.0-0.1) 3 4.2 0.0 (0.0-0.1)
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2nd year after index date 2nd year after index date
Men with TH Men with NPC Women with TH Women with NPC
Cancer site n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
n %
Incidence
% (95% CI)
Other 40 17.9 0.5 (0.3-0.6) 10 28.6 0.4 (0.2-0.7) 93 25 0.4 (0.4-0.5) 12 16.7 0.2 (0.1-0.4)
Ovary - - - - - - 14 3.8 0.4 (0.3-0.6) 1 1.3 0.3 (0.2-0.5)
Pancreas 5 2.2 0.1 (0.0-0.1) 1 2.9 0.0 (0.0-0.2) 11 3 0.1 (0.0-0.1) 5 6.9 0.1 (0.0-0.2)
Prostate 45 20.1 0.6 (0.4-0.7) 5 14.3 0.2 (0.1-0.5) - - - - - -
Stomach 5 2.2 0.1 (0.1-0.2) 1 2.9 0.2 (0.1-0.5) 8 2.1 0.3 (0.2-0.4) 0 0 0.1 (0.0-0.3)
Testis 0 0 0 0 0 0 - - - - - -
Uterus - - - - - - 9 2.4 0.3 (0.2-0.4) 3 4.1 0.1 (0.0-0.1)
All cancers 224 100 4.1 (3.4-4.9) 35 100 1.4 (1.0-1.9) 373 100 2.2 (1.8-2.6) 72 100 1.4 (1.1-1.7)99
4. Thrombocytosis as an early marker of cancer
4.12.3 Comparison of primary cancer site between cohorts
In terms of cancer incidence, the difference in risk between patients with thrombocytosis
and a normal platelet count was most pronounced for lung and colorectal cancer. The
one year incidence of lung cancer in men with thrombocytosis was 3.2% (95% CI 2.9-
3.6); significantly higher than the value of 0.4% (95% CI 0.2-0.7) in men with a normal
platelet count. The added risk posed by thrombocytosis, or the absolute increase in
risk, is 2.8%. Similarly, the absolute increase in risk of colorectal cancer in patients with
thrombocytosis compared to those with a normal platelet count was 2.3%; an increase
from 0.4% (95% CI 0.2-0.7) in patients with a normal platelet count to 2.7% (95% CI
2.4-3.1) in patients with thrombocytosis. However, for prostate cancer, there was little
evidence of a difference in incidence between patients with thrombocytosis and patients
with a normal platelet count (thrombocytosis: 1.4% (95% CI 1.2-1.7); normal platelet
count 1.1% (95% CI 0.7-1.6).
In males, lung and colorectal cancer were much more commonly diagnosed in pa-
tients with thrombocytosis than in patients with a normal platelet count (lung: 25% of
incidence cases vs 10%; colorectal: 21% vs 9%). Conversely, prostate cancer was much
less frequently diagnosed in patients with thrombocytosis compared to those with a
normal platelet count (11% of incidence cases in men with thrombocytosis, 26% in men
with a normal platelet count).
In female patients, there was a smaller increase in the risk of lung and colorectal in
those with thrombocytosis compared to those with a normal platelet count. The risk
of lung cancer increased from 0.3% (95% CI 0.1-0.4) in patients with a normal platelet
count to 1.1% (95% CI 0.9-1.2) in patients with thrombocytosis; an absolute increase
of 0.8%. For colorectal cancer, there was a 1.1% increase from 0.4% (95% CI 0.3-0.6) in
patients with a normal platelet count to 1.6% (95% CI 1.4-1.7) in patients with throm-
bocytosis. The risk of breast cancer was no higher in patients with thrombocytosis;
0.4% (95% CI 0.3-0.5) in patients with thrombocytosis and 0.5% (95% CI 0.3-0.7) in
patients with a normal platelet count.
For female patients, colorectal and lung cancer had a higher incidence and were
more commonly diagnosed in females with thrombocytosis than in those with a nor-
mal platelet count. Lung cancer accounted for 16% of incident cases in women with
thrombocytosis vs 11% in women with a normal platelet count. Colorectal cancer ac-
counted for 23% of cases in women with thrombocytosis and 19% in women with a
normal platelet count. Although breast cancer incidence did not differ widely between
patients with thrombocytosis and a normal platelet count, breast cancer accounted for
a much smaller proportion of all incidence cases in women with thrombocytosis; 6% vs
19% of all incident cases. This could be misinterpreted as thrombocytosis protecting
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Figure 4.12: Pie chart to show the proportion of different types of cancer diagnosed
in men with a normal platelet count within one year of index date (date of first raised
platelet count). Corresponding values available in Table 4.9.
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Figure 4.13: Pie chart to show the proportion of different types of cancer diagnosed
in women with a normal platelet count within one year of index date (date of first
raised platelet count). Corresponding values available in Table 4.9.
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against breast cancer; this is not the case. Breast cancer is less commonly diagnosed in
patients with thrombocytosis compared to those with a normal platelet count, and this
analysis reports the percentage of each type of cancer diagnosed out of all diagnoses in
each cohort.
The differences described here suggest that thrombocytosis is more strongly associ-
ated with some types of cancer than others. Not only are patients with thrombocytosis
more likely to be diagnosed with cancer, but they are more likely to be diagnosed
with lung or colorectal cancer than a patient with a normal platelet count. Breast
and prostate cancer are less commonly diagnosed in patients with thrombocytosis com-
pared to patients with a normal platelet count. The evidence reviewed in Chapter 2
found that the lungs are an important site for platelet production; this could be part of
the explanation for the stronger relationship between thrombocytosis and lung cancer
compared to other cancer sites. Colorectal cancer is often associated with bleeding; a
condition which usually induces the production of platelets. For other types of cancer,
incidence was higher in patients with thrombocytosis than in patients with a normal
platelet count - specifically for stomach and kidney cancer and for lymphoma. For other
cancer types, the difference was less pronounced. However, for these types of cancer
there were few incident cases in either cohort; a larger sample size may have revealed
larger differences in incidence.
4.12.4 Comparison of cancer site between the thrombocytosis cohort
and the general population
The cancers diagnosed in the thrombocytosis cohort were compared to national cancer
incidence data showing the most common types of cancer in the general population.
The pie chart in Figure 4.14 shows the proportion of each type of cancer diagnosed
in men with thrombocytosis in the outer ring, and the incidence of the most common
cancer types in the general population in the inner ring (image from CRUK).
Lung and colorectal cancer were most commonly diagnosed in the thrombocyto-
sis group and were diagnosed more commonly in these patients than in the general
population. Prostate cancer was the most commonly diagnosed cancer in the gen-
eral population, accounting for a quarter of all cancers in men over 40 years of age.
Bowel and lung cancer are the second most commonly diagnosed, accounting for 14%
of diagnoses each.
In females with thrombocytosis, colorectal was the most commonly diagnosed cancer
(23% of diagnoses) followed by lung (16%) and breast (6%) (see Figure 4.15). In the
general population, breast is the most commonly diagnosed cancer in women (30% of
all cases). Colorectal and lung are the second most commonly diagnosed (11% and
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Figure 4.14: Pie chart to show commonly diagnosed cancer types in men. Outer ring
shows incidence of cancers diagnosed at different sites in men with thrombocytosis.
Inner ring shows incidence of cancer types in the general population. OG: oesophago-
gastric (image and values from Cancer Research UK).
Figure 4.15: Pie chart to show commonly diagnosed cancer types in women. Outer
ring shows incidence of cancers diagnosed at different sites in men with thrombocytosis.
Inner ring shows incidence of cancer types in the general population (image and values
from Cancer Research UK).
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12% respectively). Colorectal cancer in women with thrombocytosis accounts for more
than double the proportion of total diagnoses compared to the general population
(23% vs 11%). Conversely, the proportion of breast cancer diagnoses in women with
thrombocytosis is less than a quarter of that in the general population (6% vs 31%).
4.13 The relationship between change in platelet count
over time and cancer
The analyses presented thus far reflect the patient’s risk of being diagnosed with cancer
within one year of having a single blood test result showing thrombocytosis. In a
clinical setting, patients will often have multiple blood tests measuring platelet count
over time. Therefore, the objective of this analysis was to investigate how patient’s risk
of cancer changes depending on how their platelet count changes over time. Only the
thrombocytosis cohort were included in this analysis. Sub-groups were defined based
on the value of the patients’ second platelet count, if taken within six months of their
index date. The results are based on one year cancer incidence. The sub-groups were:
1. Increased platelets (second blood test shows an increase in platelet count (or the
same reading));
2. Decreased platelets (second blood test shows a decrease in platelet count, but still
exceeding normal values);
3. Normalised platelets (second blood test shows a decrease in platelet count to
normal levels);
4. No second platelet count available.
The number of patients in each of these categories and the corresponding one-year
incidence of cancer in each group is shown in (Table 4.10). The risk of cancer was
greatest in males whose next platelet count showed an increase in platelets or the
same platelet count: the cancer incidence was 18.1% (95% CI 15.9-20.5). The cancer
incidence in those whose next platelet count decreased, but still exceeded 400× 109/L
was 15.5% (95% CI 13.3-17.8). In patients whose platelet count returned to normal
within six months, the cancer incidence was 7.1% (95% CI 6.2-8.1). Finally, the cancer
incidence was 8.5% (95% CI 7.8-9.3) in those for whom no second platelet count was
available.
For female patients, the same four groups were examined. Those whose second
platelet count was still abnormally high were at the greatest risk of cancer, with an
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Table 4.10: The one year cancer incidence for men and women with thrombocytosis
categorised by their change in platelet count over time. Increasing platelets: second
platelet count within six months shows an increase in count or the same count. De-
creasing platelets: second platelet count has decreased compared to the first, but is
still within the abnormal range. Normalising platelets: second platelet count shows
that levels have returned to the normal range. N : sample size.
Men Women
N
Incidence
% (95% CI)
N
Incidence
% (95% CI)
Increasing platelets 1, 121
18.1
(15.9-20.5)
2, 637
10.1
(9.0-11.3)
Decreasing platelets 1, 061
15.5
(13.3-17.8)
2, 522
7.3
(6.3-8.4)
Normalising platelets 3, 065
7.1
(6.2-8.1)
6, 314
4.0
(3.5-4.5)
No second platelet count 5, 767
8.5
(7.8-9.3)
13, 615
4.5
(4.2-4.9)
increasing or steady platelet count presenting the greatest risk (cancer incidence 10.1%,
95% CI 9.0-11.3). A lower second reading, still within the abnormal range, resulted in
a one–year cancer incidence of 7.3% (95% CI 6.3-8.4). Finally, for those whose second
platelet count showed a return to normal value, the cancer incidence was 4.0% (95% CI
3.5-4.5). For females with no second platelet count within six months, the value was
4.5% (95% CI 4.2-4.9).
4.14 Thrombocytosis accompanied by symptoms
Most cancers are diagnosed through primary care consultations in which patients
present to their GP with symptoms. The primary analysis in this thesis investigated
the risk of any type of cancer being diagnosed within one year of a single raised platelet
count irrespective of other features, whereas in a clinical setting, GPs will use the pa-
tient’s symptoms, past medical history, risk factors, and their own clinical judgement
to consider which type of cancer, if any, is likely in the patient. The following anal-
yses addressed the objective of investigating the risk of cancer in patients who report
symptoms in addition to thrombocytosis. The most common symptoms for the two
most common cancers in patients with thrombocytosis were chosen: cough as a sign
of lung cancer (Hamilton et al., 2005a), and rectal bleeding and change in bowel habit
as symptoms of colorectal cancer (Hamilton et al., 2005b) Two common vague and
‘generic’ symptoms of many types of cancer, weight loss and loss of appetite, were also
studied. Only symptoms recorded within the month prior to or three months after the
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index date were included in this sub–analysis, to maximise the chance that both the
thrombocytosis and the additional symptom were related to the same clinical episode.
4.14.1 Lung cancer and cough
A cough is the most common symptom of lung cancer in adults; around 65% of pa-
tients subsequently diagnosed with lung cancer consult their GP with a cough in the
year prior to their diagnosis (Hamilton et al., 2005a) 2,915 patients with thrombocyto-
sis also reported a cough. 125 of these were diagnosed with lung cancer within one year.
The one year incidence of lung cancer in patients with thrombocytosis and a cough was
3.9% (95% CI 3.2–4.7). The one year incidence of lung cancer in male patients with
thrombocytosis alone was 3.2% (95% CI 2.9-3.6). These values show that thrombo-
cytosis plus a cough is not much more predictive of lung cancer than thrombocytosis
alone.
The PPV of cough as a single symptom of lung cancer is 0.4% (95% CI 0.3-0.5) and
when the patient has attended twice with a cough, the value is 0.6% (95% CI 0.4-0.8)
(Hamilton et al., 2005a). Thrombocytosis in addition to a cough therefore has the
potential to identify patients with lung cancer with a much greater predictive value.
4.14.2 Colorectal cancer, rectal bleeding, and change in bowel habit
A change in bowel habit (usually constipation or diarrhoea) is the most common symp-
tom of colorectal cancer; 63% of colorectal cancer patients consult their GP regarding
a change in bowel habit in the year prior to their diagnosis (Hamilton et al., 2005b).
The second most common symptom, rectal bleeding, is reported by 42% of colorectal
cancer patients. 2530 patients with thrombocytosis also reported a change in bowel
habit at around the same time as their first raised platelet count; 153 of these were
subsequently diagnosed with colorectal cancer.
The one year incidence of colorectal cancer in patients with thrombocytosis and
a change in bowel habit is 5.7% (95% CI 4.8–6.7). 354 patients with thrombocytosis
also had a record of rectal bleeding; 32 of these were diagnosed with colorectal cancer
within a year. The one year incidence of colorectal cancer in patients with thrombocy-
tosis and rectal bleeding was 8.4% (95% CI 5.8-11.9). The fact that rectal bleeding is a
less commonly reported symptom and therefore provides a smaller sample size for this
calculation is reflected in the wider confidence intervals for the incidence. For compar-
ison, the one year incidence of colorectal cancer in male patients with thrombocytosis
only was 2.7 (2.4-3.1); additional alarm symptoms results in increased incidence.
The risk of colorectal cancer increased when patients presented with a change in
bowel habit or rectal bleeding in addition to thrombocytosis. The PPV of diarrhoea
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alone is 0.9% (95% CI 0.7-1.1) and for constipation it is 0.4% (95% CI 0.3-0.5) (Hamil-
ton et al., 2005b). Therefore, the presence of thrombocytosis could be an important
addition in predicting colorectal cancer in patients with a change in bowel habit (which
encompasses diarrhoea and constipation); the risk of cancer for patients with both was
5.7% (95% CI 4.8–6.7).
The PPV of rectal bleeding as a single symptom is 2.4% (95% CI 1.9-3.2) (Hamilton
et al., 2005b). This is already an alarm symptom of colorectal cancer and may prompt
suspicions of cancer in practice without the addition of thrombocytosis.
4.14.3 Loss of appetite and weight loss
The increased incidence with known alarm symptoms shown above may be of limited
clinical use as the presence of the alarm symptom may alert GPs to the possibility of
cancer without needing blood test results as an additional prompt. Alternatively, the
raised platelet count in addition to vague, non-specific symptoms may be of greater
clinical use. Loss of appetite has been reported as a marker of several types of cancer
NICE (2015). 257 thrombocytosis patients also reported a loss of appetite, and 64 of
these were subsequently diagnosed with cancer. The one year incidence of any type of
cancer in patients with thrombocytosis and a loss of appetite is 22.6% (95% CI 17.6–
28.2). Weight loss was also reported by 698 thrombocytosis patients, with 182 diagnosed
with cancer. The one year incidence of cancer in patients with thrombocytosis and
weight loss is 24.1% (95% CI 20.9–27.4). The one year incidence of any type of cancer
for male patients with thrombocytosis alone was 11.6 (11.0-12.3). Therefore, there is
a sizeable increase in cancer incidence in patients who are experiencing weight loss or
loss of appetite, and have thrombocytosis; around double the number of incident cases.
4.15 Symptom profiles and NICE guidance
The following section addresses the objective of estimating the potential impact of the
recognition of thrombocytosis as a marker of cancer in UK suspected cancer guidance
by examining the proportion of patients who have thrombocytosis but no other cancer
symptoms or markers. For patients who have symptoms that, according to UK NICE
guidance, are sufficiently indicative of cancer to warrant further investigation, the ad-
dition of thrombocytosis as a risk marker has little use; other symptoms will prompt
investigation. However, for patients with thrombocytosis and no other additional symp-
toms, the recognition of thrombocytosis as a risk marker has the potential to initiate
investigation and therefore diagnosis earlier. The aim of the following analysis was to
estimate the proportion of patients with cancer and thrombocytosis who fall into the
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latter group; those who would not have been referred for suspected cancer investiga-
tion based on symptom profiles that do not include thrombocytosis. The following
section addresses the objective of estimating the potential impact of the recognition of
thrombocytosis as a marker of cancer in UK suspected cancer guidance by examining
the proportion of patients who have thrombocytosis but no other cancer symptoms
or markers. For patients who have symptoms that, according to UK NICE guidance,
are sufficiently indicative of cancer to warrant further investigation, the addition of
thrombocytosis as a risk marker has little use; other symptoms will prompt investiga-
tion. However, for patients with thrombocytosis and no other additional symptoms, the
recognition of thrombocytosis as a risk marker has the potential to initiate investigation
and therefore diagnosis earlier. The aim of the following analysis was to estimate the
proportion of patients with cancer and thrombocytosis who fall into the latter group;
those who would not have been referred for suspected cancer investigation based on
symptom profiles that do not include thrombocytosis.
4.15.1 Lung cancer
The UK national guidance for suspected cancer recommends cancer investigation in
patients who do not smoke with two or more of the following symptoms: cough, fatigue,
shortness of breath, chest pain, weight loss, or appetite loss (NICE, 2015). If the
patient has ever smoked, only one of these symptoms is required to initiate investigation
(usually a chest X-ray).
573 patients in the thrombocytosis cohort were diagnosed with lung cancer. Smok-
ing data were available for 546 of these. Of the 490 patients who had ever smoked,
172 (35%) had no recorded lung cancer symptoms in the year prior to their diagnosis,
and of 56 who had never smoked, 23 (41%) reported no symptoms in the year prior
to diagnosis. For all patients with thrombocytosis and no further recorded symptoms
who were subsequently diagnosed with lung cancer, the median number of days between
their first blood test showing thrombocytosis and their cancer diagnosis was 50 (IQR
18-126). This suggests that the addition of thrombocytosis to the 2015 NICE guidance
update should result in around a third of lung cancers being diagnosed earlier, perhaps
before respiratory symptoms have developed.
4.15.2 Colorectal cancer
There are no recommendations in the 2015 NICE guidance for action in response to
thrombocytosis relating to colorectal cancer. 627 patients with thrombocytosis were
diagnosed with colorectal cancer, and 206 (33%) had no symptoms in the year before
diagnosis warranting urgent investigation for cancer. The median number of days
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between thrombocytosis and diagnosis date for asymptomatic patients with colorectal
cancer was 67 (IQR 27–174). These results suggest that in around a third of colorectal
cancer patients, thrombocytosis could have triggered investigation in a patient who
previously did not meet recommendations for investigation; the median number of
days indicates that this investigation could have occurred around two months earlier.
4.16 Two year cancer incidence
4.16.1 Thrombocytosis cohort
There were 3,050 qualifying cancer diagnoses in the patients with thrombocytosis in
the two years after their index date; 597 in addition to the 2,453 diagnosed in the first
year. Of these additional 597, 224 men and 373 women were diagnosed. In total over
the two-year period, there were 1,322 new diagnoses in men and 1,728 diagnoses in
women. The two year cancer incidence in the men with thrombocytosis was almost
double that in women: 14.0% (95% CI 13.3-14.7) for men and 7.9% (95% CI 7.6-8.3)
for women (see Table 4.11). The additional risk acquired in the second year after index
date is shown in the fourth row of Table 4.11. This row shows the incidence of cancer
within the second year after index date (rather than within the entire two year period).
Comparing the cancer incidence in 1-12 months after index date and 13-24 months
after index date, it is clear that the vast majority of new cancers in this cohort are
diagnosed within the first year after index date. In the second year after index date
(13-24 months), the cancer incidence decreased to 2.7% (95% CI 2.4-3.1) in men and
1.8% (95% CI 1.6-2.0) in women; this excludes patients who were diagnosed in the first
year, almost a return to baseline levels.
4.16.2 Normal platelet count cohort
There were 332 qualifying (meeting the inclusion criteria) cancer diagnoses in the pa-
tients with a normal platelet count in the two years after their index date; 107 in
addition to the 225 diagnosed in the first year. Of these additional 107, 35 were in men
and 72 in women. In total over the two year period, there were 141 new diagnoses in
men and 191 diagnoses in women. The two year cancer incidence in the normal platelet
count cohort was 5.4% (95% CI 4.6-6.4) for males and 3.6% (95% CI 3.1-4.1) for females
(see Table 4.11). The additional risk acquired in the second year after index date is
shown in the fourth row of Table 4.11. In the second year after index date, the cancer
incidence was 1.4% (95% CI 1.0-1.9) in men and 1.4% (95% CI 1.1-1.7) in women; this
excludes patients diagnosed in the first year.
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4.16.3 Comparison of first year cancer incidence with second year
cancer incidence
When the cancer incidence in the first year after index date is compared to that in the
second year (comparing new diagnoses 1-12 months after index date to new cases in
the 13-24 months after index date), the risk of cancer remains only slightly elevated in
men with thrombocytosis compared to those with a normal platelet count. In women
with thrombocytosis, the cancer risk in the second year after index date is no different
to that in patients with a normal platelet count. This suggests that over a year after a
raised platelet count, the risk of cancer largely returns to baseline levels.
4.16.4 Types of cancer diagnosed in the second year
The types of cancer diagnosed in patients with thrombocytosis and with a normal
platelet count were compared for the second year after index date (13-24 months).
111
4
.
T
h
ro
m
b
o
c
y
to
sis
a
s
a
n
e
a
rly
m
a
rk
e
r
o
f
c
a
n
c
e
r
Table 4.11: The percentage of patients with thrombocytosis and normal platelet counts diagnosed with cancer, within 1-12, 1-24,
and 13-24 months of platelet count index date. N: number, CI: confidence interval.
Thrombocytosis Normal platelet count
Men Women Men Women
Time
from
index
date
(months)
N
n cancers
diagnosed,
incidence
% (95% CI)
N
n cancers
diagnosed,
incidence
% (95% CI)
N
n cancers
diagnosed,
incidence
% (95% CI)
N
n cancers
diagnosed,
incidence
% (95% CI)
1-12 9, 435
1, 098
11.6 (11.0-12.3)
21, 826
1, 355
6.2 (5.9-6.5)
2, 599
106
4.1 (3.4-4.9)
5, 370
119
2.2 (1.8-2.6)
1-24 9, 435
1, 322
14.0 (13.3-14.7)
21, 826
1, 728
7.9 (7.6-8.3)
2, 599
141
5.4 (4.6-6.4)
5, 370
191
3.6 (3.1-4.1)
13-24 8, 337** 224 2.7 (2.4-3.1)
20, 471**
373
1.8 (1.6-2.0)
2, 493**
35
1.4 (1.0-1.9)
5, 251**
72
1.4 (1.1-1.7)
** Excluding patients with cancer diagnoses recorded within months 1-12.
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4.17 Chapter summary
This large scale cohort study is the first from primary care to compare the overall risk
of cancer between patients with thrombocytosis and those with normal platelet counts.
It addresses the objectives set out in the introduction to investigate the relationship
between thrombocytosis and cancer. This section of the chapter reviews the strengths
and limitations of this study, considers the results in line with existing literature, and
outlines the clinical implications of these findings.
4.17.1 Objectives addressed in this chapter
 To examine the incidence of cancer in two cohorts of patients; those
with thrombocytosis and those with a normal platelet count, to deter-
mine the risk of cancer in each cohort.
 To compare the cancer incidence between these two cohorts to deter-
mine the absolute increase in risk associated with thrombocytosis.
 To examine how the relationship between thrombocytosis and cancer
differs across subgroups defined by age, sex, and smoking status.
This study found that the one year incidence of cancer in males with thrombocytosis is
11.6% (95% CI 11.0-12.3), and in males with a normal platelet count it is 4.1% (95% CI
3.4-4.9). In females with thrombocytosis the one year cancer incidence is 6.2% (95% CI
5.9-6.5) and in female patients with a normal platelet count, the equivalent incidence
is 2.2% (95% CI 1.8-2.6). This represents an absolute increase in risk of 7.5% for raised
platelets over normal platelets for men, and an absolute increase of 4.0% for women,
although the overall risk is the primary reported value as these are more clinically
useful.
The risk of cancer increased with age in both cohorts of patients; unsurprisingly.
However, the incidence of cancer increased at a greater rate in patients with throm-
bocytosis than in patients with a normal platelet count, meaning that more cancers
are diagnosed in patients with thrombocytosis than in patients with a normal platelet
count in older age groups. Scatter plots of the cancer incidence by age group in each
cohort show the risk of cancer increasing steadily in men, but appearing to level off
in women. This could reflect fewer cancers being diagnosed in older women; it is also
possible that this reflects less recording of cancers in older women. Cancer incidence
data described in Chapter 2 appear to show a decrease in cancers diagnosed in older
patients. However, anecdotally this could be due to fewer cancers in older patients
being recorded.
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A stratified analysis estimated the risk of cancer in patients with thrombocytosis
who had ever smoked, or had never smoked. This found that although the overall cancer
incidence was higher in patients who had ever smoked than in those who had never
smoked, there was some overlap between the confidence intervals; although this does
not mean that there is no statistically significant difference between the two groups,
the difference in incidence is not clinically significant.
 To determine whether some types of cancer are more likely to be di-
agnosed than others in patients with thrombocytosis compared to pa-
tients with a normal platelet count.
The incidence was found to be higher for some types of cancer than others in patients
with thrombocytosis; it was particularly high for lung and colorectal cancer, and low
for prostate and breast cancer compared to patients with a normal platelet count, and
the general population. It could be argued that lung and colorectal cancer appeared
to have higher incidence in patients with thrombocytosis simply because they are most
commonly in the general population. However, comparing the incidence of these two
types of cancer between patients with thrombocytosis and with a normal platelet count
suggests that this is not the case. If thrombocytosis was not more strongly associated
with lung and colorectal cancer, than similar incidence would be observed for all cancer
sites among patients with thrombocytosis and a normal platelet count. However, this
is not the case. Lung cancer incidence was 3.2% in men with thrombocytosis (2.9-3.6)
and 0.4% (0.2-0.7) in men with a normal platelet count; a absolute increase of 2.8%.
Similarly, colorectal cancer incidence was 2.7% (2.4-3.1) in men with thrombocytosis
and 0.4% (0.2-0.7) in men with a normal platelet count; an increase of 2.3%. For
women, a similar pattern was observed. Lung and colorectal cancer incidence in those
with thrombocytosis was 1.1% (0.9-1.2) and 1.6% (1.4-1.7) respectively. For women
with a normal platelet count, incidence of lung and colorectal cancer was 0.3% (0.1-
0.4) and 0.4 (0.3-0.6).
For prostate and breast cancer, the other two most commonly diagnosed cancers in
the general population, there appeared to be no difference in incidence between patients
with thrombocytosis and with a normal platelet count. Breast cancer incidence was
0.5% (0.3-0.7) in women with thrombocytosis, and 0.4% (0.3-0.5) in women with a
normal platelet count. For prostate cancer, the incidence in men with thrombocytosis
was 1.4% (1.2-1.7) and the incidence in men with a normal platelet count was 1.1%
(0.7-1.6). Other hormone-dependent cancers had a similar incidence observed in each of
the cohorts; cervical cancer incidence was 0.1% (0.0-0.1) in women with thrombocytosis
and 0.1% (0.0-0.2) in women with a normal platelet count. Ovarian cancer incidence
was 1.3% (1.1-1.4) in women with thrombocytosis and 0.8% (0.7-0.9) in women with
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a normal platelet count. Uterine cancer incidence was 0.2% (0.2-0.3) in women with
thrombocytosis and 0.2% (0.1-0.2) in women with a normal platelet count. There were
only two cases of testicular cancer; both in the thrombocytosis cohort.
 To investigate how patient’s risk of cancer changes depending on how
their platelet count changes over time.
An increase in platelet count within a six month period was associated with increased
cancer incidence in patients with thrombocytosis; this fits with earlier analyses which
show increasing cancer risk with increasing baseline platelet count. However, this result
is open to bias; any other symptoms are likely to worsen or appear within a six month
period, so it is more likely that second blood tests within six months were ordered by
clinicians who suspected cancer. A more thorough investigation in to this hypothe-
sis could include an analysis of other clinical features in patients over the six month
time period, or examine patterns of symptom presentation in patients who are later
diagnosed with cancer.
 To investigate the risk of cancer in patients who report symptoms in
addition to thrombocytosis.
Patients presenting with a cough (the most common symptom of lung cancer) in addi-
tion to thrombocytosis had a similar incidence of cancer than patients presenting with
thrombocytosis alone; but a greater risk than a cough as a single symptom. For patients
with a persistent cough, the presence of thrombocytosis could be valuable prompt in
encouraging clinicians to suspect cancer.
For colorectal cancer, patients presenting with thrombocytosis and a change in
bowel habit had a much greater risk of cancer than patients with thrombocytosis or a
change in bowel habit as single symptoms. Again, the greater predictive value of these
two symptoms combined could be clinically useful. Although there was an increase in
the risk of colorectal cancer for patients with thrombocytosis and rectal bleeding com-
pared to thrombocytosis alone, rectal bleeding is already considered an alarm symptom
of colorectal cancer and thus the clinical utility of this symptom combination is more
limited than the previous two examples.
Thrombocytosis plus weight loss (24.1%, 95% 20.9-27.4) and a loss of appetite
(22.6%, 95% CI 17.6-28.2) was more strongly predictive of cancer than thrombocytosis
alone (11.6% (11.0-12.3) for men and 6.2% (5.9-6.5) for women); the incidence of any
type of cancer was roughly doubled with the addition of either of these symptoms.
The range of possible cancers is wide so clinicians would have to use other signs and
symptoms, the patient’s medical history, and their own clinical judgment to determine
which investigative services would be most appropriate for these patients.
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 To investigate the stage at which cancers are diagnosed in patients
with thrombocytosis and with a normal platelet count.
It was not possible to meet this objective due to incomplete data in the cancer registry
data file.
 To estimate the potential impact of the recognition of thrombocytosis
as a marker of cancer in UK suspected cancer guidance by examin-
ing the proportion of patients who have thrombocytosis but no other
cancer symptoms or markers.
Around a third of lung and colorectal cancer patients with thrombocytosis had no
symptoms that would have qualified them for investigation of suspected cancer as per
NICE guidance in the year before their diagnosis. This is an exciting finding which has
the potential to expedite a good proportion of cancer diagnoses annually.
4.17.2 Strengths and limitations
A key strength of this study is its size and setting. It uses primary care data, where
the initial suspicion of possible cancer is generally made, and uses data from two recog-
nised strong data sources, the CPRD and the cancer registry. The cancer registry is
considered the gold standard of cancer recording in England. Previous studies have
found cancer recording in the CPRD to be highly valid; this evidence was summarised
in Chapter 2.
The present analysis only includes data from England, not Wales, Scotland, or
Northern Ireland. Furthermore, within England, some regions were under-represented
(particularly the North East of England), with a greater proportion of practices from
the South East and North West of England. However, as patients in each of the two
cohorts were practice matched, this will not have introduced an important bias to the
differences in cancer incidence found between the two. This could, however, bias the
results if there were strong differences in cancer diagnosis between different regions of
England, or different regions of the UK. Figures released in 2016 show generally poor
performance across the UK in cancer diagnosis, with no strong geographical patterns
in diagnosis. Even if a pattern existed, it is very unlikely to have an impact on the
relationship between platelets and cancer, although in an area with very high early
diagnosis of cancer, thrombocytosis could be of lesser value in expediting diagnosis.
These results rely on the accuracy of data in the CPRD. Due to the electronic
transmission of blood test results from the laboratory to patient records, errors in the
recorded values are unlikely. However, as each patient’s record begins from the time
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they join a CPRD practice, it is possible that they had thrombocytosis earlier than
the used index date, whilst registered at a non-CPRD practice. Any under-recording
of platelet count would be similar for both cohorts.
It was not possible to meet the objective of investigating the stage at which cancers
are diagnosed in patients with thrombocytosis and with a normal platelet count; this
is because the registry staging data were incomplete. It is only possible to state that
at least one quarter of patients with thrombocytosis were diagnosed at an early stage
and therefore most likely to benefit from earlier diagnosis in terms of survival. This
proportion may be higher.
The reasons for full blood counts being ordered for patients in each of the cohorts are
not known. Blood tests could have been ordered in the thrombocytosis cohort because
their clinician already suspected cancer in the patient. Although it is not possible to
determine the reason for testing, the signs and symptoms reported by the patients in
the lead up to their blood test can be compared between the two cohorts. This can give
an indication of any differences in symptomatic presentation at baseline. Some of the
symptoms reported by each cohort were recognised cancer symptoms, but they were
reported by relatively small, and similar, proportions of each sub-cohort, and they are
low risk symptoms which would not be expected to prompt urgent cancer investigation
(NICE, 2015). This suggests that the blood tests carried out in the thrombocytosis
cohort were no more likely to be prompted by suspicions of cancer than those in the
normal platelet count cohort.
In primary care, blood tests are ordered for a wide range of reasons; sometimes in
response to symptoms, sometimes for routine reasons, and rarely to look for thrombo-
cytosis specifically. Approximately a quarter of the UK adult primary care population
have a full blood count taken in any one year (Hamilton et al., 2008) Patients selected
for a full blood count would be expected to have more ill health than those who are not;
therefore comparing cancer incidence between patients with thrombocytosis and those
with a normal platelet count, rather than those with no testing at all, is a key strength.
This should reduce (or eliminate) any bias from having been selected for blood testing.
Therefore, these results do not report the value of measuring the platelet count in pre-
dicting cancer; rather, they report the value of an elevated platelet count result. This
is a subtle but real distinction.
These limitations, and their implications for the interpretation of the results, are
discussed further in Chapter 6; the overall discussion and conclusion chapter.
The next chapter presents the validation study of CPRD data, using linked cancer
registry data. A sensitivity analysis is presented that repeats some work from the
present chapter, using only cancer registry recorded diagnoses. The is used to estimate
what, if any, impact there is of including CPRD-recorded cancer diagnoses that have
117
4. Thrombocytosis as an early marker of cancer
not been verified by cancer registry records.
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Chapter 5
CPRD validation study
5.1 Chapter summary
In this chapter, a sensitivity analysis is presented which examines the effect of the
inclusion of cancers recorded in the CPRD, but not the cancer registry, on the results.
In addition, the validity of the CPRD data sample used in Chapter 4 is examined
by comparing this source with English cancer registry data. This validation exercise
uses the same cohort as in Chapter 4 and involves comparing the recorded diagnoses
in each source, the dates these diagnoses were made, the type of cancer diagnosed,
and differences in patient characteristics between those cancers that are recorded in
both sources or either source. The sensitivity analysis involves repeating the primary
analysis from Chapter 4, the one year cancer incidence in patients with thrombocytosis
and a normal platelet count, including only cancer registry-recorded diagnoses. This
sensitivity analysis is placed here, rather than in Chapter 4, because it ties in with the
‘validation’ aims of this chapter and it relies upon data comparisons made in the first
part of this chapter. The primary aim of this chapter was to examine the validity of
the data sample used in Chapter 4, and to carry out a sensitivity analysis to determine
whether there are any effects of including non-registry validated data in the main
analysis in that chapter. Secondly, this chapter presents an opportunity to build on the
work of Boggon et al. (2013) Dregan et al. (2012) who also carried out validation studies
on CPRD data samples. In those two studies, similar to the work presented in this
chapter, selected samples of patients were used; in the case of Boggon et al. (2013), the
cohort were selected for inclusion if they had diabetes, and Dregan et al. (2012) selected
patients with certain risk symptoms including haematuria, haemoptysis, dysphagia, or
rectal bleeding, or lung, colorectal, gastro-oesophago, or urinary cancer. The selected
samples of patients used in those and in the present study are a limitation which should
be considered before generalising results about the validity of CPRD data to the data
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source as a whole.
5.2 Chapter background
Electronic medical records are increasingly being used in medical research as they
offer an opportunity to access large amounts of routinely collected data from a broad
range of patients, often collected in the setting in which any research outputs aim
to be of clinical use. Electronic medical records are not without limitation; two of
the greatest limitations are that the data are primarily collected for reasons other
than for research, and that there can be heterogeneity in recording styles between
different sources. Ideally data collection for research purposes should be homogenous
and complete, but electronic medical records are often compiled by medical professionals
for whom achieving research quality data is not a priority. Data recording errors can
also occur.
Validation studies are one way to assess the quality of the recorded data. This
involves comparing recording in the data source of interest to recording in a ‘gold
standard’ data source. The validity of diagnostic coding in the CPRD has been sys-
tematically reviewed by Khan et al. (2010) (described in Chapter 2), and more recently
the validity has been explored specifically in relation to cancer diagnoses by Dregan
et al. (2012) and Boggon et al. (2013). These studies found a high level of concordance
between the CPRD and the ‘gold standard’ cancer registry in terms of cancer diagnosis
records. Dregan et al. (2012) found that 5, 216 of 5, 429 (96%) CPRD cancer diagnoses
were confirmed by the cancer registry (Dregan et al., 2012). Boggon et al. (2013) found
that 4, 830 of 5, 797 (83%) CPRD cancer diagnoses were confirmed by the cancer reg-
istry (Boggon et al., 2013) - and of the 967 diagnoses that were not verified by cancer
registry records, 528 (54.6%) were confirmed by hospital records or practice notes.
5.3 Implications of validation of CPRD diagnoses
In Chapter 4, counting patients as cases if they had a cancer record in either source
could have resulted in an over estimate of the true association if some of these were
false positives. In the present chapter, examining the concordance between the two
data sources will enable the assessment of the extent of this overestimation, if it exists.
In an attempt to determine the impact of including patients diagnosed from either
source on the study results, a sensitivity analysis is included in this chapter in which
the primary analysis from Chapter 4 is repeated, including only patients with a cancer
registry-recorded cancer. Patients who have a cancer record in the CPRD but not
the cancer registry are excluded. These results are compared to results from the first
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‘diagnosis in either source’ results to determine what effect, if any, the inclusion of
CPRD diagnoses that are not validated by the cancer registry has on the results.
The previous chapter in this thesis described a cohort study in which the relationship
between thrombocytosis and cancer was investigated using CPRD data. Linked cancer
registry data were available for some patients in the cohort who were diagnosed with
cancer; the data linkage is described in Chapter 2. Previous validation studies indicate
that not all incident cases of cancer are captured by the CPRD, so patients were
included in the Chapter 4 analysis as having cancer if they had a recorded diagnosis
in either the CPRD, or the cancer registry. Another possible approach was to only
include patients whose CPRD record was confirmed by a cancer diagnosis recorded
in the cancer registry; this is considered the ‘gold standard’ of cancer recording in
England. There is a balance between including only cases with a record in the cancer
registry and risking the exclusion of some CPRD-recorded true positives that were not
recorded in the cancer registry, and including cases recorded in either source and risking
the inclusion of some false positives which could occur in either source. In this chapter,
the validity of the cancers recorded in the CPRD data is assessed using data from the
English cancer registry.
5.4 Research question and objectives
In this chapter, the primary aim was: To assess the validity of cancer recording
in the Clinical Practice Research Datalink sample used in this thesis, using
cancer recording in the English cancer registry as the ‘gold standard’.
The objectives developed to answer this research question were:
 To compare cancer recording in the CPRD and in the cancer registry to determine
the level of concordance between the two sources.
 To compare the age and sex of patients recorded in both, or either, source.
 For cancers recorded in both sources, to compare the date of recording between
the two.
 To estimate predictors of concordance between the two data sources.
 To examine the extent to which the inclusion of unverified CPRD-recorded cancer
diagnoses causes overestimates in incidence figures from CPRD data, by repeat-
ing the primary analysis from Chapter 4 including only cancer registry recorded
diagnoses.
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5.5 Methods
5.5.1 Data sources and included patients
This chapter uses data from the cohort of 50, 000 patients described in Chapter 4. The
analysis in Chapter 4 only included patients diagnosed with cancer after a certain date
(the date of the patient’s first recorded thrombocytosis). Any patients with a cancer
recorded prior to this index date were excluded. In the present chapter, the validation
study includes any cancers diagnosed in the cohort in the entire study period for which
cancer registry data are available: 2000-2010. All practices contributing data to the
study were in England.
Data from the CPRD data file and the cancer registry data file were combined
into one file for this study. In addition to the patient characteristics, the file detailed
the date and site of the cancer diagnosed according to each of the two sources. The
recorded date of diagnosis was available according to each of the two data sources. The
date of diagnosis is recorded in the cancer registry in the day-month-year format; this
was converted to the number of days since 1st January 1900 to enable comparison with
the CPRD data, as described in Chapter 4. A patient was considered to have been
diagnosed with cancer according to the CPRD if they had any one of the 2, 134 cancer-
related medcodes (see Appendix C) which are grouped into 20 common cancer sites.
Where more than one record of a cancer exists, the first record in time was taken as
the primary site and date. A patient was considered to have a cancer registry recorded
diagnosis if a record existed for their patient ID number in the raw cancer registry data
file.
5.5.2 Patient subgroups
The patient subgroups examined in this analysis are:
1. Cancer diagnoses recorded in both sources; patients have a record in the CPRD
and in the cancer registry.
2. CPRD only; patients have a record of a cancer diagnosis in the CPRD file, but
no record in the cancer registry.
3. Cancer registry only; patients have a record of a cancer diagnosis in the cancer
registry file, but no record in the CPRD.
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5.6 Statistical methods and analysis
5.6.1 Sample exclusions
Using the previously described ‘days since 1900’ approach, the patient’s age on the
date of diagnosis was determined by dividing the difference in days between their birth
date and diagnosis date, both as days since 1st January 1900, by 365.25 (the extra 0.25
reflects leap years). Any patients aged under 40 years at the time of diagnosis were
excluded from the analysis.
Cancer registry data were available for patients diagnosed from 2000-2010. However,
for CPRD data, a more extensive medical history is available encompassing all patient
records from when they registered at their practice, including cancer diagnoses from
any point in time. To ensure an even comparison, only cancers diagnosed between 2000
and 2010 in each data source were included. Therefore, any patients with a diagnosis
recorded prior to 2000 or after 2010 were excluded.
5.6.2 Outcome measures
To determine the level of concordance between the two sources, new variables were
created which identified each patient as having a cancer record in the CPRD or the
cancer registry. A list of CPRD-recorded diagnoses were merged into a file with a list
of cancer registry-identified diagnoses. These variables were used in combination to
determine which patients belonged in each of the subgroups described in section 5.5.2.
Where records matched between the two files, the diagnosis was considered recorded
in both sources. If a CPRD-originating ID number had no cancer registry match, or
a cancer registry-originating ID number had no CPRD match, the patient’s diagnosis
was considered recorded in only one or the other source.
The sex of patients in each source was compared by tabulating the number in
each group for patients diagnosed in both (or either) sources. Age at diagnoses was
summarised using the median and interquartile range for each of the three source
groups, and by frequency in ten year age groups (40-49, 50-59, 60-69, 70-79, and ≥ 80).
5.6.3 Distribution of diagnoses over time
The number and percentage of diagnoses made each year from 2000 to 2010 in each
source was determined and compared. Trends in incidence over the study period were
examined.
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5.6.4 Diagnoses recorded in both sources
The characteristics of patients with a cancer diagnosis that was recorded in both the
CPRD and the cancer registry were described, including the proportion of males and
females in this group, and the age distribution, both as median and IQR and in ten
year age groups. The date of diagnosis was compared between the two sources by
subtracting the date of diagnosis in the CPRD (recorded as days since 1900) from the
date of diagnosis in the cancer registry (also recorded as days since 1900). The median
difference and IQR in days between recording in the two sources was described. A
positive value indicated that the CPRD record was made first and a negative value
indicated that the cancer registry record was made first. Finally, the type or primary
site of cancer diagnosed was explored. The proportion of diagnoses recorded in both
sources with the same, and different, primary sites was described. For those diagnoses
with different primary sites, the most commonly recorded sites were examined.
5.6.5 Validation measures
Reporting guidelines for validation studies of routinely collected health data were re-
cently published by Benchimol et al. (2010). These guidelines recommend reporting
at least four estimates of diagnostic accuracy, including sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV), when comparing a large
scale health dataset (such as the CPRD) to another reference standard or ‘gold stan-
dard’ data source (in this case, the cancer registry). These measures were taken for
cancer diagnosis recording in the CPRD, compared to the cancer registry.
5.6.6 Types of cancer recorded
Where patients with a cancer record in the CPRD also had a corresponding diagnosis
recorded in the cancer registry, the primary site of diagnosis in the CPRD was compared
to that in the cancer registry. The 20 cancer sites are described in Section 4.3.14.
5.6.7 Diagnoses recorded in the CPRD only, or the cancer registry
only
The measures described above were repeated for those diagnosed in the CPRD only
or the cancer registry only. This included the proportion of males and females, the
median age, and the proportion in each ten year age group.
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5.6.8 Determining predictors of concordance
Logistic regression was used to determine predictors of concordance between the two
data sources. A binary variable, concordance, was created where 1 = sources agree
on diagnosis and 0 = sources do not agree on diagnosis. Age in ten year age groups,
gender, and year of diagnosis were included as predictor variables.
Each of these three variables were investigated individually in univariable logistic
regression models. All three were included in a multivariable model. P values were re-
ported to reflect those variables which retained significance as predictors of concordance
in the multivariable model.
5.6.9 Sensitivity analysis
The methods used in Chapter 4 to determine cancer incidence were repeated here.
However, in this analysis, patients were only counted as cases if they had a cancer
registry-recorded diagnosis. Patients with a CPRD cancer diagnosis not validated by
the cancer registry were included in the analysis as not having cancer. Cancer registry
cases with no corresponding CPRD record were included as cases.
5.7 Results
The cohort included 50, 000 patients. 4, 554 were excluded as they had a cancer di-
agnosis recorded prior to 1st January 2000, and a further 282 were excluded as they
had a recorded cancer diagnosis after 31st December 2010. 20 patients were excluded
as they were aged less than 40 years at the time of diagnosis. Therefore after exclu-
sions there were 45, 144 patients in the cohort (Figure 5.1). 8, 889 of these (19.7%)
had a recorded cancer diagnosis in either the CPRD or the cancer registry. 7, 785 diag-
noses were recorded in the cancer registry, and 7, 028 were recorded in the CPRD. The
number and percentage of diagnoses in each source is presented in Figure 5.2.
5.7.1 Distribution of diagnoses over time
The decade in which cancers were recorded in each of the two data sources was compared
(see Table 5.1). The number of recorded diagnoses increases throughout the first four
years of the study period, from 549 to 786 per year in the cancer registry and 367 to
727 per year in the CPRD. It is likely that these increases reflected increased recording
of diagnoses during this time rather than a true increase in incidence. The number
of cancers diagnosed yearly from 2004 to 2008 remains fairly steady. A decrease in
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Cohort N = 50,000 
Diagnosed pre-2000 
n = 4,554 
Diagnosed post-2010 
n = 282 
Aged < 40 years at 
diagnosis 
n = 20 
Included patients 
n = 45,144 
Figure 5.1: Patients excluded from the cohort due to having a recorded diagnosis
prior to 2000, after 2010, or being less than 40 years of age at the time of diagnosis
(when diagnosed from 2000-2010).
Figure 5.2: Venn diagram to show the number of cancers recorded in the CPRD, and
in the cancer registry. The left circle represents CPRD records and the right represents
cancer registry records. Overlap between the circles indicate matching records.
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Table 5.1: The number of recorded cancer diagnoses in the cancer registry and the
CPRD by year.
Year of
diagnosis
n in cancer
registry
%
n in
CPRD
%
2000 549 7.1 367 5.2
2001 687 8.8 599 8.5
2002 736 9.5 654 9.3
2003 786 10.1 727 10.4
2004 789 10.1 697 9.9
2005 838 10.8 776 11.1
2006 846 10.9 755 10.8
2007 804 10.3 716 10.2
2008 738 10.1 707 10.1
2009 638 8.2 573 8.2
2010 329 4.2 448 6.4
Total 7,785 100 7,019 100
incidence in 2009 and 2010 is likely to reflect delays in the process of recording new
diagnoses, not true population decreases in cancer incidence in this time.
5.7.2 Characteristics of patients diagnosed with cancer
The age and sex profile of patients diagnosed with cancer are shown in Table 5.2.
This shows the median (IQR) age at diagnosis, age at diagnosis in age groups, and
number and percentage of men and women in each of several groups: cancers recorded
in both the CPRD and the cancer registry, cancers recorded only in the CPRD (with
no corresponding record in the cancer registry), and cancers recorded only in the cancer
registry (no corresponding record in the CPRD). The following section describes and
explores cancers that were recorded in both sources or just one or the other. Records
made in one source only are investigated later in this chapter.
127
5
.
C
P
R
D
v
a
lid
a
tio
n
stu
d
y
Table 5.2: Characteristics of patients with a recorded cancer diagnosis in the CPRD and the cancer registry.
Either source
N = 8, 889
Both sources
N = 5, 924
All CPRD
N = 7, 028
All cancer
registry
N = 7, 785
CPRD only
N = 1, 104
Cancer
registry only
N = 1, 861
Age at diagno-
sis date, years
Median (IQR)
72.4 (63.6 -
79.8)
71.5 (63.1 -
78.7)
71.8 (63.2 -
79.0)
72.3 (63.3-79.6) 72.8 (63.6-80.6) 75.0 (66.0-82.6)
Age group,
years
40-49, n (%) 244 (2.7) 197 (3.3) 183 (2.6) 213 (2.7) 51 (4.6) 70 (3.8)
50-59, n (%) 1,009 (11.4) 823 (13.9) 809 (11.5) 897 (11.5) 142 (12.9) 216 (11.6)
60-69, n (%) 2,092 (23.5) 1,648 (27.8) 1,745 (24.8) 1,862 (23.9) 253 (22.9) 360 (19.3)
70-79, n (%) 2,946 (33.1) 2,013 (34.0) 2,357 (33.5) 2,592 (33.3) 354 (32.1) 593 (31.9)
80 and older, n
(%)
2,598 (29.2) 1,243 (21.0) 1,934 (27.5) 2,221 (28.5) 304 (27.5) 622 (33.4)
Sex distribu-
tion
Men, n (%) 3,800 (42.8) 2,673 (45.1) 3,071 (43.7) 3,402 (43.7) 398 (35.9) 729 (39.2)
Women, n (%)
5,089 (57.2)
3,251 (54.9)
3,957 (56.3) 4,383 (56.3) 706 (64.1) 1,132 (60.8)
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5.7.3 Diagnoses appearing in both sources
5.7.3.1 Characteristics of diagnoses with concordance
5, 924 patients had a cancer recorded in both the CPRD and the cancer registry. Of
these, 2, 673 (45.1%) were male and 3, 251 (54.9%) were female. The median age in
this group was 71.5 years (IQR 63.1-78.7). Age group distribution was as follows: 197
(3.3%) aged 40-49 years; 823 (13.9%) aged 50-59 years; 1, 648 (27.8%) aged 60-69 years;
2, 013 (34.0%) aged 70-79 years; 1, 243 (21.0%) aged 80 years and over.
5.7.3.2 Date of diagnosis
Where patients had a recorded cancer diagnosis in both sources, the date of diagnosis
was compared between the two datasets. Diagnoses in the CPRD were recorded a
median of seven days later in time than in the cancer registry (IQR -25 to 7; 25 days
later in the CPRD to 7 days later in the cancer registry).
The age and sex of patients were compared depending on whether their diagnosis
was recorded first in the CPRD or the cancer registry. There was little difference
between the two in age at diagnosis; for patients with their first record in the CPRD,
the median age was 73.1 (IQR 64.3-80.8) and for patients with their first record in the
cancer registry, the median age was 71.3 (IQR 62.7-78.5). A slightly greater proportion
of diagnoses in women were recorded in the CPRD prior to the cancer registry; 3, 122
out of 5, 092 women (61.3%) were diagnosed first in the CPRD. 2,146 out of 3,789 men
(56.5%) had their diagnosis recorded earlier in the CPRD.
5.7.3.3 Types of cancer diagnosed
The primary type of cancer was compared for patients who had a diagnosis recorded
in both sources. Of the 5, 924 cancers recorded in both datasets, 5, 339 (90.1%) had
the same primary site identified. 585 (9.9%) of the records had different primary
sites recorded in each of the two datasets. The majority of CPRD recorded cancers
with a different primary site recorded in the cancer registry were coded as either skin
(non-melanoma) cancer (191/585, 32.7%) or ‘miscellaneous’ (230/585, 39.3%). Non-
melanoma skin cancers were excluded from the analysis in Chapter 4.
5.7.4 Diagnoses recorded in the CPRD only
1, 104 recorded diagnoses in the CPRD had no corresponding record in the cancer
registry. Of these 1, 104 patients, 398 (36.0%) were male and 706 (64.0%) were female.
The median age at diagnosis was 72.8 years (IQR 63.6-80.6). The distribution of age
by 10 year age group was as follows: 51 (4.6%) aged 40-49 years; 142 (12.9%) aged
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50-59 years; 253 (22.9%) aged 60-69 years; 354 (32.1%) aged 70-79 years; 304 (27.5%)
aged 80 years and older.
5.7.5 Diagnoses recorded in the cancer registry only
1, 861 recorded diagnoses in the cancer registry had no corresponding records in the
CPRD. Of these 1, 861 patients, 729 (39.2%) were male and 1,132 (60.8%) were female.
The median age at diagnosis was 75.0 years (IQR 66.0-82.6). The distribution of age
by 10 year age group was as follows: 70 (3.8%) aged 40-49 years; 216 (11.6%) aged
50-59 years; 360 (19.3%) aged 60-69 years; 593 (31.9%) aged 70-79 years; 622 (33.4%)
aged 80 years and older.
5.7.6 Comparison of patients with diagnoses recorded in only one
source
There was no difference in the proportion of men and women with records solely in one
source or the other. Patients with a diagnosis recorded in the cancer registry only were
older than those whose diagnosis were recorded in the CPRD only; the median age was
72.8 years for CPRD only records and 75.0 years for cancer registry only records. The
cancer registry only records also had a larger proportion of patients aged ≥ 80 years of
age; 33.4% vs 27.5%.
5.7.7 Validation measures
There was concordance between the two data sources on the majority of recorded
diagnoses: 5, 924 (66.6%) of patients had a cancer record in both the CPRD and the
cancer registry. 1, 861 (20.9%) were recorded only in the cancer registry, with no record
in the CPRD. 1, 104 (12.4%) were recorded in the CPRD, and did not have a record in
the cancer registry.
A 2 by 2 table outlining the number of cancer diagnoses in each of the two sources is
shown in Table 5.3. This cross tabulates the number of patients with a recorded cancer
diagnosis, and the number with no recorded diagnosis, in the CPRD and the cancer
registry. Sensitivity reflects the proportion of patients with the disease in question
(according to the reference standard), who are correctly identified as such by the dataset
being validated (the CPRD, in this case). Using the values in Table 5.3, this was
calculated as 5,924 identified as having cancer by the CPRD, out of 7,785 with a
cancer registry record. The sensitivity of a CPRD recorded diagnosis was 76.1% (95%
CI 75.1 - 77.0). This means that 76.1% of patients with a cancer diagnosis recorded in
the cancer registry are identified as having cancer in the CPRD.
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Table 5.3: Patients with a recorded cancer diagnosis and no recorded cancer diagnosis
in the CPRD and the cancer registry
Cancer registry
Cancer
record
No cancer
record
Total
CPRD
Cancer
record
5, 924 1, 104 7, 028
No cancer
record
1, 861 36, 255 38, 116
Total 7, 785 37, 359 45, 144
Specificity measures the proportion of patients who do not have the disease in
question (according to the reference standard), who are correctly identified as being
free of disease by the dataset (the CPRD). Using the values in Table 5.3, this was
calculated as 36,255 identified as not having cancer in the CPRD, out of 37,359 with
no cancer registry record. The specificity of a CPRD recorded diagnosis was 97.0% (95%
CI 96.9-97.2); 97.0% of patients who do not have a cancer registry recorded diagnosis
also do not have a record in the CPRD. Critically, in this measure, the absence of a
cancer record in the CPRD does not mean that the patient is specifically coded as being
free of cancer. Therefore, the specificity in this case measures how likely a patient with
no cancer diagnosis record in the CPRD is to be free of disease.
The PPV estimates the proportion of cancer diagnosis records in the CPRD that
are confirmed by a corresponding cancer registry record. The PPV of a CPRD recorded
diagnosis was 84.3% (95% CI 83.4 - 85.1). Similarly, the NPV reflects the proportion
of patients who do not have a cancer recorded in the CPRD, who also do not have a
cancer recorded in the cancer registry. The NPV was 95.1% (95% CI 94.9 - 95.3).
5.7.8 Predictors of concordance between the cancer registry and the
CPRD
Logistic regression was used to investigate potential predictors of concordance between
the two data sources. Predictor variables included sex (binary), age group (40-49 years;
50-59 years; 60-69 years; 70-79 years; 80 years and over), and year of first record of
diagnosis (2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010).
In univariable (unadjusted) models, being aged 50-59 years (p = 0.042) or 60-69
years (p = 0.001) significantly predicted concordance, whereas being aged 70-79 years
(p = 0.068) or aged 80 years and over (p = 0.471) did not (the 40-49 years age group was
used as the reference group). Sex also predicted concordance (p < 0.001) with cancers in
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male patients more likely to match between the CPRD and the cancer registry. Finally,
diagnoses being recorded from 2005 onwards significantly predicted concordance in a
univariable (unadjusted) model. With 2000 as the reference group: 2001 p = 0.414;
2002 p = 0.598; 2003 p = 0.890; 2004 p = 0.052; 2005 p = 0.036; 2006 p = 0.011; 2007
p = 0.010; 2008 p = 0.034; 2009 p = 0.005; 2010 p = 0.025.
The multivariable model included age (categorical, 10 year age bands), sex, and
year of diagnosis as predictor variables. Only the 60-69 age group retained significance
as a predictor of concordance (p = 0.006) within the age groups. Sex remained a
significant predictor of concordance (p < 0.001). Years of diagnosis 2006 (p = 0.029),
2007 (p = 0.039), 2009 (p = 0.014), and 2010 (p = 0.007) also retained significance as
predictors of concordance.
5.8 Sensitivity analysis using cancer registry data
This section addresses the final objective of this chapter: to examine the extent to
which the inclusion of unverified CPRD-recorded cancer diagnoses causes overestimates
in incidence figures from CPRD data, by repeating the primary analysis from Chapter
4 including only cancer registry recorded diagnoses.
5.8.1 Primary analysis: recap of one year cancer incidence
After exclusions (defined in the previous chapter), there were 31, 261 patients with
thrombocytosis (9, 435 men and 21, 826 women) and 7, 969 patients with a normal
platelet count (2, 599 men and 5, 370 women). Table 5.4 shows the number of men and
women with thrombocytosis, and the number of each who had a record in either the
CPRD or the cancer registry showing a diagnosis of cancer within one year of their
index date (the date of their first blood test showing thrombocytosis, or equivalent).
5.8.1.1 Thrombocytosis cohort
There were 2, 453 cancers recorded in either the CPRD or the cancer registry in the
thrombocytosis cohort; this represents a cancer incidence of 11.6% (95% CI 11.0-12.3)
in men and 6.2% (95% CI 5.9-6.5) in women (Table 5.4).
5.8.1.2 Normal platelet count cohort
There were 225 diagnoses of cancer recorded in either the CPRD or the cancer registry
in the normal platelet count cohort; this represents a cancer incidence of 4.1% (95% CI
3.4-4.9) in men and 2.2% (95% CI 1.8-2.6) in women (Table 5.4).
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Table 5.4: Comparison of the number of incident cancer cases in each cohort when
data from both the CPRD and the cancer registry, or only the cancer registry, are
included.
Thrombocytosis
Men Women
Included
diagnoses
N
n cancers diagnosed
Incidence % (95% CI)
N
n cancers diagnosed
Incidence % (95% CI)
Either source 9, 435
1, 098
11.6 (11.0-12.3)
21, 826
1, 355
6.2 (5.9-6.5)
Cancer
registry
9, 333
1, 021
10.9 (10.3-11.6)
21,668
1, 265
5.8 (5.5-6.2)
Normal platelet count
Men Women
Included
diagnoses
N
n cancers diagnosed
Incidence % (95% CI)
N
n cancers diagnosed
Incidence % (95% CI)
Either source 2, 599
106
4.1 (3.4-4.9)
5, 370
119
2.2 (1.8-2.6)
Cancer
registry
2, 580
93
3.6 (2.9-4.3)
5, 345
109
2.0 (1.7-2.4)
5.8.2 Sensitivity analysis: one year cancer incidence
The number of cancer registry recorded diagnoses was determined for each group. These
and the respective incidences are presented in Table 5.4.
There were 2, 488 qualifying records of cancer diagnoses in the cancer registry.
The majority of these (2, 286, 91.9%) were in patients with thrombocytosis; 1, 021 in
men with thrombocytosis and 1, 265 in women with thrombocytosis. In patients with
thrombocytosis, the one year incidence of cancer in men with thrombocytosis, when
only cancer registry-recorded diagnoses are included, was 10.9% (95% CI 10.3-11.6)
for men and 5.8% (95% CI 5.5-6.2) for women. In patients with a normal platelet
count, there were 93 records of diagnoses in men and 109 in women. The one year
cancer incidence in this subgroup was 3.6% (95% CI 2.9-4.3) for men and 2.0% (95%
CI 1.7-2.4) for women.
5.8.3 Comparing one year incidence when all recorded diagnoses or
only cancer registry recorded diagnoses are included
Including only cancer registry-recorded diagnoses in the one year incidence analysis
resulted in 190 fewer diagnoses; 90 fewer in male patients and 100 fewer in female
patients. The one year incidence decreased in all groups by less than 1%; a decrease of
0.7% for men with thrombocytosis, 0.4% decrease for women with thrombocytosis, 0.5%
for men with a normal platelet count, and 0.2% for women with a normal platelet count.
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This plus the overlapping confidence intervals between measures for each group suggests
that the one year incidence of cancer does not greatly change in any of the subgroups
as a result of including only cancer-registry recorded diagnoses in the analysis; and that
there is little overestimation in incidence figures as a result of including CPRD-recorded
diagnoses that were not confirmed by the cancer registry.
5.9 Chapter discussion
The validation study presented in the first part of this chapter has encouraging results;
5, 924 of 7, 028 cancer diagnoses recorded in the CPRD were confirmed by the cancer
registry (a PPV of 84.3%). This result is supported by Boggon et al. (2013) who found
that 4, 830 of 5, 797 CPRD recorded cancers were confirmed by the cancer registry
(83.3%). In that study, there were more cases of colorectal, lung, urinary tract, and
pancreatic cancer recorded in the cancer registry than the CPRD; lung and pancreatic
cancer have particularly poor prognosis. Patients with these diagnoses may be more
likely to die in hospital soon after their diagnosis, and details of this may not be fed back
to their primary care record. That study also found that cancers diagnosed through
routes other than histology (such as myeloma and leukaemia) were under-recorded in
the cancer registry; some cancer registries are typically over-reliant on histology. The
majority (528 out of 967, 54.6%) of CPRD cancer records that were not validated by a
cancer registry record in Boggon et al. (2013) were validated by other means; hospital
records or practice records. CPRD cancers that are not confirmed by the cancer registry
cannot be assumed to be false records.
Dregan et al. (2012) found a higher level of concurrence between the CPRD and the
cancer registry; 92% of CPRD cancers were confirmed by the registry data. However,
that study included only colorectal, gastro-oesophago, respiratory, and urinary tract
cancers. These four sites were chosen as the validation study builds on an earlier
study from the same authors that investigated the incidence of cancer in patients with
haematuria, haemoptysis, dysphagia, and rectal bleeding. Comparing the present study
with Dregan et al. (2012)’s work, it appears that records of some types of cancer in the
CPRD are more valid than others.
The present study found that sex, year of diagnosis, and age group at diagnosis were
significant predictors of concordance in recording between the CPRD and the cancer
registry. Boggon et al. (2013) also examined predictors of concordance, and found that
age was predictive (with less CPRD recording with greater age). Sex did not predict
concordance in that study, and year of diagnosis was not examined.
It is possible that some patients have codes in their CPRD records which indicate a
cancer diagnosis, when they are not a true case. These errors can be caused by processes
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or errors in the healthcare system, or data recording issues. Healthcare system issues
include diagnoses being mistakenly recorded in the CPRD; Dregan et al. (2012) found
that 77% of incorrect CPRD cancer records had an alarm symptom recorded; this
could have resulted in mistakenly diagnosed cancer, or a ‘suspected’ cancer record
being picked up in research studies as a diagnosis. Disagreement between the two
sources on the primary site of diagnosis could also be attributed to erroneous recording
if the first wrongly diagnosed site was recorded in the CPRD, and the correct site
later recorded; the first cancer in the patient’s records would not match the later,
correct, cancer registry record. The two data sources collect data in different ways at
different points in the healthcare system; the CPRD data are updated monthly with
multiple consultations and entries per diagnosis, whereas the cancer registry aims to
make one single record for each cancer diagnosis in each patient. Data recording issues
include the possibility that a cancer registry cancer is recorded just after the end date
of the patient’s registration with a CPRD practice; and their diagnosis may not be
fed back to their old practice. The CPRD and the cancer registry each use different
coding dictionaries which could result in inconsistencies, and mistakes in the patient
ID number used to link the two data sources may mean that a CPRD patient appears
to have no record in the cancer registry, or vice versa.
The sensitivity analysis presented at the end of this chapter found that only includ-
ing cancer registry diagnoses in the primary analysis (identifying the cancer incidence
in patients with thrombocytosis and with a normal platelet count) did not greatly al-
ter the results; the estimated cancer incidence for men with thrombocytosis was 11.6%
(11.0-12.3) using CPRD and cancer registry diagnoses and 10.9% (10.3-11.6) using can-
cer registry diagnoses only. Similarly, for women with thrombocytosis the incidence was
6.2% (5.9-6.5) including CPRD and cancer registry diagnoses, and 5.8% (5.5-6.2) using
cancer registry diagnoses only.
5.10 Strength and limitations
Although this study used a large sample of 50, 000 patients from the CPRD, 40, 000 of
the patients in the sample were selected based on their having had at least one platelet
count showing thrombocytosis; therefore, the sample is not generally representative of
all CPRD patients. Therefore, whilst this chapter does examine the validity of the
CPRD data sample used in Chapter 4, the findings have limited applicability to the
CPRD as a whole. Other CPRD validation studies have also included specific popu-
lations of patients defined based on particular conditions or symptoms; Dregan et al.
(2012) included patients with haematuria, haemoptysis, dysphagia, rectal bleeding,
or lung, colorectal, gastro-oesophagic, or urinary cancer, from English practices with
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registry linked data available. Boggon et al. (2013) included patients from English
practices with cancer registry and HES linked data with diabetes.
Patients with thrombocytosis may have greater health concerns which mean that
they are more likely to come in to contact with health services. One criteria for selection
of patients from the CPRD for this study was that cancer registry data linkage must
be available for the patients. Not all CPRD-contributing practices participate in the
cancer registry linkage scheme. There could be inherent differences between practices
that do and do not participate in the linkage which affect the accuracy and validity of
cancer recording. A further limitation of this study is that the exact date of diagnosis
is not available; only the month and year. This could in part explain some of the
differences in date of diagnosis seen between the two sources, although the impact of
this is likely to be small.
Additionally, the present analysis only included data from English practices. It is
not possible to apply the findings to Welsh, Scottish, or Northern Irish data.
5.11 Chapter Summary
The findings of this validation study are encouraging for future studies that use CPRD
data; particularly those using cancer records. Overall, the quality of cancer diagnosis
recording in the CPRD was reasonably high. This is supported by results from Boggon
et al. (2013) and Dregan et al. (2012). The availability of linked cancer registry data
is a great advantage of CPRD data, and studies requiring accurate incidence figures
should make use of this linkage to ensure that all incident cases are captured.
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Discussion and conclusions
6.1 Summary of main findings
The evidence drawn together in this thesis strongly supports a link between thrombo-
cytosis and undiagnosed cancer. It suggests that for at least a proportion of patients
with an underlying malignancy, platelets begin to rise in excess of normal levels before
other symptoms become evident. Unlike some physical symptoms of cancer, which can
be subject to patient delay in presentation, which in turn can delay diagnosis (Macleod
et al., 2009), platelet count is measured in general practice as part of a full blood count
and is often an incidental finding. A full blood count is arguably the most commonly
ordered test in general practice; around a quarter of adults in the UK have one in a
year (Hamilton et al., 2008).
Both the systematic review in Chapter 3 and the cohort study presented in Chapter
4 investigated the relationship between thrombocytosis and cancer. The studies iden-
tified by the systematic review had only examined the relationship for some types of
cancer, and found thrombocytosis to be a marker of lung, kidney, oesophago-gastric,
and uterine cancer. It was not a marker of colorectal, pancreatic, ovarian, or breast
cancer. The impact of sex, age, and change in platelet count over time had not been
examined in any of the included studies. The cohort study in Chapter 4 addressed this
gap and found that the risk of cancer increases steadily with increasing platelet count
(see Figure 6.1). Thrombocytosis is more strongly indicative of cancer in men than in
women, and the presence of thrombocytosis is more predictive of cancer in older rather
than younger patients. A platelet count that remains elevated over time is also more
strongly predictive of underlying malignancy.
The association between thrombocytosis and cancer was further examined by com-
bining thrombocytosis with other symptoms. Thrombocytosis plus two ‘vague’ cancer
symptoms, loss of appetite and weight loss, was more strongly indicative of underlying
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malignancy than thrombocytosis alone, as was thrombocytosis and cough or a change
in bowel habit or rectal bleeding. It was revealed that at least a third of patients with
thrombocytosis and lung or colorectal cancer had no other recorded clinical features
of cancer in the year prior to diagnosis. The recognition of thrombocytosis as a risk
marker of cancer and the inclusion of this clinical feature in national suspected cancer
guidance could have a sizeable impact in practice, prompting earlier investigation and
potentially earlier diagnosis before other symptoms become apparent. The validation
study presented in Chapter 5 thoroughly examined the validity of cancer recording in
the CPRD and differences in data recording between the CPRD and the cancer reg-
istry. This study found the quality of data recording in the CPRD to be reasonably
high, and the sensitivity analysis indicated that the inclusion of non-cancer registry
confirmed cases in the main analysis in Chapter 4 would not have greatly altered the
results or interpretation.
6.2 Overarching findings and comparison with existing
literature
The cohort study presented in this thesis is the first and only study to examine thor-
oughly all aspects of the relationship between thrombocytosis and cancer, and to inves-
tigate the potential clinical utility of this risk marker in practice. The systematic review
(Chapter 5) found that female-only cancers (all of which are hormone-dependent) were
not as strongly associated with thrombocytosis as non-hormone-dependent cancers.
This was supported by the finding that prostate cancer (also hormone-dependent) was
much less commonly diagnosed in men with thrombocytosis compared to men with a
normal platelet count, or the general population. It is not clear whether these differ-
ences occur due to thrombocytosis being less implicated in hormone-dependent cancers
(which are more commonly diagnosed in women), or whether the difference is an arte-
fact of variation in consulting behaviour and cancer incidence between men and women
in the general population. Women aged 40 years and over consult more often than
men, and cancer incidence is lower in women than in men in this age group; these
two factors could result in a ‘dilution’ of cancer incidence in women with thrombo-
cytosis compared to men with thrombocytosis. Alternatively, this difference could be
due to thrombocytosis in women having more benign causes. There is also evidence
that women have higher baseline platelet counts than men (Bain, 1996; Biino et al.,
2013; Gader et al., 1995; Graham et al., 1987; Segal & Moliterno, 2006; Stevens &
Alexander, 1977). Overall, thrombocytosis was a much stronger risk marker of non-
hormone-dependent cancers, and a stronger marker in men than in women.
138
6. Discussion and conclusions
(a)
(b)
Figure 6.1: Fractional polynomial logistic regression model with platelet count as
a continuous predictor variable. (a) increasing cancer incidence (and 95% confidence
intervals) with increasing platelet count in males. (b) increasing cancer incidence (and
95% confidence intervals) with increasing platelet count in females.
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The studies identified by the literature review in Chapter 3 examined the rela-
tionship between thrombocytosis and cancer in a retrospective manner; starting with
patients diagnosed with a particular type of cancer and looking back to examine the
proportion that had thrombocytosis in the year prior to their diagnosis. The cohort
study in Chapter 4 examined the association prospectively; starting with patients with
thrombocytosis and observing which patients went on to be diagnosed with cancer,
compared to a group of patients with a normal platelet count.
Another key difference between the case-control studies in Chapter 3 and the cohort
study in Chapter 4 is the population being studied. Although both included patients
registered with and attending a CPRD-subscribed general practice, the case-control
patients had to have consulted one or more times within the two years prior to their
cancer diagnosis. In the cohort study, patients were eligible for inclusion only if they had
a blood test. There was no blood test criteria for inclusion in the case-control studies.
These case-control studies are therefore likely to include patients with less illness and
less likely to be diagnosed with cancer than the cohort study. It is reasonable to expect
differences between the two study types in their findings on the association between
thrombocytosis and cancer, due to these differences in the study population.
Nine cancer sites were investigated in studies found by the systematic review, and
20 cancer sites in the cohort study. Evidence from three other publications (concerning
lung (Pedersen & Milman, 1996), ovarian (Stone et al., 2012), and any type of cancer
(Davis & Mendez Ross, 1972)) was not included in the systematic review as these were
hospital based, so the included patients were further along the diagnostic pathway. As a
patient is more likely to be diagnosed with cancer from the point of referral compared to
in a primary care consultation, these studies would have found a much higher incidence
of cancer in patients with thrombocytosis, which would have introduced bias to the
results. However, the evidence from these studies is included below to give a wider
context.
The combined evidence for each cancer site is presented below.
6.2.1 Thrombocytosis and lung cancer
In a study of 100 patients with thrombocytosis seen in hospital for undisclosed reasons,
4 were diagnosed with lung cancer (4%) (Davis & Mendez Ross, 1972). In that study
thrombocytosis was defined as a platelet count > 500 × 109/L and as the study was
carried out in a hospital setting, the incidence of cancer in the study population was
likely to be higher than that in primary care. A study of patients with chest x-ray
abnormalities warranting further investigation for lung cancer found thrombocytosis
in 57% of patients with malignant disease, and 8% with benign disease (Pedersen &
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Milman, 1996); this fits with findings from the case-control study identified in Chapter
3 in which 14% of lung cancer patients had thrombocytosis prior to diagnosis (Hamilton
et al., 2005a). Data from the latter study were used to calculate the likelihood ratio of
thrombocytosis for lung cancer; this was 8.9 (95% CI 5.19-15.41).
The independently calculated PPV of thrombocytosis for lung cancer using data
from that study was 1.63 (0.92-2.90). In the cohort study in Chapter 4, the incidence
of lung cancer in male patients with thrombocytosis was 3.2% (2.9-3.6); this represents
an absolute increase of 2.8% compared to the risk in patients with a normal platelet
count (which was 0.4% (0.2-0.8)). For female patients there was also an increased risk
associated with a raised platelet count; lung cancer incidence in those with thrombo-
cytosis was 1.1% (0.9 - 1.2), an absolute increase of 0.8% compared to that in females
with a normal platelet count (0.3%, 0.1 - 0.4). The risk of lung cancer increased if
patients with thrombocytosis presented with a cough; in patients with thrombocytosis
and a cough, the risk of a lung cancer diagnosis in the following year was 3.9% (3.2-4.7).
The work presented in this thesis concerning platelet count and lung cancer sug-
gests that the platelet count rises progressively in the months before diagnosis in some
patients with lung cancer. Crucially, around a third of patients with lung cancer had
no clinical features of malignancy other than thrombocytosis in the year prior to their
diagnosis. Staging data in the study by Pedersen and Milman showed that thrombocy-
tosis was more common in patients with advanced disease (Pedersen & Milman, 1996).
The proportion of lung cancer patients with thrombocytosis rose from 14% (Hamilton
et al., 2005a) in a primary care setting to 57% in a secondary care setting (Pedersen &
Milman, 1996). Overall, this evidence strongly supports a diagnostically useful associ-
ation between thrombocytosis and undiagnosed lung cancer; one which could be used
to identify cancer at an earlier disease stage, before other symptoms become evident.
6.2.2 Thrombocytosis and colorectal cancer
The previously mentioned study by Davis & Mendez Ross (1972), of 100 patients with
thrombocytosis seen in hospital for undisclosed reasons, found that 4 patients were
diagnosed with colon cancer (4%). The case-control study identified by the systematic
review in Chapter 3 did not find thrombocytosis to be a significant predictor of col-
orectal cancer in multivariable models. This was one of the smaller studies included
in the review, with 349 cases and 1,744 controls. In Chapter 4, the incidence of col-
orectal cancer was markedly higher in men and women with thrombocytosis compared
to those with a normal platelet count. For men with thrombocytosis, the incidence of
colorectal cancer was 2.7% (2.4-3.1); this represents an absolute increase of 2.3% from
the incidence in patients with a normal platelet count, which was 0.4% (0.2-0.7). For
141
6. Discussion and conclusions
women with thrombocytosis, the incidence of colorectal cancer was 1.6% (1.4-1.7); an
absolute increase of 1.2% from the value of 0.4% in women with a normal platelet count
(0.3-0.6). These incidence values were higher in patients with a record of rectal bleeding
(8.4%, 95% CI 5.8-11.9) or a change in bowel habit (5.7%, 95% CI 4.8-6.7) although this
may be of limited clinical use since these symptoms alone may be enough to prompt
investigation for suspected cancer in practice. Certainly, NICE guidance recommends
referral for suspected colorectal cancer for any patients with rectal bleeding aged 50
years and over, or for patients aged 60 years and over with a change in bowel habit
(NICE, 2015).
There are several factors that could explain the difference in findings between the
case-control study identified by the literature search in Chapter 3, and the cohort study
presented in Chapter 4. The former found that thrombocytosis was not a predictor of
underlying colorectal cancer, whereas the latter found an association between throm-
bocytosis and undiagnosed colorectal cancer. The two studies included large samples;
2,093 in the case-control study and 39,230 in the cohort study. There are also differ-
ences between the patients included in each sample. In the case-control study, patients
were eligible for inclusion if they had a consultation recorded in the two years prior to
their cancer diagnosis. This consultation did not necessarily include a full blood count.
In that study, patients with no platelet count available were assumed to have a normal
platelet count and categorised as such. In the cohort study, patients were selected for
inclusion on the basis of their platelet count; so all included patients had a full blood
count. They are therefore likely to have more illness than the case-control sample, who
may not all have had blood tests. The base rate of cancer is likely to be different in each
sample. This difference may affect the association seen (or not seen) between platelet
count and cancer in each of the two studies.
6.2.3 Thrombocytosis and hormone-dependent cancers
The evidence surrounding thrombocytosis and various hormone-dependent cancers is
mixed.
Ovarian cancer was the most commonly diagnosed cancer (n = 7) in the Davis
& Mendez Ross (1972) study of 100 patients with thrombocytosis; there were also
five cases of breast cancer in the cohort. 60% of patients in that study were female.
Another study found that 31% of 619 patients with ovarian cancer had thrombocytosis
at the point of diagnosis (Stone et al., 2012), and others have found thrombocytosis
to be a predictor of poor prognosis for ovarian cancer (Allensworth et al., 2013). The
ovarian cancer case-control study identified by the literature search in Chapter 3 did
not find thrombocytosis to be a significant predictor of undiagnosed ovarian cancer. In
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the cohort study in Chapter 4, the risk of ovarian cancer was higher in women with
thrombocytosis (1.3%, 95% CI 1.1-1.4) than in women with a normal platelet count
(0.4%, 95% CI 0.3-0.6).
In the cohort study in Chapter 4, the incidence of uterine cancer did not differ
between women with thrombocytosis or with a normal platelet count (thrombocytosis:
0.2%, 95% CI 0.2-0.3, normal platelet count: 0.2%, 95% CI 0.2-0.4). For cervical
cancer, there was also no difference in risk between women with thrombocytosis (0.1%,
95% CI 0.0-0.1) and with a normal platelet count (0.0%, 95% CI 0.0-0.1). Cervical
cancer differs from other hormone-dependent cancers discussed in this section, in that
the majority of cases are diagnosed in women aged under 45 years; the incidence is at
its highest in women aged 25-30 (Cancer Research UK, 2015b). This does not match
the age profile of the cohorts investigated in Chapter 4 of this thesis; the median age of
patients in the cohort was 62 years of age (and the minimum age was 40 years). There
may be too few incident cases in the cohort for any association with thrombocytosis
to be evident (there were 10 cases in the thrombocytosis cohort); or it may be a true
finding. Further investigation is needed.
14% of cervical cancers are diagnosed through the national screening programme
(National Cancer Intelligence Network, 2010), and the majority of cervical cancers are
diagnosed at stage I or stage II (Cancer Research UK, 2015b). Therefore, this cancer
type may generally be diagnosed earlier, before symptoms have developed, and possibly
before the platelet count starts to rise. Additionally, the vast majority of cervical
cancers are caused by the human papilloma virus (Cancer Research UK, 2014c); this
causal mechanism may be independent of any platelet-producing pathway.
There was also little difference in the incidence of breast cancer between women
with thrombocytosis (0.4%, 95% CI 0.3-0.5) and with a normal platelet count (0.5%,
95% CI 0.3-0.7). Breast cancer also accounted for a much smaller proportion of all
cancers diagnosed in women with thrombocytosis than in the general population (6%
vs 30%). Breast cancer has an extensive screening programme in the UK. The majority
of breast cancers are diagnosed in women in their 60s, 31% are identified through
screening programmes, and 84% are either stage I or stage II at diagnosis (based on
staging data available for 84% of incidence cases in 2013) (Cancer Research UK, 2015b).
Therefore, many breast cancers are diagnosed before symptoms develop, possibly before
the platelet count begins to rise. Breast cancer also has an alarm symptom, a breast
lump, which has a PPV of 4.8% for women in their 40s and 48% for women in their
70s and over (Walker et al., 2014) so thrombocytosis may not be a clinically useful
addition, diagnostically.
Male hormone-dependent cancers include testicular and prostate cancer. There were
only two cases of testicular cancer in the thrombocytosis cohort, and none in the normal
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platelet count cohort. This is unsurprising as testicular cancer incidence is highest in
men aged 25-40 years and declines with age; this does not match the age profile of the
cohorts investigated in this study. The systematic review did not find any papers that
had investigated the early markers of testicular cancer and included thrombocytosis,
and no studies from other healthcare settings were found. Prostate cancer incidence
was only marginally higher in patients with thrombocytosis (1.4%, 1.2-1.7) compared
to those with a normal platelet count (1.1%, 0.7-1.6). No other studies were found that
had investigated thrombocytosis and prostate cancer.
6.2.4 Thrombocytosis and other types of cancer
The evidence for thrombocytosis and other types of cancer is mixed. Previous stud-
ies found thrombocytosis to be a marker of kidney and oesophago-gastric cancer, in
addition to the previously discussed cancers. The cohort study in Chapter 4 did not
find a strong association with kidney cancer. Oesophageal and stomach cancer were
investigated as separate cancer sites; combining the results for these two sites gives
an incidence of 1.2% (95% CI 0.9-1.6) in male patients with thrombocytosis and 0.2%
(95% CI 0.1-0.4) for men with a normal platelet count; an absolute increase of 1.0%.
In the case-control study of the clinical features of oesophago-gastric cancer, thrombo-
cytosis was a significant predictor of malignancy in multivariable models (OR 2.4 (95%
CI 2.0-2.9). The incidence of other types of cancer investigated in the cohort study was
low, and there is very little (or no) evidence from other previously published studies.
6.3 Limitations
6.3.1 Selection bias
One of the major limitations of the cohort study (Chapter 4) is that patients having
a blood test are a selected group, who are more likely to be ‘ill’, and therefore more
likely to be diagnosed with cancer than patients attending primary care without a
blood test, or the general population. The cancer incidence would be artificially high
in this selected group; this is why the findings presented here do not support the use
of a platelet count as a diagnostic test for cancer in patients who otherwise would not
be tested; this would require a very different type of study. In an attempt to address
this bias, the cancer incidence in patients with thrombocytosis was compared to that in
patients with a normal platelet count. This group is a more suitable comparator as they
have also been selected for a blood testing, and therefore have a comparable baseline risk
of cancer. The overall risk of cancer in patients with thrombocytosis is the primary
objective of the cohort study (and not the absolute increase in risk from a normal
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platelet count). This is the most clinically useful outcome; in practice, GPs will need
to know the risk of cancer in the patient they are currently seeing, not how much more
at risk they are compared to another patient. However, the absolute difference in the
risk of cancer between patients with and without thrombocytosis enables the additional
value of a raised platelet count, above a normal platelet count, to be demonstrated.
6.3.2 Reasons for testing
A further limitation of this work is that the reasons for full blood counts being ordered
are not known in either cohort of patients. Patients with raised platelet count could
be presenting with a clinical feature which has already prompted the GP to consider
cancer, and the decision to order a blood test is responsive to that. As a proxy for
this, the symptoms reported by patients in the month prior to their index date (those
which could have prompted a blood test) were compared between the two cohorts.
Some of the most commonly reported symptoms were indicative of cancer, including
cough, fatigue, abdominal pain, diarrhoea, and shortness of breath. The proportion of
patients reporting these symptoms was marginally higher in the thrombocytosis cohort
than in the normal platelet count cohort. However, the proportion reporting a single
symptom was less than 4% (Table 4.4). With the exception of cough (reported by 3.9%
of thrombocytosis cohort and 1.9% of the normal platelet count cohort), there was a
difference of less than 1% in the proportion reporting the symptom between the two
cohorts. This suggests that there is little difference between the cohorts in cancer alarm
symptoms that could have prompted a blood test in the month before their platelet
count index date.
6.3.3 Sample size
The cohort study in Chapter 4 found that some cancers were more strongly associated
with thrombocytosis than others. Whilst a true lack of association between thrombocy-
tosis and some types of cancer could be responsible for the low incidence of some cancer
types, it could also be due to too few cases of these types of cancer being identified
in the sample. Power calculations carried out prior to the commencement of this PhD
found that 40, 000 patients with thrombocytosis was sufficient to estimate an incidence
of any type of cancer of 5% with a margin of error no greater than 0.22%, using the
upper bound of the 95% confidence interval. 10, 000 patients was sufficient to estimate
the same incidence of cancer with a margin of error no greater than 0.45% similarly. To
accurately estimate the incidence of less common cancers may require a larger sample
size, and may be of limited clinical use.
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6.3.4 CPRD data quality
A further limitation of this work, and of six of the nine case-control studies identified
in the systematic review, is that it relies on the accuracy and validity of CPRD data.
Furthermore, only patients registered at CPRD-contributing practices that had sub-
scribed to the cancer registry linkage scheme were included in the cohort. This excludes
patients who are at non-linkage subscribed practices. There may be inherent differences
between practices that do and do not subscribe to the cancer registry linkage scheme
that could introduce bias to the study; practices with high cancer awareness and cancer
investigation rates may be more likely to subscribe to the scheme, although there is no
evidence that this is so. As earlier described, there is evidence to suggest that cancer
recording is of reasonably high quality in the CPRD (Boggon et al., 2013; Dregan et al.,
2012). The inclusion of linked cancer registry data in this study is a particular strength;
as is the testing of the validity and diagnostic accuracy of the CPRD data using the
linked registry data (Chapter 5). This study found high rates of cancer recording in
the CPRD. The sensitivity of CPRD cancer recording was 76.1%, and the PPV of a
CPRD cancer diagnosis was 84.3%. This included all types of cancer; the figure may be
higher for some types of cancer, as suggested by Dregan et al. (2012). The sensitivity
analysis which repeated the primary analysis from Chapter 4 found that the inclusion
of non-cancer registry confirmed CPRD-recorded cancers did not greatly inflate the
results.
The data sample in this validation study included cancer registry data from 2000-
2010. The UK Department of Health’s Improving Outcomes: a strategy for cancer
policy, published in 2011, initiated a drive towards better recording of cancers in the
cancer registry. It may be that more recently collected registry data are of higher
quality or more complete. Results presented in Chapter 5 suggested that CPRD cancers
recorded from 2005 onwards were more likely to be verified by cancer registry records.
CPRD cancers recorded in male patients were more likely to be matched by cancer
registry data than cancers in female patients, as were those recorded in younger patients.
These two factors are likely to be linked; cancer is more likely to be diagnosed in women
in older age groups.
6.3.5 Missing cancer staging data
The relative incompleteness of data in the 2000-2010 timeframe is illustrated by the
lack of satisfactory staging data; staging was available for only half of cases. The lack
of staging data and subsequent lack of staging analysis is a weakness of this work.
Thrombocytosis as a marker of cancer is less useful in terms of expediting diagnosis to
improve outcomes if it only identifies late stage cancers, although these are also worth
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diagnosing, even if the prognosis is poor. The staging data that were available only
suggest that at least a quarter of thrombocytosis cancers are early stage. This is a
factor that needs to be investigated in future research.
6.3.6 Misclassification bias
Laboratory test results for the platelet count were used to define the two cohorts of pa-
tients in Chapter 4. These results are electronically transmitted to patient records, and
so any misclassification bias resulting from this process is likely to be non-differential,
and small. Three of the 50,000 patients in the cohort were misclassified due to errors
in platelet count recording. In all three cases, a normal platelet count had three extra
0s mistakenly added so that the platelet count appeared to exceed the normal value.
Patients were therefore incorrectly classed as having thrombocytosis. Misclassification
bias in outcome reporting in CPRD data is more likely; patients may be incorrectly
coded as having cancer if a cancer medcode was used mistakenly by the GP, or if
a ‘suspected’ or ‘absent’ coded cancer was incorrectly taken as cancer being present.
Such records are rarely, if ever, removed from the CPRD record. In a previous CPRD
data validation study, 77% of incorrect CPRD cancer records had an alarm symptom
recorded; this could by explained by a ‘suspected’ cancer record being picked up in
research studies as a diagnosis (Dregan et al., 2012). In the present study, the use of
linked cancer registry data attempts to ameliorate this bias by providing a confirmation
of cancer diagnoses.
6.3.7 Detection bias
The main exposure variable in this study (platelet count) relies on electronically coded
data, which are unlikely to be affected by detection bias. However, some of the sec-
ondary analyses presented in this thesis rely on symptom data coded by GPs in consul-
tations; specifically, concerning cough, change in bowel habit, rectal bleeding, weight
loss, and loss of appetite. These analyses could be affected by detection bias. Whilst
all symptoms should be recorded in practice using the numerical Read codes (Booth,
1994), there is evidence to suggest that GPs do not record all symptoms in this way. A
CPRD study by Price et al. (2016) found that 38% of clinical features were recorded by
GPs only in the free text section of the patients’ medical records, and not coded using
Read codes. In that study there was some differential loss of recorded symptom data
to the free text for visible haematuria and jaundice. Patients with cancer were more
likely to have these symptoms recorded using Read codes, whereas patients without
cancer were more likely to have these symptoms recorded in the free text section of
their CPRD records. These differential coding differences may apply to some patients
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included in samples used in this thesis. However, given the similarities between the
recorded symptoms in patients with thrombocytosis and a normal platelet count, any
effect of this should be minor.
6.3.8 Generalisability of results
The generalisability of these results outside of England and the UK is limited. The sys-
tematic review found only UK-based studies, and the cohort study included data from
English practices only. Despite extensive efforts to identify international researchers
who may have relevant data or be conducting similar investigations, none were found.
A recently initiated study in Sweden is collecting data on 200 consecutive cases of
colorectal, lung, and urethral cancer from seven Swedish regions (personal communi-
cation: Hans Thulesius). Preliminary results are showing thrombocytosis in 14% of
lung cancer patients; this matches exactly the estimate from the case-control study of
clinical features of lung cancer identified by the systematic review (Hamilton et al.,
2005a). Despite the lack off data from outside of England, it is unlikely that the rela-
tionship between thrombocytosis and cancer would only be seen in patients registered
at English general practices, although factors such as ethnicity and cultural differences
in when patients choose to consult with symptoms may have an impact. The over-
representation of general practices in the South East and North West of England limits
the applicability of these findings to other regions of England. This could introduce bias
if there were significant geographical patterns in cancer diagnosis in the UK; however,
data published in 2016 (NHS England, 2016) show all regions of the UK performing
poorly in cancer diagnosis, with no geographical trend.
6.3.9 Publication and reporting bias
Five of the nine studies included in the systematic review were not identified by the
literature search as they did not report on thrombocytosis (although they had collected
the data). This reflects the publication bias which is a key limitation of all systematic
reviews. In four of these studies, thrombocytosis was not a predictor of cancer in the
multivariable (adjusted) analysis so it was not reported. However, the identification and
inclusion of these studies (and inclusion of negative unpublished results) is a strength
of the systematic review presented in this thesis. It is probable that there are other
unidentified studies that collected, but did not report, platelet count data that were
not identified through contact with experts and networking. The exclusion of non-
English language papers due to a lack of translating facilities is a further limitation of
the systematic review. The search strategy itself included three groups of search terms
relating to thrombocytosis, cancer, and primary care. The concept of primary care
148
6. Discussion and conclusions
differs from country to country, and not all healthcare systems are organised this way.
Studies set in another region’s equivalent to a primary care setting may not have been
identified if this setting is described differently.
6.3.10 Platelet count reference range
The range for a normal platelet count of 150 - 400×109/L, and threshold of 400×109/L
for thrombocytosis, was chosen in this study to encompass both definitions used in
English laboratories (400 or 450×109/L). However, a growing body of evidence showing
statistically and clinically important differences in the normal platelet count range
for different sexes (Bain, 1996; Biino et al., 2013; Gader et al., 1995; Graham et al.,
1987; Segal & Moliterno, 2006; Stevens & Alexander, 1977), ages (Biino et al., 2013;
Segal & Moliterno, 2006), and ethnic groups (Bain, 1996; Gader et al., 1995; Segal
& Moliterno, 2006) has prompted some researchers to propose new tailored reference
ranges for platelet count (Biino et al., 2013). The largest study to date, Biino et al.
(2013), included 40, 987 individuals from nine regions in Italy. The sample comprised
46.2% males, with a mean age of 50.7 years (SD 17.5, range 10 months to 105 years).
That platelet count is consistently higher in women and declines with age is reflected
in the new reference ranges proposed by this group. They are stratified by age and sex:
 Men aged 15-64 years, normal range 141 - 362× 109/L (mean 238, SD 57.9)
 Women aged 15-64 years, normal range 156 - 405× 109/L (mean 264, SD 65.3)
 Men aged 64 years and over, normal range 122 - 350×109/L (mean 220, SD 59.5)
 Women aged 64 years and over, normal range 140 - 379 × 109/L (mean 245, SD
61.2)
These findings suggest that a platelet count of under 362 × 109/L should only be
considered ’normal’ for women, and that in men, the upper limit for a normal platelet
count should lie closer to 350×109/L than 400×109/L. Using these revised thresholds
to define patients with thrombocytosis in the present study (Chapter 4) may have
produced quite different results; and accepting a lower threshold of platelets to prompt
cancer investigation could increase the clinical utility of this test result.
6.4 Implications for practice
Cancer incidence figures of 11.6% in men and 6.2% in women with thrombocytosis are
very high; well above the threshold value of 3% risk used for urgent investigation of
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suspected cancer in recent UK guidance (NICE, 2015), and even further above the 1%
risk at which patients would like to be investigated for suspected cancer (Banks et al.,
2014). National cancer incidence data show that the overall risk of cancer for an adult
aged 40 years and over is around 1.5% (Cancer Research UK, 2016). Results presented
in this thesis show that the risk of cancer in patients with thrombocytosis is 11.6%
(95% CI 11.0-12.3) for male patients and 6.2% (95% CI 5.9-6.5) for female patients;
well above the ‘background rate’ of cancer in the general population. In comparison,
the PPV of a breast lump in women aged 50-59 years is 8.5% (95% CI 6.7-11.0) (Walker
et al., 2014), and the PPV of hypercalcaemia in men aged 40 years and over is 11.5%
(95% CI 11.1-11.9) (Hamilton et al., 2014).
Notably, patients with a recorded normal platelet count also appear at an increased
risk of cancer compared to the general population. The present study found that the
risk of cancer for male patients with a normal platelet count is 4.1% (95% CI 3.4-4.9),
and 2.2% (95% CI 1.8-2.6) for female patients. This diagnostic artefact reflects the fact
that patients who experience symptoms and are unwell enough to consult primary care
are different to (and more likely to be ill than) the general population. A subgroup
of these consulting patients will cause enough concern for their general practitioner to
be sent for a blood test. In that respect, this select group are more likely to have a
medical problem than a non-consulting patient. It is, therefore, the difference in cancer
incidence between those with normal platelet counts and those with thrombocytosis
that represents the additional risk of a cancer diagnosis in those with a raised platelet
count.
The absolute increase in risk associated with thrombocytosis above that associated
with a normal platelet count is 7.5% in men and 4.0% in women. Whilst it could
be argued that this figure more accurately represents the usefulness of thrombocyto-
sis in predicting cancer, it is actually the overall risk that prove the most useful in
general practice. In a consultation, GPs will generally consider the risk of cancer in
a symptomatic patient as an individual, taking their symptoms and test results into
consideration, and through a process of diagnostic reasoning consider whether the pa-
tient’s risk is great enough to warrant further investigation. Knowing the overall risk
associated with thrombocytosis is therefore more clinically valuable than the absolute
increase in risk.
The risk figures estimated in this work may seem small, but the predictive value
of most cancer symptoms for cancer is low. To put these findings into context, the
PPV of a breast lump for a diagnosis of breast cancer in a woman aged 50-59 years
in primary care is 8.5% (95% CI 6.7-11.0%) (Walker et al., 2014). The risk of lung
cancer in patients with haemoptysis is 3.5% (95% CI 1.6-7.5) in those aged 40 years
and over (NICE, 2015). This is similar to the risk of colorectal cancer in those with
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rectal bleeding (8.1% (95% CI 6.0-11.0)) in over 50s (Astin et al., 2011). The PPV of
an elevated PSA level is 17.9% (Grubb et al., 2008). The incidence of cancer in patients
with thrombocytosis is similar to that in patients with hypercalcaemia, which has a
one year incidence of 11.5% (95% CI 11.1-11.9) in men and 4.1% (95% CI 3.9-4.4) in
women (Hamilton et al., 2014).
From a policy perspective, these results may be of even more value. Thrombocytosis
has not generally been viewed as a risk marker for cancer, at least until the 2015 update
of the UK national guidance for suspected cancer included it as a marker of lung,
oesophago-gastric, and uterine cancers (NICE, 2015). In the studies that underpinned
that guidance, the proportion of cancer patients with thrombocytosis ranged from 4-
14% (Hamilton et al., 2005a; Shephard et al., 2013; Stapley et al., 2013; Walker et al.,
2013); reviewed in Chapter 3. In those studies, patients who had no platelet count
available were merged with those who have a normal platelet count, so it is likely the
true proportion of patients with cancer and thrombocytosis is higher. Results presented
in this chapter show that at least a third of lung and colorectal cancer diagnoses could
possibly be expedited by at least two months with the inclusion of thrombocytosis
in national guidance. Based on this, even if only a conservative estimate of 5% of
patients with cancer have thrombocytosis before diagnosis (16, 500 out of 330, 000 new
cases annually in the UK), a third of them have the potential to have their diagnosis
expedited by at least three months; equating to 5, 500 earlier diagnoses annually.
6.5 Implications for research
The validation study and sensitivity analysis presented in Chapter 5 have strong im-
plications for future research. Results from this study suggest that cancer recording in
the CPRD is generally of a good standard with a high diagnostic value. Researchers
should be aware that some types of cancer appear to be more reliably recorded than
others; for example, the study by Dregan et al. (2012) found CPRD data to have a
higher diagnostic value than the present study, but they had only included four types
of cancer. Non-melanoma skin cancer (excluded in the present study), and cancers di-
agnosed through non-histological routes are particularly susceptible to under recording
in the cancer registry. The present study found that 5, 924 of 7, 785 (76.1% sensitivity)
cancer registry recorded diagnoses were picked up by the CPRD. This suggests that
future research using CPRD data that requires accurate incidence figures should obtain
cancer registry linked data to ensure all incident cases are included.
There are four main areas where future research could follow on from this work.
Firstly, a large scale study is needed to examine the stage at diagnosis for patients
with thrombocytosis and cancer. The present study failed to meet the objective of
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Figure 6.2: Risk Assessment Tool for lung cancer in smokers. This tool plots several
clinical features against one another and gives the risk of cancer in patients presenting
with both symptoms.
investigating the stage at diagnosis due to missing data. Identifying the clinical features
of patients with thrombocytosis and early stage disease would have the potential to
make a significant contribution to earlier diagnosis.
Future research should focus on combining thrombocytosis with other clinical fea-
tures to improve the predictive value. Various studies have shown that incorporating
more than one clinical feature leads to higher predictive values; this is the basis of the
Risk Assessment Tools produced by several studies by Hamilton et al.. An example of
one of these Risk Assessment Tools is shown in Figure 6.2; thrombocytosis as a single
finding carries a risk of 4.2, but this risk increases when combined with cough, chest
pain, or weight loss. Other abnormal readings in blood tests have been found to be
associated with increased risk of cancer; hypercalcaemia (Hamilton et al., 2014; Stew-
art, 2005) and iron-deficient anaemia (Hamilton et al., 2008) could be combined with
thrombocytosis to give higher predictive values.
As discussed in the limitations section of this chapter, new reference ranges for
platelet count have recently been proposed (Biino et al., 2013). Using a lower thresh-
old to define thrombocytosis could have an important impact on the cancer incidence
observed in patients with thrombocytosis; results from the present study suggest that
patients with platelet counts at the upper limit of normal could be at increased risk
of cancer. Further research would be needed to investigate this hypothesis, examining
cancer incidence using platelet count as a continuous variable from 300 × 109/L, or
categorising in bands of 20 or 50. The results presented in Chapter 4 show that the
association between platelets and cancer could begin at levels lower than 300× 109/L;
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Figure 6.1 shows that the cancer incidence in male patients was still at around 9% at
platelet counts of 400× 109/L. Those at the upper range of ’normal’ could also be at
increased risk of cancer. This is well worth investigating in future work.
Finally, a feasibility trial could investigate ways to integrate the findings from this
thesis in to clinical practice in a way that would be clinically beneficial. The platelet
count is rarely independently tested and thrombocytosis is commonly ignored in blood
panels. A warning or notification to alert GPs to unexpectedly raised platelets in
blood test results could prompt suspicions of cancer earlier. This would be particularly
beneficial for patients who have no other symptoms that would warrant investigation
for cancer.
6.6 Conclusions
The overall body of evidence presented in this thesis strongly suggests that cancer
should be considered when a full blood count is received showing thrombocytosis, even
if cancer was not being considered when the blood test was ordered. The risk of cancer
is greater the higher the platelet count. Clinicians should be particularly mindful of
cancer in patients who show a sustained high platelet count, are male, or are older.
Greater suspicions are warranted if thrombocytosis is present with other vague, low
risk cancer symptoms such as weight loss and loss of appetite. The range of possible
cancers is wide; although lung and colorectal cancer are more likely than breast or
prostate. Clinicians will have to seek additional indicators from examination and the
patient’s medical history to select the most appropriate route for investigation.
Whilst the findings presented in this thesis encourage clinicians to consider cancer,
they do not go so far as to suggest that platelet count should be used as a diagnostic
or screening test for cancer. These conclusions are based on results from data from
a specific group of patients who were attending primary care and were selected for a
full blood count. There is insufficient evidence so far to support the testing of platelet
count as a means of identifying undiagnosed cancers, especially not in the asymptomatic
general population. However, for a considerable proportion of patients with unexpect-
edly high platelets, this finding could indicate an underlying malignancy and has great
potential to improve earlier diagnosis and survival.
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 Bailey, S., Ukoumunne, O., Shephard, E., Hamilton, W. (2016) Clinical rele-
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Journal of General Practice. (In press).
 Bailey, S., Ukoumunne, O., Shephard, E., Hamilton, W. (2016) How useful is
thrombocytosis in predicting an underlying cancer in primary care?: a systematic
review. Family Practice. pii: cmw100 [epub ahead of print].
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 Bailey, S., Ukoumunne, O., Shephard, E., Hamilton, W. (2016) In symptomatic
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Study protocol
This appendix contains a copy of the study protocol.
This can be found online at http://ore.exeter.ac.uk/repository/handle/10871/20964
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How useful is thrombocytosis in predicting an underlying cancer in primary care?: systematic 
review protocol 
 
Bailey SER1, Ukoumunne OC2, Shephard EA1, Hamilton W1. 
1 Primary Care Diagnostics, University of Exeter Medical School, College House, St Luke’s Campus, 
University of Exeter, Exeter, Devon, EX1 2LU.  
2 PenCLAHRC, University of Exeter Medical School, South Cloisters, St Luke’s Campus, University of 
Exeter, Exeter, Devon, EX1 2LU.  
Corresponding author: Bailey SER s.e.r.bailey@exeter.ac.uk 
Rationale and objective 
Early diagnosis of cancer is imperative to reduce the cancer burden in the UK and improve cancer 
survival. Identifying early markers of cancer can help general practitioners to direct patients at the 
greatest risk of cancer to appropriate investigative services. A raised platelet count, or 
thrombocytosis, has been linked to malignancy1 2 and identified as a marker of poor prognosis in 
secondary care3-9, but there is little evidence around the importance of this marker in a primary care 
setting, within a diagnostic context. This review aims to identify and explore the body of evidence 
concerning the association between thrombocytosis and cancer in primary care. This protocol was 
produced using guidance from the PRISMA-P statement.10 
Research questions 
x Are adults aged over 40 with thrombocytosis at greater risk of cancer than those with normal 
platelet counts? 
x Which cancer sites have been found to be associated with thrombocytosis in primary care, and 
which are not? 
Inclusion criteria 
x Any type of cancer or cancer site 
x Studies that have investigated the association between cancer and platelets (using platelets as a 
diagnostic tool, not prognostic factor). 
x Studies based in primary care. 
x Includes adults >40y 
x English language 
x Any observational, cohort, case-control study or literature or systematic review (due to the 
nature of the research question, RCTs were excluded) 
x The last 30 years 
 
Exclusion criteria: 
x Studies that have investigated thrombocytosis or platelet count as a prognostic tool or guide to 
therapy.  
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x Case studies and RCTs 
o Case studies are excluded as this review is interested in population-level or cohort based 
studies that can provide evidence on a large number of patients.  
o RCTs are excluded as the independent variable in this study cannot be randomised.  
 
Search strategy 
The search strategy will comprise the following elements to identify relevant papers: 
x Searching of electronic bibliographies including: 
o EMBASE (OvidSP) 1996-2014 (week29) 
o Medline (OVIDpalt) 
o Web of Science 
o The Cochrane Library 
 
x Scrutiny of reference lists of included studies 
x Contact with experts in the field 
Study selection criteria and procedures  
References will be uploaded to reference management software (Endnote X5). Duplicates will be 
checked and removed. The abstracts and titles of references retrieved by the electronic searches will 
be screened for relevance by SB using the pre-defined inclusion and exclusion criteria. Hits will be 
double screened by ES. Any differences in opinion over paper to include or exclude will be resolved 
by discussion.  
Full text copies of potentially relevant studies that appear to meet all inclusion criteria will be 
obtained.  The retrieved articles will be assessed for inclusion by checking each article against the 
pre-specified inclusion and exclusion criteria. A flow chart will be produced which will outline the 
study selection process, and reasons for exclusion of full text papers will be detailed.   
Quality assessment and data extraction strategy 
Study quality will be assessed using QUADAS-2. Data will be extracted into custom made data 
extraction forms by SB and WH. Data concerning the number of patients with and without cancer 
who had pre-diagnosis thrombocytosis will be the main extracted values. 
Evidence synthesis 
The evidence will be presented and synthesised as appropriate using meta-analysis if appropriate, or 
a narrative synthesis if meta-analysis is not appropriate. 
Search strategy - Embase 
Thrombocytosis OR platelet* (as a key word) OR thrombocyte OR thrombocyte count OR 
thrombocyte volume (MeSH terms) 
AND 
neoplasm OR carcinoma (mesh terms) OR cancer, carcinoma or paraneoplastic as key words 
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AND* 
primary medical care OR primary health care OR general practice OR family medicine (mesh terms) 
Search strategy – Medline 
Thrombocytosis OR platelet* (as key words) OR blood platelets OR thrombocytosis OR platelet count 
(MeSH terms) 
AND 
neoplasms OR carcinoma (mesh terms) OR cancer as a key word 
AND* 
primary health care OR family practice OR general practice (mesh terms) OR primary care, family 
medicine, primary medical care as key words 
Search strategy – Web of Science & Cochrane Library 
Thrombocytosis OR platelet* OR thrombocyte  
AND 
neoplasm OR carcinoma OR cancer 
AND* 
primary medical care OR primary health care OR general practice OR family medicine  
*the search will be run with and without this final filter in the preliminary stages to see how the filter 
affects the results.  
 Endnote labels 
1=include 
2=exclude – not cancer 
3=exclude – not investigating association with thrombocytosis 
4=exclude – not primary care 
5=exclude – not >40y 
6=exclude – case study 
7=exclude - RCT 
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Contributions 
Study design: SB. Search strategy and execution: SB. Title and abstract screening: SB and EA. Data 
extraction: SB and WH. Data interpretation and analysis: all authors.  
Funding  
The Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis receives funding for a 
research programme from the Department of Health Policy Research Programme. It is collaboration 
between researchers from seven institutions (Queen Mary University of London, UCL, King's College 
London, London School of Hygiene and Tropical Medicine, Hull York Medical School, Durham 
University and University of Exeter). OU is funded, and WH is part-funded by the National Institute 
for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care 
(CLAHRC) for the South West Peninsula at the Royal Devon and Exeter NHS Foundation Trust.  The 
views expressed in this publication are those of the authors and not necessarily those of the NHS, 
the NIHR or the Department of Health in England.  
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Data extraction form
This appendix contains an example of a completed data extraction form.
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Thrombocytosis	systematic	review.	
Data	extraction	form	V1,	July	2014	
	
Document	reference:	 Hamilton	et	al	2005	
Endnote	record	no:	 	 Data	extracted	by:	 Sarah	Bailey	
Country:	 UK	 Date:	 18-08-2014	
Aim	of	study:		 	 	 	
	 	 	 	 	 	 	
Study	characteristics	
Study	type	 Population	based	case-control	study	
Study	population	
(n,	sex,	age)	
Men	and	women	aged	>40.	All	cases	of	lung	cancer	in	Exeter	over	a	four	year	
period	(n=247)	plus	1235	age,	sex	and	practice	matched	controls.	
Location	 Exeter,	Devon		
Cancers	recorded	 Lung	only	
	
Platelets/TH	
investigated?	
Yes	
	 	 	 	 	 	 	
What	was	the	recruitment	strategy	in	this	study?	Did	they	include	sample	size	calculations?	
All	people	diagnosed	with	lung	cancer	in	Exeter,	Devon	over	a	four	year	period	were	recruited	to	this	
study.		
Up	to	five	controls	were	recruited	for	each	case	using	computerised	random	numbers.	These	were	
age,	sex	and	practice	matched.		
Exclusion	criteria	were:	GP	record	unattainable;	no	records	in	two	years	prior	to	index	date;	subject	
had	previous	lung	cancer;	lived	outside	of	Exeter	at	the	time	of	diagnosis.	Ineligible	controls	were	
replaced	with	a	randomly	selected	back	up.		
There	were	sample	size	calculations	–	see	paper	for	full	details.		
	
How	were	cancer	cases	identified?	Which	cases	were	excluded?	
How	were	platelets	measured?		
Cases	were	IDd	from	the	cancer	registry	at	the	RD&E.	In	addition,	computerised	searches	were	
carried	out	at	21	general	practices	in	the	city.		
Histological	records	were	used	to	confirm	cases,	and	where	there	were	none	of	these,	they	were	only	
accepted	if	the	diagnosis	was	made	by	a	specialist	based	on	strong	clinical	evidence.		
Platelet	counts	were	taken	from	GP	records.	Only	132/247	(53%)	of	cases	had	a	platelet	count.	Only	
396/1235	controls	(32%)	had	platelet	counts.		
	 	 	 	 	 	
Study	results.	
132/247	(53%)	of	cases	had	a	platelet	count.	34	(26%)	of	these	had	thrombocytosis.		
396/1235	(32%)	controls	had	platelet	counts	taken.	19	(5%)	had	thrombocytosis.	
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Likelihood	ratio	8.9	(5.2-15)	
Odds	ratio	(in	multivariate	model)9.3	(3.4-26)	p<0.001	
	
	 	 	 	 	 	
Key	strengths	and	weaknesses	of	the	study.	
All	cases	occurring	within	the	study	period	(in	the	study	area)	were	included.	Cases	were	confirmed	
by	histology	in	the	most	part.		
Checks	of	GP	level	data	supplemented	cancer	registry	data	searches.	
Some	cases	will	have	been	missed	despite	GP	level	searches	and	confirming	with	histology.	Those	
missed	are	likely	to	have	been	the	most	serious	cases.	
This	analysis	only	includes	patients	from	Exeter	and	so	not	necessarily	comparable	to	other	regions	of	
the	country.	Certain	factors	including	socio-demographic	spread	and	ethnic	composition	of	the	
population	are	likely	to	have	an	influence	on	cancer	and	differ	between	Exeter	and	other	
geographical	regions.		
There	are	no	data	available	concerning	the	smoking,	drinking	or	other	lifestyle	factors	for	the	
patients.	
Coding	of	features	of	cancer	was	performed	by	research	assistants	and	although	the	same	person	
coded	all	patients	for	a	single	practice,	there	is	still	a	chance	of	differences	between	different	coders,	
or	errors	in	the	coding	process.		
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Appendix C
Cancer medcodes
This appendix details the relevant medcodes used in the investigation of cancers in this
thesis:
 Table C.1 displays a key for the codes.
 Table C.2 contains a list of medcodes with a description.
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Table C.1: Keys for codes and their cancer sites for used in the table of medcodes
(Table C.2).
Code Cancer site
1 Bladder
2 Breast
3 Cervix
4 Prostate
5 Kidney
6 Leukaemia
7 Lymphoma
8 Myeloma
9 Oesophagus
10 Pancreas
11 Stomach
12 Testis
13 Uterus
14 Brain
15 Colorectal
16 Lung
17 Ovary
18 Oral
19 Skin (non-melanoma)
20 Other
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Table C.2: Description of medcodes with reference ID fields.
Cancer
site
Medcode Description Read code
1 7187 Carcinoma in situ of bladder B837.00
1 16926 Neoplasm of unspecified nature of bladder BA04.00
1 9712 [M]Papillary transitional cell carcinoma BB4A.00
1 779 Malignant neoplasm of urinary bladder B49..00
1 97091 [X]2ndry malignant neoplasm/bladder+oth+unsp uri-
nary organs
ByuC500
1 35963 Malignant neoplasm of lateral wall of urinary bladder B492.00
1 42023 Malignant neoplasm of urachus B497.00
1 31102 Malignant neoplasm of urinary bladder NOS B49z.00
1 28241 Malignant neoplasm of ureteric orifice B496.00
1 47801 Malignant neoplasm, overlapping lesion of bladder B49y000
1 44996 Malignant neoplasm of dome of urinary bladder B491.00
1 6436 [M]Transitional cell carcinoma NOS BB43.00
1 42012 Malignant neoplasm of posterior wall of urinary bladder B494.00
1 21652 [M]Transitional cell carcinoma in situ BB42.00
1 38862 Malignant neoplasm of trigone of urinary bladder B490.00
1 41571 Malignant neoplasm of bladder neck B495.00
1 58798 [M]Transitional cell carcinoma, spindle cell type BB47.00
1 36949 Malignant neoplasm of other site of urinary bladder B49y.00
1 22146 Secondary malignant neoplasm of bladder B581100
2 10387 Lobular carcinoma in situ of breast B830000
2 16760 Secondary malignant neoplasm of breast B58y000
2 18694 Intraductal carcinoma in situ of breast B830100
2 8351 [M]Infiltrating duct carcinoma BB91.00
2 30543 Malignant neoplasm of skin of breast B335200
2 8647 Carcinoma in situ of skin of breast B825000
2 19423 Malignant neoplasm of male breast B35..00
2 23399 Malignant neoplasm of upper-outer quadrant of female
breast
B344.00
2 23380 Malignant neoplasm of nipple of female breast B340000
2 95057 Malignant neoplasm of ectopic site of female breast B34y000
2 40359 [M]Juvenile breast carcinoma BB94.00
2 3968 Malignant neoplasm of female breast B34..00
2 54202 Malignant neoplasm of other site of male breast B35z.00
2 37969 Malignant neoplasm of skin of chest, excluding breast B335100
2 68480 Malignant neoplasm of nipple of male breast B350000
2 9956 [M]Intraductal carcinoma and lobular carcinoma in situ BB9E000
2 27728 [M]Intraductal carcinoma, noninfiltrating NOS BB90.00
2 53803 [X]Other carcinoma in situ of breast ByuFG00
2 31546 Malignant neoplasm of central part of female breast B341.00
2 12499 [X]Malignant neoplasm of breast Byu6.00
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2 42070 Malignant neoplasm of lower-outer quadrant of female
breast
B345.00
2 42542 [M]Paget’s disease and infiltrating breast duct carcinoma BB9K.00
2 48809 Malignant neoplasm of male breast NOS B35zz00
2 59831 Malignant neoplasm of nipple or areola of female breast
NOS
B340z00
2 64686 Malignant neoplasm of areola of female breast B340100
2 49148 Malignant neoplasm, overlapping lesion of breast B347.00
2 12427 [M]Lobular carcinoma NOS BB9F.00
2 29826 Malignant neoplasm of upper-inner quadrant of female
breast
B342.00
2 12300 [M]Paget’s disease, mammary BB9J.00
2 20685 Malignant neoplasm of axillary tail of female breast B346.00
2 45222 Malignant neoplasm of lower-inner quadrant of female
breast
B343.00
2 7833 Carcinoma in situ of breast B830.00
2 54494 Malignant neoplasm of nipple and areola of male breast B350.00
2 45906 Neoplasm of unspecified nature of breast BA03.00
2 9505 Secondary malignant neoplasm of skin of breast B582600
2 26853 Malignant neoplasm of nipple and areola of female breast B340.00
2 12480 [M]Paget’s disease and intraductal carcinoma of breast BB9K000
2 38475 Malignant neoplasm of other site of female breast NOS B34yz00
2 56715 Malignant neoplasm of other site of female breast B34y.00
2 348 Ca female breast B34..11
2 67701 [M]Secretory breast carcinoma BB94.11
2 39760 [M]Infiltrating duct and lobular carcinoma BB91100
2 9470 Malignant neoplasm of female breast NOS B34z.00
2 60803 [M]Paget’s disease, breast BB9J.11
2 67884 Malignant neoplasm of areola of male breast B350100
2 95323 Malignant neoplasm of ectopic site of male breast B35z000
3 50297 Malignant neoplasm of exocervix B411.00
3 50285 Malignant neoplasm of endocervix NOS B410z00
3 28311 Malignant neoplasm of cervix uteri NOS B41z.00
3 44534 [M]Intraepit neop,grade III,of cervix, vulva and vagina BB2N.00
3 58094 Malignant neoplasm, overlapping lesion of cervix uteri B412.00
3 3230 Cervical carcinoma (uterus) B41..11
3 97832 Secondary cancer of the cervix B58y211
3 53103 Malignant neoplasm of endocervical gland B410100
3 50126 Carcinoma in situ of exocervix B831100
3 95505 Malignant neoplasm of cervical stump B41y000
3 24228 Carcinoma in situ of endocervix B831000
3 43435 Malignant neoplasm of other site of cervix NOS B41yz00
3 73616 Secondary malignant neoplasm of cervix uteri B58y200
3 4087 CIN III - carcinoma in situ of cervix B831.11
3 48820 Malignant neoplasm of endocervix B410.00
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3 57235 Malignant neoplasm of endocervical canal B410000
3 2747 Malignant neoplasm of cervix uteri B41..00
3 32955 Malignant neoplasm of other site of cervix B41y.00
3 3279 Carcinoma in situ of cervix uteri B831.00
3 72695 [X]Carcinoma in situ of other parts of cervix ByuFA00
3 57719 Malignant neoplasm of squamocolumnar junction of
cervix
B41y100
4 6328 Carcinoma in situ of prostate B834.00
4 21590 Secondary malignant neoplasm of prostate B58y500
4 780 Malignant neoplasm of prostate B46..00
5 1952 Secondary malignant neoplasm of kidney B580.00
5 13559 Malig neop of kidney and other unspecified urinary or-
gans
B4A..00
5 15419 [M]Hypernephroma BB5a012
5 17314 [M]Wilms’ tumour BBL7112
5 54594 [M]Mesoblastic nephroma BBL7000
5 54184 Malignant neoplasm of renal pelvis NOS B4A1z00
5 21681 [M]Nephroblastoma NOS BBL7100
5 10668 [M]Renal cell carcinoma BB5a000
5 18712 Renal malignant neoplasm B4A..11
5 18771 [M]Clear cell sarcoma of kidney BBLJ.00
5 1599 Malignant neoplasm of kidney parenchyma B4A0.00
5 27697 [M]Hypernephroid tumour BB5Y.00
5 12389 Malignant neoplasm of renal pelvis B4A1.00
5 11178 Warthin’s tumour B702300
5 65159 Malignant neoplasm of perinephric tissue B180100
5 52266 [M]Grawitz tumour BB5a011
5 27540 Malignant neoplasm of renal calyces B4A1000
5 7978 Hypernephroma B4A0000
5 29462 Malignant neoplasm of kidney or urinary organs NOS B4Az.00
5 19162 Malignant neoplasm of anterior wall of urinary bladder B493.00
6 12146 [M]Lymphoid leukaemia NOS BBr2000
6 57316 [M]Acute promyelocytic leukaemia BBr6600
6 67700 Monoblastic leukaemia B66..12
6 16416 Chronic leukaemia NOS B681.00
6 31701 Chronic granulocytic leukaemia B651.11
6 27664 Acute promyelocytic leukaemia B65y100
6 66694 [M]Naegeli-type monocytic leukaemia BBr6311
6 35875 Monocytic leukaemia B66..00
6 20635 [M]Lymphatic leukaemia BBr2011
6 99015 Other monocytic leukaemia B66y.00
6 41734 [M]Leukaemia NOS BBr0000
6 7176 Myeloid leukaemia B65..00
6 41500 [M]Chronic lymphoid leukaemia BBr2300
6 38914 Lymphoid leukaemia NOS B64z.00
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6 48049 [M]Chronic myelomonocytic leukaemia BBr6800
6 67029 [X]Other lymphoid leukaemia ByuD500
6 93342 Monocytic leukaemia NOS B66z.00
6 70935 [M]Erythroleukaemia BBr4000
6 37461 Adult T-cell leukaemia B64y200
6 5137 Leukaemic reticuloendotheliosis B624.11
6 4072 Acute leukaemia NOS B680.00
6 54585 [M]Acute myeloid leukaemia BBr6100
6 27330 Leukaemic reticuloendotheliosis B624.00
6 63570 [M]Stem cell leukaemia BBr0113
6 94174 Other and unspecified leukaemia B67y.00
6 19974 Acute monocytic leukaemia B660.00
6 61500 Acute myelomonocytic leukaemia B690.00
6 27790 Chronic lymphatic leukaemia B641.11
6 50928 [M]Burkitt’s cell leukaemia BBr2600
6 38331 Other lymphoid leukaemia NOS B64yz00
6 71377 [M]Eosinophilic leukaemia BBr8000
6 54793 Subacute leukaemia NOS B682.00
6 6316 [M]Acute leukaemia NOS BBr0100
6 64963 [M]Blastic leukaemia BBr0112
6 39187 Plasma cell leukaemia B631.00
6 19372 Lymphoid leukaemia B64..00
6 8625 Chronic lymphoid leukaemia B641.00
6 33344 Myeloid leukaemia NOS B65z.00
6 27458 Chronic monocytic leukaemia B661.00
6 66089 Other myeloid leukaemia NOS B65yz00
6 46048 [M]Prolymphocytic leukaemia BBr2500
6 49725 Other lymphoid leukaemia B64y.00
6 37723 [M]Granulocytic leukaemia NOS BBr6011
6 73777 Leukaemic reticuloendotheliosis NOS B624z00
6 37272 Other specified leukaemia B67..00
6 34692 Other leukaemia of unspecified cell type B68y.00
6 25191 Leukaemia of unspecified cell type B68..00
6 52942 [M]Chronic myeloid leukaemia BBr6300
6 87335 Hairy cell leukaemia B624.12
6 30632 Other specified leukaemia NOS B67z.00
6 71850 [M]Myeloid leukaemia NOS BBr6000
6 59929 [M]Leukaemia unspecified, NOS BBr0z00
6 89762 [X]Other monocytic leukaemia ByuD700
6 57671 Megakaryocytic leukaemia B672.00
6 31586 Prolymphocytic leukaemia B64y100
6 72197 Lymphosarcoma cell leukaemia B67y000
6 4251 Acute lymphoid leukaemia B640.00
6 72774 Subacute lymphoid leukaemia B642.00
6 46263 [M]Acute myelomonocytic leukaemia BBr6700
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6 65777 Thrombocytic leukaemia B672.11
6 65123 Leukaemic reticuloend of intra-abdominal lymph nodes B624300
6 4222 Lymphatic leukaemia B64..11
6 37410 [M]Acute lymphoid leukaemia BBr2100
6 61693 [X]Other myeloid leukaemia ByuD600
6 4413 Acute myeloid leukaemia B650.00
6 73088 [M]Monocytic leukaemia NOS BBr9000
6 42297 [M]Leukaemia NOS BBrz.00
6 72310 [M]Aleukaemic leukaemia NOS BBr0400
6 65721 Mast cell leukaemia B673.00
6 4250 Leukaemia NOS B68z.00
6 27520 Chronic myeloid leukaemia NOS B651z00
6 69299 [M]Thrombocytic leukaemia BBrA111
6 22071 [M]Blast cell leukaemia BBr0111
6 65122 Leukaemic reticuloendotheliosis of unspecified sites B624000
6 22050 Chronic myelomonocytic leukaemia B691.00
6 89329 [X]Other specified leukaemias ByuD800
6 5915 [M]Hairy cell leukaemia BBrA400
6 65165 [X]Other leukaemia of unspecified cell type ByuD900
6 10726 Chronic myeloid leukaemia B651.00
6 72179 [M]Subacute leukaemia NOS BBr0200
6 63475 Subacute myeloid leukaemia B652.00
6 72222 [M]Megakaryocytic leukaemia BBrA100
6 49327 [M]Acute megakaryoblastic leukaemia BBrA500
6 42539 Acute erythraemia and erythroleukaemia B670.00
6 31750 [M]Chronic leukaemia NOS BBr0300
7 61251 [M]Malign lymphoma,lymphocytic,intermediate differn,
diffuse
BBgN.00
7 95012 Mycosis fungoides of lymph nodes of multiple sites B621800
7 99012 Hodgkin’s disease NOS of lymph nodes inguinal region
and leg
B61z500
7 21549 Follicular non-Hodgkin’s lymphoma B627C00
7 71304 Burkitt’s lymphoma NOS B602z00
7 43415 [X]Other Hodgkin’s disease ByuD000
7 12464 Peripheral T-cell lymphoma B62x200
7 71619 [M]Malignant lymphoma, large cell, noncleaved, diffuse BBgT.00
7 46967 [M]Mycosis fungoides BBl..00
7 58082 Nodular lymphoma of lymph nodes of multiple sites B620800
7 63054 Hodgkin’s disease, nodular sclerosis NOS B614z00
7 46877 [M]Malignant lymphoma, small lymphocytic NOS BBgL.00
7 66367 HIV dis resulting oth types of non-Hodgkin’s lymphoma A789700
7 56041 [M]Hodgkin’s disease, lymphocytic predominance BBj1.00
7 69301 [M]Malignant lymphoma, convoluted cell type NOS BBg5.00
7 92380 Burkitt’s lymphoma of lymph nodes of inguinal region
and leg
B602500
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7 19140 Hodgkin’s nodular sclerosis of lymph nodes of multiple
sites
B614800
7 64336 [X]Other specified types of non-Hodgkin’s lymphoma ByuD300
7 95049 Hodgkin’s lymphocytic depletion of unspecified site B616000
7 17182 Follicular lymphoma NOS B627C11
7 68039 Hodgkin’s sarcoma of lymph nodes of axilla and upper
limb
B612400
7 34089 Malignant lymphoma NOS of lymph nodes of axilla and
arm
B62y400
7 91900 Hodgkin’s disease NOS of lymph nodes of axilla and arm B61z400
7 72725 Malignant lymphoma NOS of intrathoracic lymph nodes B62y200
7 59755 Hodgkin’s disease NOS of intrathoracic lymph nodes B61z200
7 69980 [M]Malignant lymphoma, lymphocytic, well differenti-
ated NOS
BBgC.00
7 15504 Malignant lymphoma NOS of lymph nodes of multiple
sites
B62y800
7 64515 [X]Diffuse non-Hodgkin’s lymphoma, unspecified ByuDC00
7 63699 [M]Malignant lymphoma, nodular NOS BBk0.00
7 67703 Hodgkin’s disease, lymphocytic depletion B616.00
7 91674 Mycosis fungoides of intra-abdominal lymph nodes B621300
7 92068 Nodular lymphoma of intra-abdominal lymph nodes B620300
7 44617 HIV disease resulting in Burkitt’s lymphoma A789600
7 66327 Nodular lymphoma of unspecified site B620000
7 16774 [M] Cutaneous lymphoma BBmD.00
7 94005 Hodgkin’s disease, mixed cellularity NOS B615z00
7 17460 Diffuse non-Hodgkin’s lymphoblastic (diffuse) lymphoma B627700
7 65584 [M]Hodgkin,s disease, lymphocytic predominance, dif-
fuse
BBj1000
7 55303 Hodgkin’s nodular sclerosis of head, face and neck B614100
7 59115 Burkitt’s lymphoma of lymph nodes of head, face and
neck
B602100
7 8649 [X]Non-Hodgkin’s lymphoma, unspecified type ByuDF00
7 72714 Mycosis fungoides of lymph nodes of inguinal region and
leg
B621500
7 39906 [M]Malignant lymphoma, centrocytic BBgE.00
7 58015 [M]Malignant lymphomatous polyposis BBgQ.00
7 60092 Malignant lymphoma NOS of spleen B62y700
7 42198 [M]Hodgkin’s disease, nodular sclerosis NOS BBj6.00
7 46931 [M]Malignant lymphoma, stem cell type BBg4.00
7 39798 Diffuse non-Hodgkin’s lymphoma, unspecified B627X00
7 50696 Malignant lymphoma NOS of lymph nodes of head, face
and neck
B62y100
7 89230 [M]Hodgkin’s granuloma BBj9.00
7 65489 Hodgkin’s paragranuloma B610.00
7 64036 Hodgkin’s sarcoma B612.00
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7 60275 [M]Malignant lymphoma, centroblastic type NOS BBgJ.00
7 98961 [M]Malignant lymphoma, centroblastic-centrocytic, fol-
licular
BBk2.00
7 51285 [M]Hodgkin’s disease, mixed cellularity BBj2.00
7 97577 Burkitt’s lymphoma of intra-abdominal lymph nodes B602300
7 21463 [M]Lymphocytic lymphoma NOS BBgC.11
7 28639 Follicular non-Hodgkin’s small cleaved cell lymphoma B627000
7 49605 Hodgkin’s disease, mixed cellularity B615.00
7 95630 True histiocytic lymphoma B62x600
7 53397 Hodgkin’s disease NOS B61z.00
7 40508 [M]Hodgkin,s disease, nodular sclerosis, lymphocytic pre-
dom
BBj6000
7 41754 [M]Malignant lymphoma, lymphoplasmacytoid type BBg7.00
7 44318 Oth and unspecif peripheral & cutaneous T-cell lym-
phomas
B62xX00
7 53551 Diffuse non-Hodgkin’s immunoblastic (diffuse) lym-
phoma
B627600
7 48253 [M]Malignant lymphoma, immunoblastic type BBg8.00
7 12335 Malignant lymphoma NOS B62y.00
7 65180 Diffuse non-Hodgkin’s lymphoma undifferentiated (dif-
fuse)
B627800
7 69767 [X]HIV disease resulting in other non-Hodgkin’s lym-
phoma
AyuC600
7 35014 Sezary’s disease B622.00
7 7940 [X]Non-Hodgkin’s lymphoma NOS ByuDF11
7 31726 [M]Malignant lymphoma, small cleaved cell, diffuse BBgM.00
7 93951 Hodgkin’s, lymphocytic-histiocytic pred inguinal and leg B613500
7 94279 Hodgkin’s disease NOS of spleen B61z700
7 3371 [M]Non Hodgkins lymphoma BBg2.11
7 68964 [M]Malignant lymphoma, centroblastic-centrocytic, dif-
fuse
BBgA.00
7 98596 [X]Other types of diffuse non-Hodgkin’s lymphoma ByuD200
7 57225 Hodgkin’s disease, nodular sclerosis of unspecified site B614000
7 96183 [M]Hodgkin’s disease,lymphocytic depletion,diffuse fi-
brosis
BBj4.00
7 40766 [M] Peripheral T-cell lymphoma NOS BBm5.00
7 45264 Nodular lymphoma of lymph nodes of head, face and
neck
B620100
7 71262 Malignant lymphoma NOS of intrapelvic lymph nodes B62y600
7 67518 [X]Other types of follicular non-Hodgkin’s lymphoma ByuD100
7 71142 Hodgkin’s, lymphocytic-histiocytic predominance un-
spec site
B613000
7 63625 Hodgkin’s lymphocytic depletion lymph nodes axilla and
arm
B616400
7 42461 Hodgkin’s disease NOS B61zz00
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7 31741 [M]Hodgkin,s disease, nodular sclerosis, lymphocytic de-
plet
BBj6200
7 71117 [M]Malignant lymphoma, undifferentiated cell type NOS BBg3.00
7 92245 Hodgkin’s, lymphocytic-histiocytic pred intrathoracic
nodes
B613200
7 68330 Hodgkin’s, lymphocytic-histiocytic pred of head, face,
neck
B613100
7 15027 Malignant lymphoma NOS B62yz00
7 29876 Hodgkin’s, lymphocytic-histiocytic predominance NOS B613z00
7 57427 Malignant lymphoma NOS of unspecified site B62y000
7 23711 [M]Malignant lymphoma, diffuse NOS BBg1000
7 31537 [M]Hodgkin,s disease, lymphocytic predominance, nodu-
lar
BBj1100
7 42769 [M]Hodgkin’s disease NOS BBjz.00
7 73532 Hodgkin’s, lymphocytic-histiocytic pred intra-abdominal
node
B613300
7 96379 Mycosis fungoides of lymph nodes of axilla and upper
limb
B621400
7 12006 Mycosis fungoides B621.00
7 42579 Malignant lymphoma NOS of intra-abdominal lymph
nodes
B62y300
7 1483 [M]Lymphoma NOS BBg1.11
7 16460 [M]Malignant lymphoma, non Hodgkin’s type BBg2.00
7 61662 Hodgkin’s disease NOS, unspecified site B61z000
7 57544 [M]True histiocytic lymphoma BBm4.00
7 94995 Nodular lymphoma of lymph nodes of inguinal region
and leg
B620500
7 71652 [M]Malignant lymphoma, mixed small and large cell, dif-
fuse
BBgP.00
7 63994 [M]Malignant lymphoma, large cell, cleaved, diffuse BBgS.00
7 51680 [M]Malignant lymphoma, small cell, noncleaved, diffuse BBgV.00
7 57737 Lymphoepithelioid lymphoma B62x100
7 61997 [M]Hodgkin’s disease NOS BBj0.00
7 38939 Hodgkin’s disease, lymphocytic-histiocytic predomi-
nance
B613.00
7 97756 [M]Sezary’s disease BBl1.00
7 95338 Hodgkin’s, lymphocytic-histiocytic pred intrapelvic
nodes
B613600
7 99200 [M]Hodgkin’s disease, nodular sclerosis, cellular phase BBj7.00
7 44196 Hodgkin’s granuloma B611.00
7 94407 Hodgkin’s mixed cellularity of lymph nodes head, face,
neck
B615100
7 98840 Hodgkin’s paragranuloma of intra-abdominal lymph
nodes
B610300
7 31794 Unspecified B-cell non-Hodgkin’s lymphoma B627W00
7 38005 Mycosis fungoides NOS B621z00
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7 70509 Diffuse non-Hodgkin’s centroblastic lymphoma B627D00
7 64947 [M]Brill - Symmers’ disease BBk0.11
7 34352 [M]Lymphoblastic lymphoma NOS BBgG.12
7 51852 [M]Malig lymphoma, lymphocytic, intermediate different
NOS
BBgD.00
7 65483 Hodgkin’s nodular sclerosis of lymph nodes of axilla and
arm
B614400
7 50695 Diffuse non-Hodgkin mixed sml & lge cell (diffuse) lym-
phoma
B627500
7 3604 Non - Hodgkin’s lymphoma B627.00
7 49301 Malignant neoplasm lymphatic or haematopoietic tissue
NOS
B6z..00
7 2462 Hodgkin’s disease B61..00
7 70842 Follicular non-Hodg mixed sml cleavd & lge cell lym-
phoma
B627100
7 18383 [M] Large cell lymphoma BBmH.00
7 29335 [M]Adult T-cell leukaemia/lymphoma BBr2700
7 31576 Other types of follicular non-Hodgkin’s lymphoma B627B00
7 33869 [M]Malignant lymphoma, large cell, diffuse NOS BBgR.00
7 31749 [M]Monocytoid B-cell lymphoma BBv0.00
7 49262 Follicular non-Hodgkin’s large cell lymphoma B627200
7 59778 Hodgkin’s disease NOS of lymph nodes of head, face and
neck
B61z100
7 63375 [X]Unspecified B-cell non-Hodgkin’s lymphoma ByuDE00
7 31492 [M] Monocytoid B-cell lymphoma BBm9.00
7 97863 Hodgkin’s disease, mixed cellularity of unspecified site B615000
7 41841 [M]Malignant lymphoma, follicular centre cell NOS BBgB.00
7 90201 T-zone lymphoma B62x000
7 61149 Hodgkin’s nodular sclerosis of intra-abdominal lymph
nodes
B614300
7 72196 [M]Malignant lymphoma, lymphocytic, poorly different
NOS
BBgG.00
7 64343 [M]Hodgkin,s disease, nodular sclerosis, mixed cellularity BBj6100
7 97852 [M]Malignant lymphoma, centroblastic type, follicular BBk7.00
7 95464 [M]Mycosis fungoides BBl0.00
7 97746 Hodgkin’s disease NOS of lymph nodes of multiple sites B61z800
7 63105 Malignant lymphoma NOS of lymph node inguinal region
and leg
B62y500
7 27965 [M]AngiocentricT-cell lymphoma BBv2.00
7 49253 [M]Giant follicular lymphoma BBk0.13
7 21402 Burkitt’s lymphoma B602.00
7 67506 Hodgkin’s nodular sclerosis of intrathoracic lymph nodes B614200
7 29178 Hodgkin’s disease, nodular sclerosis B614.00
7 5179 Nodular lymphoma (Brill - Symmers disease) B620.00
7 98909 Hodgkin’s granuloma of lymph nodes of head, face and
neck
B611100
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7 50668 Diffuse non-Hodgkin’s small cell (diffuse) lymphoma B627300
7 36114 [M]Malignant lymphoma NOS BBg1.00
7 65701 Nodular lymphoma NOS B620z00
7 95949 Mycosis fungoides of unspecified site B621000
7 3710 [M]Adenolymphoma BBB1.00
7 58684 Hodgkin’s mixed cellularity of intrathoracic lymph nodes B615200
8 73135 [M]Solitary myeloma BBn2.12
8 63864 [M]Plasmacytoma NOS BBn2.00
8 4944 Multiple myeloma B630.00
8 26135 [M] Alpha heavy chain disease BBm6.00
8 3672 [M]Myeloma NOS BBn0.12
8 43450 Immunoproliferative neoplasm or myeloma NOS B63z.00
8 52593 [M] Gamma heavy chain disease BBmE.00
8 46042 Lambda light chain myeloma B630300
8 31671 [M]Plasma cell myeloma BBn0.00
8 22158 Malignant plasma cell neoplasm, extramedullary plasma-
cytoma
B630000
8 9172 [M]Waldenstrom’s macroglobulinaemia BBmK.00
8 38321 Plasmacytoma NOS B936.12
8 19028 Solitary myeloma B630100
8 18744 [M]Multiple myeloma BBn0.11
8 49530 [M] T-gamma lymphoproliferative disease BBmC.00
8 53647 [M]Myelomatosis BBn0.13
8 39490 [M]Plasmacytic myeloma BBn0.14
8 15211 Myelomatosis B630.12
8 43312 Myeloma - solitary B936.11
8 21329 Plasmacytoma NOS B630200
9 94278 Malignant neoplasm of gastro-oesophageal junction B110111
9 30700 Malignant neoplasm of oesophagus NOS B10z.00
9 56077 Carcinoma in situ of lower 1/3 oesophagus B801200
9 63470 Malignant neoplasm of abdominal oesophagus B102.00
9 41362 Malignant neoplasm of thoracic oesophagus B101.00
9 42416 Malignant neoplasm of lower third of oesophagus B105.00
9 50789 Malignant neoplasm of upper third of oesophagus B103.00
9 64274 Carcinoma in situ of middle 1/3 oesophagus B801100
9 8244 Carcinoma in situ of oesophagus B801.00
9 61695 Malignant neoplasm of cervical oesophagus B100.00
9 53591 Malignant neoplasm of other specified part of oesophagus B10y.00
9 4865 Oesophageal cancer B10z.11
9 99155 Carcinoma in situ of upper 1/3 oesophagus B801000
9 44228 Carcinoma in situ of oesophagus NOS B801z00
9 67497 Malignant neoplasm, overlapping lesion of oesophagus B106.00
10 16931 Carcinoma in situ of pancreas B80z000
10 97875 Malignant neoplasm, overlapping lesion of pancreas B175.00
10 63102 [M]Islet cell carcinoma BB5B100
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10 51656 [M]Mucinous cystadenocarcinoma NOS BB81E00
10 39870 Malignant neoplasm of tail of pancreas B172.00
10 55663 [M]Apudoma BB5y300
10 40810 Malignant neoplasm of body of pancreas B171.00
10 58022 [M]Glucagonoma NOS BB5B400
10 9224 [M]Insulinoma NOS BB5B200
10 95150 [M]Serous surface papillary carcinoma BB81B00
10 8771 Malignant neoplasm of head of pancreas B170.00
10 49629 [M]Gastrinoma, malignant BB5C100
10 65051 [M]Papillary cystadenocarcinoma, NOS BB81500
10 44930 [M]Papillary serous cystadenocarcinoma BB81800
10 34388 Malignant neoplasm of pancreas NOS B17z.00
10 48537 Malignant neoplasm of other specified sites of pancreas B17y.00
10 96635 Malignant neoplasm of ectopic pancreatic tissue B17y000
10 98825 [M]Mixed islet cell and exocrine adenocarcinoma BB5B600
10 95783 Malignant neoplasm of specified site of pancreas NOS B17yz00
10 35718 [M]Gastrinoma NOS BB5C000
10 11469 [M]Nesidioblastoma BB5B011
10 21792 Carcinoma in situ of ampulla of Vater B808600
10 38442 [M]Serous cystadenocarcinoma, NOS BB81200
10 35535 Malignant neoplasm of pancreatic duct B173.00
10 55675 Endocrine tumour of pancreas B717011
10 10949 Malignant neoplasm of ampulla of Vater B162.00
10 54749 [M]Papillary mucinous cystadenocarcinoma BB81H00
10 66876 [M]Pseudomucinous adenocarcinoma BB81E11
10 32294 [M]Glucagonoma, malignant BB5B500
10 95609 [M]Insulinoma, malignant BB5B300
10 35795 Malignant neoplasm of Islets of Langerhans B174.00
11 72947 Carcinoma in situ of fundus of stomach B802100
11 41215 Malignant neoplasm of pyloric canal of stomach B111100
11 21620 Malignant neoplasm of pylorus of stomach B111.00
11 27440 [M]Linitis plastica BB55.00
11 14800 Malignant neoplasm of stomach NOS B11z.00
11 54171 Malignant neoplasm of middle third of oesophagus B104.00
11 59092 Malignant neoplasm of pylorus of stomach NOS B111z00
11 32362 Malignant neoplasm of fundus of stomach B113.00
11 22894 Malignant neoplasm of cardio-oesophageal junction of
stomach
B110100
11 37859 Malignant neoplasm of cardia of stomach NOS B110z00
11 37774 Carcinoma in situ of stomach NOS B802z00
11 55434 Malignant neoplasm of greater curve of stomach unspec-
ified
B116.00
11 65312 Malignant neoplasm of anterior wall of stomach NEC B11y000
11 51690 Malignant neoplasm, overlapping lesion of stomach B117.00
11 63087 Carcinoma in situ of body of stomach B802200
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11 17258 Carcinoma in situ of cardia of stomach B802000
11 19318 Malignant neoplasm of pyloric antrum of stomach B112.00
11 65372 Malignant neoplasm of other specified site of stomach
NOS
B11yz00
11 43572 Malignant neoplasm of body of stomach B114.00
11 42193 Malignant neoplasm of lesser curve of stomach unspeci-
fied
B115.00
11 32022 Malignant neoplasm of cardia of stomach B110.00
11 17093 Carcinoma in situ of stomach B802.00
11 55019 Malignant neoplasm of other specified site of stomach B11y.00
11 48237 Malignant neoplasm of prepylorus of stomach B111000
11 96802 Malignant neoplasm of posterior wall of stomach NEC B11y100
12 9476 Teratoma of descended testis B471100
12 91509 Malignant neoplasm of descended testis NOS B471z00
12 15148 Malignant neoplasm of testis B47..00
12 35223 [M]Spermatocytic seminoma BBQ1100
12 21786 Seminoma of descended testis B471000
12 8177 Carcinoma in situ of testis B836000
12 15989 Teratoma of testis B47z.12
12 38510 Malignant neoplasm of testis NOS B47z.00
12 47668 Malignant neoplasm of tunica vaginalis B48y100
12 7740 Seminoma of undescended testis B470200
12 57084 [M]Seminoma, anaplastic type BBQ1000
12 19475 Malignant neoplasm of descended testis B471.00
12 34145 Secondary malignant neoplasm of testis B58y600
12 96429 Malignant neoplasm of undescended testis NOS B470z00
12 36325 Teratoma of undescended testis B470300
12 64602 Malignant neoplasm of undescended testis B470.00
12 9859 [M]Seminoma NOS BBQ1z00
12 2961 Seminoma of testis B47z.11
12 21319 [M]Testicular stromal tumour BBC0.13
13 7904 Carcinoma in situ of endometrium B832000
13 49400 Malignant neoplasm of endometrium B430211
13 59097 Malignant neoplasm of lower uterine segment B431000
13 43940 Malignant neoplasm of isthmus of uterine body B431.00
13 33617 Malignant neoplasm of body of uterus NOS B43z.00
13 49828 Malignant neoplasm of fallopian tube B441.00
13 45793 Malignant neoplasm of myometrium of corpus uteri B430300
13 68155 Malignant neoplasm of fundus of corpus uteri B430100
13 45490 Malignant neoplasm of corpus uteri NOS B430z00
13 10588 [M]Leiomyosarcoma NOS BBK0200
13 97996 Malignant neoplasm of other site of uterine adnexa B44y.00
13 72723 Malignant neoplasm of cornu of corpus uteri B430000
13 64596 [M]Myxoid leiomyosarcoma BBK0700
13 55090 Secondary malignant neoplasm of uterus B58y100
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13 2890 Malignant neoplasm of endometrium of corpus uteri B430200
13 3213 Malignant neoplasm of corpus uteri, excluding isthmus B430.00
13 9447 [M]Endometrioid carcinoma BB5j200
13 61803 Carcinoma in situ of body of uterus B832.11
13 70729 Malignant neoplasm of isthmus of uterine body NOS B431z00
13 7046 Malignant neoplasm of body of uterus B43..00
13 65106 Malignant neoplasm of uterine adnexa NOS B44z.00
13 2744 Malignant neoplasm of uterus, part unspecified B40..00
13 64497 [X]Malignant neoplasm of uterine adnexa, unspecified Byu7000
13 59499 Carcinoma in situ of fallopian tube B833100
13 34030 [M]Endometrial stromal sarcoma BBL0.00
13 31608 Malignant neoplasm of other site of uterine body B43y.00
13 29898 Carcinoma in situ of other and unspecified parts of uterus B832.00
13 16967 Malignant neoplasm of overlapping lesion of corpus uteri B432.00
13 46153 Malignant neoplasm of parametrium B443.00
13 56740 [M]Leiomyoblastoma BBK0311
14 46789 Malignant neoplasm of choroid plexus B515000
14 27744 [M]Oligodendroglioma NOS BBbQ.00
14 61783 [M]Juvenile astrocytoma BBbG.11
14 68479 [M]Neuroastrocytoma BBc7.11
14 59170 Malignant neoplasm of corpus callosum B51y000
14 52751 [M]Ependymoma, anaplastic type BBb8.00
14 18617 Malignant neoplasm of brain B51..00
14 39386 [M]Mixed glioma BBb2.11
14 44089 Malignant neoplasm of brain stem B517.00
14 33843 Secondary malignant neoplasm of brain and spinal cord B583.00
14 8550 Malignant neoplasm of pituitary gland B542000
14 9575 [M]Glioblastoma multiforme BBbL.11
14 50151 [M]Pineoblastoma BBa3.00
14 38551 [M]Gliomatosis cerebri BBb1.00
14 93537 Malignant neoplasm of midbrain B517200
14 41520 Malignant neoplasm of brain NOS B51z.00
14 42460 Malignant neoplasm of pineal gland B543.00
14 98800 [M]Piloid astrocytoma BBbG.12
14 49132 Malignant neoplasm of medulla oblongata B517100
14 96798 [M]Meningothelial sarcoma BBd2.12
14 47848 [M]Meningioma NOS BBdz.00
14 94267 [M]Subependymal glioma BBb3.00
14 46490 [M]Angioblastic meningioma BBd7.11
14 23083 [M]Glioblastoma NOS BBbL.00
14 54133 Malignant neoplasm of cerebrum NOS B510z00
14 52511 Malignant neoplasm of cerebral ventricles B515.00
14 30273 [M]Pilocytic astrocytoma BBbG.00
14 59718 Malig neop pituitary gland or craniopharyngeal duct
NOS
B542z00
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14 8328 [M]Astrocytoma, anaplastic type BBbC.00
14 90487 [M]Subependymal astrocytoma NOS BBb3.11
14 5199 Cerebral metastasis B583200
14 50235 [M]Astroblastoma BBbK.00
14 43114 [M]Myxopapillary ependymoma BBbA.00
14 60347 [M]Leptomeningeal sarcoma BBd2.11
14 31574 [M]Glioma, malignant BBb0.00
14 15991 Malignant neoplasm of choroid B506.00
14 48073 Malignant neoplasm of basal ganglia B510000
14 66064 [M]Giant cell glioblastoma BBbM.00
14 28919 Malignant neoplasm of cerebral meninges B521.00
14 10851 Cerebral tumour - malignant B51..11
14 46404 [M]Oligodendroblastoma BBbS.00
14 70942 Malignant neoplasm of hypothalamus B510400
14 5198 Secondary malignant neoplasm of brain B583000
14 63925 [X]Malignant neoplasm of meninges, unspecified ByuA200
14 91240 Malignant neoplasm of pons B517300
14 47556 Malignant neoplasm of temporal lobe NOS B512z00
14 28344 [M]Subependymal astrocytoma NOS BBb3.12
14 49875 Malignant neoplasm of meninges, unspecified B52X.00
14 63973 [M]Microglioma BBm0.00
14 31767 [M]Medullomyoblastoma BBbV.00
14 46769 [M]Ependymoblastoma BBb8.11
14 71139 Malignant neoplasm of other parts of brain B51y.00
14 67587 [M]Pleomorphic xanthoastrocytoma BBbZ.00
14 45154 Malignant neoplasm of cerebellum B516.00
14 42426 Malignant neoplasm of frontal lobe B511.00
14 45909 Carcinoma in situ of pituitary gland B8yy300
14 64557 Malignant neoplasm of cerebral peduncle B517000
14 59823 Malignant neoplasm pituitary gland and craniopharyn-
geal duct
B542.00
14 61399 Malignant neoplasm of cerebral cortex B510100
14 1044 Neoplasm of unspecified nature of brain BA06.00
14 37473 [M]Cerebellar sarcoma NOS BBbW.00
14 49168 [M]Subependymal giant cell astrocytoma BBb4.00
14 65241 Malignant neoplasm, overlapping lesion of brain B51y200
14 8547 [M]Astrocytoma NOS BBbB.00
14 41695 [M]Primitive neuroectodermal tumour BBba.00
14 47633 [X]Malig neopl, overlap lesion brain & other part of CNS ByuA300
14 70104 Malignant neoplasm of cerebral meninges NOS B521z00
14 65952 [M]Desmoplastic medulloblastoma BBbU.00
14 7319 [M]Infiltrating ductular carcinoma BB9G.00
14 98677 [M]Meningiomatosis NOS BBd1.00
14 19226 Malignant neoplasm of parietal lobe B513.00
14 62126 Malignant neoplasm of thalamus B510500
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14 67236 Malignant neoplasm of hippocampus B512000
14 31629 [M]Ganglioglioma BBc6.00
14 27748 [M]Astrocytic glioma BBbB.11
14 38870 [M]Psammomatous meningioma BBd5.00
14 27363 [M]Meningioma, malignant BBd2.00
14 39088 Malignant neoplasm of occipital lobe B514.00
14 95108 [M]Diffuse meningiomatosis BBd1.11
14 68641 Malignant neoplasm of brain stem NOS B517z00
14 34763 [M]Medulloblastoma NOS BBbT.00
14 59375 Secondary malignant neoplasm of brain or spinal cord
NOS
B583z00
14 15711 Malignant neoplasm cerebrum (excluding lobes and ven-
tricles)
B510.00
14 34252 [M]Gliosarcoma BBb0.12
14 8523 [M]Glioma NOS BBb0.11
14 49186 [M]Oligodendroglioma, anaplastic type BBbR.00
14 27846 [M]Fibrillary astrocytoma BBbF.00
14 45531 [M]Gemistocytic astrocytoma BBbE.00
14 68808 [M]Mixed glioma BBb2.00
15 93478 Malignant neoplasm, overlapping lesion of colon B138.00
15 27811 Carcinoma in situ of rectosigmoid junction B804000
15 62909 Secondary malignant neoplasm of rectum B575100
15 48231 Malignant neoplasm of other specified sites of colon B13y.00
15 22163 Carcinoma of caecum B134.11
15 17144 Carcinoma in situ of sigmoid colon B803300
15 39080 Carcinoma in situ of hepatic flexure of colon B803000
15 7219 Carcinoma of rectum B141.11
15 10864 Malignant neoplasm of descending colon B132.00
15 29975 Carcinoma in situ of rectum B804100
15 11628 Cancer of bowel B1z0.11
15 10946 Malignant neoplasm of ascending colon B136.00
15 33561 Carcinoma in situ of colon NOS B803z00
15 31893 Carcinoma in situ of ascending colon B803600
15 50974 Malignant neoplasm rectum,rectosigmoid junction and
anus NOS
B14z.00
15 36200 Secondary malig neop of large intestine or rectum NOS B575z00
15 27855 Malignant neoplasm of rectosigmoid junction B140.00
15 47667 Carcinoma in situ of descending colon B803200
15 28163 Malignant neoplasm of colon NOS B13z.00
15 44529 Secondary malignant neoplasm of large intestine and rec-
tum
B575.00
15 18619 Malignant neoplasm of splenic flexure of colon B137.00
15 22699 Carcinoma in situ of splenic flexure of colon B803700
15 2815 Malignant neoplasm of sigmoid colon B133.00
15 3811 Malignant neoplasm of caecum B134.00
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15 38883 Carcinoma in situ of rectum or rectosigmoid junction
NOS
B804z00
15 5901 Rectal carcinoma B141.12
15 9088 Malignant neoplasm of hepatic flexure of colon B130.00
15 30165 Malignant neoplasm of mesorectum B18y200
15 9118 Colonic cancer B13z.11
15 6935 Malignant neoplasm of transverse colon B131.00
15 55659 Malig neop other site rectum, rectosigmoid junction and
anus
B14y.00
15 60477 Carcinoma in situ of rectum and rectosigmoid junction B804.00
15 6903 Carcinoma in situ of colon B803.00
15 28727 Secondary malignant neoplasm of colon B575000
15 1800 Malignant neoplasm of rectum B141.00
15 37125 Carcinoma in situ of transverse colon B803100
15 16916 Carcinoma in situ of caecum B803400
16 21770 [M]Mesothelioma, unspecified BBPX.00
16 52373 Carcinoma in situ of lower lobe bronchus and lung B812400
16 40595 [X]Malignant neoplasm of bronchus or lung, unspecified Byu2000
16 52178 [M]Intravascular bronchial alveolar tumour BBTL.00
16 41523 Malignant neoplasm of middle lobe bronchus B223000
16 27509 [M]Mesothelioma, malignant BBP1.00
16 86820 [M]Mesothelioma, biphasic type, malignant BBP7.00
16 10358 Malignant neoplasm of upper lobe, bronchus or lung B222.00
16 31700 Malignant neoplasm of upper lobe bronchus B222000
16 9156 [M]Oat cell carcinoma BB1K.00
16 31573 Malignant neoplasm of pleura B23..00
16 38756 [M]Cystic mesothelioma BBP9.00
16 31268 Malignant neoplasm of middle lobe, bronchus or lung B223.00
16 62124 Secondary and unspec malig neop bronchopulmonary
lymph nodes
B561800
16 69392 Secondary and unspec malig neop inferior tracheo-
bronchial LN
B561700
16 67797 Secondary and unspec malig neop superfic tracheo-
bronchial LN
B561600
16 9267 Carcinoma in situ of bronchus and lung B812.00
16 29283 Malignant neoplasm of other site of respiratory tract B2zy.00
16 20170 Pancoast’s syndrome B222.11
16 25886 Malignant neoplasm of upper lobe of lung B222100
16 44169 Malignant neoplasm of upper lobe, bronchus or lung NOS B222z00
16 39923 Malignant neoplasm of middle lobe of lung B223100
16 17391 Malignant neoplasm of carina of bronchus B221000
16 37579 Carcinoma in situ of upper lobe bronchus and lung B812200
16 4137 Secondary malignant neoplasm of lung B570.00
16 30526 [X]Mesothelioma, unspecified Byu5100
16 64810 Malignant neoplasm of thorax NOS B551z00
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16 36371 Malignant neoplasm of overlapping lesion of bronchus &
lung
B225.00
16 34015 [M]Bronchiolo-alveolar adenocarcinoma BB5S200
16 21715 [X]Mesothelioma of lung Byu5011
16 9600 Mesothelioma of pleura B232.00
16 18678 Malignant neoplasm of lower lobe bronchus B224000
16 2587 Lung cancer B22z.11
16 31188 Malignant neoplasm of lower lobe, bronchus or lung B224.00
16 25372 Carcinoma in situ of bronchus or lung NOS B812z00
16 12870 Malignant neoplasm of main bronchus B221.00
16 21698 Malignant neoplasm of main bronchus NOS B221z00
16 3903 Malignant neoplasm of bronchus or lung NOS B22z.00
16 47897 Carcinoma in situ of middle lobe bronchus and lung B812300
16 35058 Carcinoma in situ of main bronchus B812100
16 38961 Malignant neoplasm of other sites of bronchus or lung B22y.00
16 48348 [M]Pulmonary blastoma BBLM.00
16 16723 [M]Bronchiolar carcinoma BB5S212
16 47734 [M]Epithelioid mesothelioma, malignant BBP5.00
16 7484 Mesothelioma B226.00
16 66646 Malignant neoplasm, overlap lesion of resp & intrathor
orgs
B26..00
16 33444 Malignant neoplasm of hilus of lung B221100
16 49159 Carcinoma in situ of carina of bronchus B812000
16 47286 Malignant neoplasm of thorax B551.00
16 42566 Malignant neoplasm of lower lobe, bronchus or lung NOS B224z00
16 54134 Malignant neoplasm of middle lobe, bronchus or lung
NOS
B223z00
16 13243 Malignant neoplasm of trachea, bronchus and lung B22..00
16 12582 Malignant neoplasm of lower lobe of lung B224100
17 19141 Malignant neoplasm of ovary and other uterine adnexa B44..00
17 18065 [M]Sertoli-Leydig cell tumour BBC7.00
17 21435 [M]Ovarian stromal tumour BBC0.12
17 21173 [M]Mullerian mixed tumour BBL5.00
17 71301 [M]Struma ovarii, malignant BBQA100
17 17137 Carcinoma in situ of ovary B833000
17 70383 [M]Brenner tumour, malignant BBM0100
17 44793 [M]Brenner tumour NOS BBM0z00
17 44615 Secondary malignant neoplasm of ovary B586.00
17 53694 [M]Krukenberg tumour BB85111
17 95373 [M]Leydig cell tumour, malignant BBCC100
17 71490 [M]Brenner tumour, borderline malignancy BBM0000
17 60530 [M]Thecoma NOS BBC1000
17 73623 [M]Leydig cell tumour NOS BBCCz00
17 40742 [M]Thecoma, luteinized BBC1200
17 6751 [M]Granulosa cell tumour NOS BBC3.00
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17 7805 Malignant neoplasm of ovary B440.00
17 1986 Cancer of ovary B440.11
17 29945 [M]Malignant teratoma, trophoblastic BBR4.00
17 31609 [M]Granulosa cell tumour, malignant BBC4.00
17 52306 [M]Struma ovarii NOS BBQA000
17 59995 [M]Lipid cell tumour of ovary BBCE.00
17 48957 [M]Granulosa cell-theca cell tumour BBC5.00
18 91895 Malignant neoplasm of glossoepiglottic fold B064100
18 36716 Malignant neoplasm of floor of mouth NOS B04z.00
18 96869 Malignant neoplasm of posterior wall of nasopharynx
NOS
B071z00
18 61510 Malignant neoplasm of palatoglossal arch B062200
18 57248 Malignant neoplasm aryepiglottic fold, hypopharyngeal
aspect
B082.00
18 55066 Malignant neoplasm of tonsillar pillar B062.00
18 55833 [M]Odontogenic tumour NOS BBZ1.00
18 45824 Secondary malignant neoplasm of tongue B58y900
18 72443 [M]Odontogenic tumour, malignant BBZ2.00
18 33388 Malignant neoplasm of adenoid B071000
18 51926 Malignant neoplasm of faucial pillar B062000
18 50296 Malignant neoplasm of upper lip, lipstick area B000100
18 37590 Malignant neoplasm of hard palate B052.00
18 66384 Malignant neoplasm of lower lip, external B001000
18 27944 Carcinoma in situ of tongue B800100
18 63957 Carcinoma in situ of skin of lip B820.00
18 43781 Malignant neoplasm of dorsum of tongue NOS B011z00
18 58550 [M]Adenoameloblastoma BBZD.11
18 45189 [M]Squamous odontogenic tumour BBZJ.00
18 59274 [M]Calcifying epithelial odontogenic tumour BBZP.00
18 22441 Malignant neoplasm of subglottis B212.00
18 57864 [M]Melanoameloblastoma BBa4.11
18 71147 Malignant neoplasm of lower lip, inner aspect B003.00
18 67504 Malignant neoplasm of lower lip, buccal aspect B003000
18 98740 Malignant neoplasm of upper lip, vermilion border NOS B000z00
18 99001 Malignant neoplasm of upper lip, frenulum B002100
18 94441 Malignant neoplasm of lower lip, oral aspect B003300
18 37724 Malignant neoplasm of retromolar area B056.00
18 40557 Malignant neoplasm of tongue NOS B01z.00
18 49360 Malignant neoplasm of lower gum B031.00
18 97530 Malignant neoplasm of lower buccal sulcus B051100
18 7697 Carcinoma in situ of vocal fold - glottis B810800
18 36948 Carcinoma in situ of cricoid cartilage B810100
18 98861 [M]Odontoameloblastoma BBZH.00
18 43642 Malignant neoplasm of dorsal surface of tongue B011.00
18 37505 Carcinoma in situ of oral cavity B800.11
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18 95429 Malignant neoplasm of posterior wall of nasopharynx B071.00
18 38488 Malignant neoplasm of ventral tongue surface NOS B013z00
18 55374 Malignant neoplasm of epiglottis NOS B215.00
18 96783 Malignant neoplasm of commissure of lip B005.00
18 69951 Malignant neoplasm of roof of mouth B055100
18 44663 Carcinoma in situ of hypopharynx B800900
18 43431 Malignant neoplasm of base of tongue B010.00
18 98500 Malignant neoplasm of upper lip, mucosa B002200
18 37516 Malignant neoplasm of uvula B054.00
18 45408 Malignant neoplasm of anterior portion of floor of mouth B040.00
18 45986 Malignant neoplasm of lateral portion of floor of mouth B041.00
18 73962 Malignant neoplasm of upper lip, vermilion border B000.00
18 69671 Malignant neoplasm of posterior third of tongue B010.11
18 37916 Malignant neoplasm of other specified mouth parts B05y.00
18 36104 Carcinoma in situ of nasopharynx B800700
18 30966 Carcinoma in situ of palate B800600
18 40292 Malignant neoplasm of soft palate B053.00
18 37940 Malignant neoplasm of pharyngeal recess B072000
18 55630 Malignant neoplasm of other specified site of nasophar-
ynx
B07y.00
18 59004 Malignant neoplasm of lateral wall of nasopharynx B072.00
18 91035 Malignant neoplasm of fixed part of tongue NOS B010z00
18 67323 Malignant neoplasm of oropharynx, other specified sites B06y.00
18 73439 Malignant neoplasm of anterior epiglottis NOS B064z00
18 26134 Malignant neoplasm of epiglottis, free border B064000
18 95480 Malignant neoplasm of lower lip, lipstick area B001100
18 62840 Malignant neoplasm of ventral surface of tongue B013.00
18 66422 Malignant neoplasm, overlapping lesion of nasopharynx B074.00
18 53884 Malignant neoplasm tonsil NOS B060z00
18 26448 Malignant neoplasm of faucial tonsil B060000
18 68399 Malignant neoplasm of lip unspecified, mucosa B004200
18 70819 Malignant neoplasm of palate unspecified B055.00
18 46548 Malignant neoplasm of pharyngeal tonsil B071100
18 34409 Malignant neoplasm of base of tongue dorsal surface B010000
18 30402 Malignant neoplasm of buccal mucosa B050.11
18 28559 Malignant neoplasm of palate NOS B055z00
18 24801 Carcinoma in situ of floor of mouth B800400
18 98483 [M]Odontogenic fibrosarcoma BBZN.11
18 63979 Malignant neoplasm of frenulum linguae B013100
18 37549 Kaposi’s sarcoma of palate B05z000
18 16297 Malignant neoplasm of pharynx unspecified B0z0.00
18 318 Malignant neoplasm of glottis B210.00
18 50419 Carcinoma in situ of oropharynx B800800
18 24397 Malignant neoplasm of tonsillar fossa B061.00
18 94251 Malignant neoplasm of lip, unspecified, lipstick area B00z100
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18 39430 Malignant neoplasm of lip, oral cavity and pharynx NOS B0zz.00
18 56709 Malignant neoplasm of other sites of floor of mouth B04y.00
18 95772 Malignant neoplasm of upper buccal sulcus B051000
18 44139 Malignant neoplasm of anterior wall of nasopharynx B073.00
18 93842 Malignant neoplasm of palatopharyngeal arch B062300
18 40467 [M]Ameloblastoma NOS BBZF.00
18 42129 Carcinoma in situ of pharynx B800.12
18 31860 Carcinoma in situ of aryepiglottic fold B810600
18 37096 Malignant neoplasm of tongue, junctional zone B015.00
18 56355 Malignant neoplasm of lateral wall of oropharynx B066.00
18 90124 Malignant neoplasm of posterior wall of oropharynx B067.00
18 46741 [M]Ameloblastic odontosarcoma BBZC.00
18 18882 Malignant neoplasm of overlapping lesion of lip B006.00
18 64462 Malignant neoplasm of posterior pharynx B083.00
18 91037 Malignant neoplasm of other specified site of oropharynx
NOS
B06yz00
18 28665 Malignant neoplasm of nasopharynx NOS B07z.00
18 47205 Malignant overlapping lesion of tongue B017.00
18 17912 Malignant neoplasm, overlapping lesion of floor of mouth B042.00
18 50288 Carcinoma in situ of salivary glands B800200
18 47737 Carcinoma in situ of lip B800000
18 88362 Malignant neoplasm of other specified hypopharyngeal
site
B08y.00
18 53460 Carcinoma in situ of epiglottis B810200
18 32024 Malignant neoplasm of upper gum B030.00
18 93218 Malignant neoplasm of gum NOS B03z.00
18 49758 Malignant neoplasm of other sites lip, oral cavity, phar-
ynx
B0zy.00
18 95016 Malignant neoplasm of Waldeyer’s ring B0z1.00
18 96782 Malignant neoplasm of lower lip, inner aspect NOS B003z00
18 66270 Malignant neoplasm of upper lip, external B000000
18 36161 Malignant neoplasm of tongue, tip and lateral border B012.00
18 89909 Malignant neoplasm of lower lip, mucosa B003200
18 94390 Malignant neoplasm of roof of nasopharynx B070.00
18 90610 Malignant neoplasm of upper lip, oral aspect B002300
18 91843 Malignant neoplasm of lower lip, frenulum B003100
18 57866 Carcinoma in situ of gums B800300
18 46728 Malignant neoplasm of anterior epiglottis B064.00
18 73614 Malignant neoplasm of lip unspecified, buccal aspect B004000
18 39897 Malignant neoplasm of pyriform sinus B081.00
18 31364 Malignant neoplasm of cheek mucosa B050.00
18 37187 Carcinoma in situ of lip, oral cavity and pharynx NOS B800z00
18 67446 Malignant neoplasm of lower lip, vermilion border B001.00
18 28451 Malignant neoplasm of hypopharynx NOS B08z.00
18 26165 Malignant neoplasm of supraglottis B211.00
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18 55015 Malignant neoplasm of mouth NOS B05z.00
18 95390 Carcinoma in situ of lip, oral cavity and pharynx B800.00
18 43548 Malignant neoplasm of postcricoid region B080.00
18 48519 Malignant neoplasm of junctional region of epiglottis B065.00
18 10375 Carcinoma in situ of glottis B810811
18 61692 Malignant neoplasm of lip unspecified, inner aspect B004.00
18 24852 Malignant neoplasm of lingual tonsil B016.00
18 18245 Malignant neoplasm of skin of lip B330.00
18 58121 Malignant neoplasm of anterior 2/3 of tongue unspecified B014.00
18 69761 Malignant neoplasm of lip, vermilion border NOS B00zz00
18 43200 Malignant neoplasm of oropharynx NOS B06z.00
18 99185 Malignant neoplasm of glossopalatine fold B062100
18 96003 Malignant neoplasm of junction of hard and soft palate B055000
19 57446 Malignant neoplasm of skin of trunk, excluding scrotum B335.00
19 51054 Carcinoma in situ of anal canal B805.00
19 29282 [M]Basal cell tumour BB30.00
19 12273 Carcinoma in situ of anus NOS B806.00
19 69720 Carcinoma in situ of skin of eyebrow B823100
19 49403 Malignant neoplasm of skin of chin B333100
19 59100 [M]Mucoepidermoid tumour BB70.00
19 3135 Carcinoma in situ of skin of nose B823400
19 46469 Carcinoma in situ of skin of thigh B827100
19 52328 Carcinoma in situ of skin of trunk, excluding scrotum B825.00
19 50189 Carcinoma in situ skin of ear and external auricular canal B822.00
19 47767 Malignant neoplasm of scrotum B486.00
19 42212 Carcinoma in situ of skin of abdominal wall B825400
19 67755 Carcinoma in situ of skin of foot B827400
19 69601 Carcinoma in situ of skin of knee B827200
19 19678 [M]Intraepithelial squamous cell carcinoma BB29.13
19 54790 Carcinoma in situ of skin of lower arm B826200
19 57358 Carcinoma in situ of skin of groin B825500
19 27370 Malignant neoplasm skin of other and unspecified parts
face
B333.00
19 65782 Malignant neoplasm of skin of toe B337800
19 64270 Malignant neoplasm of skin of ankle B337500
19 30576 Malignant neoplasm of skin of forehead B333300
19 56954 Malignant neoplasm of skin of knee B337200
19 38032 Carcinoma in situ of skin of back B825300
19 68447 [M]Blue naevus, malignant BBEV.00
19 61321 Carcinoma in situ of skin of buttock B825700
19 12084 Carcinoma in situ of skin B82..00
19 30853 [M]Basal cell neoplasm NOS BB3z.00
19 67914 Malignant neoplasm of skin of great toe B337900
19 43761 Malignant neoplasm of labia majora B451.00
19 30747 Malignant neoplasm of skin of upper limb and shoulder B336.00
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19 53515 Malignant neoplasm skin of ear and external auricular
canal
B332.00
19 37016 Malignant neoplasm of sebaceous gland B33..14
19 19665 Carcinoma in situ of scalp B824000
19 60162 [X]Malignant neoplasm overlapping lesion of skin Byu5A00
19 21327 Malignant neoplasm of skin of temple B333500
19 42429 Malignant neoplasm overlapping lesion of skin B33X.00
19 62939 Carcinoma in situ of skin of chest wall NOS B825100
19 29524 [M]Basal cell carcinoma, fibroepithelial type BB34.00
19 27542 Carcinoma in situ of skin of lower leg B827300
19 32249 Carcinoma in situ of ear B822.11
19 708 Carcinoma in situ of skin of leg B827.11
19 62305 Malignant neoplasm of skin of buttock B335800
19 20539 Neoplasm of unspecified nature of skin BA02200
19 9885 [M]Basal cell carcinoma, morphoea type BB33.00
19 24370 Malignant neoplasm of anal canal B142.00
19 49358 Carcinoma in situ of skin of hand B826300
19 24551 [M]Melanocarcinoma BBE1.11
19 36731 Malignant neoplasm of canthus B331000
19 59614 Carcinoma in situ of skin of auricle B822000
19 61103 Carcinoma in situ of skin of cheek B823300
19 70918 [M]Mucoepidermoid neoplasm NOS BB7z.00
19 56554 Carcinoma in situ of skin of shoulder B826000
19 67912 [M]Papillary epidermoid carcinoma BB26.11
19 8917 [M]Bowen’s disease BB2L.00
19 46568 Carcinoma in situ of skin of upper limb and shoulder B826.00
19 47789 Carcinoma in situ of skin of forehead skin B823000
19 56374 Carcinoma in situ of perianal skin B825800
19 42707 Malignant neoplasm of skin of upper arm B336100
19 25245 Malignant neoplasm of skin of finger B336400
19 33271 Malignant neoplasm of pinna NEC B332200
19 34823 Carcinoma in situ of cheek B800500
19 57450 Carcinoma in situ of other specified sites of skin B82y.00
19 2467 Bowen’s disease B8...11
19 43122 Malignant neoplasm of skin of shoulder B336000
19 15868 Malignant neoplasm of skin of trunk, excluding scrotum,
NOS
B335z00
19 55670 Malignant neoplasm of skin of eyebrow B333200
19 49254 Carcinoma in situ of skin of other parts of face B823.00
19 60563 Carcinoma in situ of skin of trunk NOS B825z00
19 60526 Malignant neoplasm of skin of upper limb or shoulder
NOS
B336z00
19 28625 [M]Mucoepidermoid carcinoma BB71.00
19 61194 Malignant neoplasm of skin of lower limb or hip NOS B337z00
19 66447 Malignant neoplasm of skin of scapular region B335A00
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19 33682 Malignant neoplasm of skin of lower leg B337400
19 71655 Carcinoma in situ of skin of hip B827000
19 48182 [M]Epidermoid carcinoma in situ BB29.11
19 14815 Carcinoma in situ of skin of lower limb and hip B827.00
19 70380 Malignant neoplasm of skin of axillary fold B335000
19 23480 Malignant neoplasm of perianal skin B335900
19 62399 Malig neop skin of ear and external auricular canal NOS B332z00
19 68783 [M]Skin appendage carcinoma BB60100
19 67748 Malignant neoplasm of skin of umbilicus B335400
19 58601 Malignant neoplasm of skin of thigh B337100
19 43087 Malignant neoplasm of eyelid including canthus B331.00
19 68197 Malignant neoplasm of skin of popliteal fossa area B337300
19 70295 Carcinoma in situ skin of ear/external auricular canal
NOS
B822z00
19 46008 Malignant neoplasm skin other and unspec part of face
NOS
B333z00
19 45077 Malignant neoplasm of skin of back B335700
19 31511 Carcinoma in situ of skin of temple B823500
19 30577 Malignant neoplasm of skin of fore-arm B336200
19 43717 [M]Verrucous epidermoid carcinoma BB24.11
19 56121 [X]Malignant neoplasm of skin, unspecified Byu4300
19 90339 Carcinoma in situ of skin of upper limb or shoulder NOS B826z00
19 41958 Malignant neoplasm of lower eyelid B331200
19 64406 Malignant neoplasm of skin of thumb B336500
19 57513 [M]Epidermoid carcinoma, keratinising type BB2C.11
19 64630 Carcinoma in situ of skin of lower limb or hip NOS B827z00
19 43930 Secondary malignant neoplasm of skin of head B582000
19 4632 Other malignant neoplasm of skin B33..00
19 37165 Malignant neoplasm of scalp B334000
19 29787 [M]Squamous cell carcinoma, keratinising type NOS BB2C.00
19 27897 Malignant neoplasm of anus unspecified B143.00
19 70587 Malignant neoplasm of skin of foot B337700
19 39390 Carcinoma in situ of skin of axilla B825200
19 70988 Malignant neoplasm of skin of hip B337000
19 57442 Malignant neoplasm of skin of lower limb and hip B337.00
19 54352 Malignant neoplasm of skin of hand B336300
19 57284 Carcinoma in situ of skin of upper arm B826100
19 66319 Malignant neoplasm of skin of groin B335500
19 18618 Malignant neoplasm of skin of abdominal wall B335300
19 876 Basal cell carcinoma B33..11
19 1940 Rodent ulcer B33..13
19 62080 Malignant neoplasm of skin of external auditory meatus B332100
19 68787 Malignant neoplasm of back NOS B55y000
19 63142 Carcinoma in situ of skin NOS B82z.00
19 16202 Malignant neoplasm of skin of nose (external) B333400
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19 2492 Malignant neoplasm of skin NOS B33z.00
19 58879 Carcinoma in situ of scrotum B836300
20 42856 Malignant neoplasm of nasal cavities NOS B200z00
20 26846 Carcinoma in situ of ethmoidal sinus B81y700
20 11403 Carcinoma in situ of larynx B810.00
20 49463 Malignant neoplasm of tarsus of eyelid B310400
20 64918 Secondary and unspec malig neop of superficial parotid
LN
B560000
20 50475 Malignant neoplasm of major salivary gland NOS B02z.00
20 26813 Malignant neoplasm of larynx, other specified site B21y.00
20 73023 [M]Retinal angle tumour BBa4.13
20 98911 Malignant neoplasm of nasal conchae B200100
20 62182 Malignant neoplasm of vestibule of nose B200300
20 64427 Unspec malig neop lymphoid/histiocytic lymph node
head/neck
B62z100
20 95458 Malignant neoplasm of nasal bone B300300
20 73537 Malig neop auditory tube, middle ear, mastoid air cells
NOS
B201z00
20 97332 Malignant neoplasm of laryngeal cartilage NOS B213z00
20 62761 Malignant neoplasm of septum of nose B200200
20 50579 Malignant neoplasm, overlapping lesion of larynx B214.00
20 98537 Malignant neoplasm of tympanic cavity B201100
20 59036 Malignant neoplasm of bones of skull and face B300.00
20 43380 Carcinoma in situ of maxillary sinus B81y600
20 70928 Malignant neoplasm of sublingual gland B022.00
20 58903 Malignant neoplasm of head, neck and face NOS B550z00
20 73760 Malignant neoplasm of scalp or skin of neck NOS B334z00
20 43475 Malig neop of connective and soft tissue head, face and
neck
B310.00
20 32174 Malignant neoplasm of maxillary sinus B202.00
20 27594 [M]Warthin’s tumour BBB1.11
20 50299 Malignant neoplasm of zygomatic bone B300900
20 53599 Malignant neoplasm of frontal bone B300100
20 39590 Malignant neoplasm, overlapping lesion of accessory si-
nuses
B206.00
20 70696 Malignant neoplasm of other major salivary glands B02y.00
20 68135 Carcinoma in situ of mastoid air cells B81y500
20 43619 Malignant neoplasm of skin of neck B334100
20 54234 Malignant neoplasm of scalp and skin of neck B334.00
20 12490 Malignant neoplasm of nose NOS B550200
20 39717 Carcinoma in situ of nasal cavity B81y100
20 59382 Malignant neoplasm of soft tissue of head B310000
20 15684 Malignant neoplasm of frontal sinus B204.00
20 9237 Malignant neoplasm of larynx NOS B21z.00
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20 73718 Malig neop connective and soft tissue head, face, neck
NOS
B310z00
20 71238 Lymphosarcoma of lymph nodes of head, face and neck B601100
20 23389 Malignant neoplasm of nasal cavities B200.00
20 53594 Malignant neoplasm of ethmoid bone B300000
20 4388 Malignant neoplasm of parotid gland B020.00
20 51786 Malignant neoplasm of submandibular gland B021.00
20 71946 Malignant neoplasm of mastoid air cells B201300
20 71204 Malignant neoplasm of cartilage of nose B200000
20 54636 Malignant neoplasm of ethmoid sinus B203.00
20 49214 Secondary and unspec malig neop lymph nodes
head/face/neck
B560.00
20 39064 Carcinoma in situ of sphenoidal sinus B81y900
20 65215 Malignant neoplasm of sphenoidal sinus B205.00
20 43111 Malignant neoplasm of laryngeal cartilage B213.00
20 68236 Malignant neoplasm of head, neck and face B550.00
20 54140 Carcinoma in situ of skin of neck B824100
20 71584 Malignant neoplasm of lacrimal duct B507.00
20 65222 Carcinoma in situ of skin of jaw B823600
20 71031 Reticulosarcoma of lymph nodes of head, face and neck B600100
20 17475 Malignant neoplasm of maxilla B300A00
20 59426 Carcinoma in situ of nasal sinuses B81y.11
20 33833 Malignant neoplasm of mandible B301.00
20 48517 Malignant neoplasm of soft tissue of neck B310200
20 67129 Secondary unspec malig neop lymph nodes
head/face/neck NOS
B560z00
20 319 Malignant neoplasm of larynx B21..00
20 55098 Malignant neoplasm of head NOS B550000
20 16280 Malignant neoplasm of neck NOS B550400
20 64817 Malignant neoplasm of lacrimal gland B502.00
20 39084 Malignant neoplasm of laryngopharynx B0z2.00
20 55550 Malignant neoplasm of upper eyelid B331100
20 40014 Malignant neoplasm of soft tissue of face B310100
20 69345 Carcinoma in situ of scalp and skin of neck B824.00
20 53882 Carcinoma in situ of larynx NOS B810z00
20 65357 Malignant neoplasm of nasolacrimal duct B507100
20 35999 Secondary malignant neoplasm of skin of neck B582200
20 17841 Malignant neoplasm of glans penis B481.00
20 19321 Malignant neoplasm of connective and soft tissue of hand B311300
20 57191 [X]Malignant neoplasm/other specified male genital or-
gans
Byu8000
20 38777 Carcinoma in situ of skin of perineum B825600
20 55101 Malignant neoplasm of pelvis NOS B553z00
20 70126 Malignant neoplasm of optic nerve B520100
20 62610 Carcinoma in situ of respiratory organ NOS B81z.00
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20 44915 Carcinoma in situ other and unspecified female genital
organ
B833.00
20 56718 Malignant neoplasm of eyeball NOS B500z00
20 48952 [M]Retinoblastoma NOS BBc9z00
20 8627 [M]Tumour cells, malignant BB07.00
20 86997 [X]Malignant neoplasm/ill-defined sites within resp sys-
tem
Byu2400
20 39734 [M]Hilar cell tumour BBCD.00
20 28059 Secondary and unspec malig neop of facial lymph nodes B560600
20 37618 Malignant neoplasm of axilla NOS B551000
20 98104 Malignant neoplasm of other specified pleura B23y.00
20 62396 [M]Epithelioid cell sarcoma BBF6.00
20 94614 [M]Arrhenoblastoma NOS BBC6z11
20 6701 Secondary and unspec malig neop intrapelvic lymph
nodes
B565.00
20 8930 [M]Adenocarcinoma NOS BB52.00
20 59381 Malignant neoplasm of iris B500100
20 52963 [M]Juvenile granulosa cell tumour BBC3000
20 8693 Carcinoma of other and unspecified sites B5...11
20 40240 [M]Hepatocellular carcinoma NOS BB5D500
20 63659 [M]Juxtacortical chondrosarcoma BBW6.00
20 63598 [X]Malignant neoplasms/independent (primary) multi-
ple sites
ByuE.00
20 46792 Malignant neoplasm of temporal lobe B512.00
20 64195 Malig neop of endocrine gland or related structure NOS B54z.00
20 72803 Secondary and unspec malig neop intrapelvic LN NOS B565z00
20 17874 Mesothelioma of peritoneum B181.00
20 97954 Carcinoma in situ of other specified part respiratory sys-
tem
B81y.00
20 54679 Secondary malignant neoplasm of unknown site B594.00
20 5842 Secondary malignant neoplasm of other specified sites B58..00
20 37919 Secondary and unspec malig neop internal mammary
lymph nodes
B561000
20 30988 [M]Small cell carcinoma, intermediate cell BB1M.00
20 39388 [M]Olfactory neuroblastoma BBcC.11
20 70374 Reticulosarcoma of intra-abdominal lymph nodes B600300
20 51115 Malignant neoplasm of spinal cord B522.00
20 89258 Malignant neoplasm of peripheral nerve of low limb, incl
hip
B524200
20 94975 Malignant neoplasm of pericardium B241300
20 46771 [M]Hepatocellular carcinoma, fibrolamellar BB5D800
20 35071 [M]Mixed germ cell tumour BBQB.00
20 67203 [M]Lymphoblastic lymphosarcoma NOS BBgG.11
20 65124 Malignant neoplasm of interlobular bile ducts B151000
20 55946 Secondary malignant neoplasm of duodenum B574000
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20 67018 [M]Aortic body tumour BBD5.00
20 58888 [M]Polycythaemia rubra vera BBs0.11
20 27449 Malignant neoplasm of upper limb NOS B554.00
20 46905 Malignant neoplasm of coccygeal body B545200
20 68055 Malignant neoplasm of long bones of leg B307.00
20 65047 [M]Phaeochromocytoma, malignant BBDA.00
20 21217 [M]Small cell-large cell carcinoma BB1N.00
20 96072 [M]Haemangiopericytic neoplasm NOS BBTDz00
20 61643 Malignant neoplasm of intrahepatic bile ducts NOS B151z00
20 6966 [M]Spindle cell carcinoma BB1D.00
20 17098 [M]Pseudomyxoma peritonei BB83.00
20 29160 Malignant neoplasm of connective and soft tissue of axilla B313000
20 58692 Secondary and unspec malig neop paratracheal lymph
nodes
B561500
20 17292 [M]Melanocytoma of eyeball BBE8.11
20 62828 Secondary malignant neoplasm of other urinary organ
NOS
B581z00
20 93384 Unspec malig neop lymphoid/histiocytic of intrathoracic
node
B62z200
20 55468 [M]Mucocarcinoid tumour, malignant BB5R600
20 46939 Malignant neoplasm of cervical vertebra B302000
20 68611 Secondary and unspec malig neop deep cervical LN B560900
20 58131 [M]Comedocarcinoma NOS BB93.00
20 22156 [M]Malignant tumour, small cell type BB08.00
20 21914 [M]Intraepithelial carcinoma NOS BB11.11
20 45814 [M]G cell tumour NOS BB5C011
20 35474 [M]Giant cell carcinoma BB1C.00
20 69981 [M]Neurilemmoma, malignant BBe7.00
20 67575 HIV disease resulting in unspecified malignant neoplasm A788W00
20 72433 [M]Reticulosarcoma NOS BBh0.00
20 95671 [X]Malignant neoplasm of peritoneum, unspecified Byu5700
20 62492 [M]Osteoblastoma BBV8.00
20 60045 [M]Tubular adenocarcinoma BB5M100
20 51934 Carcinoma in situ of biliary system B808.11
20 42082 [M]Alveolar rhabdomyosarcoma BBK3700
20 65253 Secondary and unspec malignant neoplasm occipital
lymph node
B560300
20 67339 [M]Malignant mastocytosis BBp2.00
20 67970 [M]Small cell carcinoma, fusiform cell type BB1L.00
20 57471 Malig neop of connective and soft tissue trunk unspeci-
fied
B316.00
20 67019 [M]Angiomyosarcoma BBK1100
20 17212 [M]Rhabdoid sarcoma BBLH.00
20 58953 [M]Malig lymp,follicular centre cell,noncleaved,follicular BBk8.00
20 28628 [M]Liposarcoma, well differentiated type BBJ3.00
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20 28599 [M]Liposarcoma NOS BBJ1.00
20 37553 Malignant neoplasm of lip, unspecified B007.00
20 1969 [M]Haemangioblastoma BBTF.00
20 70463 Malignant neoplasm of connective and soft tissue of but-
tock
B315000
20 69300 [M]Polygonal cell carcinoma BB1F.00
20 51965 Malignant neoplasm of connective and soft tissue of
pelvis
B315.00
20 64116 Secondary and unspec malig neop intrathoracic lymph
nodes
B561.00
20 44435 [M]Phaeochromocytoma NOS BBD9.00
20 45071 Malignant neoplasm of connective and soft tissue of ab-
domen
B314.00
20 66908 Malignant neoplasm of coccygeal vertebra B306400
20 56640 Carcinoma in situ of other specified site NOS B8yyz00
20 27827 [M]Adenocarcinoma in situ BB51.00
20 58902 [M]Olfactory neurogenic tumour BBcA.00
20 40740 [X]Malignant neoplasms of lymphoid, haematopoietic
and rela
ByuD.00
20 45364 [M]Giant cell tumour of soft parts NOS BBX2.00
20 60134 Secondary malignant neoplasm of ureter B581000
20 72522 Malignant neoplasm of great vessels B313200
20 60335 Secondary malignant neoplasm of vulva B58y400
20 72713 Secondary and unspec malig neop superficial mesenteric
LN
B562100
20 40592 [X]Malignant neoplasm of mesothelial and soft tissue Byu5.00
20 64848 Malignant neoplasm of ulna B304400
20 95421 Malignant neoplasm of other specified female genital or-
gan
B45y.00
20 59362 Malignant neoplasm of labia majora NOS B451z00
20 61542 [M]Malignant teratoma, undifferentiated type BBQ7400
20 10134 [M]Squamous cell carcinoma in situ NOS BB29.00
20 1056 Malignant neoplasm of other and unspecified site NOS B5z..00
20 35348 [M]Papillary adenocarcinoma NOS BB5T100
20 96231 [M]Fibroxanthoma, malignant BBGJ.00
20 36876 [M]Eosinophil carcinoma BB5V311
20 50035 Malignant neoplasm of aortic body and other paraganglia B545.00
20 52029 [X]Malignant neoplasm without specification of site ByuC800
20 50298 Malignant neoplasm of orbital bone B300500
20 53989 Malig neop connective and soft tissue upper
limb/shoulder
B311.00
20 99096 [X]Malignant neopl/overlapping les/resp+intrathoracic
organs
Byu2300
20 34228 Neoplasm of unspecified nature NOS BAz..00
20 43614 Malignant neoplasm/bones+articular carti-
lage/limb,unspfd
B30X.00
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20 59919 [M]Multicentric basal cell carcinoma BB32.00
20 66088 Malig neop of connective and soft tissue of hip and leg B312.00
20 69443 [M]Gigantiform cementoma BBZ7.00
20 27715 Malignant neoplasm of anterior mediastinum B242.00
20 31772 [M]Dermatofibrosarcoma NOS BBGM.00
20 63286 [M]Clear cell sarcoma of tendons and aponeuroses BBN5.00
20 55096 Secondary malignant neoplasm of skin NOS B582z00
20 21741 [M]Follicular adenocarcinoma NOS BB5f100
20 46594 Carcinoma in situ of gall bladder B808300
20 36870 [M]Adenosarcoma BBL7111
20 44074 [M]Mucin-producing adenocarcinoma BB84.00
20 31421 [M]Rhabdomyosarcoma NOS BBK3100
20 27971 [M]Germinoma BBQ2.00
20 40814 Malignant neoplasm of tibia B307200
20 41515 [X]Malignant neoplasm/central nervous system, unspec-
ified
ByuA100
20 38938 Malignant neoplasm of pelvis, sacrum or coccyx NOS B306z00
20 68757 [M]Nonencapsulated sclerosing carcinoma BB5f700
20 99240 Reticulosarcoma NOS B600z00
20 13569 Disseminated malignancy NOS B590.00
20 12497 [M]Mucinous adenocarcinoma BB82100
20 51921 Malignant neoplasm of pubis B306200
20 39883 [M]Malig lymp, follicular centre cell, cleaved, follicular BBk5.00
20 66444 [X]Malignant neoplasm/overlap le-
sion/heart,mediastinm+pleura
Byu2100
20 35034 [M]Fibroxanthosarcoma BBGJ.11
20 16704 Malignant neoplasm of vertebral column B302.00
20 36530 [M]Alveolar cell carcinoma BB5S211
20 16677 [M]Medullary carcinoma NOS BB9B.00
20 49811 [M]Mesodermal mixed tumour BBL6.00
20 95792 Lymphoid and histiocytic malignancy NOS B62zz00
20 47330 [M]Histiocytic medullary reticulosis BBm2.00
20 64516 Malignant neoplasm of parietal peritoneum B18y400
20 58061 Malignant neoplasm of labia minora B452.00
20 39531 Malig neo, overlapping lesion of heart, mediastinum &
pleura
B25..00
20 27439 [M]Kaposi’s sarcoma BBTA.00
20 92720 Malignant neoplasm of posterior mediastinum B243.00
20 35186 [X]Malignant neoplasm of ill-defined, secondary and un-
speci
ByuC.00
20 97463 [M]Giant cell sarcoma (except of bone) BBF4.00
20 61588 [M]Signet ring cell carcinoma BB85000
20 41349 [M]Angioblastoma BBTF.11
20 59284 [M]Mucous adenocarcinoma BB82114
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20 63896 Secondary malignant neoplasm of skin of shoulder and
arm
B582400
20 31004 [M]Adenoid squamous cell carcinoma BB2G.00
20 24539 [M]Chondroblastic osteosarcoma BBV2.00
20 61716 Malignant neoplasm of peripheral nerve,upp limb,incl
should
B524100
20 67107 Malignant neoplasm of parietal pleura B230.00
20 70736 Secondary malignant neoplasm of vagina B58y300
20 55429 [M]Mucoid adenocarcionoma BB82113
20 73530 Malignant neoplasm of hand bones B305.00
20 60035 Malignant neoplasm of cartilage of ear B310300
20 28272 [M]Adenocarcinoma, intestinal type BB57.00
20 69927 Malignant neoplasm of first metatarsal bone B308800
20 12388 [M]Urothelial carcinoma BB43.11
20 59240 [M]Carcinoma, diffuse type BB58.00
20 68524 [M]Chondroblastoma NOS BBW7.00
20 93762 Malignant neoplasm of placenta B42..00
20 4473 [M]Ewing’s sarcoma BBY0.00
20 38477 [M]Giant cell tumour of bone NOS BBX0.00
20 29385 [M]Osteoclastoma BBX0.11
20 27617 Malignant neoplasm of overlapping lesion of vulva B45y000
20 9622 Malignant neoplasm of cauda equina B525.00
20 46761 [M]Papillary and follicular adenocarcinoma BB5f600
20 46423 Cystosarcoma phyllodes B933.11
20 49023 [M]Endothelial bone sarcoma BBY0.11
20 67430 [M]Tibial adamantinoma BBY1.11
20 49491 Malignant neoplasm of sternum B303100
20 40622 [M]Mucoid cell carcinoma BB5V711
20 93175 [M]Intraosseous carcinoma BBZ2.11
20 49701 Malignant neoplasm of vertebral column NOS B302z00
20 47840 Malignant neoplasm of aortic body B545100
20 48828 Secondary malignant neoplasm of skin of hip and leg B582500
20 63460 Malignant neoplasm of arytenoid cartilage B213000
20 67217 Malignant neoplasm of trunk NOS B55y100
20 15221 Malignant neoplasm of trachea B220.00
20 29337 [M] Small cell osteosarcoma BBVA.00
20 45667 Malignant neoplasm of orbit B501.00
20 67934 [M]Carcinosarcoma, embryonal type BBLA.00
20 66639 Malignant neoplasm of clavicle B303200
20 97200 Carcinoma in situ of Eustachian tube B81y400
20 16105 Malignant neoplasm of gallbladder B160.00
20 44452 Malignant neoplasm of vomer B300C00
20 9366 [M]Secondary carcinoma BB13.11
20 69497 Malignant histiocytosis of unspecified site B623000
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20 50904 Secondary and unspec malig neop infraclavicular lymph
nodes
B563200
20 98559 [M]Chondroblastoma, malignant BBW8.00
20 59520 Malignant neoplasm of malar bone B300200
20 40443 Malignant neoplasm of sweat gland B33..15
20 7982 Malignant neoplasm of common bile duct B161200
20 64700 Carcinoma in situ of spleen B80z100
20 4852 [M]Verrucous squamous cell carcinoma BB24.12
20 21447 [M]Fibroblastic osteosarcoma BBV3.00
20 4555 Malig neop of other and unspecified female genital organs B45..00
20 8711 [M]Cholangiocarcinoma BB5D100
20 2481 Polycythaemia vera B934.00
20 94355 Malignant neoplasm of flank NOS B55y200
20 36401 Secondary malignant neoplasm of adrenal gland B587.00
20 6471 Metastases of respiratory and/or digestive systems B57..11
20 64670 Lymphosarcoma of intra-abdominal lymph nodes B601300
20 59918 [M]Follicular adenocarcinoma, well differentiated type BB5f200
20 56513 Malignant neoplasm of femur B307000
20 8695 [M]Carcinoma NOS BB12.00
20 8088 [M]Fibromyxosarcoma BBG3.00
20 35772 Carcinoma in situ of thyroid cartilage B810000
20 51255 Malignant neoplasm of digestive tract and peritoneum
NOS
B1zz.00
20 60247 Malig neop of connective and soft tissue of abdomen NOS B314z00
20 60511 Carcinoma in situ of digestive organs B80..00
20 94286 [M]Congenital fibrosarcoma BBG8.11
20 44108 Malignant neoplasm of retroperitoneum and peritoneum B18..00
20 95378 Secondary and unspec malig neop diaphragmatic lymph
nodes
B561200
20 72464 Malignant neoplasm of metacarpal bones B305.12
20 59223 Malignant neoplasm of ischium B306100
20 7473 Carcinoma in situ B8...00
20 35364 Secondary malignant neoplasm of retroperitoneum B576000
20 10541 [M]Papillary carcinoma NOS BB22.00
20 73538 Secondary and unspec malig neop axilla and upper limb
LN NOS
B563z00
20 20160 Malignant neoplasm of eye B50..00
20 22524 Secondary malignant neoplasm of other specified site
NOS
B58yz00
20 57854 Malignant neoplasm of inguinal region NOS B553000
20 4118 [M]Myxoid chondrosarcoma BBV9.00
20 32472 [M]Inflammatory carcinoma BB9H.00
20 54691 Malignant neoplasm of lumbar vertebra B302200
20 41953 [M]Gangliocytoma BBc0011
20 38736 Malignant neoplasm of other and unspecified site OS B5y..00
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20 98626 Secondary and unspec malig neop supratrochlear lymph
nodes
B563100
20 41313 [M]Bile duct cystadenocarcinoma BB5D300
20 38481 [M]Epithelioid haemangioendothelioma, malignant BBTK.00
20 21732 [M]Myxosarcoma BBH1.00
20 26393 Malignant neoplasm of liver unspecified B152.00
20 50519 [M]Adrenal rest tumour BBCF.00
20 8958 Carcinoma in situ of thyroid gland B8yy000
20 91896 [X]Mal neoplasm/connective+soft tissue of
trunk,unspecified
Byu5800
20 55268 [M]Myosarcoma BBK2100
20 93778 Malignant neoplasm of spleen NOS B1z1z00
20 20564 [M]Carcinoma in situ NOS BB11.00
20 52190 Secondary and unspec malig neop pulmonary lymph
nodes
B561900
20 3923 [M]Carcinoid tumours BB5R.00
20 70716 Immunoproliferative neoplasm B62zz11
20 34878 Malignant neoplasm of medial cuneiform B308300
20 26814 [M]Hepatoma, malignant BB5D512
20 69146 Malignant neoplasm of bones of skull and face NOS B300z00
20 57988 Malignant neoplasm of carpal bone - scaphoid B305000
20 37477 [M]Schwannoma, malignant BBe7.11
20 39629 Granulocytic sarcoma B653100
20 60312 Malignant neoplasm other gallbladder/extrahepatic bile
duct
B16y.00
20 46458 Malignant neoplasm of skin of perineum B335600
20 11009 Malig neop oth/ill-defined sites digestive
tract/peritoneum
B1z..00
20 69821 Malignant neoplasm of the pouch of Douglas B18y600
20 94810 [M]Adenocarcinoma with spindle cell metaplasia BBB4.00
20 5542 Polycythaemia rubra vera B934.11
20 28069 Malignant neoplasm of retina B505.00
20 50777 Malignant neoplasm,overlap lesion periph nerve & auton
ns
B524600
20 68332 [X]2ndry malignant neoplasm/oth+unspec
parts/nervous system
ByuC600
20 54627 [M]Choriocarcinoma combined with teratoma BBR3.00
20 91457 [X]Malignant neoplasm/connective + soft tis-
sue,unspecified
Byu5900
20 67354 [M]Sweat gland tumour NOS BB61100
20 39554 Malignant neoplasm of vallecula B063.00
20 16922 [M]Polycythaemia vera BBs0.00
20 31673 [M]Osteoclastoma, malignant BBX1.12
20 73992 Malignant neoplasm of cornea B504.00
20 90290 Malignant neoplasm of mesentery B18y700
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20 71609 Unspec malig neop lymphoid/histiocytic nodes in-
guinal/leg
B62z500
20 42218 Malignant neoplasm of other specified sites B55y.00
20 69104 Malignant neoplasm of carpal bone - lunate B305100
20 11991 Primary vulval cancer B454.11
20 63723 Lymphosarcoma NOS B601z00
20 61390 Malignant neoplasm of adrenal cortex B540000
20 63988 Malignant neoplasm of connective and soft tissue of
thumb
B311500
20 62104 Malignant neoplasm of temporal bone B300800
20 48048 [M]Giant cell and spindle cell carcinoma BB1B.00
20 60127 [M]Myxoliposarcoma BBJ5.12
20 24048 Malignant neoplasm of retrocaecal tissue B180200
20 59041 Malignant neoplasm of ciliary body B500000
20 93716 Secondary and unspec malig neop intrathoracic LN NOS B561z00
20 40671 [X]Malignant neoplasm of male genital organs Byu8.00
20 58016 Carcinoma in situ of parathyroid gland B8yy200
20 21682 [M]Malignant teratoma, intermediate type BBQ7500
20 66775 Secondary and unspec malignant neoplasm mastoid
lymph nodes
B560100
20 63239 [M]Malignant histiocytosis BBm1.00
20 57550 Carcinoma in situ of skin of eyelid including canthus B821.00
20 54120 Secondary malignant neoplasm of other part of nervous
system
B584.00
20 54631 Malignant neoplasm of pelvic bones, sacrum and coccyx B306.00
20 18632 Malignant neoplasm of appendix B135.00
20 63915 Secondary and unspec malig neop inguinal and lower
limb LN
B564.00
20 63430 Malignant neoplasm of endocardium B241000
20 73213 Secondary malignant neoplasm of other urinary organs B581.00
20 37680 [M]Fibrous histiocytoma, malignant BBGF.00
20 64345 Malignant neoplasm of connective and soft tissue, upper
arm
B311100
20 34395 [M]Verrucous carcinoma NOS BB24.00
20 62256 [M]Adrenal cortical tumours NOS BB5hz00
20 72684 [M]Papillary cystic tumour BB81L00
20 50289 Malignant neoplasm of heart NOS B241z00
20 46409 Secondary and unspec malig neop pectoral lymph nodes B563300
20 61467 [M]Follicular adenocarcinoma, trabecular type BB5f300
20 37805 Malignant neoplasm of cricoid cartilage B213100
20 53349 Carcinoma in situ of other specified site B8yy.00
20 44805 Malig neop of connective and soft tissue thigh and upper
leg
B312100
20 50379 [M]Synovial sarcoma NOS BBN1.00
20 25961 [M]Large cell carcinoma NOS BB17.00
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20 3969 [M]Intracystic carcinoma NOS BB9M.00
20 30542 Malig neop of connective and soft tissue of lower leg B312300
20 58088 Malignant neoplasm of intrahepatic gall duct B151400
20 38979 [M]Sertoli cell tumour BBC9.13
20 33497 [M]Squamous cell carcinoma, microinvasive BB2J.00
20 52493 [M]Teratoblastoma, malignant BBQ7213
20 67712 [M]Choriocarcinoma BBR2.00
20 16126 Primary carcinoma of liver B150000
20 72224 Fibrosarcoma of spleen B1z1100
20 92371 Malignant neoplasm of radius B304300
20 45217 Carcinoma in situ of ileum B807200
20 68358 Carcinoma in situ of urinary organs NOS B83z.00
20 95008 [M]Gelatinous adenocarcinoma BB82112
20 62437 Malignant reticulosis B62x400
20 60242 Reticulosarcoma of unspecified site B600000
20 59310 [M]Osteochondrosarcoma BBV1.12
20 30645 Malignant neoplasm of skin of cheek, external B333000
20 57680 [M]Spinous cell carcinoma BB2A.12
20 64567 Other immunoproliferative neoplasms B63y.00
20 33951 [M]Pineocytoma BBa2.00
20 49825 [M]Reticulum cell sarcoma NOS BBh0.11
20 54186 Malignant neoplasm of diaphragm B313100
20 58836 Malig neop of connective and soft tissue of pelvis NOS B315z00
20 39433 Secondary and unspec malig neop submandibular lymph
nodes
B560500
20 40492 [M]Triton tumour, malignant BBe9.00
20 6170 Carcinomatosis B590.11
20 62584 Secondary malignant neoplasm of other respiratory or-
gans
B573.00
20 55953 Malignant neoplasm of occipital bone B300400
20 40966 Malignant neoplasm of sacral vertebra B306300
20 98408 Malig neop of connective and soft tissue of thorax NOS B313z00
20 66166 Malignant neoplasm, overlapping lesion of small intestine B124.00
20 63995 Malignant neoplasm of Meckel’s diverticulum B123.00
20 45573 [M]Carcinoid tumours NOS BB5Rz00
20 61115 [M]Sex cord tumour with annular tubules BBC0000
20 54253 [X]Secondary malignant neoplasm of other specified sites ByuC700
20 60775 [M]Adrenal cortical carcinoma BB5h100
20 40608 [X]Malignant neoplasm of thyroid and other endocrine
glands
ByuB.00
20 27528 Malignant neoplasm of ribs, sternum and clavicle B303.00
20 54182 Naevoid basal cell carcinoma syndrome B33z100
20 55658 [M]Orchioblastoma BBQ4.12
20 44267 Malignant histiocytosis B623.00
20 54276 [M]Pseudosarcomatous carcinoma BB1E.00
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20 34879 [M]Cylindroid adenocarcinoma BB5J.11
20 64309 [X]Malignant neoplasm of endocrine gland, unspecified ByuB100
20 37081 [M]Smooth muscle tumour NOS BBK3800
20 38575 [M]Apocrine adenocarcinoma BB62100
20 58883 Carcinoma in situ of pyloric canal B802400
20 51237 Malignant neoplasm of rib, sternum and clavicle NOS B303z00
20 53504 Malig neopl, overlap lesion brain & other part of CNS B52W.00
20 54654 [M]Sex cord-stromal tumour BBC0.00
20 64874 [M]Melanotic neuroectodermal tumour BBa4.00
20 42553 [M]Adenocarcinoma with cartilaginous and osseous
metaplasia
BBB3.00
20 16915 Malignant neoplasm of intrahepatic bile ducts B151.00
20 8154 Malignant ascites B576200
20 70724 Myeloid sarcoma B653.00
20 40749 [X]Malignant neoplasm of bone and articular cartilage Byu3.00
20 49862 [M]Osteoblastic sarcoma BBV1.11
20 52570 Malignant neoplasm, overlapping lesion of penis B487.00
20 55947 [M]Pleomorphic liposarcoma BBJ7.00
20 18658 Secondary and unspec malig neop common iliac lymph
nodes
B562300
20 45458 [M]Squamous cell carcinoma, spindle cell type BB2F.00
20 34713 [M]Ganglioneuroma BBc0000
20 87003 [M]Mesenchymoma, malignant BBLC100
20 60504 [M]Lymphocytic lymphosarcoma NOS BBgC.12
20 73988 Malignant neoplasm of peripheral nerve of pelvis B524500
20 98009 [M]Granulocytic sarcoma BBrA312
20 39413 Malignant neoplasm of pelvic peritoneum B18y500
20 34269 [M]Sebaceous adenocarcinoma BB69100
20 49525 Kaposi’s sarcoma, unspecified B59zX00
20 23861 Malignant neoplasm of chest wall NOS B551100
20 24456 Malig neop auditory tube, middle ear and mastoid air
cells
B201.00
20 58871 Malignant histiocytosis NOS B623z00
20 60052 Malignant neoplasm of specified site NOS B55yz00
20 65642 Malignant histiocytosis of intra-abdominal lymph nodes B623300
20 61579 Neoplasm of unspecified nature of respiratory system BA01.00
20 21609 [M]Carcinoma, undifferentiated type, NOS BB18.00
20 67396 Secondary malig neop of retroperitoneum and peri-
toneum
B576.00
20 37501 Carcinoma in situ of hepatic duct B808200
20 66541 [M]Round cell carcinoma BB1J.12
20 39312 [M]Cystosarcoma phyllodes NOS BBM8.00
20 44066 [M]Eccrine acrospiroma BB63.00
20 45262 [X]Malignant neoplasm of male genital organ, unspecified Byu8200
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20 94415 Malignant histiocytosis of lymph nodes head, face and
neck
B623100
20 89657 Malignant mast cell tumour NOS B626z00
20 43968 Neoplasm of unspecified nature of digestive system BA00.00
20 47810 Malignant neoplasm of unspecified site B59..00
20 35039 Malignant neoplasm, overlapping lesion of biliary tract B163.00
20 11754 [M]Sclerosing stromal tumour BBCG.00
20 24375 Dermatofibrosarcoma protuberans B339.00
20 88144 Malignant neoplasm of other specified part of nervous
system
B52y.00
20 44931 Secondary and unspec malig neop intra-abdominal LN
NOS
B562z00
20 29789 Histiocytic tumour NOS B935.11
20 54267 Malignant neoplasm of unspecified site NOS B59z.00
20 68730 [M]Ameloblastic fibrosarcoma BBZN.00
20 73556 Malignant neoplasm of hand bones NOS B305z00
20 59651 [M]Mixed type liposarcoma BBJ8.00
20 32213 [M]Malignant tumour, fusiform cell type BB0A.00
20 40598 [X]Malignant neoplasm of female genital organs Byu7.00
20 57677 [M]Hepatoblastoma BBL8.00
20 69210 [M]Goblet cell tumour BB5R611
20 34110 [M]Carcinoid tumour, malignant BB5R100
20 28806 [M]Oncocytoma BB5W013
20 42569 Malignant neoplasm of respiratory tract NOS B2zz.00
20 4554 Malignant neoplasm of vulva unspecified B454.00
20 92703 Secondary and unspec malig neop deep parotid lymph
nodes
B560400
20 88593 [M]Placental site trophoblastic tumour BBR6.00
20 63247 [M]Sarcoma botryoides BBK3611
20 89916 Malignant neoplasm of presacral region B553100
20 50946 [M]Medullary carcinoma with amyloid stroma BB9C.00
20 94083 [M]Solid carcinoma NOS BB5P.00
20 64050 Carcinoma in situ of respiratory system B81..00
20 48275 [M]Embryonal rhabdomyosarcoma BBK3600
20 69208 Carcinoma in situ of female genital organs NOS B833z00
20 37810 Malignant neoplasm of trachea NOS B220z00
20 30189 [M]Intraductal papillary adenocarcinoma with invasion BB91000
20 28941 [M]Embryonal carcinoma NOS BBQ3.00
20 95644 Malignant neoplasm of heart B241.00
20 88022 [X]Secondary malignant neoplasm/oth+unspcfd diges-
tive organs
ByuC400
20 49054 Malignant neoplasm of scapula B304000
20 56600 [M]Epidermoid carcinoma NOS BB2A.11
20 95559 Carcinoma in situ of specified parts respiratory system
NOS
B81yz00
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20 62941 [M]Neurofibrosarcoma BBe2.00
20 52684 [M]Mesenchymal chondrosarcoma BBW9.00
20 72445 Malignant neoplasm of cystic duct B161000
20 54613 Malignant neoplasm of tympanic antrum B201200
20 50681 Malignant neoplasm of prepuce (foreskin) B480.00
20 26413 [M]Pleomorphic carcinoma BB1A.00
20 39027 [X]Malignant neoplasm of other specified sites ByuC000
20 36790 Primary polycythaemia B934.12
20 12609 [M]Carcinoma, anaplastic type, NOS BB19.00
20 58949 Malignant neoplasm of phalanges of foot B308D00
20 15182 Malignant neoplasm of connective and soft tissue, site
NOS
B31z.00
20 10913 [M]Paraganglioma NOS BBD0.00
20 50569 Neo/uncertn+unknwn behav/lymph,h’matopetc+rel
tiss,unspcf
B93X.00
20 89593 Malignant neoplasm of intrahepatic biliary passages B151200
20 67949 Malignant neoplasm of other male genital organ B48y.00
20 73076 Carcinoma in situ of vestibular fold B810700
20 98797 [M]Embryonal sarcoma BBLD.00
20 38611 Carcinoma in situ of other and unspecified sites B8y..00
20 61289 Secondary and unspec malig neop deep inguinal lymph
nodes
B564100
20 31324 Mast cell malignancy of lymph nodes of multiple sites B626800
20 34000 [M]Cystadenocarcinoma NOS BB80100
20 31399 Malignant neoplasm of lower limb NOS B555.00
20 12119 Carcinoma in situ of vulva B833300
20 27651 Secondary carcinoma of other specified sites B58..11
20 54965 Malig neop connective and soft tissue of popliteal space B312200
20 37540 Secondary and unspec malig neop axillary lymph nodes B563000
20 38918 Secondary malignant neoplasm of spinal cord B583100
20 73296 [X]Malignant neoplasm/bones+articular carti-
lage/limb,unspfd
Byu3100
20 67763 Malignant neoplasm of costo-vertebral joint B303400
20 10995 Malignant neoplasm of other and unspecified sites B5...00
20 5136 Choriocarcinoma B911013
20 49292 [X]Malignant neoplsm/ill-defin sites within digestive sys-
tem
Byu1300
20 64089 Carcinoma in situ of common bile duct B808500
20 92382 Malignant neoplasm of fourth metatarsal bone B308B00
20 22187 Hepatocellular carcinoma B150300
20 46613 Malignant neoplasm of specified parts of peritoneum B18y.00
20 18314 Malignant neoplasm of bone and articular cartilage B30..00
20 57729 [M]Lymphangiosarcoma BBU1.00
20 18266 [M]Granular cell tumour NOS BBf0.00
20 68456 [M]Chromophobe carcinoma BB5V100
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20 51352 Malignant neoplasms of independent (primary) multiple
sites
B592.00
20 65233 Malig neop connective and soft tissue other specified site B31y.00
20 16298 Malignant neoplasm of retroperitoneum and peritoneum
NOS
B18z.00
20 70740 [M]Malignant reticulosis BBm1.11
20 66750 Malignant neoplasm of heart, thymus and mediastinum
NOS
B24z.00
20 72503 Neoplasm uncert / unkn behav brain, infratentorial B925300
20 59152 Malignant neoplasm of connective and soft tissue of per-
ineum
B315200
20 9291 [M]Small cell carcinoma NOS BB1J.00
20 15036 Malignant mast cell tumours B626.00
20 27853 HIV disease resulting in Kaposi’s sarcoma A789500
20 31393 Carcinoma gallbladder B160.11
20 38770 [M]Epithelial-myoepithelial carcinoma BBB7.00
20 98322 [M]Haemangioendothelioma, malignant BBT7100
20 60631 [M]Osteosarcoma in Paget’s disease of bone BBV5.00
20 54222 Malignant neoplasm of connective and soft tissue of foot B312400
20 65605 Malignant neoplasm of myocardium B241200
20 19437 Osteosarcoma B30z000
20 92275 [M]Gonadal stromal tumour BBC0.11
20 65861 [M]Dermoid cyst with malignant transformation BBQ9.00
20 65466 Kaposi’s sarcoma of multiple organs B592X00
20 45267 Malignant neoplasm of other and ill defined site NOS B55z.00
20 33997 Malignant neoplasm of skin of auricle (ear) B332000
20 54190 [M] Angioimmunoblastic lymphadenopathy BBm8.00
20 50292 [X]Malignant neoplasm of mediastinum, part unspecified Byu2500
20 94272 Malig neoplasm of connective and soft tissues of lumb
spine
B314100
20 36147 Secondary malignant neoplasm of liver B153.00
20 61082 [M]Pneumoblastoma BBLA.11
20 31323 [M]Fibrosarcoma NOS BBG1.00
20 21833 [M]Duct carcinoma NOS BB91.11
20 57756 [X]Malignant neoplasm/other specified female genital or-
gans
Byu7100
20 66083 Secondary malig neop of respiratory or digestive system
NOS
B57z.00
20 59415 [M]Thymoma, malignant BBB6100
20 12580 [M]Adenosquamous carcinoma BBB0.00
20 65458 Malig neop of other and unspecified parts of nervous sys-
tem
B52..00
20 71625 Lymphosarcoma of unspecified site B601000
20 27416 Lymphosarcoma B601.00
20 28148 Malignant neoplasm of adrenal gland B540.00
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20 95058 Reticulosarcoma of spleen B600700
20 42528 [M]Hibernoma BBJD.00
20 43392 Malignant neoplasm of penis, part unspecified B483.00
20 63518 [M]Adenosarcoma BBLE.00
20 1481 Reticulosarcoma B600.00
20 43479 Malignant neoplasm of jejunum B121.00
20 22290 Malignant neoplasm of connective and soft tissue of tho-
rax
B313.00
20 8085 [M]Sarcoma NOS BBF1.00
20 20807 [M]Papillary squamous cell carcinoma BB26.00
20 64106 Malignant neoplasm of specified parts of peritoneum
NOS
B18yz00
20 46497 Carcinoma in situ of pleura B81y000
20 38444 [M]Carcinoid tumour NOS BB5R000
20 50290 Kaposi’s sarcoma of lymph nodes B6z0.00
20 57184 [X]Oth malignant neoplasm/skin of oth+unspecfd parts
of face
Byu4200
20 65490 Secondary cancer of the vulva B58y411
20 10698 Malignant neoplasm of vaginal vault B450100
20 50605 [M]Glomangiosarcoma BBDB.00
20 33250 Ca-in-situ of G.I. tract B80..11
20 37842 Malignant neoplasm of rib B303000
20 50222 Malignant neoplasm of connective and soft tissue of
shoulder
B311000
20 27311 Carcinoma in situ of penis B835.00
20 27931 Kaposi’s sarcoma of skin B33z000
20 48223 [M]Scirrhous adenocarcinoma BB54.00
20 57336 [M]Epithelioma, malignant BB16.00
20 53528 Secondary malignant neoplasm of urethra B581200
20 66000 [M]Adenocarcinoma with apocrine metaplasia BBB5.00
20 44399 Primary malignant neoplasm of liver NOS B150z00
20 45953 [M]Glomus jugulare tumour BBD4.00
20 31026 [M]Spindle cell sarcoma BBF3.00
20 68410 Primary angiosarcoma of liver B150200
20 73164 Carcinoma in situ of cystic duct B808400
20 50140 [M]Cribriform carcinoma BB5K.00
20 41144 Secondary malignant neoplasm of skin of trunk B582300
20 51748 Carcinoma in situ of pyloric antrum B802300
20 51795 Malignant neoplasm of glomus jugulare B545000
20 96893 [M]Myeloid sarcoma BBrA300
20 19945 Secondary malignant neoplasm of skin B582.00
20 63568 Malignant neoplasm of peripheral nerves of head, face &
neck
B524000
20 72500 [X]Mal neoplasm/lymphoid,haematopoietic+related
tissu,unspcf
ByuDB00
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20 70728 Carcinoma in situ other and unspecified small intestine
NOS
B807z00
20 32641 [M]Merkel cell carcinoma BB5RA00
20 50199 Secondary and unspec malig neop axilla and upper limb
LN
B563.00
20 74896 Malignant neoplasm of extrahepatic bile ducts NOS B161z00
20 55463 Secondary and unspec malig neop post mediastinal
lymph nodes
B561400
20 43390 Malignant neoplasm of small intestine NOS B12z.00
20 56345 Secondary malignant neoplasm of other digestive organ B57y.00
20 16500 Secondary malignant neoplasm of other specified site
NOS
B58z.00
20 72440 [M]Acinar cell tumour BBA1.00
20 34742 Malignant neoplasm of pleura NOS B23z.00
20 55246 Malignant neoplasm of accessory sinus NOS B20z.00
20 64680 Secondary malignant neoplasm of small intestine and
duodenum
B574.00
20 58962 Malignant immunoproliferative small intestinal disease B62x500
20 71810 Malignant neoplasm of scapula and long bones of upper
arm
B304.00
20 70026 Secondary malig neop of small intestine or duodenum
NOS
B574z00
20 66673 Carcinoma in situ of liver and biliary system B808.00
20 45922 Malignant neoplasm, overlapping lesion of eye and ad-
nexa
B508.00
20 16213 Secondary malignant neoplasm of pleura B572.00
20 61064 Malignant neoplasm of mediastinum, part unspecified B24X.00
20 24301 Secondary carcinoma of respiratory and/or digestive sys-
tems
B57..12
20 98540 Carcinoma in situ of liver or biliary system NOS B808z00
20 35053 Secondary malig neop of respiratory and digestive sys-
tems
B57..00
20 20159 Secondary and unspec malig neop lymph nodes multiple
sites
B56y.00
20 94750 [M]Mastocytoma NOS BBp0.00
20 62380 Lymphosarcoma of intrathoracic lymph nodes B601200
20 63300 [X]Malignant neoplasm/overlap lesion/bone+articulr
cartilage
Byu3200
20 51878 [M]Aesthesioneuroblastoma BBcC.00
20 71869 [M]Alveolar soft part sarcoma BBf2.00
20 40437 Malignant neoplasm of other specified site of eye B50y.00
20 51551 Secondary malignant neoplasm of mediastinum B571.00
20 34891 [M]Sarcomatosis NOS BBF2.00
20 47656 Carcinoma in situ of appendix B803500
20 98361 [X]Kaposi’s sarcoma of other sites Byu5B00
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20 66163 [X]2ndry+unspcf malignant neoplasm lymph
nodes/multi regions
ByuC200
20 18613 Malignant neoplasm of duodenum B120.00
20 51714 Carcinoma in situ of trachea B811.00
20 65793 Malig neop of upper respiratory tract, part unspecified B2z0.00
20 69132 Secondary and unspec malig neop external iliac lymph
nodes
B562400
20 22392 Carcinoma in situ of other and unspecified small intestine B807.00
20 57481 [X]Secondary malignant neoplasm/oth+unspc respira-
tory organs
ByuC300
20 72912 [M]Tubular androblastoma with lipid storage BBCB.00
20 15103 Secondary malignant neoplasm of liver B577.00
20 41691 Secondary and unspec malig neop coeliac lymph nodes B562000
20 71895 [M]Superficial spreading adenocarcinoma BB56.00
20 68161 Malignant neoplasm of seminal vesicle B48y000
20 72127 Malignant neoplasm of epididymis B484.00
20 86996 Malignant neoplasm of connective tissue of orbit B501000
20 94438 [M]Signet ring carcinoma NOS BB85z00
20 52736 Secondary and unspec malig neop intra-abdominal
lymph nodes
B562.00
20 72212 Malignant neoplasm of calcaneum B308200
20 97593 [M]Ameloblastoma, malignant BBZG.00
20 25366 Secondary and unspec malig neop ant mediastinal lymph
nodes
B561300
20 65880 Malig neop of scapula and long bones of upper arm NOS B304z00
20 7830 Lymph node metastases B56..11
20 54278 Secondary and unspec malig neop superficial inguinal LN B564000
20 18354 Malignant neoplasm of other specified skin sites B33y.00
20 33871 Malignant neoplasm of ileum B122.00
20 37688 [M]Acinar cell carcinoma BBA2.00
20 9618 Secondary and unspecified malignant neoplasm of lymph
nodes
B56..00
20 53129 [M]Oncytic adenocarcinoma BB5W112
20 95024 [M]Infantile fibrosarcoma BBG8.00
20 97672 Secondary malig neop of retroperitoneum or peritoneum
NOS
B576z00
20 18231 Phaeochromocytoma B540.11
20 3152 [M]Carcinoma, metastatic, NOS BB13.00
20 52316 Malignant neoplasm of pelvis B553.00
20 73916 [M]Epithelioid leiomyosarcoma BBK0400
20 46159 Malignant neoplasm of cloacogenic zone B142000
20 97547 Malignant neoplasm of intrathoracic site NOS B551200
20 36124 [M]Eccrine dermal cylindroma BB5H.00
20 41816 [M]Squamous cell carcinoma, small cell, non-keratinising BB2E.00
20 51818 Malignant neoplasm of jaw NOS B550300
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20 40449 [M]Gonadoblastoma BBQ6.00
20 2123 [M]Neuroblastoma NOS BBc1.00
20 41931 Malignant neoplasm of cheek NOS B550100
20 24293 [M]Squamous cell carcinoma, metastatic NOS BB2B.00
20 9030 Malignant neoplasm of other and ill-defined sites B55..00
20 55588 [X]Malignant neoplasm of female genital organ, unspec-
ified
Byu7300
20 59251 [M]Cystosarcoma phyllodes, malignant BBM9.00
20 87113 Malignant neoplasm-pluriglandular involve-
ment,unspecified
B54X.00
20 67211 Malignant neoplasm of spinal meninges NOS B523z00
20 15907 Malignant neoplasm gallbladder/extrahepatic bile ducts
NOS
B16z.00
20 39121 [M]Ganglioneuroblastoma BBc0100
20 67324 Malig neop of connective and soft tissue of inguinal region B315100
20 8660 [M]Osteosarcoma NOS BBV1.00
20 33395 Secondary and unspec malig neop superficial cervical LN B560200
20 99219 [M]Interstitial cell tumour NOS BBCCz11
20 30646 Malignant neoplasm lymphatic or haematopoietic tissue
OS
B6y..00
20 53910 Malignant neoplasm of clitoris B453.00
20 26253 [M]Neuroendocrine carcinoma BB5R900
20 70824 Malignant neoplasm of adrenal gland NOS B540z00
20 35136 Carcinoma in situ NOS B8z..00
20 94239 [M]Mast cell sarcoma BBp1.00
20 37542 [M]Teratocarcinoma BBQ7300
20 5637 Malignant neoplasm of thyroid gland B53..00
20 56490 Malignant neoplasm of nervous system NOS B52z.00
20 16146 [M]Adenocarcinoma with squamous metaplasia BBB2.00
20 86046 Malignant neoplasm of peripheral nerve of abdomen B524400
20 28003 Choriocarcinoma B420.00
20 34946 Carcinoma in situ of vagina B833200
20 37354 [M]Clear cell adenocarcinoma NOS BB5X100
20 16902 [M]Basal cell adenocarcinoma BB5y000
20 34096 [M]Granular cell carcinoma BB5b.00
20 94220 Malignant neoplasm of adrenal medulla B540100
20 96226 [X]Malignant neoplasm/overlap lesion/other+ill-defined
sites
ByuC100
20 26034 Other malignant neoplasm NOS B591.00
20 27391 Secondary malignant neoplasm of peritoneum B576100
20 36495 Carcinoma common bile duct B161211
20 21330 Malignant neoplasm of retroperitoneum B180.00
20 61928 [M]Squamous cell ca-in-situ, questionable stromal inva-
sion
BB2H.00
20 61741 Malignant neoplasm of humerus B304200
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20 16692 [M]Carcinomatosis BB14.00
20 20166 Malignant neoplasm of female genital organ NOS B45z.00
20 65953 Carcinoma in situ of arytenoid cartilage B810300
20 44157 [M]Melanosarcoma NOS BBE1.13
20 21847 [M]Follicular carcinoma BB5f111
20 26454 Malignant neoplasm/overlapping lesion/feml genital or-
gans
B45X.00
20 67034 [X]Mesothelioma of other sites Byu5000
20 39899 Malignant neoplasm of craniopharyngeal duct B542100
20 7654 Secondary malignant neoplasm of bone and bone marrow B585.00
20 61677 Secondary and unspec malig neop inferior mesenteric LN B562200
20 50859 [M]Giant cell bone sarcoma BBX1.11
20 27849 [M]Villous adenocarcinoma BB5U200
20 5052 [M]Osteogenic sarcoma NOS BBV1.13
20 52537 Malignant neoplasm of hepatic duct B161100
20 49145 Secondary malignant neoplasm of penis B58y700
20 47899 Malignant neoplasm of greater vestibular (Bartholin’s)
gland
B451000
20 73510 Malignant neoplasm of supraclavicular fossa NOS B550500
20 50898 Malignant neoplasm of omentum B18y300
20 44217 [M]Mixed tumour NOS BBL3.12
20 49900 [M]Klatskin’s tumour BB5y200
20 61984 [M]Spheroidal cell carcinoma BB1G.00
20 66488 Malig neop of connective and soft tissue of abdominal
wall
B314000
20 56794 [M]Adenocarcinoid tumour BB5R800
20 39130 [M]Carcinoid tumour, argentaffin, NOS BB5R200
20 47920 [M]C cell carcinoma BB9B.11
20 37328 Malignant neoplasm of vagina B450.00
20 60186 [M]Refractory anaemia+excess of blasts with transfor-
mation
BBmB.00
20 68027 [X]Malignant neoplasm/other and unspecified cranial
nerves
ByuA000
20 38343 Secondary and unspec malig neop submental lymph
nodes
B560700
20 17559 Malignant neoplasm of intestinal tract, part unspecified B1z0.00
20 63695 Malignant neoplasm of peripheral nerve of thorax B524300
20 24511 [M]Malignant tumour, giant cell type BB09.00
20 57482 Malignant neoplasm of connective and soft tissue of fore-
arm
B311200
20 33636 [M]Teratoma, malignant, NOS BBQ7200
20 98781 [M]Trabecular adenocarcinoma BB5F.00
20 60772 Malignant neoplasm of vagina NOS B450z00
20 23433 Malignant neoplasm of extrahepatic bile ducts B161.00
20 25641 [M]Liver cell carcinoma BB5D513
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20 60403 Malignant neoplasm of costal cartilage B303300
20 59388 Malignant neoplasm of mesocaecum B18y100
20 31210 Hepatoblastoma of liver B150100
20 71627 [M]Sweat gland adenocarcinoma BB61200
20 46581 [M]Pleomorphic cell sarcoma BBF4.11
20 56918 Malignant neoplasm other spec digestive tract and peri-
toneum
B1zy.00
20 72277 [M]Basophil carcinoma BB5V700
20 65434 Malignant neoplasms of lymphoid and histiocytic tissue
NOS
B62z.00
20 32442 [M]Chondromatous giant cell tumour BBW7.11
20 54493 Malignant neoplasm of xiphoid process B303500
20 54747 Malignant neoplasm of parietal bone B300600
20 11035 Primary malignant neoplasm of unknown site B593.00
20 4218 Malignant neoplasm of parathyroid gland B541.00
20 25535 Primary malignant neoplasm of liver B150.00
20 43151 [X]Malignant neoplasm/bone+articular cartilage, un-
specified
Byu3300
20 31090 [M]Pigmented dermatofibrosarcoma protuberans BBGP.00
20 44356 Malig neop other/ill-defined sites resp/intrathoracic or-
gans
B2z..00
20 4403 Liver metastases B577.11
20 60181 Neoplasm of unspecified nature of other specified sites BA0y.00
20 98883 [M]Medullary carcinoma with lymphoid stroma BB9D.00
20 92329 Malignant neoplasm of other male genital organ NOS B48yz00
20 5455 [M]Adenocarcinoma, metastatic, NOS BB53.00
20 48743 Malignant neoplasm of body of penis B482.00
20 40438 [M]Bile duct carcinoma BB5D111
20 47366 Secondary and unspec malig neop sacral lymph nodes B565300
20 44166 Carcinoma in situ of other and unspecified digestive or-
gans
B80z.00
20 63331 Malignant neoplasm of spermatic cord B485.00
20 86812 Malignant neoplasm of phalanges of hand B305D00
20 68824 Malignant neoplasm, overlapping lesion male genital orgs B48y200
20 63224 Malignant neoplasm of penis and other male genital or-
gan NOS
B48z.00
20 65216 [M]Cloacogenic carcinoma BB49.00
20 22561 [M]Telangiectatic osteosarcoma BBV4.00
20 59143 [M]Squamous cell carcinoma, large cell, non-keratinising BB2D.00
20 93665 [X]Kaposi’s sarcoma, unspecified Byu5300
20 45510 [M]Lymphoepithelial carcinoma BB2M.00
20 47862 Malignant neoplasm of thyroid cartilage B213300
20 32372 Malignant neoplasm of thoracic vertebra B302100
20 9491 Anal carcinoma B142.11
20 71497 [M]Oxyphilic adenocarcinoma BB5W100
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20 68956 [M]Giant cell tumour of bone, malignant BBX1.00
20 91586 Malignant neoplasm of connective and soft tissue of fin-
ger
B311400
20 27483 Malignant neoplasm of thymus B240.00
20 16075 Malignant neoplasm of bone and articular cartilage NOS B30z.00
20 25310 Carcinoma in situ of liver B808000
20 29008 [M]Hurthle cell adenocarcinoma BB5W111
20 35457 [M]Basosquamous carcinoma BB35.00
20 27562 [M]Follicular lymphosarcoma NOS BBk0.12
20 1624 [M]Squamous cell carcinoma NOS BB2A.00
20 21861 [M]Lobular carcinoma in situ BB9E.00
20 38593 [M]Adamantinoma of long bones BBY1.00
20 19041 [M]Intraepidermal carcinoma NOS BB29.12
20 19334 [M]Carcinosarcoma NOS BBL9.00
20 63104 Malignant neoplasm of orbit NOS B501z00
20 52591 [M]Lymphoblastoma NOS BBgG.13
20 33775 [M]Adenoid cystic carcinoma BB5J.00
20 7856 [M]Dedifferentiated liposarcoma BBJH.00
20 28178 [M]Craniopharyngioma BBa0.00
20 49714 Malignant neoplasm of spinal meninges B523.00
20 49797 [M]Argentaffinoma NOS BB5R211
20 18616 Secondary malignant neoplasm of other specified sites B58y.00
20 45070 Carcinoma in situ of duodenum B807000
20 68220 [M]Fibrochondrosarcoma BBW4.11
20 37621 [M]Endodermal sinus tumour BBQ4.00
20 65599 Malignant neoplasm of acoustic nerve B520200
20 65460 Malignant neoplasm of spleen NEC B1z1.00
20 57796 [M]Synovial sarcoma, biphasic type BBN4.00
20 64971 Malignant neoplasm of olfactory bulb B520000
20 70747 Secondary and unspec malig neop of inguinal and leg LN
NOS
B564z00
20 62630 Malignant neoplasm of long bones of leg NOS B307z00
20 39038 [M]Signet ring carcinoma BB85.00
20 38454 [M]Basaloid carcinoma BB48.00
20 62348 [M]Haemangiosarcoma BBT1.00
20 44420 Refractory anaemia with excess of blasts with transfor-
mation
B937300
20 66607 [M]Mixed tumour, malignant, NOS BBL4.00
20 90659 Malignant neoplasm of other specified endocrine gland B54y.00
20 14825 Neoplasm of unspecified nature BA0..00
20 57802 [M]Alveolar adenocarcinoma BB5S400
20 94427 Malignant neoplasm of fifth metacarpal bone B305C00
20 48282 Neoplasm of unspecified nature of bone BA02000
20 54874 [M]Metastatic signet ring cell carcinoma BB85100
20 7941 [M]Chondrosarcoma NOS BBW4.00
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20 22650 [M]Angiosarcoma BBT1.11
20 43490 [X]Other specified carcinomas of liver Byu1100
20 50402 Malignant neoplasm of fibula B307100
20 58837 [M]Small cell sarcoma BBF5.00
20 63804 Carcinoma in situ of jejunum B807100
20 67451 Malignant neoplasm/overlap lesion/bone+articulr carti-
lage
B30W.00
20 10258 [M]Neoplasms NOS BB0..00
20 21868 [M]Neoplasm, malignant BB02.00
20 3197 [M]Neoplasm, metastatic BB03.00
20 6985 [M]Secondary neoplasm BB03.11
20 64897 [X]Malignant neoplasms/independent(primary)multiple
sites
ByuE000
20 90546 Malig neop connective and soft tissue hip and leg NOS B312z00
20 12265 Primary thrombocythaemia B937411
20 59787 [M]Tubular androblastoma NOS BBC9.00
20 15507 Secondary and unspec malig neop lymph nodes NOS B56z.00
20 30416 [M]Colloid adenocarcinoma BB82111
20 24235 Malig neopl peripheral nerves and autonomic nervous
system
B524.00
20 26630 Unspecified nature neoplasm BA...00
20 58124 Carcinoma in situ of eye B8y0.00
20 55595 Malignant neoplasm of sphenoid bone B300700
20 69844 [M]Round cell sarcoma BBF5.11
20 44609 Malignant neoplasm of ilium B306000
20 57505 [M]Pleomorphic rhabdomyosarcoma BBK3200
20 63657 Malignant neoplasm of conjunctiva B503.00
20 38651 [M]Papillary carcinoma in situ BB21.00
20 35285 [X]Malignant neoplasm of eye, brain and other parts of
cent
ByuA.00
20 94776 Malignant neoplasm, overlapping lesion of digestive sys-
tem
B1z2.00
20 3028 [M]Basal cell carcinoma NOS BB31.00
20 56676 [M]Myxoid liposarcoma BBJ5.00
20 3348 [M]Histiocytoma NOS BBGK.12
20 93852 [M]Lymphangiomyoma BBU5.00
20 96445 Malignant neoplasm of turbinate B300B00
20 95182 Malignant neoplasm of talus B308100
20 44627 Secondary and unspec malig neop anterior cervical LN B560800
20 95818 [M]Paraganglioma, malignant BBD1.00
20 29580 [M]Sertoli cell carcinoma BBCA.00
20 84368 Secondary and unspec malig neop internal iliac lymph
nodes
B565000
20 61555 Malignant neoplasm of retroperitoneum NOS B180z00
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20 98813 Malig neop eyeball excl conjunctiva, cornea, retina,
choroid
B500.00
20 62871 [M]Comedocarcinoma, noninfiltrating BB92.00
20 36209 [M]Carotid body tumour BBD6.00
20 67966 [M]Naevocarcinoma BBE1.14
20 13574 [M]Metatypical carcinoma BB36.00
20 15976 Malignant neoplasm of abdomen B552.00
20 57047 Malignant neoplasm of carotid body B544.00
20 45766 [X]Malignant neoplasm of intestinal tract, part unspeci-
fied
Byu1200
20 54956 Malignant neoplasm of eye NOS B50z.00
20 46478 Carcinoma in situ of adrenal gland B8yy100
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Appendix D
Symptom codes
This appendix details the relevant medcodes used in the investigation of symptoms of
cancer in this thesis:
 Table D.1 displays a key for the codes.
 Table D.2 contains a list of medcodes with a description.
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Table D.1: Keys for codes and their symptoms used in the table of medcodes (Table
C.2).
Code Symptom
1 Abdominal pain
2 Iron-deficient anaemia
3 Diarrhoea
4 Constipation
5 Rectal bleed
6 Change in bowel habit
7 Abdominal mass
8 Cough
9 Fatigue
10 Shortness of breath
11 Chest pain
12 Loss of appetite
13 Weight loss
14 Lower abdominal pain
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Table D.2: Description of symptoms with medcode reference ID fields.
Medcode Description
Symptom
code
177 Abdominal pain 1
628 [D]Hypochondrial pain 1
716 [D]Abdominal cramps 1
1239 [D]Colic NOS 1
1336 [D] Groin pain 1
1763 [D]Abdominal pain 1
1976 Abdominal pain type 1
2056 [D]Abdominal colic 1
2234 [D]Recurrent acute abdominal pain 1
2383 Abdominal discomfort 1
3338 [D]Abdominal pain NOS 1
4617 Central abdominal pain 1
4771 [D]Umbilical pain 1
5691 Non-colicky abdominal pain 1
5782 O/E - abdomen tender 1
5960 Site of abdominal pain 1
6357 Subcostal pain 1
6395 Type of GIT pain - symptom 1
7726 [D]Right upper quadrant pain 1
7812 Colicky abdominal pain 1
8362 [D]Left upper quadrant pain 1
9695 Right upper quadrant pain 1
11070 General abdominal pain-symptom 1
12639 O/E - abd.pain-R.hypochondrium 1
14916 O/E -abd.pain on palpation NOS 1
14989 Type of GIT pain 1
15180 O/E - abdo. pain on palpation 1
15908 Appendicular colic 1
16402 [D]Abdominal tenderness 1
17324 Griping pain 1
17636 O/E - umbilical pain on palp. 1
19283 [D]Nonspecific abdominal pain 1
23756 [D]Evening colic 1
23872 Left subcostal pain 1
24627 O/E - abd. pain - umbilical 1
24661 Generalised abdominal pain 1
24821 Right subcostal pain 1
25118 Site of GIT pain 1
28285 [D]Gas pain (abdominal) 1
29352 Abdominal wall pain 1
29922 Site of GIT pain NOS 1
31062 [D]Other specified abdominal pain 1
37101 O/E - abd.pain-L.hypochondrium 1
42195 O/E - guarding-R.hypochondrium 1
42211 O/E - abd. pain - hypogastrium 1
47423 [D]Other abdominal and pelvic symptoms 1
50590 O/E - abdominal rigidity 1
52402 [X]Other and unspecified abdominal pain 1
56084 O/E - guarding - hypogastrium 1
56094 O/E - guarding-L.hypochondrium 1
62927 O/E - rebound - umbilical 1
62933 O/E - guarding - umbilical 1
73235 O/E - abdominal rigidity NOS 1
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Medcode Description
Symptom
code
539 Microcytic - hypochromic anaemia 2
795 Iron deficiency anaemias 2
882 Hypochromic - microcytic anaemia 2
4839 Microcytic hypochromic anaemia 2
4858 [X]Other iron deficiency anaemias 2
9537 Other specified iron deficiency anaemia NOS 2
15439 Iron deficiency anaemia NOS 2
18137 Unspecified iron deficiency anaemia 2
21127 Iron deficiency anaemia due to dietary causes 2
27726 Iron deficiency anaemia due to chronic blood loss 2
33420 Other specified iron deficiency anaemia 2
48338 Iron deficiency anaemia due to blood loss 2
192 Diarrhoea 3
1695 Loose stools 3
2133 Dysenteric diarrhoea 3
2182 Diarrhoea & vomiting, symptom 3
4343 Diarrhoea 3
4542 Infectious diarrhoea 3
5036 Functional diarrhoea 3
5090 Diarrhoea of presumed infectious origin 3
5134 Diarrhoea symptoms 3
6007 Diarrhoea due to Campylobacter jejuni 3
6016 Noninfective diarrhoea 3
6083 Incontinent of faeces symptom 3
6685 Chronic diarrhoea 3
7644 Diarrhoea and vomiting 3
10158 Spurious diarrhoea 3
11155 Travellers’ diarrhoea 3
13387 Allergic diarrhoea 3
14665 Diarrhoea & vomiting -? infect 3
14695 Diarrhoea symptom NOS 3
14881 [D] Stools loose 3
15289 Viral diarrhoea 3
15371 Psychogenic diarrhoea 3
15555 [D]Incontinence of faeces NOS 3
17017 Diarrhoea - presumed non-infectious 3
17162 Dietetic diarrhoea 3
21294 Spurious (overflow) diarrhoea 3
29835 Irritable bowel syndrome with diarrhoea 3
30321 Presumed noninfectious diarrhoea 3
36613 Epidemic diarrhoea 3
43316 [X]Psychogenic diarrhoea 3
48313 Infectious diarrhoea NOS 3
52750 [X]Diarrhoea+gastroenteritis of presumed infectious origin 3
53739 Diarrhoea due to staphylococcus 3
56957 Diarrhoea due to Pseudomonas pyocyanea 3
61519 Diarrhoea due to staphylococcal toxin 3
1028 Constipation 4
1709 Constipation - functional 4
2004 Constipation symptom 4
2264 Manual removal of impacted faeces from rectum 4
5803 Constipation NOS 4
6364 Chronic constipation with overflow 4
8541 Painful defaecation 4
10687 Faecal impaction 4
15939 Psychogenic constipation 4
17652 Constipated 4
20450 Constipation NOS 4
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Medcode Description
Symptom
code
6364 Chronic constipation with overflow 4
8541 Painful defaecation 4
10687 Faecal impaction 4
15939 Psychogenic constipation 4
17652 Constipated 4
20450 Constipation NOS 4
20464 Removal of impacted faeces 4
23641 Acute constipation 4
24180 Other specified constipation 4
25797 Chronic constipation without overflow 4
26022 Drug induced constipation 4
97021 Difficulty in ability to defaecate 4
98785 O/E - defaec.ref.abn.-constip. 4
621 Rectal bleeding 5
2873 Blood in stool 5
3872 Bleeding PR 5
5462 Blood in faeces 5
6151 Blood in faeces symptom 5
6554 PRB - Rectal bleeding 5
6574 Rectal haemorrhage 5
7096 Perianal haematoma 5
9968 Blood on toilet paper 5
11698 Painless rectal bleeding 5
11718 Painful rectal bleeding 5
14256 Blood in faeces 5
19271 Haemorrhage of rectum and anus 5
20859 Blood in stools altered 5
27862 Altered blood in stools 5
32446 Anal haemorrhage 5
45911 Blood on pants 5
46479 Haemorrhage of rectum and anus NOS 5
61761 Perinatal rectal haemorrhage 5
910 Change in bowel habit 6
16665 [D]Change in bowel habit 6
19690 Altered bowel habit 6
3015 [D]Abdominal mass 7
5838 [D]Swelling, mass or lump within abdomen or pelvis 7
7073 [D]Abdominal lump 7
8731 O/E - abdominal mass palpated 7
20827 Right iliac fossa mass 7
24527 Epigastric mass 7
56675 O/E - abd. mass palpated NOS 7
92 Cough 8
292 Chesty cough 8
1025 Bronchial cough 8
1160 [D]Cough 8
1234 Productive cough NOS 8
1273 C/O - cough 8
1612 Chronic cough 8
3068 Night cough present 8
3628 Persistent cough 8
3645 Coughing up phlegm 8
4070 Morning cough 8
4836 Nocturnal cough / wheeze 8
4931 Dry cough 8
7706 Productive cough -clear sputum 8
7707 Cough symptom NOS 8
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7708 Productive cough-yellow sputum 8
7773 Productive cough -green sputum 8
8239 [D]Cough with haemorrhage 8
16717 Smokers’ cough 8
29318 Evening cough 8
43795 Unexplained cough 8
1147 [D]Tiredness 9
1371 [D]Lethargy 9
1404 Fatigue 9
1582 Nervous exhaustion 9
1688 [D]Fatigue 9
2855 Weakness present 9
3192 Exhaustion due to exposure 9
4546 Chronic fatigue syndrome 9
5583 Lethargy - symptom 9
5751 Tired all the time 9
5794 Tiredness symptom 9
5814 [D]Lassitude 9
6029 Weakness symptoms 9
6190 Postviral fatigue syndrome 9
6242 Fatigue - symptom 9
7235 Tired all the time 9
7529 CFS - Chronic fatigue syndrome 9
9127 Post-viral fatigue syndrome 9
9220 Exhaustion 9
9435 O/E - apathetic 9
9656 [X]Fatigue syndrome 9
9889 [D]General weakness 9
15516 C/O - tired all the time 9
16479 O/E - weakness 9
17083 Excessive exertion exhaustion 9
17526 Maternal exhaustion 9
17736 Malaise/lethargy 9
22923 Heat exhaustion, unspecified 9
24382 [D]Senile exhaustion 9
27877 PVFS - Postviral fatigue syn 9
29181 [D]Post polio exhaustion 9
29292 Tiredness symptom NOS 9
43550 Combat fatigue 9
44215 [D]Malaise and fatigue 9
52583 Fatigue during pregnancy 9
64099 Fatigue during pregnancy unspecified 9
68930 Fatigue during pregnancy - delivered 9
70779 [X]Combat fatigue 9
73727 Fatigue during pregnancy NOS 9
97284 Moderate chronic fatigue syndrome 9
98512 Mild chronic fatigue syndrome 9
98734 Severe chronic fatigue syndrome 9
99956 Fatigue during pregnancy with postnatal complication 9
99980 Fatigue during pregnancy - not delivered 9
735 [D]Breathlessness 10
741 [D]Shortness of breath 10
1429 Breathlessness 10
2575 Short of breath on exertion 10
2931 Difficulty breathing 10
3092 [D]Dyspnoea 10
4822 Shortness of breath 10
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5175 Breathlessness symptom 10
5349 Shortness of breath symptom 10
5896 Dyspnoea - symptom 10
6326 Breathless - moderate exertion 10
6434 Paroxysmal nocturnal dyspnoea 10
7000 O/E - dyspnoea 10
7683 Breathless - lying flat 10
7932 Breathless - mild exertion 10
12474 SOBOE 10
18116 Nocturnal dyspnoea 10
19426 MRC Breathlessness Scale: grade 3 10
19427 MRC Breathlessness Scale: grade 2 10
19429 MRC Breathlessness Scale: grade 5 10
19430 MRC Breathlessness Scale: grade 4 10
19432 MRC Breathlessness Scale: grade 1 10
21801 Breathlessness NOS 10
22094 Short of breath dressing/undressing 10
23663 Respiratory symptom NOS 10
24889 Breathless - strenuous exertion 10
31143 Breathless - at rest 10
53771 Dyspnoea on exertion 10
57903 CLASP shortness of breath score 10
374 Chest pain 11
544 [D]Chest pain, unspecified 11
726 Atypical chest pain 11
1059 Pleuritic pain 11
1270 [D]Chest tightness 11
2519 Rib pain 11
2584 [D]Chest pain 11
3518 [D]Musculoskeletal chest pain 11
3796 [D]Chest pain NOS 11
7346 Central chest pain 11
7844 [D]Non-cardiac chest pain 11
7878 [D]Chest discomfort 11
8349 Costal margin chest pain 11
9340 [D]Non cardiac chest pain 11
9698 Anterior chest wall pain 11
10370 Chest pain NOS 11
14823 [D]Anterior chest wall pain 11
15528 [D]Chest pressure 11
18134 Chest pain on exertion 11
18183 [D]Pleuritic pain 11
19199 [D]Parasternal chest pain 11
21082 [D]Retrosternal chest pain 11
24321 Chest wall tenderness 11
24704 Chest wall pain 11
29490 [D] Retrosternal chest pain 11
50477 [D]Central chest pain 11
53806 [X]Other chest pain 11
912 [D]Anorexia 12
1855 [D]Appetite loss 12
6607 Loss of appetite - symptom 12
7608 Appetite loss - anorexia 12
7743 Other and unspecified non-organic eating disorders 12
7744 Anorexia symptom 12
13081 Reduced appetite 12
17203 [X]Psychogenic loss of appetite 12
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22820 Non-organic loss of appetite 12
25189 Restricting food intake 12
53746 [D]Anorexia NOS 12
126 O/E - Underweight 13
654 Weight decreasing 13
3647 [D]Abnormal loss of weight 13
4663 Abnormal weight loss 13
5812 Abnormal weight loss - symptom 13
12398 Complaining of weight loss 13
12530 [D]Underweight 13
22005 O/E - cachexic 13
24068 [D] Cachexia 13
26473 O/E - weight > 20% below ideal 13
29029 O/E -weight 10-20% below ideal 13
32914 Body Mass Index low K/M2 13
37937 Weight loss from baseline weight 13
38995 Abnormally thin 13
53801 [D]Cachexia NOS 13
421 Iliac fossa pain 14
1181 Right iliac fossa pain 14
2781 C/O pelvic pain 14
2982 Left iliac fossa pain 14
4706 Bony pelvic pain 14
9061 [D]Left lower quadrant pain 14
9811 [d] pelvic pain 14
9920 [D]Pelvic and perineal pain 14
11647 O/E - abd. pain - R. iliac 14
16806 [D]Pain in right iliac fossa 14
16868 [D]Pain in left iliac fossa 14
17223 O/E - iliac pain on palpation 14
19360 [D]Right lower quadrant pain 14
21583 O/E - abd. pain - L. iliac 14
22608 Lower abdominal pain 14
35876 O/E - guarding - R.iliac 14
50662 [X]Pain localized to other parts of lower abdomen 14
56085 O/E - guarding - L.iliac 14
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